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INTRODUCTION
Chronic kidney disease is a major public health problem worldwide, with a global prevalence 
of 8 to 16 %.1 The “Developmental Origins of Health and Disease Hypothesis” states that vari-
ous diseases in later life originate from fetal life and early infancy.2 This hypothesis suggests 
that a suboptimal fetal environment leads to developmental adaptations that permanently 
alter growth, physiology and metabolism, which may be benefi cial in short-term but with 
long-term consequences for health.2 Adverse exposures, such as poor nutrition, in early life 
may lead to metabolic adaptations to maintain development of key body organs, including 
the kidney.3, 4 
Epidemiological evidence suggests that early life events, including low birth weight, have 
an important role for the susceptibility to develop chronic kidney disease in later life.5–8 
Additionally, historical studies suggest that adult off spring of mothers who were exposed 
to severe undernutrition during their pregnancies have an increased risk of cardiovascular 
and renal disease, independent of birth weight.9, 10 The Dutch Famine studies provide strong 
evidence that maternal undernutrition during pregnancy increases the risk of high blood 
pressure and microalbuminuria in the off spring.11, 12 
Nephrogenesis starts in early pregnancy, continues until the 36th week of gestation, and 
largely ceases thereafter. Therefore, adverse exposures during critical periods of nephron 
formation may lead to impaired kidney development.13, 14 Post mortem studies have observed 
that infants with a low birth weight have smaller kidneys with a reduced number of neph-
rons.15 Brenner’s “Hyperfi ltration Theory” suggests that adverse fetal adaptations, may lead to 
smaller kidneys with a reduced number of nephrons, and subsequently to glomerular hyper-
fi ltration and sclerosis, which predisposes to development of impaired kidney function and 
eventually kidney disease in adulthood.16–19 Investigating specifi c nutritional factors during 
pregnancy and other early life factors may provide new insights into kidney development. 
Therefore, the studies presented in this thesis focus on identifi cation of early determinants of 
early growth and kidney function in children (Figure 1.1). 
Figure 1.1. Framework of the studies included in this thesis
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FETAL FACTORS
Maternal diet and other lifestyle related factors during pregnancy are related to growth, car-
diovascular and kidney outcomes in the off spring. The Dutch Famine studies provide strong 
evidence that maternal undernutrition during pregnancy aff ects birth weight, cardiovascular 
and renal health of the off spring.11, 12 However, not much is known about the specifi c nutrients 
in modern diets that infl uence early growth and kidney development in children. Also, the 
potential mechanisms underlying these associations are not well known. The strongest 
evidence from the animal studies suggest that especially protein-restriction in pregnant rats 
can aff ect off spring kidney health.20 Protein is one of the main nutrient components which 
provides essential amino acids required for growth. In patients with mild renal insuffi  ciency, 
a high protein intake is reported to aggravate the severity of the disease.21 However, ex-
perimental studies suggest that maternal protein malnutrition impacts fetal kidney vascular 
development and prevents achievement of full kidney function in the adults.8, 20, 22 Whether 
maternal protein intake in pregnancy infl uences childhood kidney structure and function in 
a healthy population is unknown. 
Beside macronutrients, previous literature suggests that micronutrients such as B-vitamins 
and vitamin D status in fetal life may alter metabolism, vasculature, and organ growth and 
function, leading to increased risk of cardiovascular disorders, adiposity, and altered kidney 
function in the off spring.23–25 Folate is an essential B-vitamin, important for cell growth and repli-
cation and together with vitamin B12, is an important methyl donor in many reactions, including 
the production of thymidine for deoxyribonucleic acid (DNA) synthesis, polyamine synthesis, 
and biosynthesis of methionine from homocysteine.26–28 Folate and vitamin B12 contribute to 
lowering homocysteine concentrations. Adults studies have shown associations of elevated 
homocysteine concentrations with an accelerated decline in kidney function.29 However no 
previous studies have explored the associations of maternal folate, vitamin B12 and homocyste-
ine concentrations during pregnancy with childhood kidney structure and function.
Vitamin D is another micronutrient with a known role in diff erentiation and maturation 
processes of the cell. Vitamin D defi ciency during pregnancy is common.30 Next to its well-
known function in bone health and rickets in off spring,25 an accumulating body of evidence 
suggest that vitamin D status during pregnancy may be associated with persistent changes in 
off spring health including adverse birth outcomes and impaired development.31–33 Whether 
maternal vitamin D defi ciency is associated with fetal growth patterns besides birth weight 
is unclear. Some experimental studies suggest a stimulated off spring nephrogenesis and an 
altered body composition profi le from vitamin D defi cient mothers.34, 35 Studies exploring 
these associations in healthy children are lacking. 
Next to maternal nutritional factors in pregnancy, gestational hypertensive disorders are 
associated with suboptimal placental-fetal nutrition transport and increased risks of delivering 
preterm and small size for gestational age infants,36 both of which are risk factors for hyperten-
sion in adulthood.37, 38 However gestational hypertensive disorders do not represent the full 
spectrum of blood pressure development during pregnancy. Not much is known about the 
critical periods of maternal blood pressure for the development of childhood blood pressure. 
13
General introduction
1
GENETIC AND CHILDHOOD FACTORS
Risk factors for impaired kidney function track from childhood to adulthood.39, 40 Kidney 
measures in early life are associated with kidney disease in later life. Besides environmental 
factors, the associations between early life kidney characteristics and kidney disease in later 
life may also be explained by common genetic variants. These variants may aff ect early kidney 
development and function and thereby predispose individuals to kidney disease in later life. 
Large genome-wide association studies in adults have identifi ed common genetic variants 
related to measures of impaired kidney function.41 Whether these genetic variants also aff ect 
kidney function in early childhood is not known. 
Next to fetal and genetic factors, early life nutrition can aff ect kidney development and 
subsequently lead to chronic kidney disease.6 Breastfeeding is suggested to have a protec-
tive eff ect on the development of cardiometabolic diseases.42 Also, the long-term protective 
eff ects of breastfeeding on blood pressure, obesity and diabetes are recognized.43 Whether 
breastfeeding infl uences childhood kidney health is unknown. 
GENERAL AIM OF THIS THESIS
The general aim of this thesis was to identify pathways linking early life nutrition, with early 
growth and subsequent kidney structure and function in children.
GENERAL DESIGN
The studies described in this thesis are embedded in The Generation R Study, a population-
based prospective cohort study from fetal life onwards.44 Mothers who lived in Rotterdam 
and had an expected delivery date between April 2002 and January 2006 were enrolled in the 
study. Enrollment was aimed in early pregnancy, but was allowed until the birth of their child. 
Partners were also invited to participate. As shown in Figure 1.2, 9,778 mothers were enrolled 
in the study, of which 91 % (8,880) were enrolled during pregnancy. Visits were planned in 
early pregnancy (gestational age <18 weeks), mid-pregnancy (gestational age 18–25 weeks) 
and late pregnancy (gestational age >25 weeks). Physical and fetal ultrasound examinations 
were carried out and blood and urine samples were collected during each visit. Before each 
visit, mothers were asked to fi ll out postal questionnaires. A food frequency questionnaire 
was sent out in early pregnancy. Fathers participated in one postal questionnaire and one 
physical examination. Around the age of 6 years, all children were invited to visit a dedicated 
research center in the Erasmus MC-Sophia Children’s Hospital. Measurements during this 
visit included anthropometrics, body composition using Dual-energy X-ray Absorptiometry 
(DXA), blood pressure, kidney ultrasound and blood and urine samples for later determina-
tion of kidney function and cardiovascular risk factors. 
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OUTLINE
In Chapter 2, studies on fetal factors, especially maternal nutritional factors and their infl uence 
on fetal growth and childhood kidney function are presented. Chapter 2.1 describes the as-
sociations of maternal protein intake in early pregnancy and childhood kidney development. 
In Chapter 2.2, we explore the association of maternal folate, vitamin B12 and homocysteine 
concentrations during pregnancy with off spring kidney structure and function. Chapter 2.3 
presents the potential role of maternal vitamin D concentrations during pregnancy in fetal 
growth and the risk of adverse birth outcomes. In Chapter 2.4, we examine the association 
of maternal and fetal vitamin D status with childhood body composition and cardiovascular 
outcomes. Chapter 2.5 describes the relation of maternal vitamin D concentrations during 
pregnancy with childhood kidney outcomes. Chapter 2.6 focuses on potential associations 
of maternal and paternal blood pressure and hypertensive disorders in pregnancy with child-
hood blood pressure developments. In Chapter 3 we present studies focused on potential 
Figure 1.2. Design and selected data collection in the Generation R Study
School-age measurements (N=8,305) 
Questionnaires: child activity  
Physical examinations: child anthropometrics, body composition using DXA, ultrasound assessment of 
kidney growth, blood pressure 
Biological samples: child blood and urine samples 
Total Cohort (N=9,778) 
Enrolment during pregnancy (N=8,880) and at birth (N=898) 
Fetal measurements (N=8,880) 
Questionnaires: maternal diet, parental health, socio-demographic and lifestyle factors  
Physical examinations: parental anthropometrics, parental blood pressure, fetal ultrasounds 
Biological samples: maternal blood samples 
Preschool measurements (N=7,893) 
Questionnaires: infant feeding 
Community Health Centers: child anthropometrics 
Birth measurements (N=9,749) 
Midwife and hospital data: pregnancy complications, gestational age at birth, birth outcomes and 
neonatal complications 
Biological samples: cord blood samples 
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genetic, infant and childhood determinants of kidney function. In Chapter 3.1, the associa-
tions of a genetic risk score combining previously identifi ed common genetic variants re-
lated to impaired kidney function in adults with kidney outcomes in school-age children are 
explored. In Chapter 3.2, we study the associations of infant breastfeeding with childhood 
kidney structure and function. Chapter 3.3 compares the associations of body composition 
measures with estimates of glomerular fi ltration rate based on creatinine and cystatin C 
concentrations. Lastly, Chapter 4 presents an overall discussion of the main fi ndings of this 
thesis and also covers suggestions for future research and clinical implications. 
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ABSTRACT 
Background: Nutritional exposures during in utero development may have long-lasting 
consequences for postnatal renal health. Animal studies suggest that specifi cally maternal 
dietary protein intake during pregnancy infl uences childhood kidney function. 
Objective: We examined the associations of total, animal and vegetable maternal protein 
intake during pregnancy with kidney volume and function in school-age children. 
Design: This study was performed in 3,650 pregnant women and their children participating 
in a population-based cohort study from early life onwards. First trimester energy adjusted 
maternal protein intake was assessed with a food frequency questionnaire. At the child’s 
age of 6 years, we assessed kidney volume, estimated glomerular fi ltration rate (eGFR) using 
serum creatinine and cystatin C levels, and microalbuminuria using urine albumin-creatinine 
ratios. 
Results: First trimester maternal total protein intake was associated with a higher childhood 
creatinine-based eGFR (0.06 (95 % CI 0.01, 0.12) ml/min/1.73m2 per gram of protein intake). 
This association was mainly driven by vegetable protein intake (0.22 (95 % CI 0.10, 0.35) ml/
min/1.73m2 per gram of vegetable protein intake). These associations were not explained by 
protein intake in early childhood. First trimester maternal protein intake was not signifi cantly 
associated with childhood kidney volume, cystatin C-based eGFR or the risk of microalbu-
minuria.
Conclusion: Our fi ndings suggest that higher total and vegetable, but not animal, maternal 
protein intake during fi rst trimester of pregnancy is associated with a higher eGFR in child-
hood. Further follow-up studies are needed to investigate whether maternal protein intake 
in early pregnancy also aff ects the risk of kidney diseases in later life.
23
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INTRODUCTION
Maternal nutritional exposures during pregnancy may persistently aff ect off spring kidney 
development.1 Results from the Dutch Famine Study suggest that maternal exposure to ex-
treme famine in mid-gestation is linked to an increased risk of microalbuminuria in their adult 
off spring.2 The mechanisms by which suboptimal maternal nutrition aff ects off spring kidney 
development may include smaller kidneys with a reduced number of nephrons, which in turn 
leads to glomerular hyperfi ltration and sclerosis.3 These adaptations predispose individuals 
to subsequent development of higher blood pressure, impaired kidney function and end-
stage kidney disease in adulthood.3 Apart from the evidence from the Dutch Famine Study, 
not much is known about more common and contemporary adverse nutritional exposures 
during pregnancy that infl uence kidney function in the off spring. Animal studies suggest 
that low maternal protein intake during pregnancy leads to a lower number of nephrons 
in their off spring and may hence impact the risk of renal disease and hypertension in later 
life.1, 4, 5 Nine-months old lambs whose mothers were fed with a 50 % nutrient restricted diet 
during early-mid pregnancy, had fewer renal glomeruli than did those whose mothers were 
fed a normal diet.4 In addition, studies showed that a low protein diet in pregnant rats results 
in a nephron defi cit in the off spring at birth which extends into postnatal life.5 Observational 
studies in human adults showed that high dietary protein is associated with progression of 
renal disease.6 Interestingly, studies in adults also suggest diff erent eff ects of animal versus 
vegetable protein on kidney health.7, 8 
Therefore, we examined, in a population-based prospective cohort study among 3,650 
mothers and children, the associations of fi rst-trimester maternal protein intake during 
pregnancy with child’s kidney outcomes at the age of 6 years. Main kidney outcomes were 
kidney volume, eGFR based on serum creatinine and cystatin C levels and microalbuminuria. 
METHODS
Subjects
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onward in Rotterdam, the Netherlands.9 The study was conducted ac-
cording to the guidelines of the Helsinki Declaration and approved by the Medical Ethics 
Committee of Erasmus Medical Center, Rotterdam. Written informed consent was obtained 
from all mothers. Enrolment in the study was aimed at early pregnancy, but was allowed until 
the birth of the child. Information about maternal diet and other lifestyle-related variables 
during pregnancy was collected at enrolment. At the age of 6 years, all participating children 
and their mothers were invited to a dedicated research center, to participate in detailed 
hands-on measurements. Of the 4,658 singleton live-born children with maternal nutritional 
data available and who participated in the study during childhood, 3,650 (78 %) children at-
tended the follow-up visit at the age of 6 years with successful measurements on kidney 
volume and function (Figure 2.1.1). 
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Maternal dietary assessment
Maternal dietary intake was assessed at enrollment (median 13.5 weeks of gestation, 95 % 
range 9.8–22.9) using a modifi ed version of the validated semi-quantitative food frequency 
questionnaire (FFQ) of Klipstein-Grobusch et al.10 The FFQ considered food intake over the 
previous 3 months, which mostly covered dietary intake in the fi rst trimester of pregnancy. 
The FFQ consisted of 293 items structured according to the meal pattern. Questions included 
consumption frequency, portion size, preparation method, and additions. We estimated 
portion sizes by using Dutch household measures and photographs of foods that showed 
diff erent portion sizes. We used the Dutch Food-Composition Table 2006 to calculate average 
daily intakes of total energy, carbohydrates, fat, and of total, animal, and vegetable protein.11 
For this study we split protein into animal (from e.g. meat, fi sh, and dairy) and vegetable 
protein (from e.g. grains, nuts, and legumes).
Kidney outcome assessments
Children’s kidney outcomes were assessed at a median age of 6.1 years (95 % range 5.6 to 
7.3) by well-trained staff  in a dedicated research center in the Sophia Children’s Hospital in 
Rotterdam. 
Our main kidney outcomes were combined kidney volume, estimated glomerular fi ltration 
rate (eGFR) and microalbuminuria. Combined kidney volume is a structural developmental 
outcome. Post-mortem studies showed that kidney volume is correlated with the number 
of nephrons. We used eGFR, calculated from blood creatinine and cystatin C levels as main 
measure of kidney function: eGFR is a general marker of glomerular fi ltration used in both 
clinical practice and population based cohort studies. Microalbuminuria is an established 
predictor of chronic kidney disease and end-stage renal disease.
Kidney volume was measured with ultrasound, using an ATL-Philips HDI 5000 instrument 
(Seattle, WA, USA), equipped with a 2.0–5.0 MHz curved array transducer. We identifi ed the 
Figure 2.1.1 Flowchart of the study participants
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mothers with dietary data 
N=6,485 
N=1,827 excluded due to: loss to follow-up 
(1280) or withdrawal of consent (417) and twin 
pregnancies (130) 
Singletons with maternal diet available and 
participation at school age measurements  
N=4,658 
N=1,008 excluded due to no visit at research 
centre at the age of 6 years and no kidney 
measurements 
Children with kidney measurements 
N=3,650 
25
Maternal protein intake and childhood kidney health
2.1
left and right kidney in the sagittal plane along its longitudinal axis. We performed measure-
ments of maximal bipolar kidney length, width and depth. Kidney width and depth were 
measured at the level of the hilum. The cross-sectional area in which the kidney appeared 
symmetrically round at its maximum width was used. Kidney volume was calculated using 
the equation for a prolate ellipsoid: volume (cm3) = 0.523 x length (cm) x width (cm) x depth 
(cm).12 Combined kidney volume was calculated by summing right and left kidney volume. 
We previously reported good intra-observer and inter-observer correlation coeffi  cients.13
Non-fasting blood samples were drawn by antecubital venipuncture. Blood samples 
were collected, transported, and stored as described in detail elsewhere.14 Samples were 
transported on dry ice to the Erasmus Medical Center where creatinine concentrations were 
measured with enzymatic methods and cystatin C concentrations with a particle-enhanced 
immunoturbidimetric assay (using Cobas 8000 analyzers; Roche). Quality-control samples 
demonstrated intra-assay and interassay coeffi  cients of variation ranging from 0.51 % to 1.37 % 
and from 1.13 % to 1.65 %, respectively. 
The eGFR was calculated according to the revised Schwartz 2009 formula: eGFRcreat = 36.5 * 
(height (cm)/serum creatinine (μmol/l)).15 In addition, we estimated the glomerular fi ltration 
rate using Zappitelli’s formula based on cystatin C levels: eGFRcystC = 75.94/[CysC1.17].16 Urine 
creatinine (μmol/l) and urine albumin (μg/l) levels were determined with a Beckman Coulter 
AU analyzer, creatinine levels were measured with the Jaff e reaction. In line with clinical cut-
off s, microalbuminuria was defi ned as an albumin-creatinine ratio between 2.5 and 25 mg/
mmol for boys and between 3.5 and 25 mg/mmol for girls.17
Covariates
Information on maternal age, ethnicity, educational level, smoking during pregnancy, alcohol 
usage during pregnancy, and folic acid supplementation were obtained using questionnaires.9 
We classifi ed maternal ethnicity into 6 categories (Dutch, Turkish, Moroccan, Surinamese or 
Dutch Antillean, other Western, and other non-Western).18 Maternal pre-pregnancy height 
and weight were self-reported and pre-pregnancy body mass index (BMI) was calculated (kg/
m2). Information on the presence of pre-pregnancy comorbidities (defi ned as the occurrence 
of high cholesterol, diabetes, hypertension) was available from a questionnaire administered 
in the fi rst trimester. Information on child’s sex, birthweight and gestational age was available 
from medical records and hospital registries. Sex and gestational age specifi c SD scores for 
birth weight were calculated using existing reference data.19 Information on breastfeeding 
was obtained from postnatal questionnaires.20 Child protein intake at the age of 1 year was 
measured with a validated semi-quantitative FFQ in a subgroup of 2,193 children.21,22 At the 
age of 6 years, child height was determined in standing position to the nearest millimeter 
without shoes by a Harpenden stadiometer (Holtain Limited, Dyfed, U.K.). Weight was mea-
sured using a mechanical personal scale (SECA, Almere, the Netherlands). We calculated BMI 
(kg/m2), and body surface area (BSA) (m2) (using DuBois formula BSA= weight (kg)0.425 x height 
(cm)0.725 x 0.007184).23 Time spent watching television or using a computer at the age of 6 
years was assessed with a questionnaire.24
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Statistical analysis 
We adjusted protein intake for energy intake using the nutrient residual method.25 For inter-
pretation, the predicted protein intake for the mean energy intake (2,073 kcal/d) was added 
to the residuals as a constant.25 Protein intake was analyzed as a continuous variable. We used 
multivariable linear regression models to assess associations of total, animal, and vegetable 
protein intake with kidney volume, creatinine, cystatin C and eGFR. For these models, we 
examined whether the residuals were normally distributed using normal probability plots, 
whether the variance of the residuals was homoscedastic and whether the regression models 
were linear. We assessed associations of protein intake with risk of microalbuminuria with 
multivariable logistic models. All models were adjusted for child’s age and sex (basic model). 
Analyses with vegetable protein intake were additionally adjusted for animal protein intake 
and vice versa. The adjusted models were further controlled for maternal characteristics and 
socio-demographic factors (maternal age, BMI before pregnancy, gestational weight gain, 
gestational age at intake, ethnicity, and education), maternal lifestyle factors (smoking, 
and alcohol consumption during pregnancy, folic acid supplement use during pregnancy), 
pre-pregnancy comorbidities and child characteristics (birthweight adjusted for gestational 
age, breastfeeding, body surface area at 6 years visit, and screen time at the age of 6 years). 
Covariates were included in the regression models based on previous literature or a change 
of >10 % in eff ect estimates. To assess whether the associations were diff erent by maternal 
ethnicity, child sex, birthweight, gestational age, or BSA of the child at the age of 6 years, we 
evaluated the statistical interaction by adding the product term of the covariate and total 
protein intake to the models. To examine whether the associations of maternal protein intake 
with kidney outcomes could be explained by later diet of the child, we performed a sensitivity 
analysis for a subgroup of our cohort in which information was available about protein intake 
at the age of 1 year.26 Also, we performed a sensitivity analysis including Dutch women only 
(N=2,332). To prevent bias associated with missing data, we used multiple imputations (N=5) 
for covariates with missing values on the basis of the correlation of missing variables with 
other participant characteristics, according to the Markov Chain Monte Carlo method.27 The 
amount of missing values ranged from 2.2 % to 16.1 %. Because we found similar results, we 
report the pooled results. Subjects characteristics before and after imputation are shown in 
Supplementary Table 2.1.1. Statistical analyses were performed using the Statistical Package 
of Social Sciences version 21.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Characteristics of the mothers and their children are presented in Table 2.1.2. Mean (±SD) 
maternal energy intake was 2,073 kcal per day (±543). Mean protein intake in these mothers 
was 76.6 g (±20.4), which provided on average 15 % of total energy intake. Animal protein 
intake provided 9 % of total energy intake, and vegetable protein intake provided 6 %. No dif-
ferences were observed in maternal energy and protein intake between mothers of children 
with and without kidney follow up measurements (data not shown). 
27
Maternal protein intake and childhood kidney health
2.1
Table 2.1.1. Subject characteristics (N=3,650)1
Subject characteristics
Maternal characteristics
Maternal age (y) 31.1 (4.7)
Gestational age at intake (weeks) 13.5 (9.8, 22.9)
Maternal body mass index at enrolment (kg/m2) 22.6 (18.4, 34.4)
Nulliparous (%) 59.4
Education level (%)
- No higher education 44.9
- Higher education 55.1
Ethnicity (%)
- Dutch 64.3
- Turkish 5.1
- Moroccan 3.5
- Surinamese or Dutch Antilles 7.9
- Other Western 12.5
- Other non-Western 6.7
Smoking during pregnancy (%)
- Never 76.2
- Until pregnancy was known 9.6
- Continued 14.2
Alcohol during pregnancy (%)
- Never 37.9
- Until pregnancy was known 14.5
- Continued 47.6
Folic acid supplements use (%)
- No 23.2
- Start 1st to 10 weeks 31.0
- Start periconceptional 45.8
Pre-pregnancy comorbidities (%) 1.6
Maternal diet
Total energy intake (kcal) 2,073 (543)
Protein (g/d)2
- Total 76.6 (20.4)
- Animal 46.9 (15.4)
- Vegetable 29.9 (9.2)
Protein intake (E %) 15.0 (2.5)
Carbohydrate intake (E %) 48.5 (6.3)
Fat intake (E %) 36.3 (5.5)
Infant characteristics
Girls (%) 50.1
Dutch ethnicity (%) 65.8
Gestational age at birth (wk) 40.1 (36.1, 42.4)
Birth weight (g) 3,469 (538)
Breastfeeding (%)
- Exclusive ≥4 months 25.5
- Partial ≥4 months 64.6
- Never or ≤4 months 9.9
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Table 2.1.2 shows that in the multivariable adjusted models higher maternal total protein 
intake in the fi rst trimester was associated with higher childhood eGFRcreat (0.06 (95 % CI 0.01, 
0.12) ml/min/1.73m2 per gram of protein intake). Stronger associations were observed for fi rst 
trimester maternal vegetable protein intake with childhood eGFRcreat (0.22 (95 % CI 0.10, 0.35) 
ml/min/1.73m2 per gram of vegetable protein intake). Maternal animal protein intake was not 
signifi cantly associated with childhood eGFRcreat. Furthermore maternal protein intake was 
not signifi cantly associated with kidney volume, eGFRcystC or risk of microalbuminuria. In line 
with our eGFR fi ndings, fi rst trimester maternal total protein intake and vegetable protein 
intake were associated with lower levels of childhood creatinine (-0.02 (95 % CI -0.04, -0.01) 
μmol/l and (-0.07 (95 % CI -0.11, -0.03) μmol/l per gram of total and vegetable protein intake), 
but not with cystatin C (Supplementary Table 2.1.2).
After additional adjustment for child protein intake at the age of 1 year, the multivariable 
associations of maternal protein intake with kidney outcomes did not change (Supplemen-
tary Table 2.1.3). We did not observe signifi cant interactions between maternal total protein 
intake and sex, birthweight, gestational age, maternal ethnicity or child BSA in the models 
with kidney outcomes. Results of the sensitivity analyses in Dutch mothers only are presented 
in Supplementary Table 2.1.4 showing similar patterns as in the full group, however in this 
group we also observed an association between higher animal protein intake and a higher 
eGFRcystC.
Table 2.1.1. Subject characteristics (N=3,650)1 (continued)
Subject characteristics
Child protein intake at 1 y (g/d) 25.1 (29.4)
Child characteristics at 6 y visit
Age (y) 6.1 (5.6, 7.3)
Height (cm) 119.1 (5.6)
Weight (kg) 22.9 (3.8)
Body mass index (kg/m2) 16.1 (1.7)
Body surface area (m2) 0.90 (0.08)
Screen time (hour/day) 1.3 (0.3, 4.6)
Kidney volume (cm3) 119 (23)
Creatinine (μmol/l) 37.1 (5.4)
Cystatin C (μg/l) 784 (83)
eGFRcreat (ml/min/1.73m2) 120 (16)
eGFRcystC (ml/min/1.73m2) 103 (15)
Microalbuminuria (%) 7.2
1 Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. Values are based on imputed data. Abbreviations: eG-
FRcreat, estimated glomerular fi ltration rate based on creatinine levels; eGFRcystC, estimated glomerular fi ltration rate based 
on cystatin C levels. 2unadjusted for energy intake.
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DISCUSSION
In this large population-based prospective cohort study, we observed that a higher mater-
nal intake of total and vegetable protein, but not animal protein, during fi rst trimester of 
pregnancy is associated with higher eGFRcreat, but not with kidney size, eGFRcystC or microalbu-
minuria in school-age children. The observed diff erences in eGFR related to maternal protein 
intake with eGFR were small. These diff erences may be without clinical consequence at an 
individual level, but may be relevant on a population level. 
Historical cohort studies suggest that adult off spring of mothers who were exposed to 
severe undernutrition during their pregnancy have increased risk of cardiovascular and renal 
disease.28 During the winter 1944–1945 the western part of the Netherlands was struck by a 
period of severe food scarcity, where the daily rations dropped to 400–800 calories.29 Follow 
up studies among adults whose mothers were exposed to the famine during their pregnancy, 
showed an increased risk for having microalbuminuria in adults whose mothers were ex-
posed to the famine during mid-gestation.2 Blood pressure was also higher in adults whose 
pregnant mothers where exposed to the famine. The variation in blood pressure depended 
on the timing mothers were exposed to the famine, with strongest associations on blood 
pressure for famine during late gestation.29 Rooseboom et al. 29 postulated that it might be 
the macronutrient composition rather than the quantity of a pregnant woman’s diet that 
aff ects the child’s blood pressure in later life. Blood pressure was especially higher in adults 
whose mothers ate small amounts of protein in relation to carbohydrate during the third 
trimester of pregnancy.30 Interestingly, a study in Aberdeen showed higher blood pressure 
Table 2.1.2. Associations of maternal protein intake during pregnancy with childhood kidney outcomes1
Kidney volume
cm3
N=3,344
eGFRcreat
ml/min/1.73 m²
N=2,494
eGFRcystC
ml/min/1.73 m²
N=2,500
Microalbuminuria
Odds ratio
N=3,515
Basic model2
Total protein intake (g)5 0.09 (0.06, 0.11)4 0.08 (0.06, 0.11)4 0.04 (-0.01, 0.09) 1.00 (0.99, 1.01)
Animal protein intake (g)5 0.08 (0.05, 0.10)4 0.06 (0.04, 0.09)4 0.04 (-0.01, 0.09) 1.00 (0.99, 1.01)
Vegetable protein intake (g)5 0.18 (0.12, 0.23)4 0.28 (0.23, 0.33)4 0.03 (-0.08, 0.14) 1.00 (0.99, 1.01)
Multivariable adjusted model3
Total protein intake (g)5 0.03 (-0.03, 0.08) 0.06 (0.01, 0.12)4 0.03 (-0.03, 0.08) 1.00 (0.99, 1.01)
Animal protein intake (g)5 0.02 (-0.04, 0.08) 0.05 (-0.01, 0.10) 0.03 (-0.03, 0.08) 1.00 (0.99, 1.01)
Vegetable protein intake (g)5 0.05 (-0.08, 0.18) 0.22 (0.10, 0.35)4 0.01(-0.11, 0.13) 1.00 (0.97, 1.02)
1Values are based on multivariable linear or logistic regression models and refl ect diff erences or odds ratios and 95 % 
confi dence intervals in kidney volume and function measures per gram increase of protein intake. Basic model2 is adjusted 
for child’s sex and age at 6-year visit. Multivariable adjusted model3 is adjusted for child’s sex, age at 6 year visit, maternal 
characteristics (age, body mass index before pregnancy, weight gain during pregnancy, gestational age at intake), socio-
demographic factors (ethnicity, education), maternal lifestyle (smoking, and alcohol consumption during pregnancy, folic 
acid intake during pregnancy), pre-pregnancy comorbidities, and child characteristics (birthweight adjusted for gesta-
tional age, breastfeeding, body surface area, and screen time at the age of 6y). Models with animal protein intake were 
additionally adjusted for vegetable protein intake and vice versa. 4p <0.05. 5Protein intakes are energy-adjusted using the 
nutrient residual method. Abbreviations: eGFRcreat, estimated glomerular fi ltration rate based on creatinine levels; eGFRcystC, 
estimated glomerular fi ltration rate based on cystatin C levels.  
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in adults who were exposed to a low animal protein and corresponding high carbohydrate 
diet in utero.31 
The mechanisms by which maternal undernutrition aff ects kidney development in the off -
spring may include developmental adaptations that lead to smaller kidneys with a reduced 
number of nephrons, which in turn lead to glomerular hyperfi ltration and sclerosis.3 Increased 
fi ltration through each glomerulus leads to hypertrophy and hyperfi ltration injury, which is 
marked by the onset of microalbuminuria, and may eventually lead to a reduction in renal 
function.3, 32, 33 The renal eff ects of undernutrition depend upon its timing during gestation 
and the nutrients balance.2 
Thus far, not much is known about common, contemporary nutritional exposures during 
pregnancy that aff ect off spring kidney health. Studies in animals have shown that under-
nutrition, mainly protein restriction, of pregnant rats raises blood pressure in the off spring 
permanently.34, 35 Also, maternal protein restriction in rats infl uences on off spring kidney 
structure and function, it promotes a reduction in nephron number that is associated with 
reduction of GFR in postnatal life.36 In the same population-based cohort as the current 
study, we did not observe any association between maternal protein intake during the fi rst 
trimester of the pregnancy with blood pressure in 6 years old children.37
In the current study, we observed that fi rst trimester maternal protein intake was positively 
associated with eGFRcreat in 6 years old children. Our results are in line with results from stud-
ies performed in rats5 and sheep.38 We did not fi nd an association of maternal fi rst trimester 
protein intake with childhood microalbuminuria. It may be that the eff ects of impaired kid-
ney growth on microalbuminuria may not be detectable during childhood, but may become 
evident later in life. Fetal adverse exposures can be compensated for many years before the 
adverse outcomes are present.39 
In our study population, the associations with eGFR were stronger for vegetable than for 
animal protein intake during pregnancy. Previous studies in adults also reported diff erent 
associations for animal versus vegetable protein on kidney health.7, 8 A mechanism through 
which animal and vegetable protein may diff erentially aff ect eGFR is via diff erences in amino 
acid composition. Experimental studies have shown that diff erent types of amino acids have 
diff erent renal impact.40 However further studies need to explore the mechanisms underlying 
the associations of specifi cally vegetable proteins with childhood kidney function outcomes.
Nephrogenesis requires a fi ne balance of many factors that can be disturbed by intra-
uterine growth restriction, leading to a low nephron endowment.41 Because nephrogenesis 
continues until 36 weeks of gestation and largely ceases thereafter, adverse exposures during 
this critical period may lead to impaired kidney development.42, 43 A previous study suggested 
that adult hypertension programmed by maternal exposure to a low protein diet is linked to 
marked changes in the renal expression of the glucocorticoid receptor, 11 β -hydroxysteroid 
dehydrogenase and components of the renin-angiotensin system. In addition, protein restric-
tion during pregnancy could aff ect the growth hormone-insulin-like growth factor and the 
prostaglandins axis in the off spring.38 Welham et al. suggested that maternal diet programs 
the embryonic kidney, altering cell turnover and gene expression at a time when nephrons 
and glomeruli have yet to form.44 
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Some methodological issues need to be discussed. A major strength of our study is the 
prospective design from fetal life onwards within a large population-based cohort. Our analy-
ses were based on 3,650 mother-child pairs. We used FFQs to assess maternal diet during the 
fi rst pregnancy trimester. Although the FFQ yielded valid estimates of nutrient intakes when 
validated against 3-days 24-hours recalls, measurement error may still have occurred. One 
of the limitations in our study is that the FFQ was validated only in Dutch women. However, 
a sensitivity analysis in Dutch mothers only revealed similar results as in the whole group. 
Unfortunately, we did not have information about child protein intake at a later stage in 
childhood. In a subgroup of children of the present study group (N=2,193) we had dietary 
data at the age of 1 year. When we adjusted our models additionally for child protein intake 
at the age of 1 year, the regression coeffi  cients remained similar in this subgroup, suggesting 
that child protein intake at the age of 1 year does not aff ect the association between maternal 
protein intake and childhood kidney function. This is in line with previous observations in this 
population that infant protein intake was not associated with kidney health.26 
We performed detailed measurements of childhood kidney outcomes. Because nephron 
number cannot be studied in vivo, we used kidney size as a measure of kidney develop-
ment employing ultrasound as a reliable method to measure kidney volume.13 Kidney size 
is also correlated with the number of glomeruli and can be used in epidemiological studies 
as a measure of kidney development.45 Glomerular enlargement due to hyperfi ltration may 
also increase kidney volume.46 The estimation of GFR in children remains challenging. Blood 
creatinine is most commonly used to calculate eGFR. We used the Schwartz formula based on 
creatinine levels and height, which was previously validated in a pediatric population.15 In ad-
dition to blood creatinine levels, we also measured blood cystatin C levels to calculate eGFR 
based on cystatin C levels using Zappitelli’s formula.16, 47 Interestingly, in our population, ma-
ternal protein intake was associated with creatinine-based eGFR, but not with cystatin-based 
eGFR. Our results are in line with those from a trial in adults with chronic kidney disease, in 
which protein intake aff ected creatinine but not cystatin C concentrations.48 Further stud-
ies are needed to evaluate the mechanism explaining these diff erences. Microalbuminuria 
was evaluated using urine albumin-creatinine ratio from a random urine sample.49 Finally, 
although we performed adjustment for a large number of potential maternal and childhood 
confounders, residual confounding by other lifestyle factors, might still be present. Residual 
confounding may also be present because of measurement error in several unhealthy life 
style behaviors such as underreporting of smoking and alcohol consumption. Since the main 
outcomes were correlated, we did not adjust for multiple comparisons. However, we may 
have observed false positive associations due to the multiple tests that were performed. 
CONCLUSION
In conclusion, results from this large prospective study suggests that higher fi rst trimester 
maternal intake of total and vegetable protein is associated with a higher eGFR in their 
children at school-age. These fi ndings are important from an etiological perspective. Further 
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studies are needed to investigate the underlying mechanisms. Although longitudinal stud-
ies suggest that risks factors for kidney diseases track from childhood to adulthood, follow 
up studies are needed to explore whether protein intake in pregnancy aff ects risk of kidney 
diseases in adulthood.
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Supplementary Table 2.1.1. Observed and imputed subject’s characteristics (N=3,650)
Observed Imputed
Maternal characteristics
Maternal age (y) 31.1 (4.7) 31.1 (4.7)
Gestational age at intake (weeks) 13.8 (9.8, 23.5) 13.5 (9.8, 22.9)
Maternal body mass index at enrolment (kg/m2) 22.5 (18.3, 34.2) 22.6 (18.4, 34.4)
Missing, (%) 15.3
Nulliparous (%) 59.5 59.4
Missing, (%) 0.2
Educational level, (%)
- No higher education 43.2 44.9
- Higher education 54.1 55.1
Missing, (%) 2.7
Ethnicity (%)
- Dutch 63.9 64.3
- Turkish 5.0 5.1
- Moroccan 3.5 3.5
- Surinamese or Dutch Antilles 7.8 7.9
- Other Western 12.5 12.5
- Other non-Western 6.7 6.7
Missing, (%) 0.6
Smoking during pregnancy, (%)
- Never smoked 69.3 76.2
- until pregnancy was known 8.8 9.6
- Continued 12.9 14.2
Missing, (%) 9.0
Alcohol during pregnancy, (%)
- Never alcohol in pregnancy 34.4 37.9
- Until pregnancy was known 13.1 14.5
- Continued 42.7 47.6
Missing, (%) 9.8
Folic acid supplement use, (%)
- No 13.8 23.2
- Start 1st to 10 weeks 25.2 31.0
- Start periconceptional 40.2 45.8
Missing, (%) 20.8
Prepregnancy comorbidities (%) 1.6 1.6
Missing, (%) 28.7
Maternal diet
Total energy intake (kcal) 2,073 (543) NI
Protein (g/d)1
- Total 76.6 (20.4) NI
- Animal 46.9 (15.4) NI
- Vegetable 29.9 (9.2) NI
Protein (E%) 15.0 (2.5) NI
Carbohydrates (E%) 48.5 (6.3) NI
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Supplementary Table 2.1.1. Observed and imputed subject’s characteristics (N=3,650) (continued)
Observed Imputed
Fat (E%) 36.3 (5.5) NI
Missing, % -
Infant characteristics
Girls, (%) 50.1 NI
Dutch ethnicity (%) 66.2 65.8
Missing, (%) 0.5
Gestational age at birth (wk) 40.1 (36.1, 42.4) 40.1 (36.1, 42.4)
Missing, (%) -
Birth weight, (g) 3,469 (538) 3,469 (538)
Missing, (%) 0.02
Breastfeeding (%)
- Exclusive ≥4 months 21.6 25.5
- Partial ≥4 months 55.2 64.6
- Never or ≤4 months 7.4 9.9
Missing, (%) 15.8
Child protein intake at 1 y (g/d) 26.6 (29.6) NI
Missing, (%) 39.9
Child characteristics at 6 y visit
Age (years) 6.1 (5.6 - 7.3) NI
Height (cm) 119.1 (5.6) 119.1 (5.6)
Missing, % 0.2
Weight (kg) 22.9 (3.8) 22.9 (3.8)
Missing, (%) 0.2
Body mass index, (kg/m2) 16.1 (1.7) 16.1 (1.7)
Missing, (%) 0.2
Body surface area, (m2) 0.90 (0.08) 0.90 (0.08)
Missing, (%) 0.2
Screen time (hour/day) 1.3 (0.3, 4.7) 1.3 (0.3, 4.6)
Missing, (%) 20.1
Kidney volume combined, (cm3) 119 (23) NI
Missing, (%) 8.4
Creatinine, (μmol/l) 37.1 (5.4) NI
Missing, % 31.5
Cystatin C (μg/l) 784 (83) NI
Missing, % 31.5
eGFRcreat, (ml/min/1.73m2) 120 (16) NI
Missing, (%) 31.7
eGFRcystC, (ml/min/1.73m2) 103 (15) NI
Missing, (%) 31.5
Microalbuminuria, (%) 7.2 NI
Missing, % 3.7
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Abbreviations: eG-
FRcreat, estimated glomerular fi ltration rate based on creatinine levels; eGFRcystC, estimated glomerular fi ltration rate based 
on cystatin C levels.1unadjusted for energy intake. NI - not imputed. 
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Supplementary Table  2.1.2. Associations of maternal protein intake during pregnancy with childhood 
creatinine and cystatin C1
Serum creatinine
(umol/l)
N=2,500
Serum creatinine
(umol/l)
adjusted for 
children protein 
intake at the age 
of 1 year
N=1,205
Serum cystatin C
(μg/l)
N=2,500
Serum cystatin C
(μg/l)
adjusted for 
children protein 
intake at the age 
of 1 year
N=1,206
Total protein intake (g)2 -0.02 (-0.04, -0.01)3 -0.03 (-0.05, -0.01)3 -0.12 (-0.41, 0.17) -0.03 (-0.46, 0.39)
Animal protein intake (g)2 -0.01 (-0.03, 0.004) -0.03 (-0.06, -0.01)3 -0.13 (-0.42, 0.16) -0.11 (-0.49, 0.27)
Vegetable protein intake (g)2 -0.07 (-0.11, -0.03)3 -0.08 (-0.13, -0.03)3 0.05 (-0.60, 0.69) 0.14 (-0.68, 0.45)
1Values are based on multivariable linear regression models and refl ect diff erences or odds ratios and 95 % confi dence 
intervals in kidney volume and function measures for an increase in protein intake (g/d). The model is adjusted for child’s 
sex, age at 6 year visit, maternal characteristics (age, body mass index before pregnancy, weight gain during pregnancy, 
gestational age at intake), maternal lifestyle (alcohol consumption, smoking during pregnancy, folic acid intake during 
pregnancy), socio-demographic factors (ethnicity, education), prepregnancy comorbidities, and child characteristics 
(breastfeeding, birthweight adjusted for gestational age, body surface area, and screen time at the age of 6y, child protein 
intake at 1 year). Models with animal protein intake were additionally adjusted for vegetable protein intake and vice versa. 
Protein intake is used as continuous variable in the regression models. 2Protein intakes are energy-adjusted using the 
nutrient residual method. 3p <0.05. 
Supplementary Table  2.1.3. Associations of maternal protein intake during pregnancy with childhood 
kidney outcomes, additionally adjusted for child protein intake at the age of 1 year (N=2,193)1
Kidney volume
Diff erence (95 % CI) 
cm3
N=1,603
eGFRcreat
Diff erence (95 % CI)
ml/min/1.73 m²
N=1,204
eGFRcystC
Diff erence (95 % CI)
ml/min/1.73 m²
N=1,206
Microalbuminuria
Odds ratio (95 % CI)
N=1,713
Total protein intake (g)2 0.03 (-0.06, 0.11) 0.11 (0.02, 0.19)3 0.02 (-0.06, 0.09) 1.00 (0.98, 1.02)
Animal protein intake (g)2 0.04 (-0.03, 0.12) 0.12 (0.05, 0.20)3 0.02 (-0.05, 0.10) 1.00 (0.99, 1.02)
Vegetable protein intake (g)2 -0.01 (-0.17, 0.16) 0.30 (0.13, 0.45)3 0.001 (-0.17, 0.17) 1.00 (0.99, 1.03)
1Values are based on multivariable linear or logistic regression models and refl ect diff erences or odds ratios and 95 % 
confi dence intervals in kidney volume and function measures for an increase in protein intake (g/d). The model is ad-
justed for child’s sex, age at 6 year visit, maternal characteristics (age, body mass index before pregnancy, weight gain 
during pregnancy, gestational age at intake), maternal lifestyle (alcohol consumption, smoking during pregnancy, folic 
acid intake during pregnancy), socio-demographic factors (ethnicity, education), pre-pregnancy comorbidities, and child 
characteristics (breastfeeding, birthweight adjusted for gestational age, body surface area, and screen time at the age of 
6y and child protein intake at 1 year). Models with animal protein intake were additionally adjusted for vegetable protein 
intake and vice versa. Protein intake is used as continuous variable in the regression models. 2Protein intakes are energy-
adjusted using the nutrient residual method. 3p <0.05. Abbreviations: eGFRcreat, estimated glomerular fi ltration rate based 
on creatinine levels; eGFRcystC, estimated glomerular fi ltration rate based on cystatin C levels. 
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ABSTRACT 
Background: Folate, vitamin B12 and homocysteine concentrations during pregnancy are 
important factors for early development and may persistently infl uence kidney function in 
the off spring. We examined the associations of folate, vitamin B12, and homocysteine concen-
trations during pregnancy with kidney outcomes in school-aged children.
Study design: Population-based prospective cohort study from fetal life onwards.
Settings & participants: This study was performed among 4,226 pregnant women and their 
children. 
Predictors: Folate, vitamin B12 and homocysteine blood concentrations measured in early 
pregnancy (median gestational age 13.2 weeks (25th to 75th percentiles 12.2, 14.8) and at birth 
(cord blood).
Outcomes & measurements: At the median age of 6.0 years (25th to 75th percentiles 5.9, 
6.3) we measured combined kidney volume with ultrasound, estimated glomerular fi ltration 
rate based on creatinine (eGFRcreat) and cystatin C (eGFRcystC) concentrations and microalbu-
minuria. 
Results: We observed that higher maternal folate concentrations were associated with larger 
childhood combined kidney volume, whereas higher maternal vitamin B12 concentrations 
were associated with higher childhood eGFRcystC (p-values <0.05). These associations were 
independent of homocysteine concentrations. Higher maternal homocysteine concentra-
tions were associated with smaller combined kidney volume and lower childhood eGFRcystC 
(p-values <0.05). The association of maternal homocysteine concentrations with childhood 
eGFRcystC was largely explained by combined kidney volume. Higher cord blood homocyste-
ine concentrations were associated with larger combined kidney volume and lower eGFRcystC 
(p-values <0.05). Folate, vitamin B12 or homocysteine concentrations were not associated 
microalbuminuria. 
Limitations: Observational study, so causality cannot be established. 
Conclusion: Our fi ndings suggest that folate, vitamin B12 and homocysteine concentrations 
during fetal life are associated with off spring kidney development. However, the eff ect sizes 
are small. Further studies are needed to replicate these fi ndings and assess the causality and 
consequences for kidney health in later life.
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INTRODUCTION
Adverse fetal nutritional exposures may have persistent consequences for kidney health in 
later life. Specifi cally, suboptimal nutritional exposures during fetal life may aff ect nephro-
genesis, leading to a reduced number of nephrons and smaller kidneys, which subsequently 
leads to glomerular hyperfi ltration and sclerosis.1, 2 The importance of early life nutrition for 
later kidney outcomes is illustrated by studies showing both associations of severe maternal 
undernutrition, preterm birth, and low birth weight with the risk of kidney disease in adult-
hood.3, 4, 5 
Little is known about specifi c maternal nutritional exposures that persistently infl uence 
off spring kidney development.4, 6 Folate is an essential B-vitamin, important for cell growth 
and replication; along with vitamin B12, it is a key methyl donor in several reactions, including 
the production of thymidine for DNA synthesis, polyamine synthesis and biosynthesis of me-
thionine from homocysteine.7–9 Folate and vitamin B12 contribute to lowering homocysteine 
concentrations (Figure 2.2.1).10 Animal studies indicate that elevated homocysteine concen-
trations may lead to glomerular damage, and folic acid supplementation lowers creatinine 
concentration and urinary albumin excretion induced by hyperhomocysteinemia.11 Also, 
studies in adults have shown associations of elevated homocysteine concentrations with an 
accelerated decline in kidney function.12 Based on these fi ndings, we hypothesized that lower 
folate and vitamin B12 concentrations and higher homocysteine concentrations during fetal 
life may aff ect nephrogenesis and lead to smaller kidneys with a lower kidney function. 
Thus, we examined, in a population-based prospective cohort study among 4,226 mothers 
and their children the associations of folate, vitamin B12 and homocysteine concentrations 
during fi rst trimester of pregnancy and at birth with kidney outcomes in school-aged chil-
dren.
Figure 2.2.1. Folate, vitamin B12 and homocysteine metabolism 
5-Methyl- 
TH-Folate 
TH-Folate 
Vitamin B12 
Methyl- 
Vitamin B12
Methionine 
Methionine 
synthase 
5,10 Methylene-
TH-Folate 
Homocysteine
Schematic representation of homocysteine metabolism. Folate and vitamin B12 work closely together on homocysteine 
metabolism, handing off  methyl groups to each other. TH-Folate is converted to 5, 10-Methylene-TH-Folate which is fur-
ther reduced to 5- Methyl-TH-Folate. With the demethylation of 5-Methyl-TH-Folate, the methyl group is donated into the 
methionine cycle. Vitamin B12 is involved directly in the transfer of the methyl group to homocysteine, through methionine 
synthase. Methionine synthase is a vitamin B12- dependent enzyme that catalyzes the formation of methionine from ho-
mocysteine. The methionine cycle begins with homocysteine that accepts the methyl group from the folate pool through 
5- Methyl-TH-Folate. Abbreviations: TH- Folate, Tetrahydro- folate.
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METHODS
Subjects
This study was embedded in the Generation R Study, an ongoing population-based prospec-
tive cohort study from fetal life onward in Rotterdam, the Netherlands.13 The study was con-
ducted according to the guidelines of the Helsinki Declaration and approved by the Medical 
Ethics Committee of Erasmus University Medical Center, Rotterdam (MEC-2007–413). Written 
informed consent was obtained from parents. At the age of 6 years, all participating children 
and their mothers were invited to participate in detailed measurements. Of 8,879 mother pre-
natally included in the study, 6,128 had measurements on folate, vitamin B12 or homocysteine 
concentrations. Of the 6,057 singleton live-born children from mothers with nutritional data 
available, 70 % of them attended the follow-up visit at the age of 6 years. Children with suc-
cessful information on at least one of the kidney measurements were included in the study 
(N=4,226) (Supplementary Figure 2.2.1). 
Maternal and fetal folate, vitamin B12 and homocysteine concentrations
In early pregnancy (median gestational age 13.2 weeks (25th to 75th percentile 12.2, 14.8)) 
venous samples were drawn and stored at room temperature before being transported to 
the regional laboratory for processing. Cord blood samples were taken immediately after 
delivery (40.1 weeks of gestation, 25th to 75th percentiles 39.3–41.0 weeks).13 To analyze folate, 
vitamin B12 and homocysteine concentrations, ethylenediaminetetraacetic acid plasma 
samples (folate, homocysteine) and serum samples (vitamin B12) were picked and transported 
to the Department of Clinical Chemistry at the Erasmus University Medical Centre, Rot-
terdam. After thawing, folate, homocysteine and vitamin B12 concentrations were analyzed 
using an immunoelectrochemoluminescence assay on the Architect System. These methods 
are described in detail elsewhere.14 Folate concentrations were defi ned as: defi cient when <7 
nmol/l or normal when ≥7 nmol/l.15  
Folic acid supplement intake
Information on folic acid supplement use (0.4–0.5 mg) and the initiation of supplementa-
tion was obtained by questionnaires at the enrolment of the study. We categorized folic acid 
supplement use into three groups: 1) periconceptional use; 2) start when pregnancy was 
known; 3) no use during pregnancy. Detailed information on folic acid supplement intake is 
described elsewhere.16 
Childhood kidney outcomes
As previously described, children’s kidney outcomes were assessed at a median age of 6.0 
years (25th to 75th percentiles 5.9, 6.3) in a dedicated research center in the Sophia Children’s 
Hospital in Rotterdam.17 Kidney volume was measured with ultrasound, using an ATL-Philips 
HDI 5000 instrument (Seattle, WA, USA), equipped with a 2.0–5.0 MHz curved array trans-
ducer. We calculated kidney volume using the equation for a prolate ellipsoid.18 Combined 
kidney volume was calculated by summing right and left kidney volume. Non-fasting blood 
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samples were drawn by antecubital venipuncture. Creatinine concentrations were measured 
with enzymatic methods and cystatin C concentrations with a particle enhanced immuno-
turbidimetric assay (using Cobas 8000 analyzers, Roche, Almere, the Netherlands). Estimated 
glomerular fi ltration rate (eGFR) was calculated according to the revised Schwartz 2009 
formula: eGFRcreat = 36.5 * (height (cm) / serum creatinine (μmol/l)),19 and Zappitelli’s formula 
based on cystatin C concentrations: eGFRcystC = 75.94/[CysC1.17].20 Urine creatinine (μmol/l) and 
urine albumin (μg/l) concentrations were determined with a Beckman Coulter AU analyzer, 
creatinine concentrations were measured with the Jaff e reaction. Microalbuminuria was de-
fi ned as an albumin-creatinine ratio between 2.5 and 25 mg/mmol for boys and between 3.5 
and 25 mg/mmol for girls.21 Detailed information on kidney measures is described elsewhere.17
Covariates
We obtained information on maternal age, ethnicity, educational level, vitamins supplemen-
tation, smoking and alcohol usage during pregnancy using questionnaires.13 We assessed 
maternal energy intake at enrollment using a validated semi-quantitative food frequency 
questionnaire.22 Ethnicity and educational level were defi ned according to the classifi cation 
of Statistics Netherlands.23 Maternal pre-pregnancy height and weight were self-reported and 
pre-pregnancy body mass index (BMI) was calculated (kg/m2). We measured maternal blood 
pressure in early and late pregnancy by using the Omron 907 automated digital oscillometric 
spygmanometer.24 Information on child’s sex, birthweight and gestational age was available 
from medical records and hospital registries. We obtained information on breastfeeding from 
postnatal questionnaires.17 At the age of 6 years, child height and weight were determined 
and BMI (kg/m2), and body surface area (BSA) (m2) were calculated.25 
Statistical analysis 
First, we performed a non-response analysis by comparing subject characteristics between 
children with and without follow-up kidney measurements by using T-tests, Chi-square tests 
and Mann-Whitney tests. Second, we used multivariable linear and logistic regression models 
to assess the associations of maternal fi rst trimester and fetal cord blood folate, vitamin B12 
and homocysteine concentrations with combined kidney volume, eGFRcreat and eGFRcystC, 
and risk of microalbuminuria in school-aged children. Folate, vitamin B12 and homocysteine 
concentrations were analysed continuously per standard deviation (SD)- increase to enable 
comparison between eff ect estimates. The regression models were fi rst adjusted for child’s 
sex, and age at kidney measurements (basic models), and subsequently also for maternal 
age, education, body mass index, blood pressure, vitamins supplementation, smoking, 
alcohol use, energy intake during pregnancy, and for child’s birth weight, gestational age at 
birth, breastfeeding, and body surface area at the age of 6 years (confounder model). These 
covariates were included in the regression models based on previous literature or a change 
of >10 % in eff ect estimates. To explore if the observed associations of folate and vitamin B12 
with kidney outcomes were independent of homocysteine concentrations, we additionally 
adjusted the confounder model for homocysteine concentrations (homocysteine model). In 
a separate model we additionally adjusted the kidney function measures for kidney volume 
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(kidney size model). Third, we used the same models to assess the associations between 
maternal folic acid supplement intake and childhood kidney outcomes. These analyses, were 
performed among 3,291 mothers who had information on folic acid supplements. Whether 
the associations of folate or vitamin B12 or homocysteine and kidney outcomes diff ered by 
sex or birthweight we analyzed the interaction terms. Since the interaction terms were not 
signifi cant we did not stratify our analyses. To prevent bias associated with missing data, we 
used multiple imputations (N=5) only for covariates with missing values on the basis of the 
correlation of missing variables with other participant characteristics, according to the Mar-
kov Chain Monte Carlo method.26 Detailed information on multiple information procedure 
is given in Supplementary Materials. Subjects characteristics before and after imputation 
and the percentages of missing values are shown in Supplementary Table 2.2.1. Statistical 
analyses were performed using the Statistical Package of Social Sciences version 21.0 (IBM 
SPSS Statistics for Windows, Armonk, NY: IBM Corp). 
RESULTS
Subject characteristics
Table 2.2.1 shows the characteristics of the study population stratifi ed on folate concentra-
tions. The values are based on the original data. Supplementary Table 2.2.2 shows folate, 
vitamin B12 and homocysteine concentrations per supplement group of folic acid use. The 
correlation coeffi  cients of the investigated variables are given in Supplementary Table 2.2.3. 
Maternal and cord blood folate, vitamin B12 and homocysteine concentrations correlation 
coeffi  cients ranged from r = 0.34 to 0.46. Maternal folate and vitamin B12 concentrations were 
weakly negatively correlated with child height and weight, whereas homocysteine concen-
trations were weakly positively correlated with child height and weight (Supplementary 
Table 2.2.3). Results from the non-response analyses are given in Supplementary Table 2.2.4. 
Mothers whose children had kidney follow-up measurements had higher folate and vitamin 
B12, and lower homocysteine concentrations compared to mothers whose children did not 
have kidney follow-up measurements.
Maternal and fetal folate, vitamin B12 and homocysteine concentrations and 
childhood kidney outcomes
Table  2.2.2 shows that a 1-SD higher maternal folate concentration was associated with a 
1.16 cm3 (95 % confi dence interval (CI) 0.47, 1.85) larger childhood combined kidney volume. 
No other associations were observed of maternal folate concentrations with other kidney 
outcomes. A 1-SD higher maternal vitamin B12 concentration was associated with 1.00 ml/
min/1.73m2 (95 % CI 0.43, 1.57) higher childhood eGFRcystC. The eff ects estimates were similar 
when we adjusted for maternal homocysteine concentrations (homocysteine models) and 
childhood combined kidney volume (kidney size model). Similarly, a 1-SD higher maternal 
homocysteine concentration was associated with a -1.44 cm3 (95 % CI -2.09, -0.79) smaller 
combined kidney volume and a -0.57 ml/min/1.73m2 (95 % CI -1.13, -0.02) lower childhood 
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Table 2.2.1. Subject characteristics according to folate levels (N=4,149)
Folate defi cient
(<7 nmol/l)
N=277
Normal folate
(≥7 nmol/l)
N=3,872
Maternal characteristics
Maternal age (y) 27.5 (5.6) 30.6 (4.8)
Pre-pregnancy body mass index(kg/m2) 23.7 (21.0, 27.0) 22.6 (20.8, 25.2)
Missing, n (%) 60 (22) 629 (16)
Gestational age at intake (wk) 14.2 (12.6, 16.1) 13.2 (12.1, 14.6)
Early pregnancy systolic blood pressure (mmHg) 114 (12) 116 (12)
Missing, n (%) 3 (1) 21 (0.5)
Early pregnancy diastolic blood pressure (mmHg) 67 (10) 68 (10)
Missing, n (%) 3 (1) 21 (0.5)
Late pregnancy systolic blood pressure (mmHg) 119 (12) 119 (12)
Missing, n (%) 14 (5.1) 120 (3.1)
Late pregnancy diastolic blood pressure (mmHg) 69 (10) 69 (9)
Missing, n (%) 14 (5.1) 120 (3.1)
Education level, n (%)
- No higher education 204 (73.6) 1,824 (47.1)
- Higher education 44 (15.9) 1,867 (48.2)
Missing, n (%) 29 (10.5) 181 (4.7)
Ethnicity, n (%)
- European 99 (35.7) 2,555 (66.0)
- Non-European 167 (60.3) 1,264 (32.6)
Missing, n (%) 11 (4) 53 (1.4)
Smoking during pregnancy, n (%)
- Never & until pregnancy was known 154 (55.6) 2,940 (75.9)
- Continued 90 (32.5) 545 (14.1)
Missing, n (%) 33 (11.9) 387 (10)
Alcohol during pregnancy, n (%)
- Never & until pregnancy was known 171 (61.7) 1,939 (50.1)
- Continued 59 (21.3) 1,515 (39.1)
Missing, n (%) 47 (17) 418 (10.8)
Folic acid supplements use, n (%)
- No 166 (59.9) 515 (13.3)
- Start 1st to 10 weeks 23 (8.3) 1,022 (26.4)
- Start periconceptional 15 (5.4) 1,492 (38.5)
Missing, n (%) 73 (26.4) 843 (21.8)
Maternal calories intake (kcal) 2,010 (599) 2,050 (549)
Missing, n (%) 76 (27.4) 700 (18.1)
Vitamin supplements use, n (%)
- No 211 (76.2) 2,193 (56.6)
- Yes 17 (6.1) 1,114 (28.8)
Missing, n (%) 49 (17.7) 565 (14.6)
Folate plasma concentrations (nmol/l) 6.1 (5.4, 6.6) 17.9 (11.6, 25.4)
Vitamin B12 serum concentrations (pmol/l) 154.5 (115.8, 200.8) 173.0 (131.0, 232.0)
Missing, n (%) 7 (2.5) 235 (6.1)
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eGFRcystC. The association of maternal homocysteine concentrations with childhood eGFRcystC 
was largely explained by combined kidney volume. None of the exposures were associated 
with the risk of microalbuminuria. The results from basic models are given in Supplementary 
Table 2.2.5.
Table 2.2.3 shows that a 1-SD higher fetal cord blood homocysteine concentrations was 
associated with a 1.27 cm3 (95 % CI 0.46, 2.08) larger childhood combined kidney volume and 
a -1.02 ml/min/1.73m2 (95 % CI -1.76, -0.28) lower eGFRcystC. The eff ect estimates on eGFRcystC re-
Table 2.2.1. Subject characteristics according to folate levels (N=4,149) (continued)
Folate defi cient
(<7 nmol/l)
N=277
Normal folate
(≥7 nmol/l)
N=3,872
Homocysteine plasma concentrations (μmol/l) 8.4 (7.1, 10.0) 6.8 (6.0, 7.8)
Missing, n (%) 7 (2.5) 62 (1.6)
Infant characteristics
Girls, n (%) 135 (48.7) 1,941 (50.1)
Gestational age at birth (wk) 40.1 (39.3, 40.9) 40.1 (39.3, 41.0)
Birth weight (g) 3,309 (596) 3,447 (548)
Missing, n (%) - 4 (0.1)
Breastfeeding, n (%)
- No 20 (7.2) 231 (6.0)
- Yes 178 (64.3) 2,940 (75.9)
Missing, n (%) 79 (28.5) 701 (18.1)
Cord blood folate concentrations (nmol/l) 16.6 (13.2, 21.2) 21.1 (16.5, 27.3)
Cord blood vitamin B12 concentrations (pmol/l) 267.5 (210.3, 379.8) 302.0 (220.0, 422.0)
Child characteristics at 6y visit
Age (y) 6.1 (5.9, 6.5) 6.0 (5.9, 6.2)
Height (cm) 120.0 (6.9) 119.3 (5.9)
Missing, n (%) - 6 (0.2)
Weight (kg) 23.0 (20.8, 27.5) 22.4 (20.4, 25.0)
Missing, n (%) - 6 (0.2)
Body mass index (kg/m2) 16.1 (15.3, 18.1) 15.8 (15.0, 16.9)
Missing, n (%) - 6 (0.2)
Body surface area (m2) 0.9 (0.1) 0.9 (0.1)
Missing, n (%) - 6 (0.2)
Combined kidney volume (cm3) 122.1 (28.6) 120.0 (23.2)
Creatinine (μmol/l) 38.2 (5.2) 37.3 (5.6)
Cystatin C (mg/l) 783.1 (74.8) 784.4 (81.8)
eGFRcreat (ml/min/1.73m2) 117.1 (14.8) 119.2 (16.3)
eGFRcystC (ml/min/1.73m2) 102.4 (13.5) 102.5 (14.7)
Microalbuminuria, n (%) 24 (8.7) 279 (7.2)
Values are frequency counts and percentages for categorical variables, means (SD) for continuous variables with a normal 
distribution, or medians (25th to 75th percentiles) for continuous variables with a skewed distribution. Values are based on 
the original data. Folate defi ciency was defi ned as a folate concentration <7 nmol/l. Abbreviations: eGFRcreat estimated glo-
merular fi ltration rate calculated based on creatinine blood levels: eGFRcystC estimated glomerular fi ltration rate calculated 
based on cystatin C blood levels.
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mained similar after additional adjustment for kidney size. Higher cord blood homocysteine 
concentrations was associated with lower eGFRcreat after additional adjustment for kidney size 
-0.91 ml/min/1.73m2 (95 % CI -1.71, -0.12). No other associations were observed of cord blood 
folate and vitamin B12 concentrations with kidney outcomes. The results from basic models 
are given in Supplementary Table 2.2.6.
Table 2.2.4 shows that there was no association between folic acid supplement intake and 
kidney outcomes. 
Table 2.2.2. Associations of maternal folate, vitamin B12 and homocysteine concentrations during preg-
nancy with kidney outcomes at the age of 6 years (N=4,226)
First trimester maternal 
concentrations
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
Combined kidney 
volume (cm3)
eGFRcreat
(ml/min/1.73m2)
eGFRcystC  
(ml/min/1.73m2)
Folate
Confounder Model 1.16 (0.47, 1.85)**
N=3,818
0.01 (-0.65, 0.67)
N=2,792
-0.03 (-0.63, 0.58)
N=2,792
0.97 (0.85, 1.10)
N=4,011
Homocysteine Model 1.02 (0.32, 1.72)**
N=3,757
-0.06 (-0.74, 0.61)
N=2,741
-0.11 (-0.73, 0.51)
N=2,741
0.96 (0.84, 1.10)
N=3,944
Kidney size Model -0.24 (-0.90, 0.42)
N=2,601
0.01 (-0.59, 0.61)
N=2,601
0.95 (0.83, 1.09)
N=3,686
Vitamin B12 
Confounder Model 0.47 (-0.17, 1.11)
N=3,666
0.20 (-0.43, 0.83)
N=2,663
1.00 (0.43, 1.57)**
N=2,663
1.06 (0.95, 1.19)
N=3,849
Homocysteine Model 0.20 (-0.45, 0.85)
N=3,563
0.22 (-0.42, 0.85)
N=2,579
0.95 (0.36, 1.53)**
N=2,579
1.07 (0.96, 1.20)
N=3,737
Kidney size Model 0.09 (-0.53, 0.71)
N=2,481
0.96 (0.39, 1.52)**
N=2,482
1.08 (0.96, 1.21)
N=3,538
Homocysteine 
Confounder Model -1.44 (-2.09, -0.79)**
N=3,779
-0.55 (-1.15, 0.05)
N=2,755
-0.57 (-1.13, -0.02)*
N=2,755
1.08 (0.98, 1.20)
N=3,969
Kidney size Model -0.35 (-0.97, 0.28)
N=2,566
-0.52 (-1.10, 0.06)
N=2,556
1.10 (0.99, 1.23)
N=3,649
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Confounder model is adjusted for maternal 
characteristics (age, body mass index before pregnancy, blood pressure in early pregnancy, ethnicity, education, vitamins 
supplementation, smoking, alcohol consumption, energy intake during pregnancy), and child characteristics (birthweight, 
gestational age, sex, breastfeeding, age, and body surface area at 6-year visit). Homocysteine model is confounder model 
additionally adjusted for homocysteine concentrations during pregnancy. Kidney size model is confounder model ad-
ditionally adjusted for child combined kidney volume. *p <0.05, **p <0.01. Maternal folate, vitamin B12 and homocysteine 
concentrations were analyzed per 1 standard deviation in folate, vitamin B12 and homocysteine. Abbreviations: eGFRcreat, 
estimated glomerular fi ltration rate based on creatinine concentrations; eGFRcystC, estimated glomerular fi ltration rate 
based on cystatin C concentrations.
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DISCUSSION
Results from this population-based prospective cohort study suggest that maternal higher fo-
late and lower homocysteine concentrations are associated with larger childhood combined 
kidney volume, whereas maternal higher vitamin B12 and lower homocysteine concentrations 
are associated with higher childhood eGFRcystC. Lower cord blood homocysteine concentra-
tions were associated with smaller childhood combined kidney volume and higher eGFR.
Interpretation of main fi ndings
Various lines of investigation suggest that an adverse fetal nutrition may have persistent 
consequences for kidney health in later life. Because nephrogenesis continues until 36 weeks 
of gestation and mainly stops thereafter, adverse fetal nutritional exposures may have a per-
sistent impact on kidney function in later life.1, 2 For this study, we specifi cally hypothesized 
Table 2.2.3. Associations of cord blood folate, vitamin B12 and homocysteine concentrations with kidney 
outcomes at the age of 6 years (N=2,674)
Cord blood 
concentrations
(Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
Combined kidney 
volume (cm3)
eGFRcreat
(ml/min/1.73m2)
eGFRcystC 
(ml/min/1.73m2)
Folate
Confounder Model 0.36 (-0.46, 1.18)
N=2,384
0.41 (-0.36, 1.17)
N=1,753
0.51 (-0.19, 1.22)
N=1,753
0.97 (0.83, 1.13)
N=2,517
Homocysteine Model 0.74 (-0.12, 1.59)
N=2,308
0.30 (-0.50, 1.10)
N=1,702
0.31 (-0.43, 1.06)
N=1,702
1.00 (0.85, 1.17)
N=2,439
Kidney size Model 0.37 (-0.39, 1.14)
N=1,625
0.48(-0.24, 1.20)
N=1,625
0.97 (0.82, 1.14)
N=2,306
Vitamin B12
Confounder Model -0.47 (-1.27, 0.34)
N=2,413
-0.52 (-1.28, 0.25)
N=1,776
0.35 (-0.36, 1.05)
N=1,776
0.99 (0.84, 1.15)
N=2,548
Homocysteine Model -0.05 (-0.90, 0.80)
N=2,271
-0.76 (-1.56, 0.05)
N=1,674
0.17 (-0.58, 0.92)
N=1,674
1.00 (0.85, 1.17)
N=2,403
Kidney size Model -0.48 (-1.25, 0.29)
N=1,645
0.42 (-0.30, 1.14)
N=1,645
1.00 (0.85, 1.18)
N=2,335
Homocysteine
Confounder Model 1.27 (0.46, 2.08)**
N=2,311
-0.74 (-1.53, 0.06)
N=1,705
-1.02 (-1.76, -0.28)**
N=1,705
1.09 (0.95, 1.26)
N=2,443
Kidney size Model -0.91 (-1.71, -0.12)*
N=1,579
-1.14 (-1.89, -0.39)**
N=1,579
1.09 (0.93, 1.27)
N=2,236
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Confounder model is adjusted for maternal 
characteristics (age, body mass index before pregnancy, blood pressure in late pregnancy, ethnicity, education, vitamins 
supplementation, smoking and alcohol consumption, energy intake during pregnancy), and child characteristics (birth-
weight, gestational age, sex, breastfeeding, age and body surface area at the age of 6year visit). Homocysteine model is 
confounder model additionally adjusted for homocysteine concentrations at birth. Kidney size model is confounder model 
additionally adjusted for child combined kidney volume. *p <0.05, **p <0.01. Cord blood folate, vitamin B12 and homo-
cysteine concentrations were analyzed per 1 standard deviation in folate, vitamin B12 and homocysteine. Abbreviations: 
eGFRcreat, estimated glomerular fi ltration rate based on creatinine concentrations; eGFRcystC, estimated glomerular fi ltration 
rate based on cystatin C concentrations.
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that low folate and vitamin B12 concentrations and higher homocysteine concentrations dur-
ing fetal life may aff ect nephrogenesis and lead to persistently smaller kidneys with a lower 
kidney function.
Not many studies have explored the eff ect of maternal folate concentrations or folic acid 
supplements during pregnancy on childhood kidney measures. Results from a trial follow-up 
study in Rural Bangladesh among 3,267 mother and their 4 to 5 year old children indicated no 
eff ect of early maternal multiple micronutrient supplementation or food supplementation 
with iron and folate on off spring’s kidney volume.27 A study exploring the eff ect of maternal 
folic acid supplements during pregnancy has suggested that folic acid supplements alone 
are a risk factor for congenital anomalies of kidney and urinary tract.28 In our study only 
few children (N=6) had evidence of congenital kidney abnormalities. We did not observe 
an association of maternal folic acid supplements or cord blood folate concentrations with 
childhood kidney volume. However, our results suggest that higher maternal folate concen-
trations in early pregnancy are associated with a larger childhood combined kidney volume, 
independent of homocysteine concentrations. Specifi cally, folate concentrations in early 
pregnancy may aff ect child kidney volume. Compared to selfreported folic acid intake, folate 
concentrations are more directly linked to the body’s biological processes; because they can 
be used to measure actual folate status with greater precision, slight eff ects could potentially 
be detected. This could account for maternal folate concentrations being associated with 
childhood kidney volume as opposed to folic acid supplementation. Furthermore, statisti-
Table 2.2.4. Associations of maternal folic acid supplements intake during pregnancy with kidney mea-
surements at the age of 6 years (N=3,291)
Folic acid supplement use
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=3,179
Combined kidney 
volume (cm3)
N=3,025
eGFRcreat
(ml/min/1.73m2)
N=2,211
eGFRcystC  
(ml/min/1.73m2)
N=2,215
Basic Model
No (N=696) -1.63 (-3.78, 0.53) 0.18 (-1.58, 1.94) 0.50 (-1.14, 2.14) 0.77 (0.54, 1.10)
Started when pregnancy was 
known (N=1,065)
-0.89 (-2.74, 0.97) -0.64 (-1.94, 0.66) 0.86 (-0.56, 2.28) 0.71 (0.52, 0.97)
Started periconceptional 
(N=1,530)
Reference Reference Reference Reference
Confounder Model
No (N=696) -2.08 (-4.32, 0.15) 1.47 (-0.61, 3.55) 1.14 (-0.79, 3.08) 0.82 (0.54, 1.25)
Started when pregnancy was 
known (N=1,065)
-1.49 (-3.16, 0.18) -0.27 (-1.83, 1.30) 1.17 (-0.29, 2.63) 0.75 (0.54, 1.03)
Started periconceptional 
(N=1,530)
Reference Reference Reference Reference
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Basic model is adjusted for child’s sex and 
age at 6-year visit. Confounder model is additionally adjusted for maternal characteristics (age, body mass index before 
pregnancy, blood pressure in early pregnancy, ethnicity, education, vitamin supplements, smoking, alcohol consumption, 
energy intake during pregnancy), and child characteristics (birthweight, gestational age, breastfeeding, age and body 
surface area at the age of 6y). *p <0.05. Abbreviations: eGFRcreat, estimated glomerular fi ltration rate based on creatinine 
concentrations; eGFRcystC, estimated glomerular fi ltration rate based on cystatin C concentrations.
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cally, a continuous measure of folate concentration has greater power to detect diff erences 
compared to the categorical approach of folic acid supplementation. A study among young 
adults suggested that folic acid supplementation in individuals with low dietary folic acid 
content was associated with decreased creatinine concentrations and subsequently higher 
eGFRs.29 Another study among 6 to 8 year old children in rural Nepal suggested that maternal 
folic acid supplementation reduced the risk of microalbuminuria.30 
Folate is important for homocysteine metabolism. Animal studies have shown that folic 
acid supplementation attenuates glomerular damage induced by hyperhomocysteinemia.11 
In our study, we did not observe any association of maternal or cord blood folate concentra-
tions or folic acid supplementations with eGFR or microalbuminuria in 6 year old children. 
The diff erences in results may be explained by the diff erent study populations. Together with 
folate, vitamin B12 leads to lower homocysteine concentrations. We observed that higher vita-
min B12 concentrations during fetal life were associated with a higher eGFRcystC. To our knowl-
edge, no previous studies have explored the relationship of vitamin B12 with kidney function 
measures in children. Epidemiological studies in patients with kidney failure suggested that 
parenteral vitamin B12 lowers homocysteine concentrations independent of serum vitamin 
B12 concentrations.31 Previous studies have shown that after adjustment for homocysteine 
concentrations, higher vitamin B12 concentrations were associated with an increased risk 
of albuminuria. In individuals with high baseline homocysteine concentrations, increased 
vitamin B12 was associated with reduced kidney function.32 Specifi cally, among patients with 
hyperhomocysteinemia, vitamin B supplementation modulated cystatin C concentrations.33 
In our study the observed associations of vitamin B12 with eGFR were independent of homo-
cysteine concentrations. We did not observe any association of vitamin B12 concentrations 
with childhood microalbuminuria. Further research is needed to observe the eff ect of early 
life folate and vitamin B12 with kidney outcomes in later life. 
Our results suggest that higher maternal homocysteine concentrations were associated 
with smaller combined kidney volume and lower eGFR. Nephrogenesis starts in early preg-
nancy; therefore high homocysteine concentrations since early pregnancy may infl uence on 
nephron formation. As we have previously reported, kidney size is positively correlated with 
eGFR.34 We observed that an increased kidney volume explained the associations of mater-
nal homocysteine concentrations with kidney function. Higher cord blood homocysteine 
concentrations were associated with larger combined kidney volume and lower eGFR. Our 
fi ndings suggest time specifi c eff ects of homocysteine concentrations on kidney volume. It 
may be that a constant exposure to high homocysteine concentration induces kidney hyper-
trophy in originally smaller kidneys. 
To our knowledge, there are no other studies in children to compare these fi ndings. In 
line with our fi ndings, in adults, elevated homocysteine concentrations are associated 
with an accelerated decline in eGFR.12, 35 Our fi ndings are also supported by experimental 
studies in rats suggesting that elevated homocysteine concentrations can be an important 
pathogenic factor in glomerular damage.11 Results from a study among 340 adults aged 50–75 
years, suggested that increased homocysteine concentrations infl uence on the development 
of microalbuminuria.36 In our study, we did not observe any association of homocysteine con-
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centrations with the risk of microalbuminuria. Perhaps the eff ects of impaired kidney growth 
on microalbuminuria are undetectable during childhood, and become apparent in later life. 
Altogether, these fi ndings suggest time specifi c eff ects of homocysteine concentrations 
on kidney development. Previous studies using data from the same cohort have observed 
that low folate and high homocysteine but not vitamin B12 concentrations were associated 
with fetal growth restriction.14 However, a previous study did not observe any association of 
maternal folate, vitamin B12 or homocysteine concentrations with blood pressure at the age 
of 6 years.16
Although we observed small eff ect sizes, our results may be important from a population-
based perspective. In the Netherlands, food supplies are not fortifi ed with folic acid, but 
women are advised to use folic acid supplements (400 μg/day) prior to and up to week 10 to12 
of pregnancy. Although results presented in this study do not provide a basis to make causal 
statements, they support population strategies to increase folate and vitamin B12 concentra-
tions and subsequently lower homocysteine concentrations in pregnant women.
Potential mechanisms
From our observational study, it is not possible to establish the causality for the observed 
associations. However, some biological mechanisms may link maternal folate, vitamin B12 
and homocysteine concentrations with childhood kidney outcomes. Both observational and 
experimental studies relate low folate and high homocysteine concentrations with endothe-
lial dysfunction and altered vascular development.12, 37–39 High homocysteine concentrations 
negatively aff ect endothelial vasodilatation via inhibition of the generation of endothelial 
mediators and promotion of adhesion between neutrophil and endothelial cells.40 It is also 
possible that homocysteine decreases adenosine levels in plasma and interstitial tissue and 
induces proliferation and apoptosis of glomerular mesangial cells, renal vascular injury would 
directly result.41 Suboptimal vascular development and endothelial dysfunction could lead to 
hypertension in childhood which could be a predictor to chronic kidney diseases in later 
life.2, 4 Also, maternal diet predetermines the embryonic kidney by changing cell turnover 
and gene expression during a period when nephrons and glomeruli are as yet unformed.42 
The concentration of the methyl donors folate and vitamin B12 having a benefi cial eff ect 
on childhood kidney outcomes supports the hypothesis that epigenetic changes program 
future kidney health. 
Methodological considerations
To our knowledge, this is the largest prospective population-based cohort study examin-
ing the associations of folate, vitamin B12 and homocysteine concentrations during fetal 
life with childhood kidney outcomes. We measured folate, vitamin B12 and homocysteine 
concentrations during early pregnancy and at birth, assessing critical periods of kidney 
development. Cord blood folate and vitamin B12 concentrations were higher compared to 
maternal concentrations. This has also been reported previously in literature.43 According 
to Dutch recommendations, we assume that after gestational week 10 to12, women did not 
take folic acid supplements. We obtained information for maternal folic acid supplementa-
Chapter 2.2
52
tion using questionnaires. Mothers not taking folic acid supplements in pregnancy had 
lower folate and higher homocysteine concentrations compared with mothers who started 
folic acid supplements periconceptional. Furthermore, these mothers had lower folate and 
vitamin B12 and higher homocysteine concentrations as compared with normal ranges of 
these concentrations during pregnancy.44 Of the total group of singleton live-born children 
70 % had available information on kidney measurements. Selection bias in follow-up studies 
largely results from loss to follow-up rather than from non-response at baseline. Mothers of 
children without follow-up kidney measurements had lower folate and higher homocysteine 
concentrations, were younger, smoked more frequently and had lower alcohol intake dur-
ing pregnancy and there were more with a non-European origin compared with mothers of 
children with available kidney measurements. Loss to follow-up would lead to selection bias 
if the associations of maternal fi rst trimester micronutrient concentrations with childhood 
kidney outcomes were diff erent between those included and those not included in the fi nal 
analyses. Because this is diffi  cult to determine, selection bias cannot be excluded. 
We performed detailed measurements on kidney outcomes. Kidney size was used as a 
measure of kidney development. Ultrasonography is reliable for measuring kidney volume.18 
Kidney size correlates with the number of glomeruli; in epidemiologic studies, it can be used 
to measure kidney development.1 BSA is a well-known predictor of kidney volume. Replace-
ment of BSA with BMI did not change the results. Similar eff ect estimates to combined kidney 
volume were observed when we explored Kidney volume/BSA as an additional outcome.45 
To estimate GFR, we used the Schwartz formula based on creatinine concentrations and 
height, and also Zappitelli’s formula based on cystatin C concentrations.19, 20 In our analy-
ses we observed small diff erences in eff ect estimates between eGFRcreat and eGFRcystC, with 
slightly stronger eff ect estimates for eGFRcystC. A random urine sample was used to evalu-
ate the presence of microalbuminuria.46 Our results apply to a relatively healthy sample of 
pregnant women and children. It may be that our fi ndings could underestimate the true 
eff ect measures. Therefore, the generalizability of our results to other populations should be 
interpreted with caution. Last, although we adjusted for many potential maternal and child-
hood confounders, residual confounding (eg, like child nutritional status) can still be present. 
In conclusion, results from our prospective study, suggest that folate, vitamin B12, and 
homocysteine concentrations during fetal life aff ect off spring kidney measures. However, 
the eff ect sizes presented in the study are small, and results could refl ect confounding. Our 
fi ndings should be considered as hypothesis generating and require further replication. Ad-
ditional follow-up studies are warranted to examine the long term consequences for the risk 
of kidney diseases in later life.
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Supplementary Information. Statistical analyses.
Multiple Imputation: We imputed missing data of the covariates using multiple imputa-
tions.1 The percentages of missing values for the covariates within the population for analysis 
were lower than 20 %. Five imputed datasets were created and analyzed.1–3 The effi  ciency of 5 
imputations is >96 %. For the multiple imputation, we used Fully Conditional Specifi cation, an 
iterative of the Markov chain Monte Carlo approach. For each variable, the fully conditional 
specifi cation method fi ts a model using all other available variables in the model as predic-
tors, and then imputes missing values for the specifi c variable being fi t. In the imputation 
model, we included all covariates, plus maternal height and weight measured at enrollment, 
household income, paternal age, ethnicity and education level, breastfeeding duration and 
child height, weight and BMI. These variables were added to increase plausibility of miss-
ing at random assumption. Additionally, in the imputation model, we added the studied 
determinants and outcomes as prediction variables only; they were not imputed themselves. 
Therefore, numbers of participant are diff erent in each model.
Supplementary Figure 2.2.1. Flowchart of study participants


Children participating in 6-years follow up 
measurements 
/
/ Excluded twins pregnancies (N=70) and 
loss to follow up (N=1)  
/ Excluded children who did not 
attend follow up visits at the age of 6 years 
/ Excluded children without any kidney 
measurements (N=21), congenital kidney 
abnormalities (N=6) or with high albumin to 
creatinine ratio (N=14) 
Final population for analysis 
/
With measurements on: 
Kidney volume  N=3,885 
eGFRcreat    N=2,842 
eGFRcystC   N=2,842 
Microalbuminuria N=4,087 
 Singleton life born children 
/
Mothers with measurements of folate or 
vitamin B12 or homocysteine concentrations 
/
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Supplementary Table 2.2.1. Subject characteristics (N=4,226)
Observed Imputed
Maternal characteristics
Maternal age (y) 30.4 (4.9) NI
Pre-pregnancy body mass index(kg/m2) 22.6 (20.8, 25.4) 22.6 (20.8, 25.4)
Missing, n (%) 701 (16.6) -
Gestational age at intake (wk) 13.2 (12.2, 14.8) NI
Early pregnancy systolic blood pressure (mmHg) 116 (12) 116 (12)
Missing, n (%) 27 (0.6) -
Early pregnancy diastolic blood pressure (mmHg) 68 (10) 68 (10)
Missing, n (%) 27 (0.6) -
Late pregnancy systolic blood pressure (mmHg) 119 (12) 119 (12)
Missing, n (%) 137 (3.2) -
Late pregnancy diastolic blood pressure (mmHg) 69 (9) 69 (9)
Missing, n (%) 137 (3.2) -
Education level, n (%) 
- No higher education 2,060 (48.7) 2,223 (52.6)
- Higher education 1,952 (46.2) 2,003 (47.4)
Missing, n (%) 214 (5.1) -
Ethnicity, n (%)
- European 2,701 (63.9) 2,738 (64.8)
- Non-European 1,460 (34.5) 1,488 (35.2)
Missing, n (%) 65 (1.6) -
Smoking during pregnancy, n (%)
- Never & until pregnancy was known 3,148 (74.5) 3,509 (83.0)
- Continued 647 (15.3) 717 (17.0)
Missing, n (%) 431 (10.2) -
Alcohol during pregnancy, n (%)
- Never & until pregnancy was known 2,147 (50.8) 2,440 (57.7)
- Continued 1,602 (37.9) 1,786 (42.3)
Missing, n (%) 477 (11.3) -
Folic acid supplements use, n (%)
- No 696 (16.5) NI
- Start 1st to 10 weeks 1,065 (25.2) NI
- Start periconceptional 1,530 (36.2) NI
Missing, n (%) 935 (22.1) -
Maternal calories intake (kcal) 2,045 (553) 2,037 (558)
Missing, n (%) 795 (18.8) -
Vitamin supplements use, n (%)
- No 2,443 (57.8) 2,889 (68.4)
- Yes 1,152 (27.3) 1,337 (31.6)
Missing, n (%) 631 (14.9) -
Folate plasma concentrations (nmol/l) 16.8 (10.7, 24.8) NI
Vitamin B12 serum concentrations (pmol/l) 171 (129.0, 228.0) NI
Homocysteine plasma concentrations (μmol/l) 6.9 (6.0, 8.0) NI
Infant characteristics
Girls, n (%) 2,121 (50.2) NI
Gestational age at birth (wk) 40.1 (39.3, 41.0) NI
Birth weight (g) 3,437 (551) 3,437 (551)
Missing, n (%) 4 (0.1) -
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Supplementary Table 2.2.1. Subject characteristics (N=4,226) (continued)
Observed Imputed
Breastfeeding, n (%)
- No 257 (6.1) 329 (7.8)
- Yes 3,172 (75.1) 3,897 (92.2)
Missing, n (%) 797 (18.8) -
Cord blood folate concentrations (nmol/l) 20.8 (16.2, 27.0) NI
Cord blood vitamin B12 concentrations (pmol/l) 299.0 (219.0, 419.0) NI
Cord blood homocysteine concentrations (μmol/l) 9.0 (7.5, 10.7) NI
Child characteristics at 6y visit
Age (y) 6.0 (5.9, 6.3) NI
Height (cm) 119.3 (5.9) 119.3 (5.9)
Missing, n (%) 6 (0.1) -
Weight (kg) 22.4 (20.4, 25.0) 22.4 (20.4, 25.0)
Missing, n (%) 6 (0.1) -
Body mass index (kg/m2) 15.8 (15.0, 16.9) 15.8 (15.0, 16.9)
Missing, n (%) 6 (0.1) -
Body surface area (m2) 0.9 (0.1) 0.9 (0.1)
Missing, n (%) 6 (0.1) -
Combined kidney volume (cm3) 120.0 (23.6) NI
Creatinine (μmol/l) 37.4 (5.6) NI
Cystatin C (mg/l) 784.4 (81.1) NI
eGFRcreat (ml/min/1.73m2) 119.1 (16.3) NI
eGFRcystC (ml/min/1.73m2) 102.4 (14.6) NI
Microalbuminuria, n (%) 307 (7.3) NI
Values are frequency counts and percentages for categorical variables, means (SD) for continuous variables with a normal 
distribution, or medians (25th to 75th percentiles) for continuous variables with a skewed distribution. Percentage of missing 
variables: maternal pre-pregnancy body mass index (16.6 %), early pregnancy systolic and diastolic blood pressure (0.6 %), 
late pregnancy systolic and diastolic blood pressure (3.2 %), educational level (5.1 %), ethnicity (1.6 %), smoking (10.2 %), 
alcohol consumption (11.3 %), calories intake (18.8 %), vitamin supplements use (14.9 %), birth weight (0.1 %), breastfeed-
ing (18.8 %), child height at measurement (0.1 %), weight at measurement (0.1 %), body mass index at measurement (0.1 %), 
and body surface area at measurement (0.1 %). Maternal age, gestational age at intake, gestational age at birth and gender 
had no missing values. Abbreviations: GFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels: eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. NI not imputed.
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Supplementary Table 2.2.2. Biomarkers concentrations per supplement group of folic acid (N=3,291)
Concentrations during 1st trimester
Folate
(nmol/l)
Vitamin B12
(pmol/l)
Homocysteine
(μmol/l)
Folic acid supplement use
No (N=696) 8.7 (7.0, 11.2) 158.0 (122.0, 213.0) 7.4 (6.3, 8.9)
Started when pregnancy was known (N=1,065) 17.7 (12.1, 23.7) 177.0 (131.0, 233.5) 6.9 (6.1, 8.0)
Started periconceptional (N=1,530) 22.7 (16.4, 28.7) 177.0 (134.0, 239.0) 6.7 (5.9, 7.6)
Cord blood concentrations
Folate
(nmol/l)
Vitamin B12
(pmol/l)
Homocysteine
(μmol/l)
Folic acid supplement use
No (N=425) 18.8 (14.6, 23.2) 289.0 (204.0, 404.0) 9.4 (8.0, 11.3)
Started when pregnancy was known (N=684) 20.2 (15.8, 26.5) 297.0 (216.0, 422.0) 9.1 (7.5, 216.0)
Started periconceptional (N=980) 22.7 (17.6, 28.6) 304.0 (224.8, 424.0) 8.8 (7.2, 10.4)
Values are medians (25th to 75th percentiles).
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Supplementary Table 2.2.4. Subject characteristics with and without kidney measurements (N=6,043)
Kidney 
measurements 
available
N=4,226
Without 
kidney
measurements
N=1,817 p-value
Maternal characteristics
Maternal age (y) 30.4 (4.9) 28.4 (5.2) <0.001
Pre-pregnancy body mass index(kg/m2) 22.6 (20.8, 25.4) 22.4 (20.5, 25.4) 0.5
Missing, n (%) 701 (16.6) 371 (20.4)
Gestational age at intake (wk) 13.2 (12.2, 14.8) 13.4 (12.2, 15.1) <0.001
Early pregnancy systolic blood pressure (mmHg) 116 (12) 115 (12) 0.03
Missing, n (%) 27 (0.6) 15 (0.8)
Early pregnancy diastolic blood pressure (mmHg) 68 (10) 68 (10) 0.06
Missing, n (%) 27 (0.6) 15 (0.8)
Late pregnancy systolic blood pressure (mmHg) 119 (12) 118 (12) <0.001
Missing, n (%) 137 (3.2) 177 (9.7)
Late pregnancy diastolic blood pressure (mmHg) 69 (9) 69 (10) <0.001
Missing, n (%) 137 (3.2) 177 (9.7)
Education level, n (%) <0.001
- No higher education 2,060 (48.7) 1,037 (57.1)
- Higher education 1,952 (46.2) 567 (31.2)
Missing, n (%) 214 (5.1) 213 (11.7)
Ethnicity, n (%) <0.001
- European 2,701 (63.9) 850 (46.8)
- Non-European 1,460 (34.5) 792 (43.6)
Missing, n (%) 65 (1.6) 175 (9.6)
Smoking during pregnancy, n (%) <0.001
- Never & until pregnancy was known 3,148 (74.5) 1,226 (67.5)
- Continued 647 (15.3) 356 (19.6)
Missing, n (%) 431 (10.2) 235 (12.9)
Alcohol during pregnancy, n (%) <0.001
- Never & until pregnancy was known 2,147 (50.8) 1,085 (59.7)
- Continued 1,602 (37.9) 471 (25.9)
Missing, n (%) 477 (11.3) 261 (14.4)
Folic acid supplements use, n (%) <0.001
- No 696 (16.5) 458 (25.2)
- Start 1st to 10 weeks 1,065 (25.2) 405 (22.3)
- Start periconceptional 1,530 (36.2) 456 (25.1)
Missing, n (%) 935 (22.1) 498 (27.4)
Maternal calories intake (kcal) 2,045 (553) 2,003 (586) 0.03
Missing, n (%) 795 (18.8) 583 (32.1)
Vitamin supplements use, n (%) <0.001
- No 2,443 (57.8) 1,107 (60.9)
- Yes 1,152 (27.3) 363 (20.0)
Missing, n (%) 631 (14.9) 347 (19.1)
Folate plasma concentrations (nmol/l) 16.8 (10.7, 24.8) 13.2 (8.8, 21.8) <0.001
Vitamin B12 serum concentrations (pmol/l) 171.0 (129.0, 228.0) 165.0 (123.0, 222.0) 0.05
Homocysteine plasma concentrations (μmol/l) 6.9 (6.0, 8.0) 7.0 (6.0, 8.1) 0.02
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Supplementary Table  2.2.4. Subject characteristics with and without kidney measurements (N=6,043) 
(continued)
Kidney 
measurements 
available
N=4,226
Without 
kidney
measurements
N=1,817 p-value
Infant characteristics
Girls, n (%) 2,121 (50.2) 863 (47.5) 0.07
Gestational age at birth (wk) 40.1 (39.3, 41.0) 40.0 (39.0, 41.0) <0.001
Birth weight (g) 3,437 (551) 3,379 (592) <0.001
Missing, n (%) 4 (0.1) 34 (1.9)
Breastfeeding (%) <0.001
- No 257 (6.1) 102 (5.6)
- Yes 3,172 (75.1) 924 (50.9)
Missing, n (%) 797 (18.8) 791 (43.5)
Cord blood folate concentrations (nmol/l) 20.8 (16.2, 27.0) 20.3 (16.0, 25.9) 0.08
Cord blood vitamin B12 concentrations (pmol/l) 299.0 (219.0, 419.0) 301.0 (211.8, 432.0) 0.4
Cord blood homocysteine concentrations (μmol/l) 9.0 (7.5, 10.7) 9.3 (7.6, 11.3) <0.001
Values are frequency counts and percentages for categorical variables, means (SD) for continuous variables with a normal 
distribution, or medians (25th to 75th percentiles) for continuous variables with a skewed distribution. Values are based on 
the original data.
Supplementary Table  2.2.5. Associations of maternal folate, vitamin B12 and homocysteine concentra-
tions during pregnancy with kidney outcomes at the age of 6 years (N=4,226)
First trimester maternal 
concentrations
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
Kidney volume
(cm3)
eGFRcreat
(ml/min/1.73m2)
eGFRcystC  
(ml/min/1.73m2)
Folate N=3,818 N=2,788 N=2,792 N=4,011
Basic Model 0.83 (0.10, 1.55)* 0.30 (-0.31, 0.91) 0.21 (-0.35, 0.76) 1.01 (0.90, 1.14)
Vitamin B12 N=3,666 N=2,659 N=2,663 N=3,849
Basic Model 0.21 (-0.52, 0.94) 0.28 (-0.34, 0.89) 1.11 (0.55, 1.67)** 1.07 (0.96, 1.20)
Homocysteine N=3,779 N=2,755 N=2,751 N=3,969
Basic Model -1.66 (-2.40, -0.93)** -0.78 (-1.37, -0.18)* -0.75 (-1.29, -0.20)** 1.07 (0.97, 1.19)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Basic model is adjusted for child’s sex and 
age at 6-year visit. *p <0.05, **p <0.01. Maternal folate, vitamin B12 and homocysteine concentrations were analyzed per 1 
standard deviation in folate, vitamin B12 and homocysteine. Abbreviations: eGFRcreat, estimated glomerular fi ltration rate 
based on creatinine concentrations; eGFRcystC, estimated glomerular fi ltration rate based on cystatin C concentrations.
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Supplementary Table 2.2.6. Associations of cord blood folate, vitamin B12 and homocysteine concentra-
tions with kidney outcomes at the age of 6 years (N=2,674)
Cord blood 
concentrations
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
Kidney volume
(cm3)
eGFRcreat
(ml/min/1.73m2)
eGFRcystC  
(ml/min/1.73m2)
Folate N=2,384 N=1,750 N=1,753 N=2,517
Basic Model 0.04 (-0.87, 0.94) 0.51 (-0.24, 1.25) 0.72 (0.03, 1.41)* 0.98 (0.84, 1.14)
Vitamin B12 N=2,413 N=1,772 N=1,776 N=2,548
Basic Model -0.93 (-1.82, -0.04)* -0.43 (-1.18, 0.33) 0.41 (-0.28, 1.10) 1.01 (0.88, 1.17)
Homocysteine N=2,311 N=1,702 N=1,705 N=2,443
Basic Model 1.25 (0.33, 2.16)** -1.06 (-1.85, -0.28)** -1.22 (-1.95, -0.50)** 1.07 (0.93, 1.23)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Basic model is adjusted for child’s sex and 
age at 6-year visit. *p <0.05, **p <0.01. Cord blood folate, vitamin B12 and homocysteine concentrations were analyzed 
per 1 standard deviation in folate, vitamin B12 and homocysteine. Abbreviations: eGFRcreat, estimated glomerular fi ltration 
rate based on creatinine concentrations; eGFRcystC, estimated glomerular fi ltration rate based on cystatin C concentrations.
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ABSTRACT 
Background: Maternal vitamin D defi ciency during pregnancy may impact fetal outcomes. 
Objective: To examine whether maternal 25-hydroxyvitamin D (25(OH)D) concentrations in 
pregnancy aff ect fetal growth patterns and birth outcomes.
Design: Population-based prospective cohort in Rotterdam, the Netherlands among 7,098 
mothers and their off spring. We measured 25(OH)D concentrations at a median gestational 
age of 20.3 weeks (range 18.5–23.3 weeks). Vitamin D concentrations were analyzed continu-
ously and in quartiles. Fetal head circumference, length and weight were estimated by re-
peated ultrasounds, preterm birth (gestational age <37 weeks) and small-size for gestational 
age (less than the fi fth percentile) were determined.
Results: Adjusted multivariate regression analyses showed that as compared to mothers 
with second trimester 25(OH)D concentrations in the highest quartile, those with 25(OH)D 
concentrations in the lower quartiles had off spring with third trimester fetal growth restric-
tion leading to a smaller birth head circumference, shorter birth length and lower weight at 
birth (all P values <0.05). Mothers who had 25(OH)D concentrations in the lowest quartile had 
increased risks of preterm delivery (Odds Ratio (OR) 1.72, 95 % Confi dence Interval (CI) 1.14, 
2.60) and small-size for gestational age children (OR 2.07, 95 % CI 1.33, 3.22). The estimated 
population attributable risks of 25(OH)D concentrations <50 nmol/L for preterm birth or 
small-size for gestational age were 17.3 % and 22.6 %, respectively. The observed associations 
were not based on extreme 25(OH)D defi ciency, but present within the common ranges.
Conclusions: Low maternal 25(OH)D concentrations are associated with proportional fetal 
growth restriction and with increased risks of preterm birth and small-size for gestational age 
at birth. Further studies are needed to investigate the causality of these associations and the 
potential for public health interventions.
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INTRODUCTION 
Vitamin D defi ciency is common and related to various non-communicable disease.1 An ac-
cumulating body of evidence suggest that vitamin D is also crucial for fetal development 
because of its important role during cell proliferation, diff erentiation and maturation pro-
cesses.2, 3 Suboptimal vitamin D concentrations may aff ect early organogenesis and subse-
quently aff ect later health and disease.4 Also, vitamin D is important for placental function, 
calcium homeostasis, and bone mineralization, which are all important determinants for fetal 
growth and development.5, 6 Thus far, most published studies focused on the associations of 
maternal vitamin D status during pregnancy with fetal development have been mainly based 
on birth weight and have shown inconsistent results.7–9 However, birth weight is just a proxy 
for fetal growth and development. Diff erent fetal growth patterns and body proportions 
may lead to the same birth weight. Not much is known about the direct eff ects of maternal 
vitamin D status on fetal growth and development patterns in healthy populations.8, 10–13 
The inconsistent results from previous studies may be explained by diff erences between 
study populations. Because ethnic diff erences in both vitamin D concentrations and birth 
outcomes have been reported, the eff ects of maternal vitamin D status on fetal outcomes 
may diff er between specifi c populations.14, 15 Based on previous studies suggesting that low 
vitamin D concentrations, may lead to suboptimal placentation and fetal skeletal growth, 
we hypothesized that low vitamin D concentrations may lead to fetal growth restriction and 
increased risks of adverse birth outcomes.
Therefore, we examined the associations of circulating 25-hydroxyvitamin D (25(OH)D) 
concentrations with repeatedly measured fetal growth characteristics during second and 
third trimester and the risks of adverse birth outcomes, in a multi-ethnic population-based 
prospective cohort study in 7,098 mother-off spring pairs. In addition, we explored whether 
adverse birth outcomes were associated with cord blood 25(OH)D concentrations.
METHODS
Design and study population 
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onwards in Rotterdam, the Netherlands.16 All children were born between 
April 2002 and January 2006. Enrolment in the study was aimed at early pregnancy, but was 
allowed until the birth of the child. The study protocol was approved by the local Medical 
Ethical Committee. Written consent was obtained from all participating mothers. Second 
trimester 25(OH)D concentrations were measured in 7,176 mothers. For the present study, we 
excluded pregnancies leading to twin births (N=77) and loss to follow-up at birth (N=1). Thus, 
the cohort for analysis comprised 7,098 mothers with any fetal or birth outcome available. 
(Supplementary Figure 2.3.1. Flowchart).
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Maternal and cord 25(OH)D blood concentrations
Maternal venous blood samples were collected in second trimester (median 20.3 weeks of 
gestation, range 18.5–23.3 weeks), whereas umbilical cord blood samples were collected im-
mediately after delivery (median 40.1 weeks of gestation, range 35.9–42.3 weeks).
Cord blood vitamin D concentrations represent neonatal vitamin D status at birth. Measure-
ments of 25(OH)D concentrations were conducted at the Eyles Laboratory at the Queensland 
Brain Institute, University of Queensland, Australia, in 2014. 
Total 25(OH)D was calculated as the sum of 25(OH)D2 and 25(OH)D3 measured in plasma as 
previously described.17 Samples were quantifi ed using isotope dilution liquid chromatogra-
phy-tandem mass spectrometry. The linearity of 25(OH)D concentration was assessed using 
matrix-matched calibration standards, with R2 values of >0.99 across the calibration range 
(10–125 nmol/L). Inter-assay inaccuracy and imprecision were assessed at four concentration 
levels for 25(OH)D3 (48.3, 49.4, 76.4, 139.2 nmol/L) and a single level (32.3 nmol/L) for 25(OH)D2 
using certifi ed reference materials and were excellent at all concentration levels tested. Inter-
assay inaccuracy and imprecision were both <10 % for 25(OH)D3 and <17 % for 25(OH)D2, re-
spectively. We categorized vitamin D status into quartiles (quartile 1: median (full range) 14.7 
nmol/L (1.5 to 24.1); quartile 2: 35.1 nmol/L (24.2 to 46.6); quartile 3: 59.0 nmol/L (46.7 to 73.7); 
quartile 4: 91.6 nmol/L (73.8 to 193.2)). Because optimal vitamin D concentrations remain a 
subject of debate,18, 19 we performed a sensitivity analysis by using cut-off s concentrations ac-
cording to previously used cut-off s and recommendations (severely defi cient: <25.0 nmol/L; 
defi cient: 25.0 to 49.9 nmol/L; suffi  cient: 50.0 to 74.9 nmol/L; optimal ≥75.0 nmol/L).18, 20–24
Fetal growth measurements
Fetal ultrasound examinations were carried out in two dedicated research centers in second 
(median 20.5 weeks of gestation, 95 % range 18.6–24.3) and third trimester (median 30.3 weeks 
of gestation, 95 % range 28.4–32.8).25 The fi rst trimester ultrasound was primarily used for 
establishing gestational age.26 In second and third trimester, we measured fetal head circum-
ference, abdominal circumference and femur length to the nearest millimeter using stan-
dardized ultrasound procedures.27 Estimated fetal weight was subsequently calculated using 
the formula of Hadlock et al.28 Longitudinal growth curves and gestational-age-adjusted 
standard deviation scores (SDS) were constructed for all fetal growth measurements.26 These 
gestational-age-adjusted SDS were based on reference growth curves from the whole study 
population, and represent the equivalent of z-scores.26
Birth outcomes
We obtained information about off spring sex, gestational age, head circumference, length 
and weight at birth from medical records.29 Because head circumference and length were 
not routinely measured at birth in each delivery center, fewer measurements were available 
(N=3,681 and N=4,533 for head circumference and length at birth, respectively), as compared 
to birth weight. Gestational-age-adjusted SDS for head circumference, length and weight 
were constructed using North European growth standards.30 We defi ned preterm birth as a 
gestational age of <37 weeks at birth, low birth weight as a birthweight <2500 grams, and 
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small-size for gestational age at birth as a gestational-age-adjusted birthweight below the 
5th percentile (-1.79 SD).
Covariates
We used questionnaires at enrollment in the study to collect information about maternal 
age, ethnicity, educational level, parity, the presence of anorexia, smoking, alcohol usage, 
folic acid and vitamins supplementation.29 Maternal energy, iron, zinc and calcium dietary 
intake during pregnancy was measured at enrollment with a validated semi-quantitative 
food frequency questionnaire.31 Ethnicity and educational level were defi ned according to 
the demographic classifi cation of Statistics Netherlands.32 Ethnicity was categorized in the 
following groups: European, Cape Verdean, Dutch Antillean, Moroccan, Surinamese, Turkish 
and Others. We measured maternal height and weight at enrollment and calculated body 
mass index (kg/m2). Information about gestational hypertensive disorders (gestational hy-
pertension, preeclampsia) and gestational diabetes was available from medical records.33 The 
date of blood sampling was categorized into summer, fall, winter, and spring, based on the 
European seasons. 
Statistical analysis 
First, we performed regression analyses to relate second trimester maternal 25(OH)D concen-
trations with fetal growth characteristics in second, and third trimester separately. Second, 
we assessed the associations of maternal 25(OH)D concentrations with longitudinally mea-
sured fetal head circumference, fetal femur length and body length at birth, and fetal weight, 
expressed as SDS, with the use of unbalanced repeated measurement regression analyses. 
These analyses enable optimal use of available data, taking into account correlations within 
subjects and assessing both time dependent and independent associations.34 Because body 
length cannot be estimated during fetal life, we used femur length in second and third 
trimester and body length at birth to assess length growth. We measured femur length to 
the nearest millimeter using standardized ultrasound procedures.27 For weight we used 
estimated fetal weight in second and third trimester and birth weight. Third, we used logistic 
regression models to assess the associations of maternal 25(OH)D concentrations with the 
risks of preterm birth, low birth weight, and small-size for gestational age. For all the analyses, 
25(OH)D concentrations were analyzed both continuously and by using quartiles. As sensitiv-
ity analysis, we also analysed 25(OH)D concentrations in groups of previously used and rec-
ommended cut-off s instead of quartiles.18, 20–24 We calculated the population attributable risk 
(PAR) for these outcomes with the following equation: PAR% = [(Ratetotal population - Rateunexposed)/
(Ratetotal population)]*100 %. Finally, we explored the associations of birth characteristics with 
cord blood 25(OH)D concentrations using linear regression models. All regression models 
were fi rst adjusted for season when blood samples were drawn and maternal ethnicity (basic 
models), and subsequently in addition for maternal age; education; parity; BMI at enrol-
ment; smoking; alcohol use; the presence of anorexia; folic acid and vitamins supplement 
use; energy and dietary iron, zinc and calcium dietary intake during pregnancy; gestational 
hypertensive disorders; and gestational diabetes (adjusted models). These covariates were 
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included in the models based on their associations on fetal and birth outcomes in previous 
studies, or a change in eff ect estimates of >10 %. Adding maternal nutritional data (dietary 
iron, zinc and calcium intake and vitamin supplements) did not materially change the eff ect 
estimates but slightly improved the model fi t (R2, -2log Likelihood or the Nagelkerk R2 values). 
Because of the strong associations of ethnicity with both 25(OH)D concentrations with and 
fetal outcomes, we fi rst adjusted the regression models for maternal ethnicity and second, 
we restricted the analyses to Europeans only, the largest ethnic subgroup in our cohort.35, 36 
P value of <0.05 was considered as statistically signifi cant. To adjust for multiple testing in 
the analyses of adverse birth outcomes with cord blood 25(OH)D concentrations, we applied 
Bonferroni correction considering a P value <0.025 (0.05/2) to be signifi cant. To diminish 
potential bias associated with attrition, missing values of covariates, were multiple imputed 
by generating 5 independent datasets using the Markov Chain Monte Carlo (MCMC) method. 
The multiple imputation procedure was based on the correlation between each variable with 
missing values and the other subject characteristics.37, 38 Statistical analyses were performed 
using SPSS version 21.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp). Subject 
characteristics before and after imputation, including the percentage of missing values are 
given in the Supplementary Table 2.3.1. The unbalanced repeated-measurements analysis, 
including the Prox Mixed module, was performed with the Statistical Analysis System (ver-
sion 9.3; SAS Institute Inc, Cary NC).
RESULTS
Subject characteristics
The median value (95 % range) for maternal 25(OH)D was 46.7 nmol/L (7.0, 119.4 nmol/L) 
(Table  2.3.1) Maternal and cord blood 25(OH)D concentrations were correlated (r  =  0.62, P 
value <0.01). Growth characteristics during second and third trimester and at birth are shown 
in Table 2.3.2. 
Supplementary Table 2.3.2 gives the subject characteristics for each quartile of 25(OH)D 
concentrations. We observed that mothers with a Turkish or Moroccan ethnicity had the low-
est 25(OH)D concentrations.
Maternal 25(OH)D concentrations and fetal growth characteristics
The associations of maternal 25(OH)D concentrations during pregnancy with longitudinally 
measured fetal head circumference, length and weight are shown in Figure 2.3.1. Compared 
with mothers with 25(OH)D concentrations in the highest quartile (range 73.8 to 193.2 nmol/L), 
those with 25(OH)D concentrations in the fi rst (range 1.5 to 24.1 nmol/L) and second (range 
24.2 to 46.6 nmol/L) quartiles had off spring with restricted fetal head circumference growth 
from second trimester onwards, leading to a smaller head circumference at birth (diff erences: 
-0.20 SDS 95 % Confi dence Interval (CI) (-0.29, -0.12) and -0.09 SDS 95 % CI (-0.17, -0.01) for fi rst 
and second quartile of 25(OH)D concentrations, respectively). The associations of second tri-
mester maternal 25(OH)D concentrations with fetal length growth and weight growth tended 
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Table 2.3.1. Subject characteristics (N=7,098)1
Characteristics
Maternal Characteristics
Age, mean (SD), y 29.7 (5.2)
Body mass index at enrolment, median (95 % range), kg/m2 23.7 (18.7, 36.3)
Gestational age at enrollment, median (95 % range), wk 13.9 (9.9, 22.9)
Nulliparous, No. (%) 3,987 (56.2)
Education level, No. (%)
- No higher education 4,204 (59.2)
- Higher education 2,894 (40.8)
Ethnicity, No. (%)
- European 4,069 (57.3)
- Cape Verdean 311 (4.4)
- Dutch Antillean 253 (3.5)
- Moroccan 471 (6.6)
- Surinamese 643 (9.1)
- Turkish 651 (9.2)
- Other 700 (9.9)
Presence of anorexia, No. (%)
- No 6,352 (89.5)
- Yes 503 (7.1)
- Maybe 243 (3.4)
Smoking during pregnancy, No. (%)
- Never 5,131 (72.3)
- Until pregnancy was known 665 (9.4)
- Continued 1,302 (18.3)
Alcohol consumption during pregnancy, No. (%)
- Never 3,493 (49.2)
- Until pregnancy was known 974 (13.7)
- Continued 2,631 (37.1)
Folic acid supplement use, No. (%)
- No 2,204 (31.0)
- Start in the fi rst 10 weeks 2,219 (31.3)
- Start periconceptional 2,675 (37.7)
Vitamin supplement use, No. (%)
- Yes 5,049 (71.1)
- No 2,049 (28.9)
Maternal energy intake (kcal) 2,039 (490)
Maternal zinc dietary intake (mg) 9.6 (1.6)
Maternal iron dietary intake (mg) 11.1 (2.1)
Maternal calcium dietary intake (mg) 1,087 (418)
Maternal 25(OH)D concentrations, median (95 % range), nmol/L 46.7 (7.0, 119.4)
- Severely defi cient (<25.0 nmol/L), No. (%) 1,855 (26.1)
- Defi cient (25.0 to 49.9 nmol/L), No. (%) 1,919 (27.1)
- Suffi  cient (50.0 to 74.9 nmol/L), No. (%) 1,619 (22.8)
- Optimal (≥75.0 nmol/L), No. (%) 1,705 (24.0)
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Table 2.3.1. Subject characteristics (N=7,098)1 (continued)
Characteristics
Season when maternal blood sample was take, No. (%)
- Spring 2,097 (29.5)
- Summer 1,622 (22.9)
- Autumn 1,702 (24.0)
- Winter 1,677 (23.6)
Pregnancy complications, No. (%)
- Gestational hypertensive disorders 421 (5.9)
- Gestational diabetes 67 (0.9)
Birth characteristics
Female sex, No. (%) 3,529 (49.7)
Preterm birth (<37 wk of gestation), No. (%) 370 (5.2)
Low birth weight (<2500 g), No. (%) 342 (4.8)
Small-size for gestational age at birth (<5th percentile), No. (%) 355 (5.0)
25(OH)D concentration in cord blood at birth, median (95 % range), nmol/L 27.4 (4.7, 81.4)
Season when cord blood sample was taken, No. (%) 4.264
- Spring 1,130 (26.5)
- Summer 1,164 (27.2)
- Autumn 996 (23.4)
- Winter 977 (22.9)
1Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution.
Table 2.3.2. Fetal growth characteristics (N=7,098)1
Fetal growth characteristics (N=7,098)
Second trimester (N=7,098)
- Gestational age, median (95 % range), wk 20.5 (18.6, 23.4)
- Head circumference, mean (SD), cm 17.9 (1.5)
- Femur length, mean (SD), mm 33.5 (3.6)
- Estimated fetal weight, mean (SD), g 382 (94)
Third trimester (N=7,018)
- Gestational age at birth, median (95 % range), wk 30.3 (28.4, 32.8)
- Head circumference, mean (SD), cm 28.5 (1.2)
- Femur length, mean (SD), mm 57.4 (3.0)
- Estimated fetal weight, mean (SD), g 1,614 (253)
Birth (N=7,046)
- Gestational age, median (95 % range), wk 40.1 (35.6, 42.3)
- Head circumference, mean (SD), cm 33.8 (1.7)
- Body length, mean (SD), cm 50.2 (2.4)
- Weight, mean (SD), g 3,414 (561)
1Values are means (SD) for continuous variables with a normal distribution, or medians (95 % range) for continuous vari-
ables with a skewed distribution. 
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to be similar as those observed for head circumference. Results from the regression models 
focused on the associations of 25(OH)D concentrations with one fetal growth measure at 
each time point showed similar results (Supplementary Table  2.3.3). We observed similar 
associations when using vitamin D cut-off s according to previously used clinical cut-off s and 
recommendations (Supplementary Table 2.3.4). Also, although we observed tendencies for 
similar eff ect estimates when we restricted the analyses to Europeans only (N=4069), not 
Figure 2.3.1. Associations of maternal second trimester 25(OH)D concentrations with fetal growth pat-
terns (N=7,098)
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all associations reached statistical signifi cance due to smaller sample sizes (Supplementary 
Table 2.3.5). 
Maternal 25(OH)D concentrations and risks of adverse birth outcomes
Compared with mothers who had 25(OH)D concentrations in the highest quartile (range 73.8 
to 193.2 nmol/L), those who were in the lowest quartile of 25(OH)D concentrations (range 1.5 
to 24.1 nmol/L) had increased risks of children born preterm birth (Odds Ratio (OR) 1.72 (95 % 
CI 1.14, 2.60)), with a low birth weight (OR 1.56 (95 % CI 1.02, 2.39) and with a small-size for 
gestational age at birth (OR 2.07 (95 % CI 1.33, 3.22)) (Figure 2.3.2). We observed dose-response 
associations suggesting that higher maternal 25(OH)D concentrations across the full range 
were associated with lower risks of preterm birth, low birth weight and small-size for gesta-
tional age at birth (all P values <0.05). We observed tendencies for similar associations when 
using 25(OH)D cut-off s according to previously used clinical cut-off s and recommendations 
instead of quartiles (Supplementary Figure 2.3.2). Similar eff ect estimates were observed 
when we restricted our analyses to European subjects only, but not all associations were 
signifi cant (Supplementary Figure  2.3.3). The estimated population attributable risks of 
vitamin D concentrations <50 nmol/L for preterm birth or low birth weight or for small-size 
for gestational age in our population were 17.3 %, 18.4 % and 22.6 %, respectively.
Adverse birth outcomes and cord blood 25(OH)D concentrations
Higher weight at birth and gestational age adjusted birth weight were associated with higher 
cord blood 25(OH)D concentrations (diff erences 0.04 SDS (95 % CI 0.01, 0.07)) and 0.03 SDS 
Figure 2.3.2. Associations of maternal second trimester 25(OH)D concentrations with the risks of adverse 
birth outcomes (N=7,098)
Values are logistic regression coeffi  cients (95 % confi dence interval) and refl ect the risk of adverse birth outcomes com-
pared to the reference group. Continuous analyses refl ect the risks of being preterm, having a low birth weight or being 
small-size for gestational age at birth per 1 SDS increase in maternal 25(OH)D. Multivariable model is adjusted for maternal 
characteristics (age, body mass index at intake, alcohol consumption, smoking during pregnancy, folic acid and vitamin 
supplements, energy, iron, zinc, and calcium dietary intake during pregnancy, education, ethnicity, gestational hyperten-
sive disorders, gestational diabetes, parity, season when blood samples were drawn and the presence of anorexia).
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(95 % CI 0.01, 0.06) per 1 SD increase in birth weight and gestational age adjusted birth weight, 
respectively) (Table 2.3.3). The association of higher gestational age at birth with cord blood 
25(OH)D concentrations was of borderline signifi cance (diff erence -0.01 SDS (95 % CI -0.03, 0) 
per 1SD increase in gestational age. Tendencies for similar eff ect estimates were observed 
when we restricted our analyses to European subjects only (Supplementary Table 2.3.6).
DISCUSSION
Results from this large population-based prospective cohort study suggest that second trimes-
ter lower maternal 25(OH)D concentrations are associated with third trimester fetal head, length, 
and weight growth restriction and with increased risks of preterm birth, low birth weight and 
small-size for gestational age at birth. These associations were not restricted to the extremes, 
but tended to be present across the full spectrum of maternal 25(OH)D concentrations. Also, a 
smaller size at birth was associated with lower cord blood 25(OH)D concentrations. 
Table 2.3.3. Associations of adverse birth outcomes with cord blood 25(OH)D concentrations (N=4,262)1
Birth characteristics N Cord blood 25(OH)D (nmol/L)
Gestational age 4,262
<37.0 weeks 130 0.02 (-0.13, 0.17)
37.0-41.9 weeks 3849 Reference
≥42 weeks 283 -0.06 (-0.16, 0.05)
Trend -0.01 (-0.03, 0)
Birth weight 4,258
<2,000 grams 15 -0.49 (-0.91, -0.06)2
2,000–2,499 g 94 -0.01 (-0.18, 0.17)
2,500–2,999 g 607 -0.02 (-0.11, 0.06)
3,000–3,499 g 1,535 Reference
3,500–3,999 g 1,412 0.01 (-0.05, 0.07)
4,000–4,499 g 502 -0.01 (-0.10, 0.08)
≥4,500 grams 93 0.06 (-0.12, 0.23)
Trend 0.04 (0.01, 0.07)2,3
Birth weight for gestational age 4,257
Small 164 -0.09 (-0.22, 0.05)
Normal 3,881 Reference
Large 212 0.06 (-0.06, 0.18)
Trend 0.03 (0.01, 0.06)2
1Values are linear regression coeffi  cients (95 % confi dence interval) and refl ect the change in standard deviation (SDS) of 
cord blood 25(OH)D concentrations for each birth weight or gestational age group, compared to the reference group. 
Trend estimates represent the eff ect estimates for the continuous associations per SDS change in birth characteristics. 
Multivariable model is adjusted for fetal sex, maternal characteristics (age, body mass index at intake, alcohol consump-
tion, smoking during pregnancy, folic acid and vitamin supplements, energy, iron, zinc and calcium dietary intake during 
pregnancy, education, ethnicity, gestational hypertensive disorders, gestational diabetes, parity, and the presence of an-
orexia). 2P value <0.05. 3Also signifi cant after applying Bonferroni correction (P value <0.025).
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We hypothesized that suboptimal maternal 25(OH)D concentrations aff ect fetal develop-
ment leading to an increased risk for adverse birth outcomes. Previous studies reported 
inconsistent results on the associations of maternal 25(OH)D concentrations with birth out-
comes.2, 7–9, 39 A previous study among 2,473 mother-children pairs, in a multi-center cohort 
in the United States reported that low concentrations of maternal 25(OH)D are associated 
with low weight at birth.9 In line with these fi ndings, a study among 2,146 mother-children 
pairs in the United States observed that maternal 25(OH)D concentrations were positively 
associated with weight at birth.40 Results from another population-based cohort study in the 
Netherlands among 3,730 mother-children pairs, also suggested that lower maternal 25(OH)D 
concentrations are associated with lower birth weight.7 A recent meta-analysis of random-
ized controlled trials suggested that vitamin D supplementation during pregnancy was 
associated with increased circulating 25(OH)D concentrations and a higher birth weight.40 
Thus, altogether previous studies suggest that higher vitamin D concentrations in pregnancy 
lead to higher birth weight. 
The use of birth weight as the main fetal outcome has strong limitations. Birth weight does 
not give information about longitudinal fetal growth and development patterns and fetal 
body proportions. We examined the impact of maternal 25(OH)D concentrations on head 
circumference, length and estimated fetal weight during second and third trimester of preg-
nancy and at birth. We used repeatedly and directly measured fetal growth characteristics 
and observed that lower maternal 25(OH)D concentrations were associated with restricted 
fetal head circumference growth from second trimester onwards, correlating with a small 
head circumference at birth. Similar associations were observed for fetal length growth and 
fetal weight growth. In line with our fi ndings on head circumference at birth, a multi-center 
cohort in the United States suggested that lower maternal 25(OH)D concentrations during 
mid-pregnancy are associated with a smaller head circumference at birth.39 In contrast, a 
study among 2,382 mother-child pairs in Spain, showed that higher maternal 25(OH)D con-
centrations in early pregnancy are associated with a smaller head circumference at birth.8 
Regarding birth length, results from a recent meta-analysis of randomized controlled trials 
suggested that neonates in the maternal vitamin D supplemented group had a higher birth 
length compared with the control group.40 In contrast to these fi ndings, a study among 559 
mother-children pairs in India, did not observe any association of maternal 25(OH)D concen-
trations and length at birth.41These diff erences may be due to diff erences in study popula-
tions. Results from the longitudinal analyses of our large study, suggest that low maternal 
25(OH)D concentrations are associated with a proportional growth restriction, though the 
largest eff ect may be present on fetal length growth. 
We observed that lower maternal 25(OH)D concentrations during mid-pregnancy are 
associated with a higher risk of preterm birth. A previous study among 2,382 mother-child 
pairs in Spain did not observe any association of maternal 25(OH)D concentrations during 
early pregnancy with the risk of preterm birth.8 This diff erence in outcome may be due to 
the specifi c study population, and smaller sample size in the earlier study, which limited the 
ability to detect these associations. Our results regarding the risk of low birth weight and of 
small-size for gestational age are in line with fi ndings from another cohort study in the Neth-
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erlands, which observed that lower maternal 25(OH)D concentrations during early pregnancy 
was associated with an increased risk of low birth weight and small-size for gestational age.7 
Also, a previous study among 3,658 Chinese mothers, whose 25(OH)D concentrations were 
assessed at diff erent time points during pregnancy, observed that lower maternal 25(OH)D 
concentrations throughout pregnancy elevated the risk of small-size for gestational age at 
birth.42 The observations linking low maternal vitamin D to preterm birth, low birth weight 
and small-size for gestational age at birth are important. All three outcomes are associated 
with perinatal mortality and later-life chronic disease.43 We also observed that children born 
preterm or with a small-size at birth have lower cord blood 25(OH)D concentrations. Results 
from a study in Boston among 471 infants, suggested that preterm born infants have a higher 
risk of having lower 25(OH)D cord blood concentrations.44 Thus, preterm birth and small size 
at birth may be both a consequence and a risk factor of vitamin D defi ciency. Low vitamin D 
concentrations in early life may aff ect health in later life.45, 46
Form our observational study, it is not possible to establish the causality for the observed 
associations. However, several biological mechanisms have been suggested linking maternal 
25(OH)D concentrations to fetal development. Maternal vitamin D may aff ect placental vas-
cularisation.47 It has been suggested that vitamin D receptors and 1,25-dihydroxyvitaminD 
(1,25(OH)2D) regulate placental secretion of human placental lactogen and other hormones 
that aff ect maternal glucose and fatty acid metabolism, which provide energy for fetal 
needs.44, 47 Further studies that focus on the causality and mechanisms explaining the ob-
served associations are needed.
Our fi ndings are important from a population-based perspective. The upper limit of fi rst 2 
quartiles of maternal 25(OH)D concentrations correspond to the value of <50 nmol/L, which 
is defi ned as 25(OH)D defi ciency.19, 20 In our study, 53 % of all mothers had 25(OH)D defi cient 
concentrations, leading to high estimated population attributable risks. In the Netherlands, 
pregnant women are advised to use folic acid supplements (400 μg/day) prior to and up to 
week 10–12 of pregnancy and vitamin D supplements (10 μg/day). Therefore, results from our 
study support population-strategies to improve vitamin D concentrations in pregnant women. 
Some methodological considerations need to be considered. To our knowledge, this is the 
largest multi-ethnic population-based prospective cohort study focused on the associations 
of maternal 25(OH)D concentrations with directly measured fetal growth characteristics in 
diff erent periods of pregnancy. In mothers who had available 25(OH)D concentrations, we 
had a limited loss to follow-up; therefore, we do not expect biased results from selective 
follow-up. We used 25(OH)D concentration, which is the best and most widely used indicator 
of vitamin D status.48 We analyzed vitamin D concentrations as continuous data, quartiles and 
previously used clinical cut-off s.18, 20–24 The cut off s remain subject of debate.18, 19 In line with 
recommendations of the Endocrine Society and based on previous results from our and other 
cohort studies, we created four vitamin D groups, including severely defi cient (<25.0 nmol/L), 
defi cient (25.0 to 49.9 nmol/L), suffi  cient (50.0 to 74.9 nmol/L) and optimal (≥75.0 nmol/L) 
(18, 20–24). The Institute of Medicine (IOM) defi nes vitamin D as being defi cient (<50nmol/L), 
and suffi  cient (≥50nmol/L), which would lead to categorizing our severely defi cient and 
defi cient groups as defi cient, and categorizing the suffi  cient and optimal groups as suffi  cient 
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or adequate. We consider that an advantage of our categories over the IOM categories is 
that we have more groups and can compare our results with previous pregnancy studies. 
Also, our fi ndings suggest that the eff ects of vitamin D on fetal outcomes are not restricted 
to IOM defi cient groups, but present across the full common range. 25(OH)D concentrations 
were assessed during second trimester and in cord blood at birth. The correlation coeffi  cient 
between maternal serum 25(OH)D concentrations during second trimester and in cord blood 
was r = 0.62 (P value <0.01). This correlation varies between studies. Some studies report a 
higher degree of correlation, but still report a diff erence between maternal 25(OH)D concen-
trations during third trimester of pregnancy and 25(OH)D concentrations in cord blood at 
birth.49 A limitation of our study may be that we do not have maternal 25(OH)D concentrations 
measured during fi rst trimester. We measured fetal development by direct second- and third 
trimester fetal ultrasound examinations. Because the main outcomes were correlated, we did 
not adjust the main analyses for multiple comparisons. Another limitation of our study is 
the lack of detailed information on vitamin D supplementation and on conditions that may 
infl uence vitamin D status, such as bariatric surgery or diff erent gastrointestinal diseases. 
However, other nutritional factors may infl uence the observed associations. As previous stud-
ies suggested that iron, zinc, calcium and other vitamin supplements infl uence fetal growth 
and birth outcomes, we included these nutritional factors in our regression models. Adjust-
ment for these factors did not change the eff ect estimates materially. Several trials suggested 
that supplementation of these micronutrients lowers the risks of pregnancy complications 
in women at risk of defi ciencies or adverse outcomes.50–55 Because, the intake of these mi-
cronutrients was estimated from a food frequency questionnaire, we may not have achieved 
the precision in these concentrations compared to studies with concentrations. Maternal 
ethnicity is related to both vitamin D concentrations and fetal growth patterns.35, 36 The study 
cohort was a multi-ethnic sample in the city of Rotterdam, the Netherlands. Compared with 
the overall population distribution in the city of Rotterdam, the percentage of Europeans 
in our study was higher whereas the percentage of Moroccans was lower.35 We used two 
approaches to explore the role of maternal ethnicity. First, all main analyses were adjusted 
for maternal ethnicity. Second, we observed tendencies for similar associations when we 
restricted the analyses to Europeans only. However, not all eff ect estimates were signifi cant, 
probably because of smaller numbers. Unfortunately, we did not have enough numbers in 
the other ethnic subgroups, to perform ethnic specifi c analyses. The results of these addi-
tional analyses suggest that the associations of vitamin D concentrations with fetal outcomes 
are not explained by maternal ethnicity. Further studies are needed to explore diff erences in 
eff ect estimates between ethnic subgroups. Finally, although we performed adjustment for 
a large number of potential maternal confounders, residual confounding by other lifestyle 
factors, might still be present, as in any observational study. The causality for the associations 
of vitamin D with fetal developmental outcomes cannot be established from observational 
studies only. Therefore, future studies are needed to establish causal relationships.
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CONCLUSION 
Our fi ndings suggest that second trimester low maternal 25(OH)D concentrations are as-
sociated with third trimester fetal grow restriction and with increased risks of preterm birth, 
low birth weight, and small-size for gestational age at birth. These associations were not 
restricted to the extremes, but tended to be present across the full spectrum of maternal 
25(OH)D concentrations. Although the causality of the observed associations need to be 
further established, these fi ndings support current strategies to increase 25(OH)D concentra-
tions in pregnant women. 
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Supplementary Figure 2.3.1. Flowchart of the study participants
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mothers with information  
on vitamin D blood levels  
N=7,176 
N=1,703 excluded, due to missing 
information on vitamin D levels 
N=78 excluded due to: twin birth (77), 
 lost to follow up (1) 
Mothers included during pregnancy 
N=8,879 
 Singletons with available information on 
maternal vitamin D blood levels  
N=7,098 
Total population for analyses 
N=7,098 
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Supplementary Table 2.3.1. Subject characteristics observed and imputed1
Original Imputed
Maternal characteristics
Age, mean (SD), y 29.7 (5.2) NI
Body mass index at enrolment, median (95 % range), kg/m2 23.8 (18.7, 36.3) 23.7 (18.7, 36.3)
Missing, No. (%) 46 (0.6)
Gestational age at enrollment, median (95 % range), wk 13.9 (9.9, 22.9) NI
Nulliparous, No. (%) 3,955 (55.7) 3,987 (56.2)
Missing, No. (%) 67 (0.9)
Education level,No. (%)
- No higher education 3,756 (52.9) 4,204 (59.2)
- Higher education 2,786 (39.3) 2,894 (40.8)
Missing, No. (%) 556 (7.8)
Ethnicity, No. (%)
- European 3,897 (54.9) 4,069 (57.3)
- Cape Verdean 294 (4.1) 311 (4.4)
- Dutch Antillean 242 (3.4) 253 (3.5)
- Moroccan 447 (6.3) 471 (6.6)
-  Turkish 630 (8.9) 651 (9.2)
- Surinamese 610 (8.6) 643 (9.1)
- Other 665 (9.4) 700 (9.9)
Missing, No. (%) 313 (4.4)
Presence of anorexia, No. (%)
- No 5,254 (74.0) 6,352 (89.5)
- Yes 244 (3.4) 503 (7.1)
- Maybe 114 (1.6) 243 (3.4)
Missing, No. (%) 1,486 (20.9)
Smoking during pregnancy, No. (%)
- Never 4,536 (63.9) 5,131 (72.3)
- Until pregnancy was known 551 (7.8) 665 (9.4)
- Continued 1,179 (16.6) 1,302 (18.3)
Missing, No. (%) 832 (11.7)
Alcohol consumption during pregnancy, No. (%)
- Never 3,001 (42.3) 3,493 (49.2)
- Until pregnancy was known 863 (12.2) 974 (13.7)
- Continued 2,315 (32.6) 2,631 (37.1)
Missing, No. (%) 919 (12.9)
Folic acid supplement use, No. (%)
- No 1,515 (21.4) 2,204 (31.0)
- Start in the fi rst 10 weeks 1,677 (23.6) 2,219 (31.3)
- Start periconceptional 2,123 (29.9) 2,675 (37.7)
Missing, No. (%) 1,783 (25.1)
Vitamin supplement use, No. (%)
- Yes 4,128 (58.2) 5,049 (71.1)
- No 1,730 (24.4) 2,049 (28.9)
Missing, No. (%) 1,240 (17.5)
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Supplementary Table 2.3.1. Subject characteristics observed and imputed1 (continued)
Original Imputed
Maternal energy intake (kcal) 2,041 (566) 2,039 (490)
Missing, No. (%) 1,813 (25.5)
Maternal zinc intake (mg) 9.6 (1.7) 9.6 (1.6)
Missing, No. (%) 1,813 (25.5)
Maternal iron intake (mg) 11.1 (2.1) 11.1 (2.1)
Missing, No. (%) 1,813 (25.5)
Maternal calcium intake (mg) 1,100 (453) 1,087 (418)
Missing, No. (%) 1,813 (25.5)
Maternal 25(OH)D concentrations, median (95 % range), nmol/L 46.7 (7.0, 119.4) NI
Season when maternal blood sample was take, No. (%)
- Spring 2,097 (29.5) NI
- Summer 1,622 (22.9) NI
- Autumn 1,702 (24.0) NI
- Winter 1,677 (23.6) NI
Pregnancy complications, No. (%)
- Gestational hypertensive disorders 388 (5.5) 421 (5.9)
- Gestational diabetes 67 (0.9) 67 (0.9)
Missing, No. (%) 422 (5.9)
Birth characteristics
Female sex, No. (%) 3,529 (49.7) 3,529 (49.7)
Missing, No. (%) 1 (0.01)
Preterm birth (<37 wk of gestation), No. (%) 370 (5.2) NI
Low birth weight (<2500 g), No. (%) 342 (4.8) NI
Small-size for gestational age at birth (<5th percentile), No. (%) 355 (5.0) NI
25(OH)D concentration in cord blood at birth, median (95 % range), nmol/L 27.4 (4.7, 81.4) NI
Season when cord blood sample was taken, No. (%)
- Spring 1,130 (26.5) NI
- Summer 1,164 (27.2) NI
- Autumn 996 (23.4) NI
- Winter 977 (22.9) NI
1Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. NI- not imputed.
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Supplementary Table 2.3.3. Associations of maternal second trimester 25(OH)D concentrations with fetal 
growth patterns from multiple regression models (N=7,098)1
25(OH)D concentrations
Head circumference SDS
(95 % Confi dence Interval)
2nd trimester
N=6,967
3rd trimester
N=6,800
Birth
N=3,681
Quartile 1 (N=1,774) -0.01 (-0.10, 0.08) 
N=1,734
-0.07 (-0.15, 0.02)
N=1,633
-0.14 (-0.28, -0.01)2
N=919
Quartile 2 (N=1,773) -0.05 (-0.12, 0.03)
N=1,736
-0.03 (-0.10, 0.05)
N=1,692
-0.07 (-0.19, 0.04)
N=940
Quartile 3 (N=1,777) 0.01 (-0.06, 0.08)
N=1,750
0 (-0.07, 0.07)
N=1,722
-0.03 (-0.13, 0.07)
N=983
Quartile 4 (N=1,774) Reference Reference Reference
Continuously (per SD) 0.01 (-0.02, 0.04) 0.02 (-0.01, 0.05) 0.05 (0.01, 0.10)2
25(OH)D concentrations
Length SDS
(95 % Confi dence Interval)
2nd trimester
N=6,988
3rd trimester
N=6,851
Birth
N=4,533
Quartile 1 (N=1,774) -0.01 (-0.10, 0.08)
N=1,741
0.01 (-0.08, 0.10)
N=1,674
-0.20 (-0.33, -0.07)2,3
N=1,038
Quartile 2 (N=1,773) -0.01 (-0.08, 0.07)
N=1,745
0.04 (-0.04, 0.11)
N=1,705
-0.09 (-0.19, 0.02)
N=1,119
Quartile 3 (N=1,777) 0.01 (-0.06, 0.08)
N=1,751
0.05 (-0.02, 0.12)
N=1,732
-0.09 (-0.18, 0.01)
N=1,164
Quartile 4 (N=1,774) Reference Reference Reference
Continuously (per SD) 0.01 (-0.02, 0.04) -0.01 (-0.04, 0.02) 0.06 (0.02, 0.11)2,3
25(OH)D concentrations
Weight SDS
(95 % Confi dence Interval)
2nd trimester
N=6,952
3rd trimester
N=6,828
Birth
N=7,043
Quartile 1 (N=1,774) -0.07 (-0.15, 0.02)
N=1,737
-0.04 (-0.13, 0.05)
N=1,666
-0.17 (-0.26, -0.09)2,3
N=1,751
Quartile 2 (N=1,773) -0.02 (-0.09, 0.06)
N=1,731
0.02 (-0.06, 0.09)
N=1,701
-0.07 (-0.14, -0.01)2
N=1,759
Quartile 3 (N=1,777) -0.01 (-0.07, 0.06)
N=1,742
0.07 (-0.01, 0.13)
N=1,728
-0.02 (-0.09, 0.05)
N=1,766
Quartile 4 (N=1,774) Reference Reference Reference
Continuously (per SD) 0.02 (-0.01, 0.06) 0.01 (-0.02, 0.04) 0.06 (0.03, 0.09)2,3
1Values are linear regression coeffi  cients (95 % confi dence interval) and refl ect the diff erences in fetal growth compared 
to the reference group. Continuous analyses refl ect the diff erences in head circumference, femur length, estimated fetal 
weight during second and third trimester of pregnancy and head circumference, length and weight at birth per 1 SDS 
increase in maternal 25(OH)D. Multivariable model is adjusted for maternal characteristics (age, body mass index at intake, 
alcohol consumption, smoking during pregnancy, vitamin supplements, folic acid, iron, calcium, zinc and energy intake 
during pregnancy, education, ethnicity, gestational hypertensive disorders, gestational diabetes, parity and season when 
blood samples were drawn, and the presence of anorexia). 2P value <0.05. Abbreviations: SDS standard deviation scores. 
3Also signifi cant after applying Bonferroni correction (P value <0.025).
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Supplementary Table 2.3.4. Associations of maternal second trimester 25(OH)D concentrations in clinical 
cut-off  groups with fetal growth patterns (N=7,098)1
25(OH)D concentrations
Head circumference SDS
(95 % Confi dence Interval)
2nd trimester
N=6,967
3rd trimester
N=6,800
Birth
N=3,681
<25.0 nmol/L (N=1,828) -0.02 (-0.11, 0.07) -0.07 (-0.16, 0.02) -0.13 (-0.27, 0)
25.0 to 49.9 nmol/L (N=1,893) -0.03 (-0.11, 0.04) -0.02 (-0.09, 0.05) -0.08 (-0.19, 0.03)
50.0 to 74.9 nmol/L (N=1,604) 0.01 (-0.06, 0.08) -0.01 (-0.08, 0.06) -0.04 (-0.14, 0.07)
≥75.0 nmol/L (N=1,693) Reference Reference Reference
Continuously (per SD) 0.01 (-0.02, 0.04) 0.02 (-0.01, 0.05) 0.05 (0.01, 0.10)2,3
25(OH)D concentrations
Length SDS
(95 % Confi dence Interval)
2nd trimester
N=6,988
3rd trimester
N=6,851
Birth
N=4,533
<25.0 nmol/L (N=1,828) -0.01 (-0.09, 0.08) 0.02 (-0.07, 0.11) -0.18 (-0.30, -0.05)2,3
25.0 to 49.9 nmol/L (N=1,893) -0.01 (-0.09, 0.06) 0.04 (-0.04, 0.11) -0.08 (-0.19, 0.02)
50.0 to 74.9 nmol/L (N=1,604) 0 (-0.07, 0.07) 0.06 (-0.01, 0.12) -0.08 (-0.18, 0.02)
≥75.0 nmol/L (N=1,693) Reference Reference Reference
Continuously (per SD) 0.01 (-0.02, 0.04) -0.01 (-0.04, 0.02) 0.06 (0.02, 0.11)2,3
25(OH)D concentrations
Weight SDS
(95 % Confi dence Interval)
2nd trimester
N=6,952
3rd trimester
N=6,828
Birth
N=7,043
<25.0 nmol/L (N=1,828) -0.07 (-0.16, 0.01) -0.06 (-0.15, 0.03) -0.16 (-0.25, -0.08)2,3
25.0 to 49.9 nmol/L (N=1,893) -0.03 (-0.10, 0.05) 0.02 (-0.06, 0.09) -0.07 (-0.14, 0)
50.0 to 74.9 nmol/L (N=1,604) -0.01 (-0.08, 0.06) 0.05 (-0.02, 0.12) -0.05 (-0.11, 0.02)
≥75.0 nmol/L (N=1,693) Reference Reference Reference
Continuously (per SD) 0.02 (-0.01, 0.06) 0.01 (-0.02, 0.04) 0.06 (0.03, 0.09)2,3
1Values are linear regression coeffi  cients (95 % confi dence interval) and refl ect the diff erences in fetal growth compared 
to the reference group. Continuous analyses refl ect the diff erences in head circumference, femur length, estimated fetal 
weight during second and third trimester of pregnancy and head circumference, length and weight at birth per 1 SDS 
increase in maternal 25(OH)D. Multivariable model is adjusted for maternal characteristics (age, body mass index at intake, 
alcohol consumption, smoking during pregnancy, folic acid and vitamin supplements, energy, iron, calcium and zinc di-
etary intake during pregnancy, education, ethnicity, gestational hypertensive disorders, gestational diabetes, parity and 
the presence of anorexia and season when blood samples were drawn). 2P value <0.05. Abbreviations: SDS standard devia-
tion scores. 3Also signifi cant after applying Bonferroni correction (P value <0.025).
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Supplementary Table 2.3.5. Associations of maternal second trimester 25(OH)D concentrations with fetal 
growth outcomes among Europeans only (N=4,069)1
25(OH)D concentrations
Head circumference SDS
(95 % Confi dence Interval)
2nd trimester 3rd trimester Birth
Quartile 1 (N=328) -0.06 (-0.20, 0.08) -0.01 (-0.14, 0.13) -0.16 (-0.38, 0.06)
Quartile 2 (N=940) -0.01 (-0.10, 0.08) 0.01 (-0.08, 0.09) -0.04 (-0.17, 0.09)
Quartile 3 (N=1,260) 0.02 (-0.06, 0.10) -0.02 (-0.09, 0.06) -0.01 (-0.12, 0.01)
Quartile 4 (N=1,543) Reference Reference Reference
Continuously (per SD) 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) 0.04 (-0.01, 0.10)
25(OH)D concentrations
Length SDS
(95 % Confi dence Interval)
2nd trimester 3rd trimester Birth
Quartile 1 (N=328) -0.08 (-0.22, 0.05) -0.01 (-0.15, 0.14) -0.17 (-0.37, 0.03)
Quartile 2 (N=940) 0.03 (-0.06, 0.11) 0.06 (-0.02, 0.15) -0.08 (-0.21, 0.04)
Quartile 3 (N=1,260) 0.03 (-0.05, 0.10) 0.05 (-0.03, 0.13) -0.09 (-0.19, 0.02)
Quartile 4 (N=1,543) Reference Reference Reference
Continuously (per SD) 0.01 (-0.03, 0.04) -0.02 (-0.06, 0.02) 0.06 (0.01, 0.11)2
25(OH)D concentrations
Weight SDS
(95 % Confi dence Interval)
2nd trimester 3rd trimester Birth
Quartile 1 (N=328) -0.14 (-0.28, -0.01)* -0.08 (-0.22, 0.06) -0.17 (-0.32, -0.03)2,3
Quartile 2 (N=940) 0.04 (-0.05, 0.13) 0.05 (-0.04, 0.14) -0.06 (-0.14, 0.03)
Quartile 3 (N=1,260) 0.02 (-0.06, 0.10) 0.06 (-0.01, 0.14) -0.04 (-0.11, 0.04)
Quartile 4 (N=1,543) Reference Reference Reference
Continuously (per SD) 0.01 (-0.03, 0.05) 0 (-0.04, 0.04) 0.05 (0.01, 0.10)2,3
1Values are linear regression coeffi  cients (95 % confi dence interval) and refl ect the diff erences in fetal growth measures 
compared to the reference group. Continuous analyses refl ect the diff erences in head circumference, femur length, esti-
mated fetal weight during second and third trimester of pregnancy and head circumference, length and weight at birth 
per 1 SDS increase in maternal 25(OH)D. Multivariable model is adjusted for maternal characteristics (age, body mass index 
at intake, alcohol consumption, smoking during pregnancy, folic acid and vitamin supplements, energy, iron, calcium and 
zinc dietary intake during pregnancy, education, gestational hypertensive disorders, gestational diabetes, parity and the 
presence of anorexia and season when blood samples were drawn.2P value <0.05. 3Also signifi cant after applying Bonfer-
roni correction (P value <0.025). Abbreviations: SDS standard deviation scores.
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Supplementary Figure 2.3.2. Associations of maternal second trimester 25(OH)D concentrations, in cut-
off  groups with the risks of adverse birth outcomes (N=7,098)1
1Values are logistic regression coeffi  cients (95 % confi dence intervals) and refl ect the risk of adverse birth outcomes com-
pared to the reference group. Continuous analyses refl ect the risks of being preterm, having a low birth weight or being 
small-size for gestational age at birth per 1 SDS increase in maternal 25(OH)D. Multivariable model is adjusted for maternal 
characteristics (age, body mass index at intake, alcohol consumption, smoking during pregnancy, folic acid and vitamin 
supplements, energy, iron, calcium and zinc dietary intake during pregnancy, education, ethnicity, gestational hyperten-
sive disorders, gestational diabetes, parity and the presence of anorexia and season when blood samples were drawn).
Supplementary Figure 2.3.3. Associations of maternal second trimester 25(OH) concentrations with the 
risks of adverse birth outcomes among Europeans only (N=4,069) 1
1Values are logistic regression coeffi  cients (95 % confi dence intervals) and refl ect the risks of adverse birth outcomes com-
pared to the reference group. Continuous analyses refl ect the risk of being preterm, having a low birth weight or being 
small-size for gestational age at birth per 1 SDS increase in maternal 25(OH)D. Multivariable model is adjusted for maternal 
characteristics (age, body mass index at intake, alcohol consumption, smoking during pregnancy, folic acid and vitamin 
supplements, energy, iron, calcium and zinc dietary intake during pregnancy, education, gestational hypertensive disor-
ders, gestational diabetes, parity, the presence of anorexia and season when blood samples were drawn). 
91
Maternal 25(OH)D and fetal outcomes
2.3
Supplementary Table 2.3.6. Associations of adverse birth outcomes with cord blood 25(OH)D concentra-
tions among Europeans only (N=2,550)1
Birth characteristics N Cord blood 25(OH)D nmol/L
Gestational age 2,553
<37.0 weeks 73 0.03 (-0.25, 0.32)
37.0-41.9 weeks 2,302 Reference
≥42 weeks 178 -0.17 (-0.34, 0.01)
Trend -0.03 (-0.06, 0.01)
Birth weight 2,552
<2,000 grams 9 -0.60 (-1.46, 0.26)
2,000-2,499 g 45 0.22 (-0.12, 0.57)
2,500-2,999 g 318 -0.10 (-0.26, 0.05)
3,000-3,499 g 864 Reference
3,500-3,999 g 893 -0.02 (-0.13, 0.09)
4,000-4,499 g 354 -0.04 (-0.18, 0.10)
≥4,500 grams 69 -0.09 (-0.38, 0.19)
Trend 0.03 (-0.02, 0.09)
Birth weight for gestational age 2,553
Small 79 -0.23 (-0.49, 0.04)
Normal 2,313 Reference
Large 161 -0.04 (-0.23, 0.15)
Trend 0.03 (-0.02, 0.07)
1Values are linear regression coeffi  cients (95 % confi dence interval) and refl ect the change in standard deviation (SDS) of 
cord blood 25(OH)D for each birth weight or gestational age group, compared to the reference group. Trend estimates 
represent the eff ect estimates for the continuous associations per SDS change in birth characteristic. Multivariable model 
is adjusted for fetal sex, maternal characteristics (age, body mass index at intake, alcohol consumption, smoking during 
pregnancy, folic acid and vitamin supplements, energy, iron, calcium and zinc dietary intake during pregnancy, education, 
gestational hypertensive disorders, gestational diabetes, parity and the presence of anorexia). 
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ABSTRACT 
Background: Maternal vitamin D defi ciency during pregnancy may have persistent adverse 
eff ects on childhood growth and development. We examined whether 25-hydroxyvitamin D 
(25(OH)D) concentrations during pregnancy and at birth are associated with childhood body 
composition and cardiovascular outcomes.
Methods: This study was embedded in a population-based prospective cohort in Rotterdam, 
the Netherlands among 4,903 mothers and their off spring. We measured 25(OH)D concentra-
tions at a median gestational age of 20.4 weeks (95 % range 18.5–23.4 weeks) and at birth (40.1 
weeks (95 % range 35.8–42.3 weeks)). We categorized 25(OH)D concentrations into severely 
defi cient (<25.0 nmol/L); defi cient (25.0 to 49.9 nmol/L); suffi  cient (50.0 to 74.9 nmol/L) and 
optimal (≥75.0 nmol/L). At 6 years, we measured childhood body mass index (BMI), fat and 
lean mass by Dual-energy X-ray Absorptiometry, blood pressure, and cholesterol, triglycer-
ides and insulin concentrations. 
Results: Compared to children from mothers with optimal 25(OH)D concentrations, those 
of severely defi cient vitamin D mothers had a 0.11 standard deviation score (SDS) (95 % Con-
fi dence Interval (CI) (0.02, 0.20)) higher fat mass percentage and a 0.12 SDS (95 % CI (-0.21, 
-0.03)) lower lean mass percentage. These associations were independent of child current 
vitamin D status. Maternal and cord blood 25(OH)D concentrations were not associated with 
cardiovascular risk factors in childhood. 
Conclusion: Severe maternal 25(OH)D defi ciency during pregnancy is associated with an ad-
verse childhood body fat profi le, but not with childhood cardiovascular risk factors. Further 
studies are needed to replicate our fi ndings, to examine the underlying mechanisms and to 
explore causality and the potential for public health interventions. 
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INTRODUCTION 
Vitamin D is essential for fetal development because of its signifi cant role during prolifera-
tion, diff erentiation and maturation processes of cells, including adipose tissues and muscle 
cells.1–4 We have previously shown that suboptimal concentrations of maternal vitamin D are 
associated with low birth weight and small size for gestational age,5 which are known to be 
associated with cardiovascular risk factors in the off spring.6, 7 Studies in adults suggest that 
vitamin D plays an important role in cardiovascular protection and body composition pro-
fi le.8–10 Furthermore, cross-sectional studies in children reported associations of lower vitamin 
D status with higher adiposity measures and cardiovascular risk factors such as blood pres-
sure, plasma lipids and insulin concentrations.11–13 The relations of vitamin D with calcium are 
well known. It has previously been reported that calcium supplementation during pregnancy 
has long term eff ects on childhood blood pressure.14 Thus far, only few studies have explored 
the associations of circulating fetal 25(OH)D concentrations with childhood adiposity, body 
composition and cardiovascular risk factors, with inconsistent results.1, 15–18 These inconsistent 
fi ndings may be due to diff erences between study populations. The small sample sizes of the 
previous studies could have limited their ability to detect associations.1, 16, 17
Therefore, for the current study, we hypothesized that adverse exposure to suboptimal 
25(OH)D concentrations during critical periods of fetal organ development aff ects childhood 
adiposity and cardiovascular health. We explored in a population-based prospective cohort 
study among 4,903 mother and children pairs the associations of 25(OH)D concentrations 
during mid-pregnancy and in cord blood with body composition and cardiovascular risk fac-
tors at school-age. We also explored whether any association was explained by child’s current 
25(OH)D concentrations.
METHODS
Design and study population 
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onwards in Rotterdam, the Netherlands.19 All children were born between 
April 2002 and January 2006. Enrolment in the study was aimed at early pregnancy, but was 
allowed until the birth of the child. The study protocol was approved by the local Medical 
Ethical Committee. Written consent was obtained for all children. Mid-pregnancy 25(OH)D 
concentrations were measured in 7,176 mothers. For the present study, we excluded pregnan-
cies leading to twin births (N=78) and children with congenital heart abnormalities (N=21). 
Among 7,077 singletons available for follow up measurements, 2,174 did not visit the research 
centre at the age of 6 years. Thus, the cohort for analysis comprised of 4,903 mothers and 
children with vitamin D measurements and childhood outcomes available. (Supplementary 
Figure 2.4.1. Flowchart).
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Maternal and cord 25(OH)D blood concentrations
As previously described, maternal venous blood samples were collected in mid-pregnancy 
(median 20.4 weeks of gestation, 95 % range 18.5–23.4 weeks), whereas umbilical cord blood 
samples were collected at birth (median 40.1 weeks of gestation, 95 % range 35.8–42.3 weeks).19 
25(OH)D concentrations were measured at the Eyles Laboratory at the Queensland Brain 
Institute, University of Queensland, Australia.5, 20 Total 25(OH)D was calculated as the sum of 
25(OH)D2 and 25(OH)D3 measured in plasma.21 Samples were quantifi ed using isotope dilu-
tion liquid chromatography-tandem mass spectrometry. Detailed information on 25(OH)D 
measurements has been described previously.5 According to current recommendations we 
categorized vitamin D status into severely defi cient: <25.0 nmol/L (<10.0 mg/L); defi cient: 25.0 
to 49.9 nmol/L (10.0 to 19.9 mg/L); suffi  cient: 50.0 to 74.9 nmol/L (20.0 to 29.9 mg/L); optimal 
≥75.0 nmol/L (≥30.0 mg/L).5, 22, 23
Body composition and cardiovascular outcomes
Children’s anthropometrics and body composition were measured at a median age of 6.0 
years (95 % range 5.7 to 8.0) by well-trained staff  in our research center.24 Height (m) was 
determined in standing position to the nearest millimeter without shoes using a Harpenden 
stadiometer (Holtain Limited, Dyfed, U.K.). Weight (kg) was measured using a mechanical 
personal scale (SECA, Almere, The Netherlands) and body mass index (BMI) (kg/m2) was 
calculated. We performed whole body Dual-energy X-ray Absorptiometry (DXA) scans (iDXA, 
GE-Lunar, 2008, Madison, WI, USA), that analyzed fat, and lean mass. We calculated fat mass 
percentage as (fat mass (kg) /weight (kg)) and lean mass percentage as (lean mass (kg) /
weight (kg)). 
Blood pressure was measured at the right brachial artery four times with one-minute 
intervals, using the validated automatic sphygmanometer Datascope Accutor Plus (Paramus, 
NJ, US).25 We calculated the mean value for systolic and diastolic blood pressure using the 
last three blood pressure measurements of each participant. Thirty-minutes fasting blood 
samples were collected to measure total-cholesterol, triglycerides, and insulin concentra-
tions, using Cobas 8000 analyzer (Roche, Almere, The Netherlands). Quality control samples 
demonstrated intra and inter‐assay coeffi  cients of variation ranging from 0.77‐1.17 %, and 
0.87‐1.69 %, respectively.
Covariates
We used questionnaires at enrollment in the study (median 13.5 weeks of gestation) to col-
lect information about maternal age, ethnicity, educational level, parity, and on smoking 
and folic acid supplementation during pregnancy.24 Maternal energy and calcium dietary 
intake during pregnancy were measured at enrollment with a validated semi-quantitative 
food frequency questionnaire.26 Ethnicity and educational level were defi ned according to 
the classifi cation of Statistics Netherlands.27, 28 Maternal height and weight were self-reported 
and pre-pregnancy body mass index was calculated (kg/m2). The date of blood sampling 
was categorized into spring, summer, fall, and winter based on the Dutch standard seasons. 
Infant sex, gestational age and weight at birth were obtained from midwifes, medical records 
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and hospital registries. Information on breastfeeding was collected using postnatal ques-
tionnaires.29 At the age of 6 years, child participation at sports was reported and 25(OH)D 
concentrations were measured in a subgroup of 3,068 subjects.30 
Statistical analysis 
We performed a non-response analysis by comparing subject characteristics between 
children with and without follow-up body composition and cardiovascular outcomes using 
T-tests, Chi-square tests and Mann-Whitney tests. We created standard deviations scores 
(SDS) for all outcomes to enable comparison between eff ect estimates. We used multivari-
able linear regression models to assess the associations of maternal and cord blood 25(OH)D 
concentrations with childhood BMI, fat mass percentage, lean mass percentage, systolic and 
diastolic blood pressure, and total-cholesterol, triglycerides, and insulin concentrations. We 
log-transformed the not-normally distributed outcomes, childhood triglycerides and insulin 
concentrations. Vitamin D concentrations were analyzed both continuously per standard 
deviation (SD)- increase and using clinical cut-off s.5, 22, 23 The regression models were fi rst 
adjusted for child’s sex, child’s age at outcome measurements and maternal ethnicity (basic 
models), and subsequently additionally for maternal age, education, pre-pregnancy body 
mass index, parity, smoking, folic acid supplement use and energy and dietary calcium intake 
during pregnancy, and season when blood samples were drawn, and for child’s birth weight, 
gestational age at birth, breastfeeding in early life and playing sports at the age of 6 years 
(adjusted model). The models on cardiovascular outcomes were additionally adjusted for 
childhood BMI. The covariates were included in the models based on their associations with 
adiposity and cardiovascular outcomes in previous studies,15, 31 or a change in eff ect estimates 
of >10 %. To explore if childhood 25(OH)D status explained the associations between maternal 
25(OH)D and childhood body composition measures, we performed a sensitivity analysis in 
which we additionally adjusted for child 25(OH)D in the subgroup of N=3,068 children with 
data on 25(OH)D concentrations available (childhood vitamin D model). Because of the cor-
relations between diff erent outcomes we did not apply adjustment for multiple testing in the 
main analyses. However, as sensitivity analysis we also present statistical signifi cance after 
taking account for three groups of outcomes (body composition, blood pressure, blood con-
centrations) (P value <0.017 (0.05/3)). Ethnicity is strongly associated with 25(OH)D concentra-
tions, therefore, we fi rst adjusted the regression models for maternal ethnicity and second, 
we restricted the analyses to Europeans only, the largest ethnic subgroup in our cohort.20 
Since the interactions of maternal 25(OH)D with child sex were not signifi cant, we did not 
stratify our analyses on child sex. To diminish potential bias associated with attrition, missing 
values of covariates (less than 23.5 %), were multiple imputed by generating 5 independent 
datasets using the Markov Chain Monte Carlo (MCMC) method. The multiple imputation 
procedure was based on the correlation between each variable with missing values and the 
other subject characteristics.32, 33 Subjects characteristics before and after imputation are 
shown in Supplementary Table 2.4.1. Statistical analyses were performed using SPSS ver-
sion 21.0 (SPSS Inc., Chicago, IL, USA).
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RESULTS 
Subject characteristics
Table 2.4.1 shows the subject characteristics. Results from the non-response analysis showed 
that as compared to children who did not have follow up measurements at the age of 6 years, 
those who did have these measurements had mothers who were on average higher educated 
and had higher 25(OH)D concentrations during pregnancy (Supplementary Table 2.4.2). The 
correlation coeffi  cients of the investigated variables are given in Supplementary Table 2.4.3. 
The correlation coeffi  cient between mid-pregnancy maternal 25(OH)D concentrations and 
cord blood 25(OH)D concentrations was r = 0.61.
Table 2.4.1. Subject characteristics (N=4,903)
Characteristics
Maternal characteristics
Age (y) 30.4 (5.03)
Pre-pregnancy body mass index (kg/m2) 22.7 (18.1, 34.8)
Nulliparous (%) 57.8
Education level (%)
- No higher education 54.9
- Higher education 45.1
Ethnicity (%)
- European 60.6
- Cape Verdean 4.5
- Dutch Antillean 2.7
- Moroccan 5.9
- Turkish 8.9
- Surinamese 8.2
- Other 9.2
Smoking during pregnancy (%)
- Never 74.2
- Until pregnancy was known 9.4
- Continued 16.4
Folic acid supplement use (%)
- No 26.8
- Start in the fi rst 10 weeks 31.6
- Start periconceptional 41.6
Maternal energy intake (kcal) 2,049 (490)
Maternal dietary calcium intake (mg) 1,106 (329)
Maternal blood concentrations of 25(OH)D (nmol/L) 50.4 (7.5, 122.5)
Season when blood sample was taken (%)
- Spring 28.6
- Summer 22.6
- Autumn 25.1
- Winter 23.7
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Maternal and cord 25(OH)D concentrations and childhood body composition 
Table 2.4.2 shows the associations of maternal and cord blood 25(OH)D concentrations and 
childhood body composition measures. As compared to children of mothers who had opti-
mal 25(OH)D concentrations, those of mothers who were severely vitamin D defi cient had a 
0.11 standard deviation score (SDS) (95 % Confi dence Interval (CI) (0.02, 0.20)) higher fat mass 
percentage and a 0.12 SDS (95 % CI (-0.21, -0.03)) lower lean mass percentage. The associations 
of maternal 25(OH)D status with childhood lean mass percentage remained signifi cant after 
considering multiple testing and after additional adjustment for childhood vitamin D status. 
When we examined the observed associations in the subgroup of children with vitamin D 
measurements at the age of 6 years the general pattern of fi ndings persisted. Children of 
mothers who were vitamin D severely defi cient had a 0.11 SDS (95 % CI (0, 0.22)) higher fat 
Table 2.4.1. Subject characteristics (N=4,903) (continued)
Characteristics
Infant characteristics
Girls (%) 50.4
Gestational age at birth (wk) 40.1 (35.8, 42.3)
Birth weight (g) 3,431 (554)
Breastfeeding in the fi rst 4 months (%)
- Ever 92.3
- Never 7.7
25(OH)D concentration in cord blood at birth (nmol/L) 28.8 (5.0, 81.7)
Season when cord blood sample was taken (%)
- Spring 27.6
- Summer 26.6
- Autumn 22.5
- Winter 23.3
Child characteristics at 6 years’ visit
Age (y) 6.0 (5.7, 7.8)
Height (cm) 119.4 (6.0)
Weight (kg) 22.6 (17.6, 33.8)
Playing sports, yes (%) 43.3
Childhood blood concentrations of 25(OH)D (nmol/L) 64.0 (18.0, 133.0)
Body composition
- Body mass index (kg/m2) 15.9 (13.6, 21.2)
- Fat mass percentage 24.9 (5.7)
- Lean mass percentage 71.5 (5.4)
Cardiovascular risk factors
- Systolic blood pressure (mmHg) 102.7 (8.3)
- Diastolic blood pressure (mmHg) 60.7 (6.9)
- Total-cholesterol (mmol/L) 4.2 (0.6)
- Triglycerides (mmol/L) 0.95 (0.4, 2.3)
- Insulin (pmol/L) 114.2 (17.0, 397.7)
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution.
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mass percentage and a 0.11 SDS (95 % CI (-0.23, 0)) lower lean mass percentage, as compared 
to children of mothers who had optimal 25(OH)D concentrations. Cord blood 25(OH)D con-
centrations were not associated with child body composition. Supplementary Table 2.4.4 
shows the results from the basic regression models for the associations of maternal and cord 
blood 25(OH)D concentrations and childhood body composition measures. We observed 
tendencies for similar eff ect estimates when we restricted the analyses to Europeans only 
(N=2,974), although the observed associations on fat mass percentage and lean mass per-
centage did not reached statistical signifi cance due to smaller sample sizes (Supplementary 
Table 2.4.5).
Maternal and cord 25(OH)D concentrations and childhood cardiovascular risk 
factors
Table 2.4.3 shows that maternal and cord blood 25(OH)D concentrations were not associated 
with childhood blood pressure, total cholesterol, triglycerides or insulin concentrations. The 
results from the basic models and the analysis restricted to Europeans only (N=2,974) are 
given in Supplementary Tables 2.4.6 & 2.4.7, respectively and showed similar results.
DISCUSSION
In this population-based prospective cohort study, we observed that severely defi cient 
maternal 25(OH)D concentrations during mid- pregnancy, but not at birth, tended to be asso-
ciated with higher fat mass and lower lean mass at school-age. These associations remained 
similar after adjustment for childhood 25(OH)D concentrations. Maternal and cord blood 
25(OH)D concentrations were not associated with childhood cardiovascular outcomes. 
Interpretation and comparison with previous studies
An accumulating body of evidence suggest that suboptimal vitamin D levels are common 
and related to the risk of cardiovascular disease.34, 35 Adults studies suggest that low 25(OH)D 
concentrations are associated with higher BMI and higher fat mass percentage.9, 33 In line 
with these results, studies in animals show that vitamin D infl uences development and dif-
ferentiation of adipocytes and muscle cells.3, 4 Also, previous childhood studies suggest a 
potential role of 25(OH)D concentrations on body composition and cardiovascular outcomes. 
11–13 Vitamin D is reported to be inversely associated with the development of adiposity in 
school-aged children.13 Moreover, childhood vitamin D status was negatively associated with 
blood pressure and plasma lipids.11, 12
Fetal life may be a critical period for the eff ects of vitamin D defi ciency because of the 
increased need and rapid fetal development. We have previously shown an association of 
maternal vitamin D with fetal growth patterns and birth outcomes.5 For the current study, we 
hypothesized that suboptimal fetal vitamin D concentrations may increase the risk of adipos-
ity and cardiovascular factors in the off spring. Results from previous birth cohort studies sug-
gest a possible programming eff ect of maternal 25(OH)D concentrations on childhood body 
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composition.16, 17 In a study among 977 women and their off spring it was observed that lower 
maternal 25(OH)D concentrations during pregnancy were associated with higher fat mass 
in 4 and 6 years old children.16 Another study among 568 Indian women and their children, 
reported that low maternal 25(OH)D concentrations were associated with a lower lean mass 
in the off spring.17 In line with these fi ndings, our results suggest that low maternal 25(OH)D 
concentrations during mid- pregnancy are associated with a higher fat mass percentage and 
lower lean mass percentage in the off spring. We observed that the associations of maternal 
25(OH)D concentrations during pregnancy with childhood fat and lean mass percentage 
were independent of birth weight and of childhood 25(OH)D concentrations. We did not 
observe any associations of cord blood 25(OH)D concentrations with childhood body compo-
sition. Furthermore, we observed tendencies for similar associations when we restricted the 
analyses to Europeans only. However, the associations were not signifi cant, probably due to 
smaller numbers. It is previously shown that body composition phenotypes track and are as-
sociated with poorer outcomes in later life.37, 38 Therefore, the observed subclinical diff erences 
in body composition in childhood may be related to adverse outcomes in later life. 
Only few studies have explored the association of fetal 25(OH)D concentrations with child-
hood cardiovascular risk factors.1, 15, 17 In a recent study among 4,109 mothers and children 
at the ages of 9.9 years and 15.4 years, a weak inverse association was observed of maternal 
25(OH)D concentrations with systolic blood pressure at the age of 9 years.15 However, this 
association was not present at the age of 15.4 years.15 We did not observe any association 
between maternal 25(OH)D concentrations and blood pressure in 6-year-old children. Also, 
we did not observe any association of maternal or cord blood 25(OH)D concentrations with 
childhood total- cholesterol, triglycerides, and insulin concentrations. A small study in India, 
observed that children of vitamin D defi cient mothers had higher fasting insulin resistance.17 
It may be that the diff erent results of our fi ndings with this study are explained by ethnic 
diff erences. When we restricted the analyses to Europeans only, we observed similar results 
as in the full group. Unfortunately, we did not have enough numbers in the other ethnic 
subgroups, to perform ethnic specifi c analyses. Our results do not support possible in utero 
eff ects of 25(OH)D concentrations on childhood cardiovascular risk factors. 
The mechanisms by which maternal 25(OH)D concentrations during pregnancy can aff ect 
off spring body composition are poorly understood. Animal experiments relate maternal 
25(OH)D concentrations to fetal muscle development. A study in rats which tracked 3H-la-
belled vitamin D injected into pregnant rats showed that 25OHD was transferred to the fetus 
and stored in fetal muscle tissue.39 1,25-dihydroxycholecalciferol (1,25(OH)D) regulates adipo-
cyte 11β-hydroxysteroid dehydrogenase type 1 activity, which generates active cortisol from 
inactive cortisone. The expression and cortisol production in human adipocytes, suggests a 
potential role for (1,25(OH)D) in fat mass.40 Furthermore, vitamin D can stop the expression of 
an important adipogenesis regulator, peroxisome proliferator-activated receptor-gamma.3, 41
Although, the observed eff ect estimates are small and without direct individual clinical 
consequence, the results of this study suggest that maternal 25(OH)D concentrations are as-
sociated with off spring fat mass percentage and lean mass percentage. Suboptimal vitamin 
D levels in pregnant women may have persistent eff ects on their off spring body composition. 
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An adverse childhood body fat profi le may increase the risk of cardiovascular and metabolic 
diseases in later life. With the design of our study, we are not able to establish causality for 
the observed associations and further studies are required. However, our fi ndings suggest 
that vitamin D supplementations during pregnancy may need to be targeted at women who 
are vitamin D severely defi cient. In the Netherlands, pregnant women are advised to use 
vitamin D supplements (10 μg/day). Therefore, our results support population-strategies to 
improve vitamin D concentrations in pregnant women to optimize off spring growth and 
development.
Strength and limitations
A major strength of our study the prospective design from fetal life onwards within a 
population-based cohort. This study is among the largest that examined the association of 
fetal vitamin D status with body composition and cardiovascular outcomes in a multi-ethnic 
sample of school-age children. We measured 25(OH)D concentrations in mid- pregnancy and 
cord blood at birth, assessing diff erent critical periods. 25(OH)D concentrations are the most 
widely used indicator of vitamin D status.42 Next to BMI, we also measured fat mass and lean 
mass using DXA. 
Due to the young age of the children, it was not possible to obtain fasting blood samples, 
which may have led to an underestimation of the associations. Of the singleton live born 
children 58 % participated in the follow up measurements. Mothers of the children who were 
lost to follow up had on average lower 25(OH)D concentrations and were on average lower 
educated, suggesting that our study population had a selection towards a healthier popula-
tion. Finally, although we performed adjustment for many potential maternal and childhood 
confounders, residual confounding for the observed associations might be present.
CONCLUSION 
Results from this population-based prospective cohort study suggest that severe vitamin 
D defi ciency during mid-pregnancy may infl uence childhood body composition. Further 
studies are needed to examine the causality of these associations and to identify the long 
term-clinical consequences.
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Supplementary Figure 2.4.1. Flowchart of the study participants
 
Children available for the analysis with 
measurements on:  
N=4,903 
 
Blood pressure  N=4,550 
Total-cholesterol  N=3,281 
Triglycerides   N=3,270 
Insulin    N=3,256 
Body mass index  N=4,898 
Fat mass percentage  N=4,805 
Lean mass percentage N=4,805
N=99 Excluded miscarriages or twin 
pregnancies (N=78) or children with 
congenital cardiac abnormalities (N =21) 
N=2,174 Excluded children who did not 
visit the research center at the age of 6 
(N=2,139) and without available adiposity 
or cardiovascular measurements (N=35) 
Singleton live births available for 
follow up measurements  
N=7,077 
Mothers with data on  
vitamin D blood levels  
N=7,176 
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Supplementary Table 2.4.1. Subject characteristics (N=4,903)
Subject characteristics Imputed Original
Maternal characteristics
Age (y) 30.4 (5.03) 30.4 (5.03)
Body mass index at enrolment (kg/m2) 22.7 (18.1, 34.8) 22.7 (18.1, 34.7)
Missing (%) 17.3
Nulliparous (%) 57.8 57.5
Missing (%) 0.7
Education level (%)
- No higher education 54.9 50.4
- Higher education 45.1 43.8
Missing (%) 5.8
Ethnicity (%)
- European 60.6 60.2
- Cape Verdean 4.5 4.3
- Dutch Antillean 2.7 2.5
- Moroccan 5.9 5.5
- Turkish 8.9 8.6
- Surinamese 8.2 8.1
- Other 9.2 9.0
Missing (%) 1.8
Smoking during pregnancy (%)
- Never 74.2 65.8
- Until pregnancy was known 9.4 8.2
- Continued 16.4 15.2
Missing (%) 10.8
Folic acid supplement use (%)
- No 26.8 18.6
- Start in the fi rst 10 weeks 31.6 24.5
- Start periconceptional 41.6 33.5
Missing (%) 23.4
Maternal energy intake (kcal) 2,049 (490) 2,051 (555)
Missing (%) 21.5
Maternal calcium dietary intake, (mg) 1,106 (329) 1,107 (339)
Missing (%) 21.5
Maternal blood concentrations of 25(OH)D (nmol/L) 50.4 (7.5, 122.5) NI
Season when blood sample was taken (%)
- Spring 28.6 NI
- Summer 22.6 NI
- Autumn 25.1 NI
- Winter 23.7 NI
Infant characteristics
Girls (%) 50.4 50.4
Gestational age at birth (wk) 40.1 (35.8, 42.3) 40.1 (35.8, 42.3)
Birth weight (g) 3,431 (554) 3,432 (553)
Missing (%) 0.2
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Supplementary Table 2.4.1. Subject characteristics (N=4,903) (continued)
Subject characteristics Imputed Original
Breastfeeding in the fi rst 4 months (%)
- Ever 92.3 73.9
- Never 7.7 5.7
Missing (%) 20.4
25(OH)D level in cord blood at birth (nmol/L) 28.8 (5.0, 81.7) NI
Season when cord blood sample was taken (%)
- Spring 28.6 NI
- Summer 22.6 NI
- Autumn 25.1 NI
- Winter 23.7 NI
Child characteristics at 6 years’ visit
Age (y) 6.0 (5.7, 7.8) 6.0 (5.7, 7.8)
Height (cm) 119.4 (6.0) NI
Weight (kg) 22.6 (17.6, 33.8) NI
Participation at sports, yes (%) 43.3 37.9
Missing (%) 15.3
Body composition
- BMI (kg/m2) 15.9 (13.6, 21.2) NI
- Fat mass percentage 24.9 (5.7) NI
- Lean mass percentage 71.5 (5.4) NI
Cardiovascular risk factors
- Systolic blood pressure (mmHg) 102.7 (8.3) NI
- Diastolic blood pressure (mmHg) 60.7 (6.9) NI
- Total-cholesterol (mmol/L) 4.2 (0.6) NI
- Triglycerides (mmol/L) 0.95 (0.4, 2.3) NI
- Insulin (pmol/L) 114.2 (17.0, 397.7) NI
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. NI- not imputed  
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Supplementary Table 2.4.2. Subject characteristics with and without adiposity and cardiovascular mea-
surements
N=4,903 N=2,174 p-value
Maternal age (y) 30.4 (5.03) 28.4 (5.4) <0.001
Maternal body mass index at enrolment (kg/m2) 22.7 (18.8, 35.8) 22.7 (17.7, 36.0) 0.45
Nulliparous (%) 57.8 52.7 <0.001
Education level (%) <0.001
- No higher education 54.9 68.9
- Higher education 45.1 31.1
Ethnicity (%) <0.001
- European 60.6 45.6
- Cape Verdean 4.5 4.9
- Dutch Antillean 2.7 6.0
- Moroccan 5.9 10.0
- Turkish 8.9 10.7
- Surinamese 8.2 11.2
- Others 9.2 11.6
Smoking during pregnancy (%) <0.001
- Never 74.2 68.9
- Until pregnancy was known 9.4 8.8
- Continued 16.4 22.3
Folic acid supplements use (%) <0.001
- No 26.8 40.3
- Start 1st to 10 weeks 31.6 30.8
- Start periconceptional 41.6 28.9
Maternal calories intake (kcal) 2,049 (490) 2,020 (481) <0.001
Maternal calcium dietary intake, (mg) 1,106 (329) 1,068 (334) <0.001
Maternal blood levels of 25(OH)D (nmol/L) 50.4 (7.5, 122.5) 38.6 (6.0, 110.7) <0.001
Season when blood sample was taken (%) <0.001
- Spring 28.6 31.6
- Summer 22.6 23.5
- Autumn 25.1 21.5
- Winter 23.7 23.4
Girls (%) 50.4 48.3 <0.001
Gestational age at birth (wk) 40.1 (35.8, 42.3) 40.0 (34.7, 42.3) <0.001
Birth weight (g) 3,431 (554) 3,375 (578) <0.001
Breastfeeding (%) <0.001
- Ever 92.3 90.5
- Never 7.7 9.5
Child 25(OH)D level in cord blood at birth (nmol/L) 28.8 (5.0, 81.7) 23.9 (4.3, 79.6) <0.001
Season when cord blood sample was taken (%) <0.001
- Spring 27.6 23.9
- Summer 26.6 28.9
- Autumn 22.5 25.2
- Winter 23.3 22.0
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or me-
dians (95 % range) for continuous variables with a skewed distribution. Diff erences in subject characteristics comparing 
the groups with and without body composition and cardiovascular measurements were evaluated using T-tests for con-
tinuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests for 
categorical variables.  
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Supplementary Table 2.4.3. Correlation coeffi  cients of the investigated variables
Maternal 
25(OH)D
Cord blood 
25(OH)D BMI FMP LMP SBP DBP CHL TGL INSL
Maternal 25(OH)D 1.00
Cord blood 25(OH)D 0.61** 1.00
BMI -0.15** -0.12** 1,00
FMP -0.17** -0.15** 0.57** 1,00
LMP 0.17** 0.16** -0.56** -0.999** 1,00
SBP -0.07** -0.08** 0.24** 0.19** -0.19** 1,00
DBP -0.05** -0.09** 0.08** 0.13** -0.14** 0.62** 1,00
CHL -0.03 -0.01 0.09** 0.14** -0.14** 0.08** 0.05* 1,00
TGL -0.01 0.03 0.05** 0.06** -0.06** -0.01** -0.02 0.15** 1,00
INSL 0.02 0.04 0.13** 0.09** -0.09** 0.08** -0.02 -0.03 0.19** 1.00
** Correlation is signifi cant at the 0.01 level (2-tailed).
* Correlation is signifi cant at the 0.05 level (2-tailed). Abbreviations: 25(OH)D- 25-hydroxyvitamin D, BMI- body mass index, 
FMP- fat mass percentage, LMP- lean mass percentage, SBP- systolic blood pressure, DBP- diastolic blood pressure, CHL- 
total cholesterol, TGL- triglycerides, INSL- insulin. 
Supplementary Table 2.4.4. Crude associations of fetal 25(OH)D concentrations and body composition 
measures at the age of 6 years (N=4,903)
Fetal 25(OH)D concentrations Diff erence in outcome measure (95 % Confi dence Interval)
Maternal 25(OH)D 
concentrations
Body mass index
(N=4,898)
Fat mass percentage
(N=4,805)
Lean mass percentage
(N=4,805)
<25.0 nmol/L (N=1,142) 0.37 (0.20, 0.55)*** 0.26 (0.18, 0.35)*** -0.27 (-0.35, -0.18)***
25.0 to 49.9 nmol/L (N=1,281) 0.19 (0.05, 0.34)** 0.12 (0.05, 0.19)*** -0.12 (-0.19, -0.05)***
50.0 to 74.9 nmol/L (N=1,195) 0.09 (-0.05, 0.23) 0.07 (0, 0.14) -0.07 (-0.14, 0)
≥75.0 nmol/L (N=1,285) Reference Reference Reference
Continuously (per SD) -0.11 (-0.17, -0.05)*** -0.08 (-0.11, -0.05)*** 0.08 (0.05, 0.11)***
Cord blood 25(OH)D 
concentrations
Body mass index
(N=3,048)
Fat mass percentage
(N=2,998)
Lean mass percentage
(N=2,998)
<25.0 nmol/L (N=665) 0.14 (-0.03, 0.32) 0.09 (-0.07, 0.26) -0.10 (-0.26, 0.07)
25.0 to 49.9 nmol/L (N=818) 0.12 (-0.05, 0.30) 0.03 (-0.13, 0.19) -0.03 (-0.19, 0.13)
50.0 to 74.9 nmol/L (N=780) 0 (-0.18, 0.19) -0.05 (-0.22, 0.11) 0.05 (-0.12, 0.22)
≥75.0 nmol/L (N=790) Reference Reference Reference
Continuously (per SD) -0.05 (-0.09, -0.01)* -0.06 (-0.10, -0.03)*** 0.06 (0.03, 0.10)***
Values are linear regression coeffi  cients (95 % confi dence interval). Basic model is adjusted for child’s sex, age at 6-year visit 
and maternal ethnicity. *p <0.05, **p <0.01, ***p <0.001. Continuously = Maternal and cord blood vitamin D concentrations 
analyzed per 1 standard deviation in 25(OH)D. 
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Supplementary Table 2.4.6. Crude associations of fetal 25(OH)D concentrations during pregnancy with 
cardiovascular risk factors at the age of 6 years (N=4,903)
Fetal 25(OH)D concentrations Diff erence in outcome measure (SDS) (95 % Confi dence Interval)
Maternal 25(OH)D 
concentrations
Systolic blood 
pressure
(N=4,550)
Diastolic blood 
pressure
(N=4,550)
Total 
cholesterol
(N=3,281)
Triglycerides
(N=3,270)
Insulin
(N=3,256)
<25.0 nmol/L (N=1,142) 0.04 (-0.06, 0.14) -0.02 (-0.12, 0.08) 0 (-0.12, 0.11) 0.01 (-0.11, 0.13) -0.06 (-0.19, 0.06)
25.0 to 49.9 nmol/L (N=1,281) 0.02 (-0.06, 0.11) 0.01 (-0.08, 0.09) 0.02 (-0.08, 0.12) 0.03 (-0.07, 0.13) -0.01 (-0.11, 0.09)
50.0 to 74.9 nmol/L (N=1,195) 0 (-0.09, 0.08) -0.03 (-0.12, 0.05) 0.07 (-0.03, 0.16) 0.04 (-0.05, 0.14) -0.09 (-0.19, 0.01)
≥75.0 nmol/L (N=1,285) Reference Reference Reference Reference Reference
Continuously (per SD) 0 (-0.04, 0.03) 0.01 (-0.03,0.04) 0.01 (-0.03, 0.05) -0.01 (-0.05, 0.03) 0.01 (-0.03, 0.06)
Cord blood 25(OH)D 
concentrations
Systolic blood 
pressure
(N=2,847)
Diastolic blood 
pressure
(N=2,847)
Total 
cholesterol
(N=2,042)
Triglycerides
(N=2,038)
Insulin
(N=2,201)
<25.0 nmol/L (N=665) 0.05 (-0.14, 0.24) 0.07 (-0.12, 0.27) 0.02 (-0.22, 0.25) -0.01 (-0.24, 0.22) 0.03 (-0.20, 0.26)
25.0 to 49.9 nmol/L (N=818) 0.06 (-0.12, 0.25) 0.02 (-0.17, 0.21) 0.15 (-0.08, 0.38) 0.04 (-0.19, 0.26) 0.12 (-0.11, 0.35)
50.0 to 74.9 nmol/L (N=780) 0.03 (-0.16, 0.23) 0 (-0.20, 0.20) 0.09 (-0.16, 0.32) 0.07 (-0.17, 0.31) 0.10 (-0.14, 0.33)
≥75.0 nmol/L (N=790) Reference Reference Reference Reference Reference
Continuously (per SD) -0.02 (-0.06, 0.02) -0.04 (-0.08,0.01) 0.02 (-0.03, 0.07) 0.03 (-0.02, 0.08) 0.01 (-0.04, 0.07)
Values are linear regression coeffi  cients (95 % confi dence interval). Basic model is adjusted for child’s sex, age at 6-year 
visit and maternal ethnicity. Continuously = Maternal and cord blood vitamin D concentrations analyzed per 1 standard 
deviation in 25(OH)D. 
Supplementary Table 2.4.7. Associations of maternal 25(OH)D concentrations during pregnancy with car-
diovascular risk factors at the age of 6 years, among Europeans (N=2,974)
Fetal 25(OH)D concentrations Diff erence in outcome measure (SDS) (95 % Confi dence Interval)
Maternal 25(OH)D 
concentrations
Systolic blood 
pressure
(N=2,753)
Diastolic blood 
pressure
(N=2,753)
Total 
cholesterol
(N=2,203)
Triglycerides
(N=2,000)
Insulin
(N=1,992)
<25.0 nmol/L (N=192) -0.05 (-0.21, 0.11) -0.09 (-0.25, 0.08) 0.15 (-0.06, 0.34) 0 (-0.20, 0.21) -0.12 (-0.33, 0.08)
25.0 to 49.9 nmol/L (N=740) 0.01 (-0.08, 0.11) 0.02 (-0.08, 0.12) 0.05 (-0.07, 0.16) 0.09 (-0.03, 0.21) 0.04 (-0.08, 0.15)
50.0 to 74.9 nmol/L (N=909) -0.02 (-0.11, 0.07) -0.04 (-0.13, 0.05) 0.08 (-0.03, 0.18) 0.09 (-0.02, 0.20) -0.07 (-0.18, 0.04)
≥75.0 nmol/L (N=1,133) Reference Reference Reference Reference Reference
Continuously (per SD) 0.01 (-0.03, 0.05) 0 (-0.04, 0.05) -0.03 (-0.08, 0.03) -0.05 (-0.10, 0.01) 0.01 (-0.04, 0.06)
Cord blood 25(OH)D 
concentrations
Systolic blood 
pressure
(N=1,786)
Diastolic blood 
pressure
(N=1,786)
Total 
cholesterol
(N=1,294)
Triglycerides
(N=1,292)
Insulin
(N=1,283)
<25.0 nmol/L (N=486) -0.06 (-0.26, 0.14) -0.01 (-0.22, 0.20) 0.05 (-0.21, 0.31) 0.15 (-0.10, 0.41) 0.04 (-0.22, 0.28)
25.0 to 49.9 nmol/L (N=853) 0.01 (-0.17, 0.20) 0.01 (-0.18, 0.20) 0.11 (-0.13, 0.35) 0.10 (-0.14, 0.33) 0.04 (-0.19, 0.27)
50.0 to 74.9 nmol/L (N=468) 0.01 (-0.18, 0.21) 0.05 (-0.15, 0.24) 0.06 (-0.19, 0.30) 0.11 (-0.13, 0.36) 0.03 (-0.21, 0.27)
≥75.0 nmol/L (N=119) Reference Reference Reference Reference Reference
Continuously (per SD) 0.02 (-0.03, 0.07) 0.01 (-0.05, 0.06) -0.01 (-0.07, 0.06) -0.02 (-0.08, 0.05) 0 (-0.06, 0.07)
Values are linear regression coeffi  cients (95 % confi dence interval). Adjusted model is adjusted for maternal characteristics 
(age, ethnicity, body mass index before pregnancy, parity, education, smoking, folic acid supplements, dietary calcium and 
energy intake during pregnancy, and season of blood sampling), and child characteristics (sex, birthweight, gestational 
age at birth, breastfeeding, and age at measurements, body mass index and playing sports at the age of 6y). *p <0.05. 
Continuously = Maternal and cord blood vitamin D concentrations analyzed per 1 standard deviation in 25(OH)D.
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ABSTRACT
Background: Maternal vitamin D defi ciency during pregnancy may infl uence off spring kid-
ney health. We aimed to examine the associations of 25-hydroxyvitamin D (25(OH)D) blood 
levels during fetal life with kidney outcomes at school-age.
Methods: This study was embedded in a population-based prospective cohort study among 
4,212 mother-child pairs. We measured maternal mid-pregnancy (18–25 weeks) and fetal cord 
blood (at birth) 25(OH)D levels. At a median age of 6.0 years, we measured children’s com-
bined kidney volume, glomerular fi ltration rate (eGFR) from creatinine and cystatin C serum 
levels and microalbuminuria from albumin and creatinine urine levels. 
Results: Of all mothers, 21.9 % had severely defi cient levels (25(OH)D <25.0 nmol/L), 25.7 % had 
defi cient levels (25.0 to 49.9 nmol/L), 25 % had suffi  cient levels (50.0 to 74.9 nmol/L), and 27.4 % 
had optimal levels (≥75.0 nmol/L). Maternal 25(OH)D levels were not consistently associated 
with childhood combined kidney volume. Higher maternal 25(OH)D levels were associated 
with lower childhood eGFR (diff erence -0.94 ml/min/1.73m2 (95 % CI -1.73; -0.15) per 1 standard 
deviation increase in 25(OH)D). Maternal 25(OH)D levels were not associated with microalbu-
minuria. Cord blood 25(OH)D levels were not associated with childhood kidney outcomes. 
The associations of maternal 25(OH)D levels with childhood eGFR were partly explained by 
childhood vitamin D status.
Conclusion: Our fi ndings suggest that maternal 25(OH)D levels during pregnancy may infl u-
ence childhood kidney outcomes. These results should be considered hypothesis-generating. 
Further studies are needed to replicate the observations, to examine the underlying mecha-
nisms, and to identify the long term-clinical consequences.
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INTRODUCTION 
Vitamin D defi ciency is related to various adverse health outcomes in early and later life.1–4 
An accumulating body of evidence suggest than vitamin D status during pregnancy may 
persistently aff ect off spring health including poor weight gain, impaired development and 
rickets.5, 6 Maternal vitamin D defi ciency during pregnancy may also aff ect off spring kidney 
health. An experimental study in rats observed that maternal vitamin D defi ciency leads to 
an increase in nephron number in the off spring, suggesting a stimulated nephrogenesis.7 
In line with these fi ndings, another study in mice has shown that off spring of mothers who 
received a vitamin D defi cient diet during pregnancy had a higher number of glomeruli 
and a delayed maturity of the glomeruli.8 However, in contrast to these fi ndings, another 
study in rats suggests that maternal vitamin D defi ciency leads to lower kidney mass and a 
compromised kidney function.9 As nephrogenesis continues until 36 weeks of gestation and 
largely ceases afterwards, suboptimal maternal vitamin D levels during specifi cally second 
half of pregnancy may infl uence kidney development.10, 11 Smaller kidneys in early life with a 
reduced number of nephrons lead to glomerular hyperfi ltration and sclerosis and predispose 
to kidney disease in adulthood.12 To the best of our knowledge there are no studies that have 
observed the eff ects of fetal life vitamin D levels on kidney function in healthy children.
Therefore, we examined in a population-based prospective cohort study among 4,212 
mother-child pairs, the associations of circulating vitamin 25-hydroxyvitamin D (25(OH)D) 
levels during mid-pregnancy and in cord blood at birth with childhood kidney outcomes. 
Additionally, we explored whether any association was explained by child’s current 25(OH)D 
levels.
METHODS
Design and study population 
This study was embedded in the Generation R Study, a population-based prospective co-
hort study from fetal life onwards in Rotterdam, the Netherlands.13, 14 All children were born 
between April 2002 and January 2006. Enrolment in the study was aimed at early pregnancy, 
but was allowed until the birth of the child. The study was conducted according to the guide-
lines of the Helsinki Declaration and approved by the Medical Ethics Committee of Erasmus 
Medical Center, Rotterdam. Written informed consent was obtained from parents. Maternal 
25(OH)D blood levels were measured in 7,176 pregnant women. In total, 4,251 of their singleton 
live born children participated in the kidney follow-up measurements at the age of 6 years. 
Children with evidence of congenital kidney abnormalities on ultrasound examination (N=7) 
or with abnormally high urinary albumin-creatinine ratio (>25) (N=12) were excluded from 
the study. Measurements on kidney ultrasound, creatinine and cystatin C from blood and 
albumin and creatinine from urine samples were available on 4,212 children. (Figure  2.5.1. 
Flowchart).
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Maternal and cord 25(OH)D blood levels 
Maternal venous blood samples were collected in mid-pregnancy (median gestational age 
20.3 weeks, range 18.5–23.3 weeks). Umbilical cord blood samples were taken immediately 
after delivery (median 40.1 weeks of gestation, range 35.9–42.3 weeks) by midwives and ob-
stetricians. Measurements of 25(OH)D levels were conducted at the Eyles Laboratory at the 
Queensland Brain Institute, University of Queensland, Australia. 
Total 25(OH)D was reported as the sum of 25(OH)D2 and 25(OH)D3 measured in plasma us-
ing a modifi cation of a method previously described.15 Samples were quantifi ed using isotope 
dilution liquid chromatography-tandem mass spectrometry. Linearity was assessed using 
matrix-matched calibration standards, with R2 values of >0.99 across the calibration range 
(10–125 nmol/L). Inter-assay inaccuracy and imprecision were assessed at four concentration 
levels for 25(OH)D3 (48.3, 49.4, 76.4, 139.2 nmol/L) and a single level (32.3 nmol/L) for 25(OH)D2 
using certifi ed reference materials and were excellent at all concentration levels tested. Inter-
assay inaccuracy and imprecision were both <10 % for 25(OH)D3 and <17 % for 25(OH)D2, 
respectively. On the basis of recommendations and previous studies, we defi ned the follow-
ing categories for vitamin D status: <25.0 nmol/L (<10.0 mg/L), severely defi cient; 25 to 49.9 
nmol/L (10.0 to 19.9 mg/L), defi cient; 50.0 to 74.9 nmol/L (20.0 to 29.9 mg/L), suffi  cient; and 
≥75.0 nmol/L (≥30.0 mg/L), optimal.16–19 In children circulating 25(OH)D levels were measured 
at a median age of 6.0 years (range 5.6–7.4), at the Endocrine Laboratory of the VU University 
Figure 2.5.1. Flowchart of the study participants
 
 
 
 
 
  
 
 
 
 
  
  
 
 
 
  
Singletons with available information on 
maternal vitamin D blood levels and visit to 
the research centre at the age of 6 years 
N=4,251 
Children with both successful measurements  
N=4,212 
N=2,925 excluded due to: twin birth (61), no 
participation on follow up phases (2,864)  
N=39 excluded due to: no kidney 
measurements (20), congenital kidney 
abnormalities (7), high albumin creatinine 
ratio (12) 
Children with both successful measurements  
N=4,212 
 
With data available on:  
Kidney volume    N=3,897 
eGFRcreat     N=2,833 
eGFRcystC                     N=2,836 
Microalbuminuria    N=4,068 
Mothers with data on vitamin D blood levels  
N=7,176 
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Medical Center, Amsterdam as described previously in detail.20 Child’s current 25(OH)D status 
was available in a subgroup of 2,644 subjects.
Childhood kidney outcomes
Children’s kidney outcomes were assessed at a median age of 6.0 (95 % range 5.6 to 7.4) years 
in a dedicated research center in the Erasmus MC-Sophia Children’s Hospital in Rotterdam.21 
We measured kidney volume with ultrasound. Left and right kidneys were identifi ed in the 
sagittal plane along its longitudinal axis. We performed measurements of maximal bipolar 
kidney length, width and depth. Kidney width and depth were measured at the level of the 
hilum. The cross-sectional area in which the kidney appeared symmetrically round at its 
maximum width was used. Using the equation for a prolate ellipsoid we calculated kidney 
volume: volume (cm3) = 0.523 x length (cm) x width (cm) x depth (cm).22 Combined kidney vol-
ume was calculated by summing right and left kidney volume. Previously, we have reported 
good intra-observer and inter-observer correlation coeffi  cients.23
We measured creatinine and cystatin C levels from non-fasting blood samples drawn by 
antecubital venipuncture. Creatinine levels were measured with enzymatic methods and 
cystatin C levels with a particle enhanced immunoturbidimetric assay (using Cobas 8000 
analyzers, Roche, Almere, the Netherlands). Quality control samples demonstrated intra-
assay and inter-assay coeffi  cients of variation ranging from 0.51 to 1.37 %, and 1.13 to 1.65 %, 
respectively. Estimated glomerular fi ltration rate (eGFR) was calculated according to the 
revised Schwartz 2009 formula: eGFRcreat  =  36.5 * (height (cm)/serum creatinine (μmol/L).24 
In addition, we calculated eGFR using Zappitelli’s formula based on cystatin C levels: eG-
FRcystC  =  75.94/[CysC1.17].25 We calculated the albumin-creatinine ratio using urine creatinine 
(mmol/L) and urine albumin (mg/l) levels. These levels were determined with a Beckman 
Coulter AU analyser, creatinine levels were measured with the Jaff e reaction. In line with clini-
cal cut-off s, microalbuminuria was defi ned as an albumin-creatinine ratio >2.5 mg/mmol for 
boys and >3.5 mg/mmol for girls.26
Covariates
We used questionnaires at enrollment in the study (median 13.5 weeks of gestation) to collect 
information about maternal age, ethnicity, educational level, and on smoking, alcohol usage 
and folic acid supplementation during pregnancy.13 The presence of high cholesterol, diabe-
tes, hypertension was available from the same questionnaires. Maternal energy intake during 
pregnancy was measured at enrollment with a validated semi-quantitative food frequency 
questionnaire.27 Ethnicity and educational level were defi ned according to the classifi cation 
of Statistics Netherlands.28, 29 We measured maternal height and weight at enrollment and 
calculated body mass index (kg/m2). The date of blood sampling was categorized into sum-
mer, fall, winter, and spring based on the Dutch standard seasons. Infant sex, gestational 
age, weight and length at birth were obtained from midwifes, medical records and hospital 
registries. We calculated sex- and gestational age-specifi c SD scores for birth weight.30 
Information on breastfeeding was collected using postnatal questionnaires as previously 
reported.21 At the age of 6 years, child height was determined in standing position to the 
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nearest millimeter without shoes by a Harpenden stadiometer (Holtain Limited, Dyfed, U.K.). 
Weight was measured using a mechanical personal scale (SECA, Almere, the Netherlands). We 
calculated body mass index (kg/m2) and body surface area (BSA) (m2) (using DuBois formula 
BSA= weight (kg)0.425 x height (cm)0.725 x 0.007184).
Statistical analysis 
We performed a non-response analysis by comparing subject characteristics between chil-
dren with and without follow-up kidney measurements. We used multivariable linear and 
logistic regression models to assess the associations of maternal and cord 25(OH)D levels 
with combined kidney volume, creatinine and cystatin C levels, eGFRcreat and eGFRcystC, and 
risk of microalbuminuria in childhood. Levels of 25(OH)D were analyzed both continuously 
per standard deviation (SD)- increase and using clinical cut-off s.16–18 The regression models 
were fi rst adjusted for child’s sex, child’s age at kidney measurements, season when blood 
samples were drawn and maternal ethnicity (basic models), and subsequently additionally 
for maternal age, education, body mass index at enrolment, smoking, alcohol use, folic acid 
supplement use and energy intake during pregnancy, and pre-pregnancy comorbidities, and 
for child’s gestational age-adjusted birth weight, breastfeeding in early life, and body surface 
area at the age of 6 years. These covariates were included in the models based on their as-
sociations with kidney outcomes in previous studies, or a change in eff ect estimates of >10 %. 
As the interactions of maternal 25(OH)D with child sex were not signifi cant, we did not stratify 
our analyses on child sex. To explore if childhood 25(OH)D status explain the associations 
between fetal 25(OH)D and childhood kidney outcomes, we performed a sensitivity analysis 
in the subgroup of children with 25(OH)D levels available. To diminish potential bias associ-
ated with attrition, missing values of covariates (less than 24 %), were multiple imputed by 
generating 10 independent datasets using the Markov Chain Monte Carlo (MCMC) method. 
The multiple imputation procedure was based on the correlation between each variable with 
missing values and the other subject characteristics.31, 32 Statistical analyses were performed 
using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
RESULTS 
Participant characteristics
Table 2.5.1 shows that in mothers median (95 % range) 25(OH)D levels were 51.9 nmol/L (7.7, 
122.1). Of all mothers, 21.9 % had severely defi cient levels (25(OH)D <25.0 nmol/L), 25.7 % had 
defi cient levels (25.0 to 49.9 nmol/L), 25 % had suffi  cient levels (50.0 to 74.9 nmol/L), and 27.4 % 
had optimal levels (≥75.0 nmol/L). In cord blood median 25(OH)D levels were 29.3 nmol/L 
range (5.6, 81.5). At the age of 6 years, mean (± SD) combined kidney volume was 120 cm3 
(±22.8), and mean eGFRcreat was 119 ml/min/1.73m2 (±16.4). Of all children, 7.6 % had microalbu-
minuria. Subjects characteristics before and after imputation are shown in Supplementary 
Table  2.5.1. Results from the non-response analysis showed that as compared to children 
who did not have kidney measurements at the age of 6 years, those who did have kidney 
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measurements had mothers with a higher educational level and higher 25(OH)D levels dur-
ing pregnancy. Children with kidney measurements also had higher 25(OH)D levels at birth 
(Supplementary Table 2.5.2).
Table 2.5.1. Subject characteristics (N=4,212) 
Characteristics
Maternal Characteristics
Age (y) 31.3 (20.2, 39.4)
Body mass index at enrolment (kg/m2) 22.6 (18.1, 34.3)
Education level (%)
- No higher education 51.2
- Higher education 48.8
Ethnicity (%)
- European 63.2
- Cape Verdean 4.1
- Dutch Antillean 2.0
- Moroccan 5.6
- Turkish 8.2
- Surinamese 7.6
- Other 9.3
Smoking during pregnancy (%)
- Never 75
- Until pregnancy was known 9.9
- Continued 15.1
Alcohol consumption during pregnancy (%)
- Never 42.8
- Until pregnancy was known 14.3
- Continued 42.9
Folic acid supplement use (%)
- No 24.5
- Start in the fi rst 10 weeks 31.2
- Start periconceptional 44.3
Maternal energy intake (kcal) 2,062 (485)
Maternal blood levels of 25(OH)D (nmol/L) 51.9 (7.7, 122.1)
Season when blood sample was taken (%)
- Spring 27.8
- Summer 22.6
- Autumn 25.5
- Winter 24.1
Infant characteristics
Girls (%) 50.4
Gestational age at birth (wk) 40.1 (35.9, 42.3)
Birth weight (g) 3,449 (545)
Breastfeeding in the fi rst 4 months (%)
- Exclusive 31.7
- Partial 61.1
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Maternal and cord 25(OH)D levels and childhood kidney outcomes 
Table 2.5.2 gives the results from the multivariable regression models for the associations 
of maternal 25(OH)D levels and childhood kidney outcomes. Children of mothers who were 
vitamin D defi cient during pregnancy had a 1.92 cm3 (95 % Confi dence Interval (CI) 0.11, 3.74) 
larger combined kidney volume compared to children of mothers who had optimal 25(OH)D 
levels. However, the overall trend analysis based on continuous data for 25(OH)D was not 
signifi cant. Maternal 25(OH)D levels were inversely associated with lower childhood eGFRcreat 
(diff erence -0.94 (95 % CI -1.73; -0.15) ml/min/1.73m2 per 1 SD increase in 25(OH)D). Maternal 
25(OH)D levels were not associated with eGFRcystC or risk of microalbuminuria. Results from 
the basic models of maternal and cord blood vitamin D and childhood kidney outcomes 
are shown in the Supplementary Table 2.5.3 & Supplementary Table 2.5.4. In line with the 
results for eGFRcreat and eGFRcystC, maternal 25(OH)D levels were associated with 0.32 μmol/L 
(95 % CI 0.07; 0.58) higher childhood creatinine levels per 1 SD increase in 25(OH)D, but not with 
childhood cystatin C levels (Supplementary Table 2.5.5). We performed a sensitivity analysis 
among a subgroup of 2,644 children to explore whether any association was explained by 
childhood 25(OH)D status. Results from this analysis are given in Supplementary Table 2.5.6, 
and suggest that the association of maternal 25(OH)D levels with childhood eGFRcreat were at 
least partly explained by child 25(OH)D status. 
Table 2.5.1. Subject characteristics (N=4,212)  (continued)
Characteristics
- Never 7.2
Child 25(OH)D level in cord blood at birth (nmol/L) 29.3 (5.2, 81.5)
Season when cord blood sample was taken (%)
- Spring 28.2
- Summer 26.5
- Autumn 21.4
- Winter 23.9
Child characteristics at 6 years visit
Age (y) 6.0 (5.6, 7.4)
Height (cm) 119 (5.6)
Weight (kg) 22.2 (17.4, 32.4)
Body mass index (kg/m2) 15.8 (13.6, 20.7)
Body surface area (m2) 0.86 (0.7, 1.1)
Childhood 25(OH)D levels (nmol/L) 64.4 (18.0, 134.0)
Combined kidney volume (cm3) 120 (22.8)
Creatinine (μmol/L) 37.2 (5.5)
Cystatin C (μg/L) 784 (80.2)
eGFRcreat (ml/min/1.73m2) 119 (16.4)
eGFRcystC (ml/min/1.73m2) 102.5 (14.5)
Microalbuminuria (%) 7.6
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. 
Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood levels and eGFRcystC esti-
mated glomerular fi ltration rate calculated based on cystatin C blood levels.
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Table 2.5.3 gives the results from the multivariable regression models for the associations 
of cord 25(OH)D levels at birth and childhood kidney outcomes. Using the same cut-off s for 
vitamin D status, 42.2 % of the children were categorized as severely vitamin D defi cient, 
36.4 % as defi cient, 17.3 % as suffi  cient, and 4.1 % as optimal. Cord 25(OH)D levels were not 
associated with any of the childhood kidney outcomes. 
Table 2.5.2. Associations of maternal 25(OH)D levels during pregnancy with child kidney outcomes at the 
age of 6 years (N=4,212) 
Multivariable model£
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=4,068
Kidney volume
(cm3)
N=3,897
eGFRcreat
(ml/min/1.73m2)
N=2,833
eGFRcystC
(ml/min/1.73m2)
N=2,836
<25.0 nmol/L (N=921) -0.76 (-3.11, 1.59) 1.52 (-0.83, 3.86) -0.33 (-2.39, 1.72) 1.31 (0.83, 2.06)
25.0 to 49.9 nmol/L (N=1,083) 1.92 (0.11, 3.74)* 1.39 (-0.37, 3.15) 0.66 (-0.93, 2.24) 0.91 (0.63, 1.32)
50.0 to 74.9 nmol/L (N=1,055) 0.90 (-0.82, 2.62) 1.44 (-0.24, 3.12) 0.64 (-0.87, 2.15) 1.15 (0.83, 1.59)
≥75.0 nmol/L (N=1,153) Reference Reference Reference Reference
Continuously (per SD) -0.55 (-1.35, 0.25) -0.94 (-1.73, -0.15)* -0.29 (-0.99, 0.41) 0.93 (0.80, 1.09)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Multivariable adjusted model £ is adjusted 
for child’s sex, age at 6-year visit, maternal characteristics (age, body mass index at intake, alcohol consumption, smok-
ing during pregnancy, folic acid and energy intake during pregnancy, education, ethnicity, prepregnancy comorbidities, 
season when blood samples were drawn) and child characteristics (birthweight adjusted for gestational age, breastfeed-
ing, and body surface area at the age of 6y). *p <0.05. Continuously = Maternal vitamin D levels analyzed per 1 standard 
deviation in 25(OH)D. 
Abbreviations: SD standard deviation; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels.
Table 2.5.3. Associations of 25(OH)D cord blood levels with kidney outcomes at the age of 6 years 
(N=2,689)
Multivariable model£
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=2,598
Kidney volume
(cm3)
N=2,480
eGFRcreat
(ml/min/1.73m2)
N=1,810
eGFRcystC
(ml/min/1.73m2)
N=1,814
<25.0 nmol/L (N=1,136) 0.80 (-3.50, 5.11) -0.11 (-4.30, 4.09) -0.33 (-4.23, 3.57) 0.68 (0.33, 1.41)
25.0 to 49.9 nmol/L (N=980) 0.70 (-3.41, 4.81) -1.64 (-5.62, 2.33) -0.14 (-3.85, 3.58) 0.61 (0.31, 1.20)
50.0 to 74.9 nmol/L (N=464) -0.34 (-4.58, 3.80) -0.85 (-4.97, 3.26) -1.14 (-4.98, 2.71) 0.56 (0.27, 1.15)
≥75.0 nmol/L (N=109) Reference Reference Reference Reference
Continuously (per SD) -0.44 (-1.43, 0.55) -0.20 (-1.18, 0.79) 0.17 (-0.73, 1.08) 0.91 (0.75, 1.11)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Multivariable adjusted model £ is adjusted 
for child’s sex, age at 6-year visit, maternal characteristics (age, body mass index at intake, alcohol consumption, smoking 
during pregnancy, folic acid and energy intake during pregnancy, education, ethnicity, prepregnancy comorbidities) and 
child characteristics (birthweight adjusted for gestational age, breastfeeding, season when blood samples were drawn 
and body surface area at the age of 6y). *p <0.05. Continuously = Cord vitamin D levels analyzed per 1 standard deviation 
in 25(OH)D. 
Abbreviations: SD standard deviation; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels
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DISCUSSION
In this population-based prospective cohort study, we observed that lower maternal, but not 
cord, 25(OH)D levels in blood, tended to be associated with higher eGFR and larger combined 
kidney volume in school-age children. The associations may be partly explained by child-
hood 25(OH)D levels.
Strength and limitations
A major strength of our study is the prospective design from fetal life onwards within a large 
population-based cohort. This study is among the fi rst that examined the association of fetal 
vitamin D status with kidney health in a large multi-ethnic sample of school-age children. We 
used 25(OH)D levels, which are the best and most widely used indicator of vitamin D status.33 
Furthermore, we used well-established methods to measure kidney size and function.23, 34 Kidney 
volume was measured by ultrasound. Kidney size is correlated with the number of glomeruli 
and can be used in epidemiological studies as measure of kidney development.35 In children 
the estimation of GFR is challenging. Blood creatinine is most commonly used to calculate 
eGFR, and Schwartz formula has been validated in a pediatric population.24 In addition to 
blood creatinine levels, we also calculated eGFR based on cystatin C levels using Zappitelli’s 
formula.25, 36 It has been suggested that blood cystatin C levels might be a better biomarker to 
estimate GFR because the production rate is constant, it is freely fi ltered, and less dependent on 
child weight, height and sex compared to creatinine.37, 38 However in this study we observe that 
maternal 25(OH)D levels are associated with eGFRcreat but not with eGFRcystC. This study also has 
some limitations to consider. Of all children with maternal levels of 25(OH)D available, 74 % had 
successful kidney measurements. Mothers of the children that were lost to follow up had on 
average lower 25(OH)D levels and were on average lower educated, suggesting that our study 
population had a selection towards a healthier population. Furthermore, we used the same cut-
off s of 25(OH)D for pregnant woman as the documented levels for general population, while it 
is still not well known what optimal 25(OH)D levels are during pregnancy.33 A limitation of our 
study is that we did not have information about childhood dietary data at the age of 6 years. 
Dietary composition can impact childhood microalbuminuria. Moreover, microalbuminuria 
was evaluated using urine albumin-creatinine ratio from a random urine sample, still we did 
not have fi rst-morning void samples. Finally, although we performed adjustment for a large 
number of potential maternal and childhood confounders, residual confounding by other 
lifestyle factors, might still be present, as in any observational study.
We hypothesized that maternal vitamin D levels may aff ect off spring kidney health, by 
reducing the number of nephrons, which in turn lead to glomerular hyperfi ltration and 
sclerosis, thus predisposing the individual to renal damage and subsequent development 
of higher blood pressure, impaired kidney function and end-stage kidney disease in adult-
hood.39 The observed eff ect estimates in the present study are small, but important from an 
etiological perspective. They provide further insights into pathways leading to changes in 
kidney function from the earliest phase of life.
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Interpretation and comparison with previous studies
In adults, vitamin D defi ciency is associated with an increased risk of having microalbu-
minuria.40 In a study among 15,068 individuals aged 20 years and older in the U.S., it was 
observed that adults who had 25(OH)D levels in the lowest quartile had an increased risk of 
microalbuminuria.40 We did not observe any association between maternal or cord 25(OH)D 
levels and the risk of childhood microalbuminuria. It might be that diff erences in this clinical 
marker of kidney dysfunction appear at older ages. The Cardiovascular Health Study, a pro-
spective community-based cohort among 1,705 participants aged 65 years and older in the 
U.S. reported that lower 25(OH)D levels were associated with a lower eGFR.41 In contrast, we 
observed that higher maternal 25(OH)D levels were associated with lower eGFR in childhood. 
Additionally, we observed that the eff ect of maternal 25(OH)D levels on childhood eGFR was 
at least partly explained by child’s current 25(OH)D levels. Childhood 25(OH)D and maternal 
25(OH)D levels are correlated due to similar dietary and lifestyle factors. 
Our fi ndings are in line with animal studies. Studies in rats observed no diff erences in kid-
ney volume in rats whose mothers were fed with a vitamin D deplete diet.7 However, maternal 
vitamin D defi ciency was associated with an increase in the number of glomeruli at 7 weeks.7 
Still, it is not known whether these additional nephrons are functional, and thus confer an 
advantage to renal function. Interestingly, another study comparing two generations of mice 
from mothers fed either standard chow or vitamin D-defi cient diet, suggests that maternal 
vitamin D defi ciency accompanies changes in the renal expression of important factors that 
may delay the maturation of glomeruli by extending the period of nephrogenesis.8 In line 
with these observations, we observed that mothers who were 25(OH)D defi cient had children 
with larger combined kidney volume. Also, lower maternal 25(OH)D levels were associated 
with an increased eGFR in school-age children. We observed no associations between cord 
25(OH)D levels and childhood kidney outcomes. Our results suggest that diff erent periods of 
fetal 25(OH)D exposure may have diff erent impact on childhood kidney outcomes.
The mechanisms by which maternal vitamin D levels during pregnancy aff ect childhood 
kidney function are not known yet. Vitamin D is an important component, during cell prolif-
eration for diff erentiation and maturation processes.42 Renal proximal tubules are the major 
site for the conversion of the 25(OH)D to the active hormone, and thus any early changes to 
renal function may have consequences for later vitamin D physiology. Maka et al.7 suggests 
that vitamin D defi cient off spring may have prolonged nephrogenic proliferation, without 
the appropriate switch to nephron maturation. If this is the case, it is likely that the nephrons, 
although more numerous, may not be fully matured and may be functionally impaired.7
CONCLUSION 
Results from this population-based prospective cohort study suggest that maternal 25(OH)D 
levels during pregnancy may infl uence childhood kidney function. Part of the observed ef-
fect may be explained by childhood 25(OH)D levels. These results should be considered as 
hypothesis generating. Further studies are needed to replicate the observations, to examine 
the underlying mechanisms and to identify the long term-clinical consequences.
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Supplementary Table 2.5.1. Subject characteristics (N=4,212)
Imputed Original
Maternal characteristics
Maternal age (y) 31.3 (20.2, 39.4) 31.3 (20.2, 39.4)
Maternal body mass index at enrolment (kg/m2) 22.6 (18.1, 34.3) 22.6 (18.1, 34.2)
Education level (%)
- No higher education 51.2 49.7
- Higher education 48.8 50.3
Ethnicity (%)
- European 63.2 63.8
- Cape Verdean 4.1 4.0
- Dutch Antillean 2.0 2.0
- Moroccan 5.6 5.4
- Turkish 8.2 8.2
- Surinamese 7.6 7.5
- Other 9.3 9.3
Smoking during pregnancy (%)
- Never 75 74.9
- Until pregnancy was known 9.9 9.5
- Continued 15.1 15.6
Alcohol during pregnancy (%)
- Never 42.8 42.2
- Until pregnancy was known 14.3 14.4
- Continued 42.9 43.5
Folic acid supplements use (%)
- No 24.5 22.0
- Start 1st to 10 weeks 31.2 31.3
- Start periconceptional 44.3 46.7
Maternal calories intake (kcal) 2,062 (485) 2,053 (544)
Maternal blood levels of 25(OH)D (nmol/L) 51.9 (7.7, 122.1) 51.9 (7.7, 122.1)
Season when blood sample was taken (%)
- Spring 27.8 27.8
- Summer 22.6 22.6
- Autumn 25.5 25.5
- Winter 24.1 24.1
Infant characteristics
Girls (%) 50.4 50.5
Gestational age at birth (wk) 40.1 (35.9, 42.3) 40.1 (35.9, 42.3)
Birth weight (g) 3,449 (545) 3,448 (544)
Breastfeeding in the fi rst 4 months (%)
- Exclusive 31.7 25.7
- Partial 61.1 65.7
- Never 7.2 8.6
Child 25(OH)D level in cord blood at birth (nmol/L) 29.3 (5.2, 81.5) 29.3 (5.2, 81.5)
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Supplementary Table 2.5.1. Subject characteristics (N=4,212) (continued)
Imputed Original
Season when cord blood sample was taken (%)
- Spring 28.2 28.2
- Summer 26.5 26.5
- Autumn 21.4 21.4
- Winter 23.9 23.9
Child characteristics at 6y visit
Age (y) NI 6.0 (5.6, 7.4)
Height (cm) 119 (5.6) 119 (5.6)
Weight (kg) 22.2 (17.4, 32.4) 22.2 (17.4, 32.4)
Body mass index (kg/m2) 15.8 (13.6, 20.7) 15.8 (13.6, 20.7)
Body surface area (m2) 0.86 (0.7, 1.1) 0.86 (0.7, 1.1)
Kidney volume (cm3) NI 120 (22.8)
Creatinine (μmol/L) NI 37.2 (5.5)
Cystatin C (μg/L) NI 784 (80.2)
eGFRcreat (ml/min/1.73m2) NI 119 (16.4)
eGFRcystC (ml/min/1.73m2) NI 102.5 (14.5)
Microalbuminuria (%) NI 7.6
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution.  
Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood levels and eGFRcystC esti-
mated glomerular fi ltration rate calculated based on cystatin C blood levels; NI, not imputed
Supplementary Table 2.5.2. Subject characteristics with and without kidney measurements
N=4,212 N=1,509 p-value
Maternal characteristics
Maternal age (y) 31.3 (20.2, 39.4) 29.4 (19.0, 38.4) 0.001
Maternal body mass index at enrolment (kg/m2) 22.6 (18.1, 34.3) 22.4 (17.6, 35.6) 0.25
Education level (%) 0.001
- No higher education 51.2 62.0
- Higher education 48.8 38.0
Ethnicity (%) 0.001
- European 63.2 50.6
- Cape Verdean 4.1 4.5
- Dutch Antillean 2.0 4.3
- Moroccan 5.6 8.4
- Turkish 8.2 11.6
- Surinamese 7.6 10.4
- Others 9.3 10.2
Smoking during pregnancy (%) 0.001
- Never 75 70.7
- Until pregnancy was known 9.9 7.9
- Continued 15.1 21.4
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Supplementary Table 2.5.2. Subject characteristics with and without kidney measurements (continued)
N=4,212 N=1,509 p-value
Alcohol during pregnancy (%) 0.001
- Never 42.8 54.2
- Until pregnancy was known 14.3 12.7
- Continued 42.9 33.1
Folic acid supplements use (%) 0.001
- No 24.5 33.8
- Start 1st to 10 weeks 31.2 31.5
- Start periconceptional 44.3 34.7
Maternal calories intake (kcal) 2,062 (485) 2,028 (581) 0.09
Maternal blood levels of 25(OH)D (nmol/L) 51.9 (7.7, 122.1) 43.3 (6.7, 111.6) 0.001
Season when blood sample was taken (%) 0.03
- Spring 27.8 30.5
- Summer 22.6 24.1
- Autumn 25.5 22.1
- Winter 24.1 23.3
Infant characteristics
Girls (%) 50.4 48.0 0.1
Gestational age at birth (wk) 40.1 (35.9, 42.3) 40.1 (35.6, 42.3) 0.01
Birth weight (g) 3,449 (545) 3,396 (565) 0.002
Breastfeeding (%) 0.001
- Exclusive ≥4 months 31.7 20.0
- Partial ≥4 months 61.1 67.2
- Never or ≤4 months 6.2 12.8
Child 25(OH)D level in cord blood at birth (nmol/L) 29.3 (5.1, 81.5) 25.7 (4.5, 80.5) 0.001
Season when cord blood sample was taken (%) 0.09
- Spring 28.2 24.4
- Summer 26.5 29.6
- Autumn 21.4 22.6
- Winter 23.9 23.4
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. Diff erences in subject characteristics comparing the 
groups with and without kidney measurements were evaluated using T-tests for continuous normally distributed vari-
ables, Mann Whitney for non-normally distributed variables, and Chi-squared tests for categorical variables.  
Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood levels and eGFRcystC esti-
mated glomerular fi ltration rate calculated based on cystatin C blood levels.
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Supplementary Table 2.5.3. Associations of maternal 25(OH)D levels during pregnancy with kidney out-
comes at the age of 6 years (N=4,212)
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=4,068
Kidney volume
(cm3)
N=3,897
eGFRcreat
(ml/min/1.73m2)
N=2,833
eGFRcystC
(ml/min/1.73m2)
N=2,836
Basic Model#
<25.0 nmol/L (N=921) -0.56 (-3.12, 2.00) 1.20 (-1.02, 3.41) -0.49 (-2.46, 1.48) 1.19 (0.78, 1.82)
25.0 to 49.9 nmol/L (N=1,083) 2.23 (0.18, 4.27)* 1.28 (-0.46, 3.02) 0.63 (-0.92, 2.19) 0.87 (0.61, 1.25)
50.0 to 74.9 nmol/L (N=1,055) 1.31 (-0.64, 3.27) 1.53 (-0.15, 3.21) 0.62 (-0.88, 2.12) 1.15 (0.84, 1.58)
≥75.0 nmol/L (N=1,153) Reference Reference Reference Reference
Continuously (per SD) -0.44 (-1.32, 0.44) -0.82(-1.57, -0.06)* -0.21 (-0.89, 0,46) 0.96 (0.82, 1.11)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Basic model# is adjusted for child’s sex, age 
at 6-year visit, season when blood samples were drawn and maternal ethnicity. *p <0.05. Continuously = Maternal vitamin 
D levels analyzed per 1 standard deviation in 25(OH)D.
Abbreviations: SD standard deviation; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels.
Supplementary Table 2.5.4. Associations of 25(OH)D cord blood levels with kidney outcomes at the age 
of 6 years (N=2,689)
        Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=2,598
Kidney volume
(cm3)
N=2,480
eGFRcreat
(ml/min/1.73m2)
N=1,810
eGFRcystC
(ml/min/1.73m2)
N=1,814
Basic Model#
<25.0 nmol/L (N=1,136) 0.71 (-4.14, 5.55) -0.46 (-4.61, 3.69) -0.83 (-4.69, 3.04) 0.88 (0.52, 1.50)
25.0 to 49.9 nmol/L (N=980) 1.84 (-2.80, 6.48) -1.29 (-5.26, 2.69) -0.17 (-3.88, 3.53) 0.72 (0.46, 1.12)
50.0 to 74.9 nmol/L (N=464) -0.23 (-4.91, 4.45) -0.73 (-4.85, 3.39) -1.16 (-4.99, 2.67) 1.09 (0.73, 1.62)
≥75.0 nmol/L (N=109) Reference Reference Reference Reference
Continuously (per SD) -0.14 (-1.23, 0.96) -0.03 (-0.91, 0.97) 0.41 (-0.46, 1.29) 0.97 (0.80, 1.16)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Basic model# is adjusted for child’s sex and 
age at 6-year visit, season when blood samples were drawn and maternal ethnicity. *p <0.05. Continuously = Cord vitamin 
D levels analyzed per 1 standard deviation in 25(OH)D. 
Abbreviations: SD standard deviation; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels.
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Supplementary Table 2.5.6. Associations of maternal 25(OH)D levels during pregnancy with child kidney 
outcomes additionally adjusted for child 25(OH)D levels at the age of 6 years (N=2,644)
Diff erence in outcome measure (95 % Confi dence Interval)
Microalbuminuria
(odds ratio)
N=2,578
Kidney volume
(cm3)
N=2,472
eGFRcreat
(ml/min/1.73m2)
N=2,627
eGFRcystC
(ml/min/1.73m2)
N=2,630
Multivariable model£
<25.0 nmol/L (N=571) 0.18 (-2.80, 3.17) 0.45 (-1.99, 2.88) -1.05 (-3.21, 1.12) 1.09 (0.61, 1.94)
25.0 to 49.9 nmol/L (N=688) 2.57 (0.30, 4.84)* 1.12 (-0.71, 2.94) 0.55 (-1.11, 2.20) 0.97 (0.62, 1.51)
50.0 to 74.9 nmol/L (N=683) 2.17 (0.02, 4.33)* 1.08 (-0.65, 2.82) 0.48 (-1.13, 2.03) 1.01 (0.67, 1.53)
≥75.0 nmol/L (N=702) Reference Reference Reference Reference
Continuously (per SD) -0.87 (-1.88, 0.15) -0.70 (-1.52, 0.15) -0.10 (-0.84, 0.63) 0.96 (0.73, 1.17)
Values are linear and logistic regression coeffi  cients (95 % confi dence interval). Multivariable adjusted model£ is adjusted 
for child’s sex, age at 6 year visit, maternal characteristics (age, body mass index at intake, alcohol consumption, smoking 
during pregnancy, folic acid and energy intake during pregnancy, education, ethnicity, prepregnancy comorbidities, sea-
son when blood samples were drawn) and child characteristics (birthweight adjusted for gestational age, breastfeeding, 
and body surface area and 25(OH)D levels at the age of 6y). *p <0.05. Continuously = Maternal vitamin D levels analyzed 
per 1 standard deviation in 25(OH)D.
Abbreviations: SD standard deviation; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels.
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ABSTRACT 
Objective: Hypertensive disorders in pregnancy may aff ect off spring cardiovascular risk. 
We examined the associations of maternal blood pressure throughout pregnancy and hy-
pertensive disorders in pregnancy with childhood blood pressure. Specifi c focus was on the 
comparison with paternal blood pressure eff ects, the identifi cation of critical periods and the 
role of birth outcomes and childhood body mass index in the observed associations.
Methods: This study was embedded in a population-based prospective cohort study among 
5,310 mothers, fathers and their children. We measured maternal blood pressure in each 
trimester of pregnancy and paternal blood pressure once. Information about hypertensive 
disorders in pregnancy was obtained from medical records. We measured childhood blood 
pressure at the median age of 6.0 years (95 % range 5.7, 8.0). 
Results: Both maternal and paternal blood pressure were positively associated with child-
hood blood pressure (all p-values <0.05), with similar eff ect estimates. Conditional regression 
analyses showed that early, mid- and late pregnancy maternal blood pressure were all inde-
pendent and positively associated with childhood blood pressure, with the strongest eff ect 
estimates for early pregnancy. As compared to children from mothers without hypertensive 
disorders in pregnancy, those from mothers with hypertensive disorders in pregnancy had 
0.13 SDS (95 % Confi dence Interval (CI) 0.05 to 0.21) higher diastolic blood pressure. The 
observed associations were not materially aff ected by birth outcomes and childhood body 
mass index. 
Conclusions: Both maternal and paternal blood pressure aff ect childhood blood pressure, 
independent of fetal and childhood growth measures, with the strongest eff ect for maternal 
blood pressure in early pregnancy. 
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INTRODUCTION
Gestational hypertension and preeclampsia aff ect up to 8 % of all pregnant women world-
wide and are associated with both maternal and off spring cardiovascular health and dis-
ease.1–4 It has been suggested that these associations are explained by maternal vasculotoxic 
factors in pregnancies with hypertensive disorders, which aff ect vascular development.5, 6 
Moreover, early placental and fetal microvasculature maladaptations may lead to a higher 
blood pressure in both pregnant women and their off spring.7 In addition to hypertensive 
disorders in pregnancy, higher blood pressure within the normal range during pregnancy 
may be associated with higher off spring blood pressure.8–12 It is not known if the associations 
of maternal blood pressure with off spring blood pressure are explained by direct maternal 
or intra-uterine mechanisms or rather refl ect shared family-based lifestyle-related or genetic 
factors. Comparing maternal and paternal blood pressure eff ects may help to disentangle the 
direct maternal or intra-uterine mechanisms.13 It is also unknown which period of pregnancy 
is most critical for the eff ects of maternal blood pressure on the off spring’s blood pressure. Fi-
nally, the associations of hypertensive disorders in pregnancy, with childhood blood pressure 
may be explained in part by lower off spring birth weight and higher body mass index (BMI).8
In a population-based prospective cohort study from early pregnancy onwards among 
5,310 mothers, fathers and children, we examined the associations of maternal blood pres-
sure in diff erent periods of pregnancy and hypertensive disorders in pregnancy with blood 
pressure in school-aged children. The specifi c focus was on the comparison with paternal 
blood pressure eff ects, the identifi cation of critical periods and the role of birth outcomes 
and childhood body mass index in the observed associations.
METHODS
Design and study population
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early pregnancy onwards in Rotterdam, the Netherlands.14, 15 The study has been 
approved by the local Medical Ethics Committee. Written informed consent was obtained 
from the parents. All pregnant women were enrolled between 2001 and 2005. Of all eligible 
children in the study area, 61 % participated at birth in the study. In total 8,713 initially nor-
motensive mothers had information about blood pressure measurements available, and of 
those, 8,475 gave birth to singleton live-born children. In total, 5,810 (69 %) of these children 
participated in detailed follow-up studies at the age of 6 years. We excluded children with 
missing blood pressure measurements (N=477) or with congenital cardiac abnormalities 
(N=23) leading to a population for analysis of 5,310 mothers and their children (Flowchart is 
given in Supplementary Figure 2.6.1).
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Maternal and paternal blood pressure 
We measured maternal and paternal blood pressure using the Omron 907 automated digital 
oscillometric spygmanometer (OMRON Healthcare Europe, Hoofddorp, the Netherlands).16 
As described previously, all participants were seated in an upright position with back sup-
port and were asked to relax for 5 minutes.17 A cuff  was placed around the non-dominant 
upper arm, which was supported at the level of the heart, with the bladder midline over 
the brachial artery pulsation. For participants with an upper arm circumference exceeding 
33cm, a larger cuff  (32–42 cm) was used. We used the mean value of 2 blood pressure readings 
over a 60-second interval. Blood pressure was measured in 4,098 mothers in early pregnancy 
(gestational age median 13.4 (95 % range 9.8–17.5) weeks), 5,006 mothers in mid-pregnancy 
(gestational age median 20.5 (95 % range 18.5–23.5) weeks) and 5,104 mothers in late preg-
nancy (gestational age median 30.2 (95 % range, 28.5–32.9) weeks). Three, two, and one blood 
pressure measurements were available for 3,842; 1,214 and 254 mothers, respectively. Of the 
population for analysis, blood pressure was measured during mid-pregnancy in 3,805 fathers.
Hypertensive disorders in pregnancy
Information on hypertensive disorders in pregnancy, including gestational hypertension and 
preeclampsia, was obtained through medical records.18 Mothers suspected of any hyperten-
sive disorder in pregnancy based on the records were crosschecked with original charts by a 
trained medical record abstractor.18 The following criteria were used to identify women with 
gestational hypertension: development of systolic blood pressure of ≥140 mmHg and/or dia-
stolic blood pressure of ≥90 mmHg after 20 weeks of gestation in previously normotensive 
women. These criteria and the presence of proteinuria (defi ned as 2 or more dipstick readings 
of 2 or greater, or 1 catheter sample reading of 1 or greater, or a 24-hour urine collection 
containing at least 300 mg of protein) were used to identify women with preeclampsia.19
Childhood blood pressure
Childhood blood pressure was measured at the right brachial artery, four times with one-
minute intervals, using the validated automatic sphygmanometer Datascope Accutor Plus 
TM (Paramus, NJ, USA).20 A cuff  was selected with a cuff  width approximately 40 % of the arm 
circumference and long enough to cover 90 % of the arm circumference.20 We used the mean 
systolic and diastolic blood pressure values using the last three blood pressure readings. 
Using normative values from the “Fourth report on the diagnosis, evaluation and treatment 
of high blood pressure in children and adolescents” from the National High Blood Pressure 
Education Program Working Group on High Blood Pressure in Children and Adolescents,21, 22 
we calculated the standard deviation scores (SDS) for individual systolic and diastolic blood 
pressure values. Subsequently, we used these individual SDS to categorize children in blood 
pressure tertiles. Children whose average systolic and/or diastolic blood pressure based on 
three readings was ≥95th percentile for age, sex and height were classifi ed as hypertensive.
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Covariates
We assessed maternal and paternal age at enrollment in the study. Information on maternal 
and paternal ethnicity and educational level, maternal parity, folic acid supplement use, 
smoking and alcohol consumption was obtained by questionnaires.14 At enrollment, we 
measured maternal and paternal height and weight without shoes and heavy clothing and 
calculated body mass index. Information on infant sex, gestational age at birth and birth 
weight was obtained from medical records. At the age of 6 years, we measured child height 
and weight and calculated body mass index.
Statistical analysis
First, we performed a non-response analysis by comparing subject characteristics between 
children with and without follow-up blood pressure measurements by using T-tests, Chi-
square tests and Mann-Whitney tests. Second, we examined maternal longitudinal blood 
pressure patterns during pregnancy for mothers in tertiles of childhood blood pressure. For 
these analyses, we used mixed eff ects regression models. These regression models enable 
analyses on repeatedly measured outcomes, accounting for the correlation between repeat-
ed measurements within the same participant, and allowing for incomplete outcome data.23 
Details of the mixed eff ects regression models are given in the Supplementary Methods. We 
also examined the associations of maternal blood pressure in diff erent periods of pregnancy 
and paternal blood pressure with childhood blood pressure in three linear regression mod-
els; 1) a confounder model, which included covariates selected based on their associations 
with the outcome of interest based on previous studies or a change in eff ect estimate of 
>10 %; 2) a birth model, which included gestational age and weight at birth in addition to the 
confounder model; 3) a childhood model, which included child current body mass index in 
addition to the confounder model. We used similar multiple regression models to examine 
the associations of hypertensive disorders in pregnancy with childhood blood pressure. 
Third, we used similar linear and logistic regression models to explore the combined eff ects 
of maternal blood pressure in early and late pregnancy and the combined eff ects of maternal 
blood pressure and paternal blood pressure on childhood blood pressure and risk of hyper-
tension. For these analyses, we created tertiles of both maternal and paternal blood pressure. 
Fourth, we performed conditional regression analyses to identify the independent associa-
tions of maternal blood pressure measurements in early, mid- and late pregnancy, taking into 
account their correlations, with childhood blood pressure and risk of hypertension.24 We con-
structed blood pressure values for each trimester, which are statistically independent from 
blood pressure values for other trimesters, by using standardized residuals obtained from 
regression of blood pressure values at a specifi c time point (dependent variable) on blood 
pressure values obtained at a previous time point.24–26 This approach enabled identifi cation 
of critical periods for maternal blood pressure during pregnancy that, independent of other 
periods during pregnancy infl uenced childhood blood pressure. Details of these conditional 
regression models are given in the Supplementary Methods. To reduce potential bias as-
sociated with missing data, missing values of covariates (maternal and paternal ethnicity, 
educational level and body mass index, paternal age, maternal parity, folic acid supplement 
Chapter 2.6
140
use, smoking and alcohol consumption, infant birth weight and child body mass index), were 
multiple imputed (n=5 imputations), according to the Fully Conditional Specifi cation method 
(predictive mean matching), assuming no monotone missing pattern. We report the pooled 
eff ect estimates after the multiple imputation procedure 27 Participant characteristics before 
and after imputation and the percentages of missing values are given in the Supplementary 
Table 2.6.1.
The multiple imputation procedure was performed using Statistical Package for the Social 
Sciences version 21.0. Statistical analyses were performed using the Statistical Package for 
the Social Sciences version 21.0 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp). The 
mixed eff ects regression analyses were performed with the Statistical Analysis System, Prox 
Mixed module (version 9.3; SAS Institute Inc, Cary NC).
RESULTS
Subject characteristics
Table 2.6.1 shows the participant characteristics. In our cohort, 410 children (7.7 %) were clas-
sifi ed as hypertensive. Results from the non-response analysis showed that as compared to 
children with blood pressure follow-up measurements, those without these measurements 
had a lower birth weight and gestational age. Mothers of children with blood pressure 
measurements were older, used less alcohol, but smoked more frequently as compared to 
Table 2.6.1. Subject characteristics (N=5,310)
Characteristics
Maternal Characteristics
Age, y 30.9 (19.7, 39.3)
Height, cm 167.5 (7.5)
Weight, kg 69.3 (12.7)
Body mass index, kg/m2 23.5 (3.8)
Parity, n (%)
- 0 3,008 (56.6)
- ≥1 2,302 (43.4)
Educational level mother, n (%)
- Primary or secondary 2,854 (53.7)
- Higher 2,456 (46.3)
Ethnicity, n (%)
- European 3,167 (59.6)
- Non-European 2,143 (40.4)
Smoking during pregnancy, n (%)
- No 3,792 (71.4)
- Yes 1,518 (28.6)
Alcohol using during pregnancy, n (%)
- No 2,478 (46.7)
- Yes 2,832 (53.3)
Folic acid supplements during pregnancy, n (%)
- No 1,695 (31.9)
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Table 2.6.1. Subject characteristics (N=5,310) (continued)
Characteristics
- Yes 3,615 (68.1)
Blood pressure
Early pregnancy
- Gestational age, weeks 13.4 (9.8, 17.5)
- Systolic blood pressure, mmHg 115.5 (12.0)
- Diastolic blood pressure, mmHg 68.1 (9.3)
Mid- pregnancy
- Gestational age, weeks 20.5 (18.5, 23.5)
- Systolic blood pressure, mmHg 116.8 (11.9)
- Diastolic blood pressure, mmHg 67.2 (9.3)
Late pregnancy
- Gestational age, weeks 30.2 (28.5, 32.9)
- Systolic blood pressure, mmHg 118.4 (11.9)
- Diastolic blood pressure, mmHg 69.1 (9.2)
Hypertensive disorders in pregnancy, n (%)
Any 308 (5.8)
Gestational hypertension 215 (4.0)
Preeclampsia 93 (1.8)
Paternal characteristics
Age, y 33.0 (21.7, 45.2)
Height, cm 181.9 (7.7)
Weight, kg 83.7 (11.6)
Body mass index, kg/m2 25.3 (3.2)
Ethnicity, n (%)
- European 3,274 (61.7)
- Non-European 2,036 (38.3)
Educational level, n (%)
- Primary or secondary 2,896 (54.5)
- Higher 2,414 (45.5)
Systolic blood pressure, mmHg 130.2 (13.5)
Diastolic blood pressure, mmHg 73.4 (10.6)
Birth characteristics
Female, n (%) 2,656 (50.0)
Gestational age, weeks 40.1 (35.9, 42.3)
Birth weight, g 3,430 (548)
Childhood characteristics
Age, y 6.0 (5.7, 8.0)
Height, cm 119.5 (6.1)
Weight, kg 23.3 (4.3)
Body mass index, kg/m2 16.2 (1.9)
Systolic blood pressure, mmHg 102.7 (8.2)
Diastolic blood pressure, mmHg 60.7 (6.9)
*Z score Systolic blood pressure 0.53 (0.7)
*Z score Diastolic blood pressure 0.34 (0.6)
# Blood pressure ≥95th percentile, n (%) 410 (7.7)
Values represent means (SD), medians (95 % range), or numbers (%). *Z scores of systolic and diastolic blood pressure are 
calculated using normative values from the “Fourth report on the diagnosis, evaluation and treatment of high blood pres-
sure in children and adolescents” from the National High Blood Pressure Education Program Working Group on High Blood 
Pressure in Children and Adolescents.
#Blood pressure ≥95th percentile (systolic and/or diastolic blood pressure ≥95th percentile) for age, sex and height on 
three measurements. Participant characteristics before and after imputation are shown Supplementary Table 2.6.1. 
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mothers of children who were lost to follow up. Moreover, maternal systolic blood pressure 
throughout pregnancy was lower for the children without follow up blood pressure measure-
ments (Supplementary Table 2.6.2).
Maternal and paternal blood pressure and childhood blood pressure 
Figure 2.6.1 shows that children in the highest tertile of systolic blood pressure had moth-
ers with higher systolic blood pressure throughout pregnancy than children in the lowest 
tertile of systolic blood pressure. For each tertile of childhood blood pressure, maternal 
blood pressure increased with advanced gestational age. There was no signifi cant diff erence 
in the slope of maternal systolic blood pressure between the tertiles of their children blood 
pressure. For all childhood diastolic blood pressure tertiles, maternal diastolic blood pressure 
had a mid-pregnancy dip, with an increase thereafter. Diastolic blood pressure was highest 
throughout pregnancy for mothers of children in the highest tertile. The exact correspond-
ing regression coeffi  cients for gestational age-independent (intercept) and gestational age 
dependent diff erences (interaction childhood blood pressure and gestational age) are given 
in Supplementary Table  2.6.3. Additional analyses showed that higher maternal blood 
pressure in early, mid- and late pregnancy and paternal blood pressure were all separately 
associated with higher childhood blood pressure (all p-values <0.05). The eff ect estimates for 
mother and father were similar and not aff ected by birth outcomes or childhood body mass 
index (Supplementary Table 2.6.4).
Figure 2.6.2A shows the combined associations of maternal blood pressure during early 
and late pregnancy. Compared with children from mothers with a blood pressure in the low-
est tertiles during both early and late pregnancy, those with a blood pressure in the highest 
tertiles during both early and late pregnancy had 0.24 SDS (95 % Confi dence Interval (CI) 0.16, 
0.31) and 0.18 SDS (95 % CI 0.11, 0.24) higher systolic and diastolic blood pressure, respectively. 
In addition, within each tertile of maternal early pregnancy blood pressure, maternal late 
pregnancy blood pressure was associated with a higher childhood blood pressure with the 
strongest eff ect estimates in early pregnancy. Figure  2.6.2B shows the combined associa-
tions of maternal early pregnancy and paternal blood pressure. Compared with children of 
mothers and fathers with a blood pressure in the lowest tertiles, those from mothers and 
fathers with a blood pressure in the highest tertiles had 0.26 SDS (95 % CI 0.17, 0.37) and 0.19 
SDS (95 % CI 0.11, 0.28) higher systolic and diastolic blood pressure, respectively. Results from 
the confounder and birth models for these stratifi ed analyses are given in Supplementary 
Figure 2.6.2(A-D). None of the statistical interactions terms were signifi cant. 
Maternal and paternal blood pressure and childhood hypertension
Figure  2.6.3A shows the results of the combined associations of maternal blood pressure 
during early and late pregnancy with the risk of childhood hypertension. Children of mothers 
with a systolic and diastolic blood pressure in the highest tertiles during both early and late 
pregnancy had a higher risk of hypertension: Odds Ratio (OR) 2.66 (95 % CI 1.71, 4.13) and 
1.63 (95 % CI 1.09, 2.46), respectively, as compared to children from mothers with a systolic 
and diastolic blood pressure in the lowest tertiles during both early and late pregnancy. Fig-
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Figure 2.6.1. Maternal blood pressure patterns from children in diff erent blood pressure tertiles (N=5,310)
A
B
Maternal blood pressure pattern per childhood blood pressure tertile. (A) Systolic blood pressure. Diff erence in maternal 
systolic blood pressure (mmHg) between childhood systolic blood pressure tertiles based on mixed eff ects regression 
models. Model: Maternal systolic blood pressure = β0 + β1* child systolic blood pressure tertile + β2 * gestational age + β3 
* gestational age-2 + β4 * child systolic blood pressure tertile* gestational age. (B) Diastolic blood pressure. Diff erence in 
maternal diastolic blood pressure (mmHg) for childhood diastolic blood pressure tertiles based on mixed eff ects regres-
sion analysis. Model: Maternal diastolic blood pressure = β0 + β1* child diastolic blood pressure tertile + β2 * gestational 
age + β3 * gestational age0.5 + β4 * child diastolic blood pressure tertile * gestational age. Eff ect estimates (95 % confi dence 
intrevals) are given in Supplementary Table 2.6.3.
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Figure 2.6.2. Combined associations of maternal and paternal blood pressure with childhood blood pres-
sure (N=5,310)
A. Maternal blood pressure in early and late pregnancy 
B. Maternal and paternal blood pressure 
Values are regression coeffi  cients (95 % confi dence intervals) from multiple linear regression models. Estimates are based 
on multiple imputed data. Estimates regarding childhood systolic blood pressure are assessed by combining parental sys-
tolic blood pressure tertiles. Estimates regarding childhood diastolic blood pressure are assessed by combining parental 
diastolic blood pressure tertiles. The interaction term of maternal late and early pregnancy blood pressure and the interac-
tion term of maternal and paternal blood pressure were not statistically signifi cant.
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ure 2.6.3B shows the combined associations of maternal early pregnancy and paternal blood 
pressure with the risk of childhood hypertension. Children of mothers and fathers with blood 
pressure in the highest tertiles had a higher risk of having hypertension OR 2.18 (95 % CI 1.25, 
3.79) and 2.20 (95 % CI 1.25, 3.93), respectively for systolic and diastolic blood pressure, as 
Figure 2.6.3. Combined associations of maternal and paternal blood pressure with childhood hyperten-
sion (N=5,310)
A. Maternal blood pressure in early and late pregnancy 
B. Maternal and paternal blood pressure
Values are regression coeffi  cients (95 % confi dence intervals) from logistic regression models. Estimates are based on mul-
tiple imputed data. Estimates regarding childhood hypertension are assessed by combining parental systolic and diastolic 
blood pressure tertiles, respectively.
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compared to children from mothers and fathers with a systolic and diastolic blood pressure 
in the lowest tertiles.
Critical periods of maternal blood pressure for childhood blood pressure and 
hypertension
Figure 2.6.4A shows that maternal blood pressure in early, mid- and late pregnancy were all 
independently associated with childhood blood pressure (all p-values <0.05). The strongest 
eff ect estimates were observed for early pregnancy maternal blood pressure (diff erences in 
Figure 2.6.4. Associations of maternal blood pressure with childhood blood pressure and hypertension 
from conditional regression models (N=5,310)
A. Associations of maternal blood pressure with childhood blood pressure 
B. Associations of maternal blood pressure with childhood hypertension
Values are linear (A) and logistic (B) regression coeffi  cients (95 % confi dence intervals) that refl ect the diff erence in child-
hood systolic and diastolic blood pressure per standardized residual for maternal blood pressure during each trimester 
of pregnancy independent from previous trimesters blood pressure measurements. Confounder models are adjusted for 
maternal age, pre-pregnancy body mass index, ethnicity, parity, educational level, smoking during pregnancy, alcohol 
consumption and folic acid supplement intake. Birth models are confounder models additionally adjusted for birth weight 
and gestational age. Childhood models are confounder models additionally adjusted for child current body mass index.
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childhood systolic and diastolic blood pressure 0.08 SDS (95 % CI 0.05, 0.10) and 0.05 SDS 
(95 % CI 0.03, 0.07) per standardized residual increase in maternal systolic and diastolic blood 
pressure).
Figure 2.6.4B shows that maternal systolic blood pressure, but not diastolic, in early, mid- 
and late pregnancy were all independently associated with the risk of childhood hyperten-
sion (all p-values <0.05). The strongest eff ect estimates were observed for early pregnancy 
maternal blood pressure (OR in childhood risk of hypertension 1.25 (95 % CI 1.11, 1.42) per 
standardized residual increase in maternal systolic blood pressure).
Hypertensive disorders in pregnancy and childhood blood pressure
Table 2.6.2 shows that as compared to children from mothers without hypertensive disorders 
in pregnancy, those from mothers with hypertensive disorders in pregnancy had a higher 
diastolic, but not systolic, blood pressure. These associations were mainly driven by gesta-
tional hypertension (diff erence in diastolic blood pressure 0.13 SDS (95 % Confi dence Interval 
(CI) 0.05, 0.21) between children from mothers with and without gestational hypertension). 
Preeclampsia was not associated with childhood blood pressure. 
DISCUSSION
In this population-based prospective cohort study, we observed that both higher maternal 
blood pressure throughout pregnancy and paternal blood pressure are associated with 
higher childhood blood pressure. Early, mid- and late pregnancy maternal blood pressure 
Table 2.6.2. Associations of hypertensive disorders in pregnancy with childhood blood pressure (N=5,310)
Childhood blood pressure (SDS)
Confounder model Birth model Childhood model
None (N=4,888) Reference Reference Reference
Any complications (N=308)
Childhood systolic blood pressure 0.07 (-0.02, 0.15) 0.03 (-0.05, 0.12) 0.06 (-0.02, 0.14)
Childhood diastolic blood pressure 0.10 (0.02, 0.17)** 0.08 (0.01, 0.15)* 0.10 (0.02, 0.17)**
Gestational hypertension (N=215)
Childhood systolic blood pressure 0.06 (-0.04, 0.15) 0.04 (-0.06, 0.13) 0.06 (-0.04, 0.15)
Childhood diastolic blood pressure 0.13 (0.05, 0.21)** 0.11 (0.03, 0.19)** 0.13 (0.05, 0.21)**
Preeclampsia (N=93)
Childhood systolic blood pressure 0.14 (-0.01, 0.28) 0.06 (-0.08, 0.21) 0.14 (-0.01, 0.28)
Childhood diastolic blood pressure 0.03 (-0.09, 0.15) -0.01 (-0.13, 0.11) 0.03 (-0.09, 0.15)
Values are regression coeffi  cients (95 % confi dence intervals) based on multiple linear regression models. Estimates are 
based on multiple imputed data. 
Pregnancies without gestational hypertension or preeclampsia were taken as reference category. Confounder models are 
adjusted for maternal age, pre-pregnancy body mass index, ethnicity, parity, educational level, smoking during pregnancy, 
alcohol consumption, and folic acid supplement intake.
Birth models are confounder models additionally adjusted for gestational age at birth and birthweight. 
Childhood models are confounders models additionally adjusted for childhood current body mass index. *P  <0.05 
**P <0.01
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were all independently associated with childhood blood pressure, with the strongest eff ect 
estimates for early pregnancy. Gestational hypertension was associated with higher child-
hood diastolic blood pressure. The observed associations were largely independent from 
fetal and childhood growth measures.
Methodological considerations
A major strength of our study is the prospective design from early pregnancy onwards within 
a large population-based cohort. Furthermore, we measured maternal blood pressure in dif-
ferent pregnancy periods. Not all mothers had blood pressure measurements in each trimes-
ter of pregnancy. Restricting our analyses to mothers who had blood pressure measurements 
in all three trimesters (N=3,842), revealed similar results as in the full group. Of all children 
from mothers with information about blood pressure and pregnancy complications 65 % 
participated in the follow-up measurements at the age of 6 years and had blood pressure 
information available. Compared to children with blood pressure follow-up measurements, 
those without follow-up measurements had mothers with lower systolic blood pressure 
throughout pregnancy and had lower weight at birth and younger gestational age at birth. 
A selective loss to follow-up may have reduced variation in blood pressure development and 
therefore reduced the power to detect diff erences. Moreover, loss to follow-up would lead to 
selection bias if the associations of maternal blood pressure with childhood blood pressure 
would be diff erent between those included and those not included in the fi nal analyses. 
Although we do not expect this likely, selection bias cannot be excluded. Blood pressure has 
a large within-participant variation and is liable to measurement error. This measurement 
error may have led to an underestimation of the observed eff ect estimates.17 Furthermore, 
the number of cases with hypertensive disorders in pregnancy was relatively small, which 
might have led to lack of power for the associations of hypertensive disorders in pregnancy 
with childhood blood pressure. Family history of hypertension may also infl uence childhood 
blood pressure. Unfortunately, information about family history of hypertension was avail-
able for only a small subset of our cohort. Finally, although we performed adjustment for a 
large number of potential maternal and paternal confounders, residual confounding by other 
socioeconomic or lifestyle related factors might still be present, as in any observational study.
Interpretation of main fi ndings
We hypothesized that higher maternal blood pressure within the normal range during 
pregnancy and hypertensive disorders in pregnancy infl uence blood pressure development 
in childhood. This hypothesis is based on previous studies suggesting that hypertensive 
disorders in pregnancy are associated with higher off spring blood pressure.2, 8, 9, 28 A study 
among 6,343 mother-children pairs in the United Kingdom, showed that gestational hy-
pertension, but not preeclampsia, was associated with a higher blood pressure in children 
aged 9 years.8 A systemic review and meta-analyses, with data from 18 studies, showed that 
children of mothers with preeclampsia had a higher blood pressure in childhood and early 
adulthood.28 A recent study from the United Kingdom suggested that children of mothers 
with hypertensive disorders in pregnancy had higher blood pressure at the ages of 7 to 18 
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years.12 In line with the results of these previous studies, we observed that higher maternal 
blood pressure during pregnancy was associated with a higher blood pressure in children 
aged 6 years. Children from mothers with hypertensive disorders in pregnancy had a higher 
diastolic blood pressure, compared with children of mothers without hypertensive disorders 
in pregnancy. These associations were driven mainly by gestational hypertension, and not 
present for preeclampsia. Consequently, results from both previous and our study suggest 
that maternal blood pressure during pregnancy aff ect childhood blood pressure. Neverthe-
less, not much is known about the specifi c maternal and paternal eff ects, critical periods, and 
role of fetal and childhood growth in the associations.
In the current study, we observed that both, maternal and paternal blood pressure were 
associated with childhood blood pressure and risk of hypertension. In addition, within each 
tertile of maternal blood pressure, higher paternal blood pressure was associated with child-
hood blood pressure. Only a few previous studies have explored the eff ect of maternal and 
paternal blood pressure on childhood blood pressure and risk of hypertension.29–31 These 
studies suggest that both higher maternal and paternal blood pressure levels are associated 
with an increased risk for higher childhood blood pressure in off spring.29, 31 The presence of 
hypertension in both parents has additive eff ects on childhood blood pressure levels.29, 32A 
recent study suggested that children from hypertensive parents had a higher risk of hyper-
tension.32 Similar associations for maternal and paternal blood pressure suggest that genetic 
or shared family based factors, rather than direct intra-uterine programming, may explain 
the associations of maternal blood pressure with childhood blood pressure.13 Our results sug-
gest that both maternal and paternal blood pressure are important, at similar magnitude, for 
childhood blood pressure. 
We aimed to identify critical periods during pregnancy that impact childhood blood pres-
sure. Our results suggest that early, mid- and late pregnancy are all independently associated 
with childhood blood pressure. Diff erences between early, mid- and late pregnancy were 
small, but slightly stronger eff ect estimates were observed for early pregnancy. A recent 
study from a prospective cohort in the United Kingdom, also showed that early pregnancy 
appeared to be the period during pregnancy with the most infl uence on childhood blood 
pressure.12 Some mechanisms have been hypothesized to underlie the association of ma-
ternal blood pressure levels during early pregnancy with blood pressure levels in off spring.7 
Higher maternal blood pressure in early pregnancy may be a marker of maternal and placen-
tal vascular maladaptation’s,33 leading to fetal growth restriction and abnormal fetal vascular 
development,34 that may subsequently aff ect childhood blood pressure.35 In addition, higher 
maternal blood pressure in early pregnancy may be predictors of hypertensive disorders in 
pregnancy that, in turn, may be predictors of maternal and off spring cardiovascular diseases 
later in life. Consequently, although blood pressure in each period of pregnancy seems to be 
independently associated with childhood blood pressure, early pregnancy in particular may 
be critical for childhood blood pressure. 
Consistent evidence suggests that preterm birth and low birth weight are associated with 
childhood blood pressure, although the eff ects seem to be small.36, 37 Moreover, BMI is one 
of the strongest predictors of blood pressure in childhood.26 Consequently, associations of 
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maternal blood pressure with childhood pressure may be partly explained by preterm birth, 
low birth weight and high BMI. We observed, however, that the eff ect estimates of parental 
blood pressure or hypertensive disorders in pregnancy with childhood blood pressure did 
not materially change after additional adjustment for birth outcomes or childhood BMI. We 
also explored whether including size at birth for gestational age, instead of birth weight, 
would aff ect the results, but this was not the case. These fi ndings are in line with the large 
study from the United Kingdom, showing that the eff ects of hypertensive disorders in 
pregnancy on childhood blood pressure were largely independent from maternal and child-
hood obesity.2 Current results suggest that the associations of parental blood pressure and 
hypertensive disorders in pregnancy with childhood blood pressure are not explained by 
fetal and childhood growth measures. 
The prevalence of hypertension in children and adolescents in the Western countries has 
been reported at 1 % to 5 %.38 In addition to the already known childhood risk factors (eg, 
BMI) for developing primary hypertension, other parental factors should be considered in 
screening guidelines.38 Young off spring of mothers, who had high blood pressure in early 
pregnancy or gestational hypertension may compose specifi c groups at risk for having a 
high blood pressure from childhood onwards. Whether these fi ndings can be translated to 
primary prevention strategies for primary hypertension in children and adolescents should 
be further studied. 
CONCLUSION
In summary, our results suggest that both higher maternal blood pressure throughout preg-
nancy and paternal blood pressure infl uence childhood blood pressure. Early, mid- and late 
pregnancy maternal blood pressure were all independently associated with childhood blood 
pressure, with the strongest eff ect estimates for early pregnancy. The observed associations 
were largely independent of fetal and childhood growth measures. Further follow-up studies 
are needed to investigate whether parental blood pressure and hypertensive disorders in 
pregnancy aff ect cardiovascular risk at older ages.
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Supplementary Methods. Statistical analyses
Mixed eff ects regression models. We used unbalanced repeated measurement regression 
models to examine maternal longitudinal blood pressure patterns in tertiles of childhood 
blood pressure. These models take the correlation between repeated measurements 
within the same subject into account by modelling the correlated errors of these measure-
ments.1 Both gestational age-independent (diff erence constant over time) and gestational 
age-dependent (diff erence not-constant over time) eff ects were assessed. We constructed 
best-fi tting models for maternal blood pressure patterns. We started with a linear model and 
examined whether adding second-degree fractional polynomial of gestational age improved 
the models by comparing the deviances and goodness of fi t. Since adding fractional polyno-
mials of gestational age to the model improved the model fi t, we included these fractional 
polynomials in the fi nal models. We used a compound symmetry covariance structure. Child-
hood blood pressure in tertiles were included in these models as intercept and as an interac-
tion term with gestational age. The fi nal models can be written as:
Maternal systolic blood pressure. Diff erence in maternal systolic blood pressure (mmHg) 
between childhood systolic blood pressure tertiles based on repeated measurement re-
gression analysis = β0 + β1* child systolic blood pressure tertile + β2 * gestational age + β3 * 
gestational age-2 + β4 * child systolic blood pressure tertile* gestational age. 
Maternal diastolic blood pressure. Diff erence in maternal diastolic blood pressure (mmHg) 
for childhood diastolic blood pressure tertiles based on repeated measurement analysis = β0 
+ β1* child diastolic blood pressure tertile + β2 * gestational age + β3 * gestational age0.5 + β4 
* child diastolic blood pressure tertile * gestational age. 
Conditional regression analyses. We performed conditional regression analyses to identify 
the independent associations of fi rst, second and third trimester maternal blood pressure, 
taking into account their correlations, with childhood blood pressure.2 We constructed blood 
pressure values for each trimester, which are statistically independent from blood pressure 
values for other trimesters, by using standardized residuals obtained from regression of 
blood pressure values at a specifi c time point (dependent variable) on blood pressure values 
obtained at a previous time point.2–4 These standardized residuals, which are assumed to be 
independent of the estimated regression line (and thus from the previous blood pressure), 
were taken forward to the regression models as independent variable with childhood blood 
pressure (dependent variable). As conditional blood pressure measurements are statistically 
independent of each other, this approach allows inclusion of blood pressure values from dif-
ferent trimesters simultaneously in one linear regression model when continuous childhood 
blood pressure was the outcome, or in one logistic regression model when childhood hyper-
tension was the outcome. For the conditional analyses, we imputed maternal blood pressure 
measures. Results from these datasets were pooled and presented in the conditional results. 
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Supplementary Figure 2.6.1. Flowchart of the study participants
Singleton live births available for follow up 
measurements  
N=8,475 
N=166 Excluded mothers without any blood 
pressure measurements during pregnancy 
(N=18) or with chronic hypertension before 
their initial enrolment (N=148) 
N=238 Excluded miscarriages or twin 
pregnancies  
Mothers with blood pressure measurements 
during pregnancy  
N=8,713 
Children available for the analysis  
N=5,310 
N=3,165 Excluded children who did not visit 
the research center at the age of 6 years 
(N=2,665), or children with congenital cardiac 
abnormalities (N =23) and without available 
blood pressure measurements (N=477)  
Mothers enrolled during pregnancy  
N=8,879 
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Supplementary Table 2.6.1. Subject characteristics in the original and imputed dataset (N=5,310)
Observed Imputed
Maternal characteristics
Age, y 30.9 (19.7, 39.3) 30.9 (19.7, 39.3)
Height, cm 167.5 (7.4) 167.5 (7.5)
Missing, n (%) 19 (3.6)
Weight, kg 69.3 (12.8) 69.3 (12.7)
Missing, n (%) 18 (3.4)
Body mass index, kg/m2 24.7 (4.3) 24.7 (4.3)
Missing, n (%) 36 (6.8)
Parity, n (%)
- 0 2,990 (56.3) 3,008 (56.6)
- ≥1 2,280 (42.9) 2,302 (43.4)
Missing, n (%) 40 (0.8)
Educational level mother, n (%)
- Primary or secondary 2,673 (50.3) 2,854 (53.7)
- Higher 2,295 (43.2) 2,456 (46.3)
Missing, n (%) 342 (6.5)
Ethnicity, n (%)
- European 3,135 (59.0) 3,167 (59.6)
- Non-European 2,059 (38.8) 2,143 (40.4)
Missing, n (%) 116 (2.2)
Smoking during pregnancy, n (%)
- No 3,476 (65.4) 3,792 (71.4)
- Yes 1,224 (23.1) 1,518 (28.6)
Missing, n (%) 610 (11.5)
Alcohol using during pregnancy, n (%)
- No 2,138 (40.3) 2,478 (46.7)
- Yes 2,512 (47.3) 2.832 (53.3)
Missing, n (%) 660 (12.4)
Folic acid supplements during pregnancy, n (%)
- No 1,017 (19.2) 1,695 (31.9)
- Yes 3,023 (56.9) 3,615 (68.1)
Missing, n (%) 1,270 (23.9)
Blood pressure
Early pregnancy
- Gestational age, weeks 13.2 (9.8, 17.4) 13.4 (9.8, 17.5)
- Systolic blood pressure, mmHg 115.5 (12.0) 115.5 (12.0)
- Diastolic blood pressure, mmHg 68.1 (9.3) 68.1 (9.3)
Mid- pregnancy
- Gestational age, weeks 20.5 (18.5, 23.5) 20.5 (18.5, 23.5)
- Systolic blood pressure, mmHg 116.8 (11.9) 116.8 (11.9)
- Diastolic blood pressure, mmHg 67.2 (9.3) 67.2 (9.3)
Late pregnancy
- Gestational age, weeks 30.2 (28.5, 32.9) 30.2 (28.5, 32.9)
- Systolic blood pressure, mmHg 118.4 (11.9) 118.4 (11.9)
- Diastolic blood pressure, mmHg 69.1 (9.2) 69.1 (9.2)
Hypertensive disorders in pregnancy, n (%)
Any 308 (5.8) 308 (5.8)
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Supplementary Table 2.6.1. Subject characteristics in the original and imputed dataset (N=5,310) (con-
tinued)
Observed Imputed
Gestational hypertension 215 (4.0) 215 (4.0)
Preeclampsia 93 (1.8) 93 (1.8)
Paternal characteristics
Age, y 33.0 (22.3, 45.8) 33.0 (21.7, 45.2)
Missing, n (%) 1,284 (24.2)
Height, cm 182.1 (7.9) 181.9 (7.7)
Missing, n (%) 1,289 (24.3)
Weight, kg 83.9 (13.0) 83.7 (11.6)
Missing, n (%) 1,286 (24.2)
Body Mass Index, m/kg2 25.3 (3.4) 25.3 (3.2)
Missing, n (%) 1,293 (24.4)
Ethnicity, n (%)
- European 2,736 (51.5) 3,274 (61.7)
- Non-European 1,155 (21.8) 2,036 (38.3)
Missing, n (%) 1,419 (26.7)
Educational level father, n (%)
- Primary or secondary 1,661 (31.3) 2,896 (54.5)
- Higher 1,841 (34.7) 2,414 (45.5)
Missing, n (%) 1,808 (34.0)
Systolic blood pressure, mmHg 130.2 (13.5) 130.2 (13.5)
Diastolic blood pressure, mmHg 73.4 (10.6) 73.4 (10.6)
Birth characteristics
Female, n (%) 2,656 (50.0) 2,656 (50.0)
Gestational age, weeks 40.1 (35.9, 42.3) 40.1 (35.9, 42.3)
Birth weight, g 3,431 (548) 3,430 (548)
Missing, n (%) 8 (0.1)
Small size for gestational age, n (%) 267 (5.0) 267 (5.0)
Appropriate size for gestational age, n (%) 4,777 (89.9) 4,777 (89.9)
Childhood characteristics
Age, y 6.0 (5.7, 8.0) 6.0 (5.7, 8.0)
Height, cm 119.5 (6.0) 119.5 (6.1)
Missing, n (%) 7 (0.1)
Weight, kg 23.3 (4.3) 23.3 (4.3)
Missing, n (%) 7 (0.1)
Body mass index, kg/m2 16.2 (1.9) 16.2 (1.9)
Missing, n (%) 7 (0.1)
Systolic blood pressure, mmHg 102.7 (8.2) 102.7 (8.2)
Diastolic blood pressure, mmHg 60.7 (6.9) 60.7 (6.9)
*Z score Systolic blood pressure 0.53 (0.7) 0.53 (0.7)
*Z score Diastolic blood pressure 0.34 (0.6) 0.34 (0.6)
# Blood pressure ≥95th percentile, n (%) 410 (7.7) 410 (7.7)
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution.
*Z scores of systolic and diastolic blood pressure are calculated using normative values from the “Fourth report on the 
diagnosis, evaluation and treatment of high blood pressure in children and adolescents” from the National High Blood 
Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.
#Blood pressure ≥95th percentile (systolic and/or diastolic blood pressure ≥95th percentile) for age, height and gender on 
repeated measurement.
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Supplementary Table 2.6.2. Subject characteristics in children with and without follow-up blood pressure 
measurements (N=8,452)
N=5,310 N=3,142 p-value
Maternal characteristics
Age, y 30.9 (19.7, 39.3) 28.9 (18.5, 39.0) <0.01
Height, cm 167.5 (7.4) 166.4 (7.4) <0.01
Weight, kg 69.3 (12.8) 69.1 (13.6) 0.55
Body mass index, kg/m2 23.5 (4.1) 23.6 (4.5) 0.55
Parity (%)
- 0 2,990 (56.3) 1,663 (54) 0.02
- ≥1 2,280 (42.9) 1,414 (46)
Educational level mother, n (%) <0.01
- Primary or secondary 2,673 (50.3) 1,781 (56.7)
- Higher 2,295 (43.2) 936 (39.8)
Ethnicity, n (%) <0.01
- European 3,135 (59.0) 1,407 (44.8)
- Non-European 2,059 (38.8) 1,386 (44.1)
Smoking during pregnancy, n (%) <0.01
- No 3,476 (65.4) 1,887 (60.1)
- Yes 1,224 (23.1) 783 (24.9)
Alcohol using during pregnancy, n (%) <0.01
- No 2,138 (40.3) 1,471 (46.8)
- Yes 2,512 (47.3) 1,152 (36.7)
Folic acid supplements during pregnancy, n (%) <0.01
- No 1,017 (19.2) 823 (26.2)
- Yes 3,023 (56.9) 1,393 (44.3)
Blood pressure
Early pregnancy
Gestational age, weeks 13.2 (9.8, 17.4) 13.4 (9.5, 17.6) <0.01
Systolic blood pressure, mmHg 115.5 (12.0) 114.7 (12.1) <0.01
Diastolic blood pressure, mmHg 68.1 (9.3) 67.7 (9.3) 0.08
Mid- pregnancy
Gestational age, weeks 20.5 (18.5, 23.5) 20.4 (18.5, 23.9) 0.07
Systolic blood pressure, mmHg 116.8 (11.9) 115.8 (11.8) <0.01
Diastolic blood pressure, mmHg 67.2 (9.3) 66.6 (9.0) 0.01
Late pregnancy
Gestational age, weeks 30.2 (28.5, 32.9) 30.3 (28.4, 32.9) 0.02
Systolic blood pressure, mmHg 118.4 (11.9) 117.4 (12.0) <0.01
Diastolic blood pressure, mmHg 69.1 (9.2) 68.5 (9.2) <0.01
Hypertensive disorders in pregnancy, n (%)
Any 305 (5.8) 160 (5.1) 0.58
Gestational hypertension 215 (4.0) 95 (3.0) 0.03
Preeclampsia 93 (1.8) 65 (2.1) 0.02
Paternal characteristics
Age, y 33.0 (22.3, 45.8) 31.8 (21.0, 44.5) <0.01
Height, cm 182.1 (7.9) 181.8 (7.7) <0.01
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Supplementary Table 2.6.2. Subject characteristics in children with and without follow-up blood pressure 
measurements (N=8,452) (continued)
N=5,310 N=3,142 p-value
Weight, kg 83.9 (13.0) 83.6 (11.6) <0.01
Body Mass Index, m/kg2 25.3 (3.4) 25.3 (3.6) 0.59
Ethnicity, n (%) <0.01
- European 2,736 (51.5) 1,150 (36.6)
- Non-European 1,155 (21.8) 697 (22.2)
Educational level father, n (%) <0.01
- Primary or secondary 1,661 (31.3) 818 (26.0)
- Higher 1,841 (34.7) 722 (23.0)
Systolic blood pressure, mmHg 130.2 (13.5) 129.8 (13.6) 0.25
Diastolic blood pressure, mmHg 73.4 (10.6) 72.9 (10.9) 0.12
Birth characteristics
Female, n (%) 2,656 (50.0) 1,534 (48.9) 0.30
Gestational age, weeks 40.1 (35.9, 42.3) 40.0 (35.0, 42.4) <0.01
Birth weight, g 3,431 (548) 3,387 (576) <0.01
 Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. Diff erences in subject characteristics comparing the 
groups with and without blood pressure measurements were evaluated using T-tests for continuous normally distributed 
variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests for categorical variables.  
Supplementary Table 2.6.3. Eff ect estimates from the longitudinally measured maternal blood pressure 
and childhood blood pressure
Childhood blood pressure
Diff erence in systolic blood pressure
Intercept
(mmHg)
P-valueb Slope
(mmHg/week of gestation)
P-valueb
Tertile 1 109.6 P <0.001 -0.02 P = 0.51
Tertile 2 111.1 P = 0.15 -0.03 P = 0.17
Tertile 3 112.0 P <0.001 Reference
Diff erence in diastolic blood pressure
Intercept
(mmHg)
P-valueb Slope
(mmHg/week of gestation)
P-valueb
Tertile 1 97.7 P <0.001 -0.02 P = 0.22
Tertile 2 97.8 P <0.001 0.01 P = 0.48
Tertile 3 99.1 P <0.001 Reference
a Values are based on mixed eff ects regression models and refl ect the change in maternal blood pressure during pregnancy 
in mmHg per tertile of childhood blood pressure compared to the reference group of children in the highest tertile.
bP–value refl ects the signifi cance level of the estimate.
159
Blood pressure in parents and children
2.6
Supplementary Table 2.6.4. Associations of maternal and paternal blood pressure during pregnancy with 
childhood blood pressure (N=5,310)
Childhood blood pressure (SDS)
Confounder model Birth model Childhood model
Maternal blood pressure (SDS)
Early pregnancy (N=4,098)
Systolic blood pressure 0.07 (0.05, 0.09)** 0.07 (0.05, 0.09)** 0.07 (0.04, 0.09)**
Diastolic blood pressure 0.04 (0.02, 0.06)** 0.04 (0.02, 0.06)** 0.04 (0.02, 0.06)**
Mid- pregnancy (N=5,006)
Systolic blood pressure 0.08 (0.06, 0.10)** 0.08 (0.06, 0.10)** 0.07 (0.05, 0.09)**
Diastolic blood pressure 0.05 (0.04, 0.07)** 0.05 (0.03, 0.07)** 0.05 (0.04, 0.07)**
Late pregnancy (N=5,104)
Systolic blood pressure 0.08 (0.06, 0.10)** 0.08 (0.06, 0.10)** 0.08 (0.06, 0.10)**
Diastolic blood pressure 0.06 (0.04, 0.08)** 0.06 (0.04, 0.08)** 0.06 (0.04, 0.08)**
Paternal blood pressure (N=3,805)
Systolic blood pressure 0.05 (0.03, 0.08)** 0.05 (0.03, 0.08)** 0.06 (0.04, 0.08)**
Diastolic blood pressure 0.06 (0.04, 0.08)** 0.05 (0.03, 0.07)** 0.06 (0.04, 0.08)**
Values are regression coeffi  cients (95 % confi dence intervals) based from multiple linear regression models. Estimates are 
based on multiple imputed data.
Confounder model is focused on maternal blood pressure are adjusted for maternal age, gestational age at measurement, 
pre-pregnancy body mass index, parity, ethnicity, educational level, smoking and alcohol consumption during pregnancy, 
and folic acid intake; Models focused on paternal blood pressure are adjusted for paternal age, body mass index, ethnicity, 
and educational level.
Birth models are confounder models additionally adjusted for gestational age at birth and birth weight. 
Childhood models are confounders models additionally adjusted for childhood current body mass index. *P  <0.05 
**P <0.01
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Supplementary Figure 2.6.2. Combined associations of maternal and paternal blood pressure with child-
hood blood pressure, confounder and birth models (N=5,310)
A. Maternal blood pressure in early and late pregnancy, confounder model
Values are regression coeffi  cients (95 % confi dence intervals) from multiple linear regression models. Estimates are based 
on multiple imputed data. Models are adjusted for maternal age, gestational age at measurement, pre-pregnancy body 
mass index, parity, ethnicity, educational level, smoking and alcohol consumption during pregnancy, folic acid supple-
ment intake. Estimates regarding childhood systolic blood pressure are assessed by combining maternal early pregnancy 
with late pregnancy systolic blood pressure tertiles. Estimates regarding childhood diastolic blood pressure are assessed 
by combining maternal early with late pregnancy diastolic blood pressure tertiles. 
B. Maternal blood pressure in early and late pregnancy, birth model
Values are regression coeffi  cients (95 % confi dence intervals) from multiple linear regression models. Estimates are based on 
multiple imputed data. Models are adjusted for maternal age, gestational age at measurement, pre-pregnancy body mass 
index, parity, ethnicity, educational level, smoking and alcohol consumption during pregnancy, folic acid supplement intake, 
birthweight and gestational age at birth. Estimates regarding childhood systolic blood pressure are assessed by combining 
maternal early pregnancy with late pregnancy systolic blood pressure tertiles. Estimates regarding childhood diastolic blood 
pressure are assessed by combining maternal early with late pregnancy diastolic blood pressure tertiles. 
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C. Maternal and paternal blood pressure, confounder model
Values are regression coeffi  cients (95 % confi dence intervals) based from multiple linear regression models. Estimates are 
based on multiple imputed data. Models focused on maternal blood pressure are adjusted for maternal and paternal age, 
ethnicity, educational level and (pre-pregnancy) body mass index; gestational age at measurement, maternal smoking 
and alcohol consumption during pregnancy, folic acid supplement intake. Estimates regarding childhood systolic blood 
pressure are assessed by combining maternal early pregnancy systolic blood pressure tertiles with paternal systolic blood 
pressure tertiles. Estimates regarding childhood diastolic blood pressure are assessed by combining maternal early preg-
nancy diastolic blood pressure tertiles with paternal diastolic blood pressure tertiles. 
D. Maternal and paternal blood pressure, birth model
Values are regression coeffi  cients (95 % confi dence intervals) based from multiple linear regression models. Estimates are 
based on multiple imputed data. Models focused on maternal blood pressure are adjusted for maternal and paternal age, 
ethnicity, educational level and (pre-pregnancy) body mass index; gestational age at measurement, maternal smoking and 
alcohol consumption during pregnancy, folic acid supplement intake, birthweight and gestational age at birth. Estimates 
regarding childhood systolic blood pressure are assessed by combining maternal early pregnancy systolic blood pressure 
tertiles with paternal systolic blood pressure tertiles. Estimates regarding childhood diastolic blood pressure are assessed 
by combining maternal early pregnancy diastolic blood pressure tertiles with paternal diastolic blood pressure tertiles. 
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ABSTRACT
Background: Kidney measures in early life are associated with kidney disease in later life. 
We hypothesized that these associations are partly explained by common genetic variants 
that lead to both smaller kidneys with lower kidney function in early childhood and kidney 
disease in adulthood. 
Methods: We examined in a population-based prospective cohort study among 4,119 chil-
dren the associations of a weighted genetic risk score combining 20 previously identifi ed 
common genetic variants related to adult eGFRcreat with kidney outcomes in children aged 6.0 
years (95 % range 5.7–7.8). Childhood kidney outcomes included combined kidney volume, 
glomerular fi ltration rate (eGFR) based on creatinine levels, and microalbuminuria based on 
albumin and creatinine urine levels. 
Results: We observed that the genetic risk score based on variants related to impaired kidney 
function in adults was associated with a smaller combined kidney volume (P-value 3.0 x 10–3) 
and with a lower eGFR (P-value 4.0 x 10–4) in children. The genetic risk score was not associ-
ated with microalbuminuria. 
Conclusion: Common genetic variants related to impaired kidney function in adults already 
lead to subclinical changes in childhood kidney outcomes. The well-known associations of 
kidney measures in early life with kidney disease in later life may at least be partly explained 
by common genetic variants.
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INTRODUCTION
End stage kidney disease seems to partly originate in early life.1, 2 Smaller kidneys in early 
life with a reduced number of nephrons lead to glomerular hyperfi ltration and sclerosis and 
predispose to kidney disease in adulthood.3, 4 Also, risk factors for impaired kidney function 
track from childhood to adulthood.5, 6 Early kidney growth and development is a complex de-
velopmental process and is infl uenced by many environmental factors.7, 8 Various nutritional 
and environmental exposures have been suggested to aff ect early kidney development and 
may subsequently infl uence the risk of kidney disease in later life.9, 10
However, the associations between early life kidney characteristics and kidney disease in 
later life may also be explained by common genetic variants. These variants may aff ect early 
kidney development and function and thereby predispose individuals to kidney disease in 
later life. Several genes are known to be involved in kidney development.8 Rare mutations in 
these genes can cause severe anomalies, such as agenesis or dysgenesis of the kidney.7 These 
mutations do not explain variation in kidney development within normal range. However, 
large genome wide association studies (GWAS) in adults have identifi ed 30 common genetic 
variants associated with impaired kidney function.11–13 For this study, we hypothesized that 
these genetic variants also aff ect kidney growth and function in early childhood, and thereby 
partly explain the well-known associations of early life kidney measures with kidney disease 
in later life. 
To test this hypothesis, we examined, in a population-based prospective cohort study 
among 4,119 children, the associations of genetic risk scores combining previously identifi ed 
common genetic variants related to impaired kidney function in adults with kidney outcomes 
in school-age children. 
METHODS
Design and study population
This study was embedded in the Generation R Study, a multiethnic population-based pro-
spective cohort study from fetal life onwards in Rotterdam, the Netherlands, which has been 
described in detail previously.14 The study has been approved by Medical Ethical Committee 
of Erasmus MC, University Medical Center Rotterdam. All children were born between April 
2002 and January 2006 and form a largely prenatally enrolled birth cohort that is currently 
being followed until young adulthood. Written consent was obtained for every participant. 
A genome wide association screen was available in 5,732 children (see below for details). 
The present analyses were performed among 4,119 singleton live births for whom we have 
detailed information on kidney outcomes at the median age of 6 years (95 % range 5.7, 7.8). 
The fl owchart of study participants is given in the Figure 3.1.1.
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Genetic variants
DNA was isolated from cord blood samples. If DNA samples from cord blood were missing (in 
6.3 % of the participants), DNA was isolated from blood samples at follow-up measurements. 
Genome-wide association arrays were run using the Illumina 610 Quad and 660 platforms.15 
A stringent process of quality control was applied. Individuals with low sample call rates or 
sex mismatches were excluded. Before imputation, Single Nucleotide Polymorphisms (SNPs) 
were excluded in case of high levels of missing data (SNP call rate <98 %), highly signifi cant 
departures from Hardy-Weinberg equilibrium (P  <1*10–6), or low minor allele frequen-
cies (<1 %).14 MACH software was used to impute genotypes to the cosmopolitan panel of 
HapMap II (release 22).16, 17 Three SNPs (rs6431731, rs2453580, and rs881858) had imputation 
qualities between 0.68 and 0.9, indicating reasonable imputation. All other SNPs had imputa-
tion qualities above 0.9, indicating good imputation. Based on previous studies, we identi-
fi ed 30 SNPs robustly associated with adult kidney function: 29 for adult eGFRcreat and 1 for 
adult microalbuminuria.11–13 Of these 30 SNPs, information on 26 was available in the GWAS. 
Information on rs11078903, rs7805747, rs2279463, and rs7422339, all previously associated with 
Figure 3.1.1. Flowchart of the study participants 
 
 
 
 
Singleton live births 
N=5,687  
Excluded: no genetic data available 
N=4,169 
Excluded: twin pregnancies  
N=45 
Excluded: 
N=1,568 
 
- kidney abnormalities (16)  
- no data on at least one outcome measure 
(1,552) 
Data on kidney outcomes: 
       Full group   Europeans 
Kidney volume        =3,784 2,009 
eGFRcreat             =2,847 1,514 
eGFRcystC             =2,854 1,519 
Microalbuminuria  =3,971 2,098 
Children with genetics data available 
N=5,732 
Children enrolled in the Generation R study 
N=9,901 
Children with genetics data and data on at 
least one outcome available  
N=4,119 
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adult eGFRcreat, was not available. However, rs3798156 was used as a perfect proxy (R2 = 1) for 
rs2279463 and rs11078902 was used as a perfect proxy for rs11078903. No perfect proxies were 
available in the GWAS dataset for the other two SNPs. As the focus of this study was to exam-
ine SNPs related to estimated glomerular fi ltration rate and not to creatinine metabolism, 20 
out of these 28 SNPs were used for the genetic risk score analyses. The individual SNPs used 
are shown in Supplementary Table 3.1.2.
Childhood kidney outcomes 
Kidney outcomes were assessed at a dedicated research center in the Erasmus MC-Sophia Chil-
dren’s Hospital in Rotterdam by well-trained staff .18. We measured kidney volume with ultrasound, 
using an ATL-Philips HDI 5000 instrument (Seattle, WA), with a 2.0–5.0 MHz curved array trans-
ducer. We identifi ed the left and right kidneys in the sagittal plane along its longitudinal axis. Also, 
we performed measurements of maximal bipolar kidney length, width and depth. Kidney width 
and depth were measured at the level of the hilum. The cross-sectional area in which the kidney 
appeared symmetrically round at its maximum width was used. Kidney volume was calculated 
using the equation for a prolate ellipsoid: volume (cm3) = 0.523 x length (cm) x width (cm) x depth 
(cm).19 Combined kidney volume was calculated by summing right and left kidney volume. We 
previously reported good intra-observer and inter-observer correlation coeffi  cients.20 
Non-fasting blood samples were drawn by antecubital venipuncture. Creatinine concentra-
tions were measured with enzymatic methods and cystatin C levels with a particle enhanced 
immunoturbidimetric assay (using Cobas 8000 analyzers, Roche, Almere, the Netherlands). 
Quality control samples demonstrated intra-assay and inter-assay coeffi  cients of variation of 
0.51 % for creatinine and 1.65 % for cystatin C, and 1.37 % for creatinine and 1.13 % for cystatin C, 
respectively. We estimated glomerular fi ltration rate (eGFR) according to the revised Schwartz 
2009 formula: eGFRcreat  =  36.5 * (height (cm)/ serum creatinine (μmol/l)).21 Additionally, we 
estimated the glomerular fi ltration rate using Zappitelli’s formula based on cystatin C levels: 
eGFRcystC = 75.94/[CysC.1.17].22 
Urine creatinine (mmol/l) and urine albumin (mg/l) levels were determined with a Beckman 
Coulter AU analyser, creatinine levels were measured with the Jaff e reaction. We also calcu-
lated the albumin-creatinine ratio. In line with clinical cut-off s, microalbuminuria was defi ned 
as an albumin-creatinine ratio >2.5 mg/mmol for boys and >3.5 mg/mmol for girls.23  
Statistical analysis
First, we performed multiple linear and logistic regression analyses, adjusted for sex, age at 
measurements and the fi rst four principal components, to examine the associations of the 21 
SNPs (20 SNPs for kidney function per se and 1 for microalbuminuria) individually with com-
bined kidney volume, creatinine and cystatin C levels, eGFRcreat and eGFRcystC and the risk of 
microalbuminuria in childhood, assuming additive genetic eff ects. To adjust for multiple testing 
in the analyses of the individual SNPs, we applied Bonferroni correction for the number of SNPs 
tested. A P value of <2.4 x 10–3 (0.05/21) was considered statistically signifi cant. Second, for each 
outcome we calculated the percentage of variance explained by all SNPs combined by deduct-
ing the unadjusted R2 of the model including only the covariates from the unadjusted R2 of the 
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full model including all SNPs and the covariates, which were sex, age at measurements, and the 
fi rst four principal components from our genome wide data. Third, we combined the 20 SNPs 
related to adult eGFRcreat in a genetic risk score that summed the number of eGFRcreat-decreasing 
alleles weighted by their previously reported eff ect sizes in adults. As for every SNP, the number 
of eff ect alleles can be 0, 1, or 2, the weighted risk score was rescaled to a score ranging from 0 
to 40, the maximum number of eff ect alleles, and rounded to the nearest integer. Additionally, 
we computed an unweighted genetic risk score based on the 20 adult eGFRcreat SNPs to see 
whether the results were independent of the weight based on adults fi ndings, by adding the 
number of risk alleles for the 20 SNPs. Linear and logistic regression analyses were performed 
to examine the association of these risk scores with combined kidney volume, creatinine and 
cystatin C levels, eGFRcreat, eGFRcystC and the risk of microalbuminuria in childhood, adjusted for 
the same covariates as mentioned above. All analyses were performed fi rst in the full group 
and subsequently repeated as sensitivity analyses in the subgroup of children of European 
ethnicity, the largest ethnic subgroup in our population. A child was classifi ed as European 
if he/she was within four standard deviations from the HapMap CEU panel mean value for all 
fi rst four principal components, based on the genetic data. To assess whether the associations 
were diff erent by child sex we evaluated the statistical interaction by adding the product term 
of the child sex and individual SNPs to the models. However, no signifi cant interactions were 
observed. We also aimed to explore whether child height aff ected the associations of the ge-
netic risk score with combined kidney volume. We performed a sensitivity analysis to explore 
whether adding 7 SNPs related to creatinine metabolism (rs10774021, rs10794720, rs491567, 
rs6465825, rs9895661, rs2453533, rs3798156) to the genetic risk score would aff ect the results.11 
In addition, we explored the association of a genetic risk score including only 11 of the 20 SNPs, 
which may have a role related to kidney developmental outcomes (nephrogenesis (rs881858, 
VEGFA; rs626277, DACH1); glomerular fi ltration barrier and podocyte function (rs11959928, 
DAB2; rs3925584, MPPED2; rs13538, NAT8), metabolic function of the kidney (rs1260326, GCKR; 
rs10109414, STC1), solute transport (rs12460876, SLC7A9; rs6420094, SLC34A1) and renal cell 
structure development (rs12917707, UMOD; rs17319721, SHROOM3)).13, 24–26 Furthermore, we 
explored the eff ect of 2 SNPs known to be associated with eGFRcystC, by adding them to the 
unweighted risk score. All analyses were performed using the Statistical Package for the Social 
Sciences version 21.0 for Windows (SPSS IBM, Chicago, IL).
RESULTS 
Participant characteristics
The fl owchart of study participants is given in the Figure 3.1.1. Table 3.1.1. shows the charac-
teristics of the participants. In the full group the mean combined kidney volume and eGFRcreat 
were 120 cm3 (SD ±23.3) and 119 ml/min/1.73m2 (SD ±16), respectively. Of all the children, 7.9 % 
had microalbuminuria and 0.07 % had an eGFR <60 ml/min/1.73 m2. The characteristics of the 
subgroup of European children only were similar to those of the full group (Supplementary 
Table 3.1.1).
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Individual genetic variants and childhood kidney outcomes
Results for the associations of the individual SNPs with childhood kidney outcomes are given 
in the Supplemental Material. Of the 20 available SNPs known to be associated with eGFRcreat 
and the single SNP associated with microalbuminuria in adults, none were individually sig-
nifi cantly associated with kidney volume, eGFRcreat, eGFRcystC, and microalbuminuria, in the 
full group (Supplementary Table 3.1.2). In both the full group and the European ancestry 
subgroup, rs3925584, located upstream of MPPED2, was associated with childhood creatinine 
blood levels (P values 1.8 x 10–3 and 5.6 x 10–4, respectively). In addition, in the European an-
cestry subgroup, rs11078902 in CDK12 was associated with childhood creatinine blood levels 
and with eGFRcreat (P values 1.1 x 10–3 and 2.3 x 10–3, respectively) (Supplementary Tables 3.1.3, 
3.1.4, and 3.1.5). The 20 adult kidney function SNPs together explained 1.3 %, 1.4 %, and 0.6 % 
of the variance in combined kidney volume, eGFRcreat and eGFRcystC in childhood, respectively.
Genetic risk score and childhood kidney outcomes
Table 3.1.2 presents the associations of the weighted genetic risk score based on 20 SNPs 
known to be associated with impaired adult eGFRcreat with childhood kidney outcomes. The 
weighted risk score ranged from 13 to 33 with a mean of 22.8 (SD 2.8) and was signifi cantly 
associated with childhood combined kidney volume (P value 3.0 x 10–3). For each additional 
average risk allele, combined kidney volume was -0.39 cm3 (95 % Confi dence Interval (CI) 
-0.64, -0.13) smaller. The diff erence in combined kidney volume between the lowest and high-
est risk categories (≤22 and ≥33 risk alleles, respectively) was 2.62 cm3 (Figure  3.1.2, panel 
a), which corresponds with a 2.2 % diff erence. A higher weighted genetic risk score was also 
associated with a lower eGFRcreat (P value 4.0 x 10–4). For each additional average risk allele, 
eGFRcreat was -0.38 ml/min/1.73m2 (95 % CI -0.60; -0.17) lower. The diff erence in mean eGFRcreat 
Table 3.1.1. Subjects characteristics (N=4,119)
Subjects characteristics
Girls (%) 49.7
Gestational age at birth (weeks) 40.1 (36.4-42.3)
Birth weight (g) 3,464 (515)
Age at kidney measurements (y) 6.0 (5.7-7.8)
Height at kidney measurements (m) 1.20 (0.06)
Weight at kidney measurements (kg) 23.3 (4.2)
Combined kidney volume (cm3) 120.0 (23.3)
Creatinine (μmol/l) 37.4 (5.7)
Cystatin C (μg/l) 783 (83)
eGFRcreat (ml/min/1.73m2) 119 (16)
eGFRcystC (ml/min/1.73m2) 103 (15)
Microalbuminuria (%) 7.9
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. Abbreviations: eGFRcreat estimated glomerular fi ltra-
tion rate calculated based on creatinine blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on 
cystatin C blood levels.
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between the lowest and highest risk categories was 4.46 ml/min/1.73m2 (Figure 3.1.2, panel 
b), which corresponds with a 3.7 % diff erence. Similarly, per additional average risk allele of 
the adult risk score, childhood eGFRcystC was -0.27 ml/min/1.73m2 (95 % CI -0.47; -0.07) lower. 
The diff erence in mean eGFRcystC between the lowest and highest risk categories was 3.38 ml/
Table 3.1.2. Associations of the genetic risk score based on adult kidney function with childhood kidney 
outcomes (N=4,119)a
Genetic risk score
Weighted Unweighted
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Childhood kidney outcomes (N)
Kidney volume (cm3)b (3,784) -0.39 (-0.64; -0.13) 3.0*10-3 0.3 -0.38 (-0.63; -0.13) 3.2*10-3 0.3
eGFRcreat (ml/min/1.73m2)b (2,847) -0.38 (-0.60; -0.17) 4.0*10-4 0.4 -0.40 (-0.61; -0.20) 1.7*10-4 0.7
eGFRcystC (ml/min/1.73m2)b (2,854) -0.27 (-0.47; -0.07) 8.0*10-3 0.2 -0.28 (-0.48; -0.09) 5.0*10-3 0.3
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
b Values are beta coeffi  cients from linear regression models adjusted for child age, sex and the fi rst four principal compo-
nents from the genetic data. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine 
blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. P value for the sig-
nifi cant associations <0.05. The percentage of variance explained by the genetic risk score, was calculated by comparing 
the unadjusted R2 between a model including the risk score and the covariates and a model including only the covariates, 
which were sex, age at measurements, and the fi rst four principal components.
Figure 3.1.2, panels a-c Eff ect of the weighted adult eGFRcreat genetic risk score on childhood kidney out-
comes (N=4,119)
a. Eff ect of adult eGFR creatinine-based genetic risk score on childhood combined kidney volume:
The x axis gives the categories of the risk score (overall sum of risk alleles, weighted by previously reported eff ect sizes, 
rescaled and rounded to the nearest integer). The left y axis gives the number of individuals in each risk-score category, 
whereas the right y axis gives the mean combined kidney volume. The histogram refl ects the observed number of indi-
viduals in each risk-score category. The dots and regression line refl ect the estimated mean combined kidney volume for 
each risk-score category. Values based on the continuous risk score, as presented in Table 2. **P value 3.0x10-3
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min/1.73m2 (Figure 3.1.2, panel c). We did not observe an association of the weighted risk 
score with the risk of childhood microalbuminuria (data not shown).
Results from the unweighted risk score (mean 21.8, SD 2.8) were similar to those of the 
weighted score (Table  3.1.2). Supplementary Table  3.1.6 shows that higher genetic risk 
scores were also associated with higher childhood creatinine blood levels and cystatin C 
blood levels (P values <0.05). Results in the subgroup of only European children tended to be 
b. Eff ect of adult eGFR creatinine-based genetic risk score on childhood eGFR creatinine-based:
The x axis gives the categories of the risk score (overall sum of risk alleles, weighted by previously reported eff ect sizes, 
rescaled and rounded to the nearest integer). The left y axis gives the number of individuals in each risk-score category, 
whereas the right y axis gives the mean eGFRcreat. The histogram refl ects the observed number of individuals in each risk-
score category. The dots and regression line refl ect the estimated mean eGFRcreat for each risk-score category. P value is 
based on the continuous risk score, as presented in Table 2. **P value 4.0x10-4
c. Eff ect of adult eGFR creatinine-based genetic risk score on childhood eGFR cystatin C-based:
The x axis gives the categories of the risk score (overall sum of risk alleles, weighted by previously reported eff ect sizes, 
rescaled and rounded to the nearest integer). The left y axis gives the number of individuals in each risk-score category, 
whereas the right y axis gives the mean eGFRcystC. The histogram refl ects the observed number of individuals in each risk-
score category. The dots and regression line refl ect the estimated mean eGFRcystC for each risk-score category. P value is 
based on the continuous risk score, as presented in Table 2. **P value 8.0x10-3
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similar to those in the full group, although the association of both risk scores with eGFRcystC 
lost its signifi cance and the unweighted risk score lost its signifi cance with combined kidney 
volume in this group (Supplementary Table  3.1.7). The eff ect of the genetic risk score on 
combined kidney volume did not change after adjusting our model additionally for child 
height (Supplementary Table 3.1.8).
The genetic risk scores including 27 SNPs, with 7 additional SNPs related to creatinine 
metabolism in adults, and the genetic risk score including 11 SNPs which may have a known 
function related to kidney development, revealed similar results as our main risk score. Results 
are shown in Supplementary Tables 3.1.9 and 3.1.10. In the Supplementary Table 3.1.11, is 
shown the eff ect of the unweighted risk score which includes the additional 2 SNPs related 
to eGFRcystC. The results did not change, but the eff ect estimates on eGFRcystC and cystatin C 
were larger.
DISCUSSION
We observed in a large population-based prospective cohort study, that a higher genetic 
risk score combining previously identifi ed common genetic variants related to lower kidney 
function in adults was also associated with a smaller combined kidney volume and lower 
eGFRcreat and eGFRcystC in childhood. 
Previous GWAS have identifi ed many common genetic variants related to impaired kidney 
function in adults.11–13 Of the 20 available SNPs known to be associated with adult eGFRcreat 
and the single SNP associated with adult microalbuminuria, only 2 were individually associ-
ated with childhood kidney outcomes. First, we observed an association of rs3925584, located 
upstream of MPPED2, with creatinine blood levels both in the full group and in the subgroup 
of European children only. In zebrafi sh, knockdown of MPPED2 caused abnormal podocyte 
anatomy.11 Rs3925584 has also been associated with magnesium levels in a large GWAS.27 
Rs3925584 is also located close to DCDC5, which has been associated with bone mineral den-
sity.28 Second, rs11078902 in CDK12 was associated with eGFRcreat and creatinine blood levels 
in the subgroup of European children only.11 CDK12, cyclin-dependent kinase 12, regulates the 
expression of genes involved in DNA repair and is required for the maintenance of genomic 
stability. CDK inhibitors have been described to play a role in human glomerular disease.29 
All these associations were directionally consistent with results reported in previous GWAS 
among adults.11, 13 None of the included common genetic variants were associated with child-
hood microalbuminuria. The results for the associations of individual SNPs with childhood 
kidney outcomes should be interpreted carefully. The original GWAS meta-analysis discovery 
studies in adults were performed in much larger samples than the current study and our 
negative results may have occurred due to a lack of power. 
In the current study, the weighted genetic risk score related to impaired kidney function in 
adults was associated with smaller combined kidney volume and lower eGFR in childhood. 
For an average child in our population, the observed eff ect estimates correspond with a 0.3 % 
smaller combined kidney volume, a 0.3 % lower eGFRcreat and a 0.3 % lower eGFRcystC per each 
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additional risk allele. We did not observe an association of the genetic risk score with micro-
albuminuria. We found similar results for the weighted and unweighted risk genetic scores, 
suggesting that the adult weights used in this score did not strongly infl uence the observed 
associations. Adding to the risk score 7 SNPs previously reported to play a role in creatinine 
production and secretion revealed similar results. Restricting the genetic risk score to the 11 
SNPs with a likely or known function related to kidney development revealed similar results 
with slightly stronger eff ect estimates. This restricted genetic risk score may be more specifi c 
to our outcomes because of the young age range. Including in the unweighted risk score 
two additional SNPs known to be associated with eGFRcystC,13, 24 showed similar associations, 
with stronger eff ect estimates on eGFRcystC and cystatin C, suggesting a strong infl uence of 
the 2 added SNPs on these 2 markers. Ideally, the weights in the genetic risk score would be 
child-specifi c, as these best refl ect the relative importance of the variants in children. For 
this, we would need results from large-scale GWAS with independent replication samples on 
childhood kidney function outcomes. However, a GWAS focused on kidney function among 
healthy children is not available yet. A recent paper described a GWAS to identify common 
genetic variants infl uencing renal function in children with CKD. Although no genome-wide 
signifi cant associations were found, a number of potentially interesting subthreshold SNPs 
were identifi ed.30 This underlines the need for large-scale GWAS eff orts to discover the ge-
netic background of kidney function in children, both with and without CKD.
We hypothesized that common genetic variants may partly explain the associations of 
early life kidney measures with kidney function in later life. The observed associations of the 
genetic risk scores related to kidney function in adults with kidney outcomes in childhood 
support this hypothesis. However, confi rmation of our fi ndings in other children cohorts and 
further functional studies are required to establish the causal genes and the mechanisms 
underlying the associations of these variants with kidney function in childhood and disease 
in adulthood. In the same cohort as the current study, we have reported associations of 
smaller kidneys with lower kidney function.31 To explore if the associations of the genetic 
risks score with kidney function outcomes were explained by kidney volume, we additionally 
adjusted the kidney function measures for combined kidney volume. However, the results 
did not change. Also, adding childhood height to the models associating the genetic risk 
score with combined kidney volume did not materially change the results. The observed ef-
fect estimates in the present study are small, but important from an etiological perspective. 
They provide further insights into pathways leading to changes in kidney function from the 
earliest phase of life. Whether common genetic variants related to kidney outcomes in child-
hood and disease in adulthood are clinically useful for identifi cation of groups at risk needs 
further study. 
Some methodological issues need to be considered. Major strengths of the current study 
are the detailed phenotypes and the relatively large number of subjects. Still, our sample 
size was too small to identify many of the associations of individual common genetic vari-
ants with childhood kidney outcomes, assuming similar eff ect sizes as in adults. It has 
been shown that kidney function and the prevalence of chronic kidney disease vary across 
ethnic groups in adults.32 Our study population was multi-ethnic, but a sensitivity analysis 
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in European children only, as the largest ethnic subgroup, revealed similar results as in the 
full group. The other ethnic subgroups were too small to analyze individually. Of all children 
with genetic information, data on kidney outcomes was available in 72 %. As compared to 
children with kidney follow-up measurements, those without these measurements had a 
lower birth weight (P value <0.05) (data not shown). A selective loss to follow-up may have 
reduced variation in birth weight and early kidney size and therefore reduced the power 
to detect diff erences. We performed detailed measurements of childhood kidney outcomes. 
Kidney size correlates with the number of glomeruli and can be used as a measure of kidney 
development.33 In children the estimation of GFR is challenging. Blood creatinine is most 
commonly used to calculate eGFR. In addition to blood creatinine levels, we also calculated 
eGFR based on cystatin C levels using Zappitelli’s formula.22, 34 It has been suggested that 
blood cystatin C levels might be a better biomarker to estimate GFR because the production 
rate is constant, it is freely fi ltered, and less dependent on child weight, height and sex com-
pared to creatinine.35, 36 Finally, in our study we have captured the vast majority of, but not all, 
known SNPs related to kidney function, as not all SNPs were available in the GWAS dataset. 
CONCLUSION 
Our results suggest that common genetic variants related to kidney function in adults could 
infl uence kidney structure and function from early childhood onwards. The previously ob-
served associations of early life kidney measures with kidney disease in later life seem to be 
partly explained by common genetic variants.
REFERENCES
 1. Lackland DT, Bendall HE, Osmond C, Egan BM, Barker DJP. Low birth weights contribute to the high 
rates of early-onset chronic renal failure in the southeastern United States. Archives of Internal Medicine. 
2000;160(10): 1472-1476
 2. White SL, Perkovic V, Cass A, et al. Is low birth weight an antecedent of CKD in later life? A systematic 
review of observational studies. Am J Kidney Dis. 2009;54(2): 248-261.
 3. Brenner BM, Lawler EV, Mackenzie HS. The hyperfi ltration theory: A paradigm shift in nephrology. Kidney 
Int. 1996;49(6): 1774-1777.
 4. Luyckx VA, Brenner BM. Birth weight, malnutrition and kidney-associated outcomes-a global concern. 
Nat Rev Nephrol. 2015;11(3): 135-149.
 5. Singh A, Satchell SC. Microalbuminuria: causes and implications. Pediatr Nephrol. 2011;26(11): 1957-1965.
 6. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-
regression analysis. Circulation. 2008;117(25): 3171-3180
 7. Shah MM, Sampogna RV, Sakurai H, Bush KT, Nigam SK. Branching morphogenesis and kidney disease. 
Development. 2004;131(7): 1449-1462.
 8. Nigam SK, Shah MM. How does the ureteric bud branch? J Am Soc Nephrol. 2009;20(7): 1465-1469.
 9. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and 
progressive renal injury. Am J Kidney Dis. 1994;23(2): 171-175.
 10. Miliku K, Voortman T, Bakker H, Hofman A, Franco OH, Jaddoe VW. Infant breastfeeding and kidney 
function in school-aged children. Am J Kidney Dis. 2015;doi 10.1053/j.ajkd.2014.12.018.
179
Genetics of childhood kidney outcomes
3.1
 11. Pattaro C, Kottgen A, Teumer A, et al. Genome-wide association and functional follow-up reveals new 
loci for kidney function. PLoS Genet. 2012;8(3): e1002584.
 12. Boger CA, Chen MH, Tin A, et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol. 2011;22(3): 
555-570.
 13. Kottgen A, Pattaro C, Boger CA, et al. New loci associated with kidney function and chronic kidney 
disease. Nat Genet. 2010;42(5): 376-384.
 14. Jaddoe VW, van Duijn CM, Franco OH, et al. The Generation R Study: design and cohort update 2012. Eur 
J Epidemiol. 2012;27(9): 739-756.
 15. Kruithof CJ, Kooijman MN, van Duijn CM, et al. The Generation R Study: Biobank update 2015. Eur J 
Epidemiol. 2014;29(12): 911-927.
 16. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet. 2009;10: 387-
406.
 17. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate 
haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34(8): 816-834.
 18. Bakker H, Kooijman MN, van der Heijden AJ, et al. Kidney size and function in a multi-ethnic population-
based cohort of school-age children. Pediatr Nephrol. 2014: 10.1007/s00467-00014-02793-00468.
 19. Geelhoed JJM, Taal HR, Steegers EAP, et al. Kidney growth curves in healthy children from the third 
trimester of pregnancy until the age of two years. The Generation R Study. Pediatr Nephrol. 2010;25(2): 
289-298.
 20. Geelhoed JJM, Kleyburg-Linkers VE, Snijders SPE, et al. Reliability of renal ultrasound measurements in 
children. Pediatr Nephrol. 2009;24(7): 1345-1353.
 21. Schwartz GJ, Munoz A, Schneider MF, et al. New Equations to Estimate GFR in Children with CKD. J Am 
Soc Nephrol. 2009;20(3): 629-637.
 22. Zappitelli M, Parvex P, Joseph L, et al. Derivation and validation of cystatin C-based prediction equations 
for GFR in children. Am J Kidney Dis. 2006;48(2): 221-230.
 23. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. Microvascular and macrovascular 
complications Microvascular and macrovascular complications. Pediatr Diabetes. 2007;8(3): 163-170.
 24. Kottgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and 
chronic kidney disease. Nat Genet. 2009;41(6): 712-717.
 25. Benetti E, Caridi G, Vella MD, et al. Immature renal structures associated with a novel UMOD sequence 
variant. Am J Kidney Dis. 2009;53(2): 327-331.
 26. Chambers JC, Zhang W, Lord GM, et al. Genetic loci infl uencing kidney function and chronic kidney 
disease. Nat Genet. 2010;42(5): 373-375.
 27. Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, potas-
sium, and sodium concentrations identify six Loci infl uencing serum magnesium levels. PLoS Genet. 
2010;6(8).
 28. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifi es 56 bone mineral 
density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5): 491-501.
 29. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D’Agati V, Alpers CE. Diff erential expression of cyclin-
dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and matura-
tion. Kidney Int. 2000;58(2): 674-683.
 30. Wuttke M, Wong CS, Wuhl E, et al. Genetic loci associated with renal function measures and chronic 
kidney disease in children: the Pediatric Investigation for Genetic Factors Linked with Renal Progression 
Consortium. Nephrol Dial Transplant. 2015; 10.1093/ndt/gfv342.
 31. Bakker H, Gaillard R, Franco OH, et al. Fetal and infant growth patterns and kidney function at school 
age. J Am Soc Nephrol. 2014;25(11): 2607-2615.
 32. Kramer H, Palmas W, Kestenbaum B, et al. Chronic kidney disease prevalence estimates among racial/
ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol. 2008;3(5): 1391-1397.
 33. Luyckx VA, Brenner BM. The clinical importance of nephron mass. J Am Soc Nephrol. 2010;21(6): 898-910.
 34. Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, Dubourg L. Which creatinine and cystatin C 
equations can be reliably used in children? Clin J Am Soc Nephrol. 2011;6(3): 552-560.
 35. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of 
GFR--history, indications, and future research. Clin Biochem. 2005;38(1): 1-8.
 36. Groesbeck D, Kottgen A, Parekh R, et al. Age, gender, and race eff ects on cystatin C levels in US adoles-
cents. Clin J Am Soc Nephrol. 2008;3(6): 1777-1785.
Chapter 3.1
180
Supplementary Table 3.1.1. European children characteristics (N=2,186)
Subjects characteristics
Girls (%) 49.4
Gestational age at birth (wk) 40.3 (36.4-42.3)
Birth weight (g) 3,449 (516)
Age at kidney measurements (y) 6.0 (5.6-7.1)
Height at kidney measurements (m) 1.20 (0.06)
Weight at kidney measurements (kg) 22.8 (3.4)
Combined kidney volume (cm3) 120.0 (22.4)
Creatinine (μmol/l) 37.0 (5.5)
Cystatin C (μg/l) 784 (85)
eGFRcreat (ml/min/1.73m2) 120 (16)
eGFRcystC (ml/min/1.73m2) 103 (16)
Microalbuminuria (%) 7.3
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. Abbreviations: eGFRcreat estimated glomerular fi ltra-
tion rate calculated based on creatinine blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on 
cystatin C blood levels.    
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Supplementary Table 3.1.4. Associations of SNPs with creatinine and cystatin C in the full group (N=2,854)a
SNP
Nearest 
Gene Chr. Position EA/OA EAF
Cystatin C 
Beta (SE)b
Cystatin C 
P value
Creatinine 
Beta (SE)b
Creatinine
P value
Previously identifi ed in eGFRcreat 
rs3925584 MPPED2 11 30,716,911 T/C 0.60 3.57 (2.29) 0.12 0.46 (0.15) 1.8*10-3
rs6431731 DDX1 2 15,780,453 T/C 0.96 6.87 (6.45) 0.29 0.29 (0.42) 0.49
rs12124078 DNAJC16 1 15,742,486 G/A 0.30 0.45 (2.38) 0.85 0.02 (0.15) 0.91
rs2453580 SLC47A1 17 19,378,913 C/T 0.41 4.92 (2.57) 0.06 0.31 (0.17) 0.06
rs2928148 INO80 15 39,188,842 G/A 0.52 0.62 (2.25) 0.79 0.25 (0.15) 0.09
rs10109414 STC1 8 23,807,096 T/C 0.36 1.76 (2.32) 0.45 0.21 (0.15) 0.17
rs11959928 DAB2 5 39,432,889 A/T 0.43 1.59 (2.25) 0.48 0.32 (0.15) 0.03
rs12460876 SLC7A9 19 38,048,731 T/C 0.62 -0.96 (2.24) 0.67 -0.05 (0.14) 0.71
rs1260326 GCKR 2 27,584,444 C/T 0.62 4.76 (2.27) 0.04 0.02 (0.15) 0.88
rs12917707 UMOD 16 20,275,191 G/T 0.86 -1.70 (3.27) 0.60 -0.12 (0.21) 0.57
rs13538 NAT8 2 73,721,836 A/G 0.75 4.93 (2.70) 0.07 0.13 (0.17) 0.45
rs1394125 UBE2Q2 15 73,946,038 A/G 0.35 1.82 (2.41) 0.45 0.16 (0.16) 0.31
rs17319721 SHROOM3 4 77,587,871 A/G 0.36 2.38 (2.30) 0.30 0.26 (0.15) 0.08
rs267734 ANXA9 1 149,218,101 T/C 0.83 2.23 (2.86) 0.44 0.32 (0.18) 0.09
rs347685 TFDP2 3 143,289,827 A/C 0.74 -0.07 (2.48) 0.98 -0.09 (0.16) 0.59
rs4744712 PIP5K1B 9 70,624,527 A/C 0.41 3.10 (2.22) 0.16 0.31 (0.14) 0.03
rs626277 DACH1 13 71,245,697 A/C 0.53 1.93 (2.22) 0.39 -0.003 (0.14) 0.98
rs6420094 SLC34A1 5 176,750,242 G/A 0.31 1.87 (2.34) 0.43 0.16 (0.15) 0.29
rs881858 VEGFA 6 43,914,587 A/G 0.92 2.97 (2.70) 0.27 0.18 (0.17) 0.31
rs11078902 CDK12 17 34,885,409 C/G 0.31 -0.17 (2.48) 0.94 -0.45 (0.16) 4.9*10-3
Previously identifi ed in microalbuminuria
rs1801239 CUBN 10 16,959,058 C/T 0.10 0.38 (3.71) 0.92 -0.35 (0.24) 0.15
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
bValues are beta coeffi  cients from linear regression models adjusted for age, gender and the fi rst four principal compo-
nents. Bonferroni adjusted P value cutoff  for the associations <2.4 x 10-3. 
Chr chromosome; EA/OA eff ect allele/other allele; EAF eff ect allele frequency; SE standard error
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Supplementary Table 3.1.5. Associations of SNPs with creatinine and cystatin C in the European children 
(N=1,519)a
SNP
Nearest 
Gene Chr. Position
EA/
OA EAF
Cystatin C 
Beta (SE)b
Cystatin C 
P value
Creatinine 
Beta (SE)b
Creatinine
P value
Previously identifi ed in eGFRcreat
rs3925584 MPPED2 11 30,716,911 T/C 0.60 6.97 (3.13) 0.03 0.67 (0.20) 5.6*10-4
rs6431731 DDX1 2 15,780,453 T/C 0.96 10.20 (7.80) 0.19 0.01 (0.49) 0.99
rs12124078 DNAJC16 1 15,742,486 G/A 0.30 -0.78 (3.30) 0.81 0.06 (0.21) 0.78
rs2453580 SLC47A1 17 19,378,913 C/T 0.41 7.95 (3.51) 0.02 0.32 (0.22) 0.14
rs2928148 INO80 15 39,188,842 G/A 0.52 0.60 (3.11) 0.85 0.04 (0.19) 0.85
rs10109414 STC1 8 23,807,096 T/C 0.36 0.37 (3.16) 0.91 0.21 (0.20) 0.30
rs11959928 DAB2 5 39,432,889 A/T 0.43 4.08 (3.14) 0.19 0.51 (0.20) 0.01
rs12460876 SLC7A9 19 38,048,731 T/C 0.62 0.81 (3.14) 0.80 0.16 (0.20) 0.41
rs1260326 GCKR 2 27,584,444 C/T 0.62 4.08 (3.18) 0.20 0.08 (0.20) 0.69
rs12917707 UMOD 16 20,275,191 G/T 0.86 2.97 (4.42) 0.50 0.01 (0.28) 0.97
rs13538 NAT8 2 73,721,836 A/G 0.75 6.92 (3.82) 0.07 0.28 (0.24) 0.25
rs1394125 UBE2Q2 15 73,946,038 A/G 0.35 1.00 (3.37) 0.77 0.17 (0.21) 0.41
rs17319721 SHROOM3 4 77,587,871 A/G 0.36 -0.71 (3.12) 0.82 0.09 (0.19) 0.63
rs267734 ANXA9 1 149,218,101 T/C 0.83 3.47 (3.74) 0.36 0.47 (0.23) 0.04
rs347685 TFDP2 3 143,289,827 A/C 0.74 0.14 (3.45) 0.97 -0.14 (0.22) 0.53
rs4744712 PIP5K1B 9 70,624,527 A/C 0.41 0.74 (3.17) 0.82 0.38 (0.20) 0.05
rs626277 DACH1 13 71,245,697 A/C 0.53 0.78 (3.11) 0.80 -0.02 (0.19) 0.91
rs6420094 SLC34A1 5 176,750,242 G/A 0.31 1.93 (3.27) 0.56 -0.08 (0.20) 0.69
rs881858 VEGFA 6 43,914,587 A/G 0.92 -0.90 (3.72) 0.81 -0.12 (0.23) 0.60
rs11078902 CDK12 17 34,885,409 C/G 0.31 -0.60 (3.45) 0.86 -0.70 (0.22) 1.1*10-3
Previously identifi ed in microalbuminuria
rs1801239 CUBN 10 16,959,058 C/T 0.10 -.200 (5.06) 0.69 -0.03 (0.32) 0.94
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
bValues are beta coeffi  cients from linear regression models adjusted for age, gender and the fi rst four principal compo-
nents. Bonferroni adjusted P value cutoff  for the associations <2.4 x 10-3. 
Chr chromosome; EA/OA eff ect allele/other allele; EAF eff ect allele frequency; SE standard error
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Supplementary Table 3.1.6. Associations of genetic risk scores with creatinine and cystatin C in the full 
group (N=2,854)a
Genetic risk score
Weighted Unweighted
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Childhood kidney outcomes (N)
Cystatin C (μg/l)b (2,854) 1.84 (0.75; 2.92) 1.0*10-3 0.4 1.93 (0.86; 3.00) 4.2*10-4 0.4
Creatinine (μmol/l)b (2,854) 0.13 (0.06; 0.19) 4.7*10-4 0.5 0.13 (0.06; 0.20) 1.9*10-4 0.5
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates 
bValues are beta coeffi  cients from linear regression models adjusted for age, gender and the fi rst four principal compo-
nents. P value for the associations <0.05. The percentage of variance explained by the genetic risk score, was calculated by 
comparing the unadjusted R2 between a model including the risk score and the covariates and a model including only the 
covariates, which were sex, age at measurements, and the fi rst four principal components.
Supplementary Table 3.1.7. Associations of genetic risk scores with kidney measures in European children 
(N=2,186)a
Genetic risk score
Weighted Unweighted
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Childhood kidney outcomes (N)
Kidney volume (cm3)b (N=2,009) -0.34 (-0.68; -0.06) 0.046 0.2 -0.31 (-0.64; 0.02) 0.06 0.2
eGFRcreat (ml/min/1.73m2)b (N=1,514) -0.40 (-0.68; -0.12) 5.0*10-3 0.5 -0.40 (-0.67; -0.12) 5.3*10-3 0.5
eGFRcystC (ml/min/1.73m2)b (N=1,519) -0.27 (-0.55; 0.01) 0.06 0.2 -0.27 (-0.55; 0.003) 0.05 0.2
Creatinine (μmol/l)b (N=1,519) 0.12 (0.03; 0.22) 9.0*10-3 0.6 0.13 (0.04; 0.22) 6.0*10-3 0.5
Cystatin C (μg/l)b (N=1,519) 1.95 (0.46; 3.44) 0.01 0.4 2.02 (0.55; 3.50) 7.0*10-3 0.5
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates 
bValues are beta coeffi  cients from linear regression models adjusted for age, gender and the fi rst four principal compo-
nents. P value for the associations <0.05; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. The percentage of variance 
explained by the genetic risk score, was calculated by comparing the unadjusted R2 between a model including the risk 
score and the covariates and a model including only the covariates, which were sex, age at measurements, and the fi rst 
four principal components.
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Supplementary Table 3.1.8. Associations of genetic risk score with childhood kidney outcomes addition-
ally adjusting for combined kidney volume (N=4,119)a
Genetic risk score
Weighted
Diff erence
(95 % Confi dence Interval)
P value
Childhood kidney outcomes (N)
eGFRcreat (ml/min/1.73m2)b (2,847) -0.35 (-0.56; -0.13) 1.0*10-3
eGFRcystC (ml/min/1.73m2)b (2,854) -0.32 (-0.52; -0.11) 2.0*10-3
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
bValues are beta coeffi  cients from linear regression models adjusted for child age, sex, kidney volume and the fi rst four 
principal components from the genetic data. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based 
on creatinine blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. P value 
for the associations <0.05. 
Supplementary Table 3.1.9. Associations of the genetic risk score based on adult eGFRcreat and creatinine 
metabolism SNPs with childhood kidney outcomes (N=4,119)a
Genetic risk score
Weighted Unweighted
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Diff erence
(95 % Confi dence 
Interval)
P value % of 
explained
variance
Childhood kidney outcomes (N)
Kidney volume (cm3)b (3,784) -0.43 (-0.66; -0.21) 2.0*10-4 0.3 -0.43 (-0.66; -0.21) 1.6*10-4 0.3
eGFRcreat (ml/min/1.73m2)b (2,847) -0.42 (-0.61; -0.23) 1.3*10-5 0.6 -0.45 (-0.63; -0.26) 3.0*10-6 0.7
eGFRcystC (ml/min/1.73m2)b (2,854) -0.23 (-0.41; -0.06) 1.0*10-2 0.2 -0.24 (-0.42; -0.07) 6.2*10-3 0.3
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
bValues are beta coeffi  cients from linear regression models adjusted for child age, sex and the fi rst four principal compo-
nents from the genetic data. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine 
blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. P value for the 
associations <0.05. The percentage of variance explained by the genetic risk score, was calculated by comparing the un-
adjusted R2 between a model including the risk score and the covariates and a model including only the covariates, which 
were sex, age at measurements, and the fi rst four principal components.
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Supplemental Table 3.1.10. Associations of the genetic risk score based on 11 SNPs with a likely function 
on kidney development and childhood kidney outcomes (N=4,119)a
Genetic risk score
Weighted Unweighted
Diff erence
(95 % Confi dence 
Interval)
P value Diff erence
(95 % Confi dence 
Interval)
P value
Childhood kidney outcomes (N)
Kidney volume (cm3)b (3,784) -0.50 (-0.84; -0.16) 3.9*10-3 -0.50 (-0.84; -0.17) 3.0*10-3
eGFRcreat (ml/min/1.73m2)b (2,847) -0.40 (-0.69; -0.12) 5.6*10-3 -0.42 (-0.70; -0.14) 3.0*10-3
eGFRcystC (ml/min/1.73m2)b (2,854) -0.29 (-0.56; -0.03) 3.0*10-2 -0.31 (-0.57; -0.05) 2.0*10-2
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates. 
bValues are beta coeffi  cients from linear regression models adjusted for child age, sex and the fi rst four principal compo-
nents from the genetic data. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine 
blood levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. P value for the 
associations <0.05. The percentage of variance explained by the genetic risk score, was calculated by comparing the un-
adjusted R2 between a model including the risk score and the covariates and a model including only the covariates, which 
were sex, age at measurements, and the fi rst four principal components.
Supplemental Table 3.1.11. Associations of the genetic risk score including 2 eGFRcystC SNPs with kidney 
measures in the full group (N=4,119)a
Genetic risk score
Unweighted
Diff erence
(95 % Confi dence Interval)
P value
Childhood kidney outcomes (N)
Kidney volume (cm3)b (N=3,784) -0.41 (-0.66; -0.17) 1.0*10-3
eGFRcreat (ml/min/1.73m2)b (N=2,847) -0.44 (-0.64; -0.23) 2.9*10-5
eGFRcystC (ml/min/1.73m2)b (N=2,854) -0.52 (-0.71; -0.33) 7.4*10-8
Creatinine (μmol/l)b (N=2,854) 0.14 (0.07; 0.20) 7.0*10-5
Cystatin C (μg/l)b (N=2,854) 3.28 (2.25; 4.31) 5.6*10-10
aAnalyses were performed in children with complete data on genetics, at least one outcome under study, and covariates 
bValues are beta coeffi  cients from linear regression models adjusted for age, gender and the fi rst four principal compo-
nents. P value for the associations <0.05; eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood 
levels; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood levels. 
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ABSTRACT
Background: Early life factors may infl uence kidney growth and function throughout the 
life course. We examined the associations of breastfeeding duration, exclusivity and age at 
introduction of solid foods with kidney outcomes at school-age.
Study Design: Prospective cohort study from fetal life onward.
Settings & participants: 5,043 children in the Netherlands. 
Predictors: Infant feeding was assessed prospectively using questionnaires.
Outcomes & measurements: At a median age of 6.0 years, we measured kidney volume with 
ultrasound, glomerular fi ltration rate (eGFR) from serum creatinine levels, and microalbumin-
uria from urinary albumin and creatinine levels.
Results: 92 % of all children were ever breastfed, of whom 27 % were breastfed for more 
than 6 months, and 21 % were breastfed exclusively for at least 4 months. Compared with 
ever breastfed children, never breastfed children had smaller combined kidney volume 
(-2.69 cm3 (95 % Confi dence Interval -4.83, -0.56)) and lower eGFR (-2.42 ml/min/1.73m2 (95 % 
CI -4.56, -0.28)) at school-age. Among breastfed children, shorter duration of breastfeeding 
was associated with lower kidney volume and lower microalbuminuria risk (p-values <0.05). 
Compared to exclusive breastfeeding for 4 months, non-exclusive breastfeeding in the fi rst 
4 months was associated with smaller combined kidney volume and lower eGFR (p-values 
<0.05). Associations with eGFR were largely explained by kidney volume. Age at introduction 
of solid foods was not associated with any of the kidney outcomes.
Limitations: Observational study, so causality cannot be established. Follow-up measure-
ments were available in 76 % of children.
Conclusion: These results suggest that breastfeeding is associated with subclinical changes 
in kidney outcomes in childhood. Further studies are needed to explore whether early life 
nutrition also aff ects the risk of kidney disease in adulthood.
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INTRODUCTION 
Adverse exposures during sensitive periods of early development may persistently aff ect 
kidney growth and function.1 The third trimester of fetal life and early infancy are thought 
to be particularly critical periods for kidney development because nephron development is 
largely completed in this period.2, 3 Suboptimal nephron development, may lead to glomeru-
lar hyperfi ltration and subsequently to impaired kidney function in later life.3 Animal studies 
have shown that although nephrogenesis is largely completed after 36 weeks of gestation, 
it continues until early infancy.4 The importance of early life for later kidney outcomes is il-
lustrated by studies in humans showing associations of preterm birth and low birth weight 
with risk of kidney disease in adulthood.5 Also, children born preterm and with small size 
for gestational age at birth have subclinical changes in kidney function in adolescence.6 We 
have recently shown that both lower fetal and early infant weight growth are associated with 
lower kidney function in childhood,7 supporting the hypothesis that exposures in both fetal 
life and infancy are critical for kidney development. Little is known about specifi c early life 
exposures that persistently aff ect kidney function. Infant diet is a key factor for early growth 
and development and may infl uence kidney function in infants.8, 9 One previous study ex-
amined the associations of breastfeeding versus formula feeding and kidney outcomes and 
observed that infants who were exclusively formula fed had increased kidney growth during 
the fi rst 3months, but this diff erence was no longer apparent at the age of 18 months.9 Infant 
feeding may infl uence kidney outcomes through diff erences in protein content and load.8
In a population-based prospective cohort study of 5,043 children, we examined the associa-
tions of breastfeeding duration and exclusiveness and age at introduction of solid foods with 
kidney outcomes in children at the age of 6 years. Subclinical diff erences in kidney outcomes 
in childhood do not have short-term consequences but may predispose individuals to kidney 
disease in later life.5
METHODS
Design and study population 
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onwards in Rotterdam, the Netherlands.10 All children were born between 
April 2002 and January 2006. The study protocol was approved by the Medical Ethical Com-
mittee of the Erasmus MC, University Medical Center, Rotterdam (MEC 198.782/2001/31). 
Written informed consent was obtained from all parents. For the present study, we included 
only singleton live births (N=7,696) who had information on breastfeeding available (N=6,616 
[86 %]). Of these children, 6,054 participated in the follow-up measurements at the age of 6 
years. Children with evidence of congenital kidney abnormalities on ultrasound examination 
were excluded from the study (N=9). At a median age of 6.0 years (95 % range 5.6, 7.4), kidney 
ultrasound and blood and urine samples were available on 5,043 children (Figure  3.2.1. 
Flowchart).
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Infant feeding assessment
Information on breastfeeding initiation and continuation was obtained from delivery reports 
and postal questionnaires at the ages of 2, 6 and 12 months after birth. We described this 
approach previously in detail.11 Briefl y, mothers were asked whether they ever breastfed their 
child (yes/ no) and at what age they stopped breastfeeding. Duration of exclusive breastfeed-
ing was defi ned by using information about at what age other types of milk and/or solids were 
introduced in the fi rst 6 months of life, according to a short food frequency questionnaire 
(FFQ). Among breastfed children, breastfeeding duration was categorized into four groups: 
1) >0–1.9 months; 2) 2–3.9 months; 3) 4–5.9 months and 4) ≥6 months. The information on 
exclusiveness of breastfeeding was categorized into the following two categories: 1) non-
exclusive in the fi rst 4 months; and 2) exclusive for at least 4 months. ‘Non-exclusive in the fi rst 
4 months’ indicates infants who received both breastfeeding and formula feeding or solids 
during the fi rst 4 months. ‘Exclusive for at least 4 months’ indicates infants who have been 
breastfed, without any other milk, solids or fl uids during the fi rst 4 months. These categories 
were available in the questionnaires and similar to those used in previous studies.11, 12 The 
analyses focused on breastfeeding duration and exclusivity were performed after exclusion 
of never breastfed children. Information on introduction of solid foods included fruit and 
vegetable snacks and was obtained from the same FFQ. Age at introduction of solid foods 
was categorized as: 1) <4 months; 2) 4–4.9 months; and 3) ≥5 months. 
Figure 3.2.1. Flowchart of study participants included for the main analysis
Children with available information  
on infant feeding 
N=6,616 
Children available for follow up 
measurements at the age of 6 years  
N=6,054 
N=1,080 excluded due to no information  
on infant feeding 
N=562 excluded due to: loss to follow-up 
(446) or withdrawal of consent (116) 
N=1,011 excluded due to: no visit to the 
research centre (1,002), or congenital kidney 
abnormalities (9) 
Children with both infant feeding and kidney 
measurements  
N=5,043 
With data available on:  
Kidney volume      N=4,637 
Creatinine              N=3,411 
Cystatin C              N=3,410 
eGFR                      N=3,404 
Microalbuminuria    N=4,855 
Singleton live born children available for 
infant feeding questionnaires 
N=7,696 
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Childhood kidney outcomes 
Childhood kidney dimensions
Children’s kidney outcomes were assessed in a dedicated research center in the Erasmus MC-
Sophia Children’s Hospital in Rotterdam by well-trained staff .13 Kidney volume was measured 
with ultrasound, using an ATL-Philips HDI 5000 instrument (Seattle, WA, USA), equipped with 
a 2.0–5.0 MHz curved array transducer. We identifi ed the left and right kidney in the sagittal 
plane along its longitudinal axis. We performed measurements of maximal bipolar kidney 
length, width and depth. Kidney width and depth were measured at the level of the hilum. 
The cross-sectional area in which the kidney appeared symmetrically round at its maximum 
width was used. Kidney volume was calculated using the equation for a prolate ellipsoid: 
volume (cm3) = 0.523 x length (cm) x width (cm) x depth (cm).14 Combined kidney volume was 
calculated by summing right and left kidney volumes. We previously reported good intra- 
and inter-observer correlation coeffi  cients.15
Childhood kidney function 
Non-fasting blood samples were drawn by antecubital venipuncture. Creatinine was mea-
sured with enzymatic methods and cystatin C levels with a particle enhanced immunoturbi-
dimetric assay (using Cobas 8000 analyzers; Roche). Quality control samples demonstrated 
intra- and inter-assay coeffi  cients of variation ranging from 0.51 to 1.37 %, and 1.13 to 1.65 %, 
respectively. Estimated glomerular fi ltration rate (eGFR) was calculated according to the 
revised Schwartz 2009 formula: eGFR  =  36.5 * (height (cm)/ serum creatinine (μmol/l).16 
Urine creatinine (mmol/l) and urine albumin (mg/l) levels were determined with a Beckman 
Coulter AU analyser; creatinine was measured with the Jaff e reaction. We calculated the 
albumin-creatinine ratio. In line with clinical cut-off s, microalbuminuria was defi ned as an 
albumin-creatinine ratio >2.5 mg/mmol for boys and >3.5 mg/mmol for girls.17 Because our 
main interest was in normal variation, we excluded children with an albumin-creatinine ratio 
>25 for the microalbuminuria analysis given that higher albumin-creatinine ratio may refl ect 
underlying kidney disease. With this cut-off , we excluded 14 children. When we included 
these children in our analysis, the eff ect estimates did not change.
Covariates
Information on maternal age, ethnicity, educational level and income were obtained with 
questionnaires at enrollment. Information about maternal smoking, alcohol use, and folic 
acid supplementation also were obtained by questionnaires.10 Information on maternal smok-
ing and alcohol use during pregnancy was categorized as follows: never; until pregnancy 
was known; or continued during pregnancy. Maternal protein intake during pregnancy was 
measured at enrollment (median 13.5 weeks of gestation) with a validated semi-quantitative 
FFQ.18 Child protein intake at the age of 1 year also was measured with a validated semi-
quantitative FFQ.19 Protein intakes were adjusted for total energy intake using the nutrient 
residual method.20 Ethnicity, educational level and income were defi ned according to the 
classifi cation of Statistics Netherlands.21, 22 We categorized ethnicity as either European or 
non-European for our analysis. Education level was categorized as higher and no higher 
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education, and net household income was categorized as <1,400 euro and ≥1,400 euro per 
month. Maternal height and weight were self-reported and pre-pregnancy body mass index 
(BMI) was calculated (kg/m2). Infant sex, gestational age and weight at birth were obtained 
from midwife and hospital registries. At the age of 6 years, child height was determined in 
a standing position to the nearest millimeter without shoes by a Harpenden stadiometer 
(Holtain Limited, Dyfed, U.K.). Weight was measured using a mechanical personal scale (SECA, 
Almere, the Netherlands). Lean body mass was measured using whole body dual-energy 
x-ray absorptiometry (DXA) scans using Lunar models, (iDXA, GE-Lunar, 2008, Madison, WI, 
USA) and enCORE software version13.6. We calculated child body mass index (kg/m2) and 
body surface area (BSA) (m2) (using DuBois formula BSA= weight (kg)0.425 x height (cm)0.725 x 
0.007184).23
Statistical analysis 
We assessed diff erences in subject characteristics between the diff erent breastfeeding 
categories using T-tests for continuous and normally distributed variables, Chi-square tests 
for categorical variables, and Mann-Whitney test for non-normally distributed variables. As-
sociations of breastfeeding, breastfeeding duration and exclusivity and age at introduction 
of solid foods with childhood kidney outcomes at the age of 6 years were explored by using 
multivariable linear regression models (kidney volume, eGFR, creatinine levels and cystatin 
C levels) or multivariable logistic models ( risk of microalbuminuria).These models were fi rst 
adjusted for child’s sex and age at kidney measurements (crude models) and subsequently 
adjusted for additional potential confounders. In the fi nal model, we included family-based 
socio-demographic factors (maternal education, maternal ethnicity, and household income); 
maternal life style related factors (pre-pregnancy body mass index, smoking and alcohol use 
during pregnancy, folic acid supplement use and protein intake during pregnancy) and child-
hood factors (birth weight and BSA at the age of 6 years). These covariates were included 
in the models based on their associations with kidney outcomes in previous studies, or a 
change in eff ect estimates of >10 %. Gestational age at birth did not fulfi ll the criteria of a 10 % 
change in the eff ect estimates. In a separate model, we additionally adjusted the kidney func-
tion measures for kidney volume. Tests for trends were performed by including the exposure 
categories as continuous variables. To assess whether the associations were diff erent for boys 
and girls, diff erent ethnic groups, preterm and term born children, or diff erent birthweight 
groups, we evaluated the statistical interaction by adding the product term of each of these 
covariates with breastfeeding duration to the adjusted models. To diminish potential bias 
associated with attrition, missing values of covariates (less than 34 %), were multiple imputed 
by generating 5 independent datasets using the Markov Chain Monte Carlo method. The 
multiple imputation procedure was based on the correlation between each variable with 
missing values and the other subject characteristics.24, 25 Regression coeffi  cients were pooled 
by taking the average of the regression coeffi  cients obtained in the 5 imputed datasets. The 
standard error of the pooled regression coeffi  cient was obtained by calculating the within-
imputation variance and the between-imputation variance. Because we found similar results 
in the imputed and non-imputed dataset, the fi nal results in the present report are presented 
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as the pooled regression coeffi  cients after the multiple imputation procedure. To assess 
whether child protein intake aff ects the associations between breastfeeding and kidney out-
comes at age of 6 years we did a sensitivity analysis in the subgroup of children with dietary 
data by adjusting our models additionally for child protein intake at the age of 1 year. Because 
kidney size is associated with lean body mass we performed a sensitivity analysis in which we 
additionally adjusted the model for lean body mass. Since ethnicity and birth weight have 
been shown to be strongly related to kidney function,13 we performed a sensitivity analysis 
in children from European mothers and in children with a normal birth weight (≥2,500 g). 
Statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
RESULTS 
Participant characteristics
As shown in Table 3.2.1, of all children with kidney volume measurements, 92 % were ever 
breastfed of whom 27 % were breastfed for 6 or more months and 22 % were exclusively 
breastfed for at least 4 months. Children who were never breastfed had a lower weight and 
gestational age at birth. At the age of 6 years, mean (± SD) combined kidney volume was 120 
cm3 (±22.6), and mean eGFR was 119 ml/min/1.73m2 (±16.4). Of all children, 7.1 % had microal-
buminuria. We provide descriptive characteristics of the individuals before and after imputa-
tion in the supplementary materials (Supplementary Table 3.2.1), and in those with eGFR 
and microalbuminuria measurements (Supplementary Tables 3.2.2 & 3.2.3). We performed 
a non-response analysis by comparing children with and without follow-up measurements at 
age 6 years (Supplementary Table 3.2.4). Compared with children who did not participate 
in the follow-up at the age of 6 years, those who did participate in the follow-up studies 
Table 3.2.1. Subject characteristics according to category of breastfeeding in the subjects with kidney 
volume measurements (N=4,637)
Total group
N=4,637
Never breastfed
N=354
Ever breastfed
N=4,283
P-value
Maternal characteristics
Pre-pregnancy body mass index (kg/m2) 22.7 (18.3, 33.9) 23.4 (18.2, 37.8) 22.6 (18.3, 33.3) <0.01
Ethnicity (%) <0.01
- European 66 76.8 65.1
- Non – European 34 23.2 34.9
Education (%) <0.01
- No higher education 49.2 69.4 47.5
- Higher education 50.8 30.6 52.5
Net household total income (%) 0.71
- <1,400 euro 24 24.1 24
- ≥1,400 euro 76 75.9 76
Smoking during pregnancy (%) <0.01
- Never smoked 80.4 58.4 81.4
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Table 3.2.1. Subject characteristics according to category of breastfeeding in the subjects with kidney volume 
measurements (N=4,637) (continued)
Total group
N=4,637
Never breastfed
N=354
Ever breastfed
N=4,283 P-value
- Smoke until pregnancy was known 7.6 7.3 7.6
- Continued smoking 12.0 24.3 11.0
Alcohol during pregnancy (%) <0.01
- Never alcohol in pregnancy 53.2 61.9 52.5
- Alcohol until pregnancy was known 11.3 7.9 11.6
- Continued alcohol during pregnancy 35.5 30.2 35.9
Folic acid supplement use, (%) 0.54
- No 23.2 22.7 23.2
- During early pregnancy 76.8 77.3 76.8
Energy adjusted protein intake (g) 74.7 (10.1) 72.7 (9.9) 75.1 (10.1) <0.01
Birth characteristics
Girls (%) 50.1 50.3 50.0 0.80
Gestational age (weeks) 40.1 (36.0, 42.3) 39.9 (35.8, 42.4) 40.1 (36.1, 42.3) <0.01
Weight (grams) 3,455 (537) 3,409 (555) 3,458 (535) 0.08
Child protein intake at 1 year (g) 25.1 (29.2) 25.9 (28.6) 25.0 (29.3) 0.37
Breastfeeding duration (%)
- >0-1.9 months (N=925) 20 0 21.6
- 2-3.9 months (N=775) 16.7 0 18.1
- 4-5.9 months (N=438) 9.4 0 10.2
- ≥6 months (N=1,143) 24.6 0 27.6
Breastfeeding exclusivity (%)
- Non- exclusively in the fi rst 4 months (N=2,452) 52.9 0 57.2
- Exclusively in the fi rst 4 months (N=952) 20.5 0 22.2
Introduction of solid foods (%) <0.01
- <4 months (N=225) 5.7 11.3 5.3
- 4-4.9 months (N=1,716) 40.3 43.5 40.1
- ≥5 months (N=914) 20.4 9.3 21.3
Child characteristics
Age (years) 6.0 (5.6, 7.4) 6.0 (5.6, 7.3) 6.0 (5.6, 7.4) 0.94
Height (cm) 118.9 (5.6) 118.5 (5.9) 118.6 (5.6) 0.13
Weight (kg) 22.2 (17.4, 32.4) 22.2 (17.2, 36.0) 22.2 (17.4, 32.2) 0.40
Body mass index, (kg/m2) 15.8 (13.6, 20.5) 15.9 (13.6, 22.4) 15.8 (13.6, 20.5) 0.40
Body surface area, (m2) 0.86 (0.7, 1.1) 0.85 (0.7, 1.1) 0.86 (0.7, 1.1) 0.17
Kidney volume combined, (cm3) 120 (22.6) 116 (23.4) 120 (22.5) <0.01
eGFR, (ml/min/1.73m2) 119 (16.4) 116 (14.2) 119 (16.5) <0.01
Microalbuminuria (%)* 7.1 5.1 7.3 0.14
Creatinine (μmol/l) 37.2 (5.4) 37.9 (4.9) 37.2 (5.5) 0.04
Cystatin C (μg/l) 783 (81.0) 793 (85.2) 782 (81) 0.04
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Diff erences in 
maternal, infant and childhood characteristics (compared with the never breastfed group) were evaluated using T-test for 
continuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests 
for categorical variables. 
eGFR - estimated glomerular fi ltration rate
*Defi ned as levels between 2.5 and 25.0 mg/mmol (boys) and 3.5 and 25.0 mg/mmol (girls)
In Supplementary Tables 3.2.2 & 3.2.3 we provide the descriptive characteristics in the individuals with eGFR and micro-
albuminuria measurements.
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were more frequently breastfed for at least 6 months and exclusively breastfed for 4 months. 
Supplementary Table 3.2.5 gives the descriptive characteristics of the study participants in 
the children with and without blood samples. We observed no diff erences in breastfeeding, 
breastfeeding duration, exclusivity, introduction to solid foods. However, we observed that 
children with blood samples available have slightly higher kidney volume and body surface 
area and were taller and heavier. Also, they had mothers with a higher socio-economic status 
compared to children without blood samples.
Infant feeding and childhood kidney outcomes 
Table 3.2.2 gives the fully adjusted eff ect estimates for the associations between infant feed-
ing and kidney outcomes. Compared with ever breastfed children, those who were never 
breastfed had smaller kidneys (-2.69 cm3 (95 % Confi dence Interval (CI) -4.83, -0.56)) and a 
lower eGFR (-2.42 ml/min/1.73m2 (95 % CI -4.56, -0.28)). Shorter breastfeeding duration also 
was associated with smaller combined kidney volume and a lower risk for microalbuminuria 
(p-values <0.05) but not with eGFR. Compared with exclusively breastfed children, children 
who received non-exclusive breastfeeding for 4 months had a 2.47 cm3 (95 % CI -3.94, -1.01) 
lower kidney volume and a 1.55 ml/min/1.73m2 lower eGFR (95 % CI -3.01, -0.11). Age at intro-
duction to solid foods was not associated with any kidney outcome. Additional adjustment 
for combined kidney volume, attenuated the associations of breastfeeding with eGFR into 
non-signifi cant. The associations between breastfeeding and risk of microalbuminuria re-
mained similar (Table 3.2.2).
Results from the analyses focused on creatinine and cystatin C levels are given in the 
Supplementary Materials (Supplementary Table  3.2.6). Non-exclusive breastfeeding was 
associated with higher creatinine levels. We did not observe any association of breastfeeding 
with cystatin C levels. Eff ect estimates from the crude models for the associations of infant 
feeding with kidney outcomes are given in Supplementary Table 3.2.7. When we addition-
ally adjusted for child protein intake in the subgroup of children with protein data available, 
the eff ect estimates remained similar (Supplementary Table 3.2.8). Furthermore, when we 
additionally adjusted the kidney volume models for lean body mass, results did not change 
(Supplementary Table 3.2.9). Because the statistical interactions of breastfeeding duration 
with maternal ethnicity, child sex, birthweight or gestational age were not signifi cant we did 
not stratify our analyses.
DISCUSSION
In this population-based prospective cohort study, we observed that breastfeeding duration 
and exclusivity are associated with larger combined kidney volume and higher eGFR in child-
hood. The associations with kidney function were explained by kidney volume. Although not 
clinically relevant yet, the observed subclinical changes in kidney function at a young age 
may predispose individuals to development of kidney disease in later life.5
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A major strength of our study the prospective design from fetal life onward within a large 
population-based cohort. Of the total group of singleton live born children in our cohort, 
86 % of them had available information on breastfeeding. This is due to the study design in 
which not all parents received the infant feeding questionnaire and to non-response.10 Of all 
children with information on breastfeeding, 24 % did not participate in the follow-up mea-
surements at the age of 6 years. Not all participants in the study consented to the collection 
of blood samples; 68 % of all children provided blood samples for measurements of creatinine 
and cystatin C levels. This loss to follow-up would result in selection bias if the associations 
of infant feeding with kidney outcomes diff ered between those included and not included in 
the fi nal analyses. Assessing breastfeeding initiation and duration by questionnaires appears 
to be a valid method, especially when the events being recalled are relatively recent (within 
3 years), which is the case in our study. In our study, we used 3 questionnaires to assess infant 
feeding during the fi rst 12 months. We performed detailed measurements of childhood 
kidney outcomes. Kidney size was used as a measure of kidney development. Ultrasound is 
a reliable method to measure kidney volume.15 Kidney size, which is correlated with number 
of glomeruli, can be used in epidemiological studies as measure of kidney development.2 
However, glomerular enlargement due to hyperfi ltration may also increase kidney volume.4 
We used urine albumin-creatinine ratio from a random urine sample to evaluate microal-
buminuria.26 Unfortunately, we did not have fi rst morning void samples. Because we had 
random samples from throughout the day, these measurements are subject to the limitation 
of substantial intraindividual variation in urinary albumin excretion.27 Finally, although we 
adjusted for a large number of potential maternal and childhood confounders, but residual 
confounding could still happen, as is the case in any observational study.
Two previous studies have investigated the relation between infant feeding and kidney 
outcomes. In a cohort of 631 children, Schmidt et al. observed that 3-months-old infants who 
were formula-fed had larger kidneys than infants who were exclusive breast-fed.9 This eff ect 
in kidney size was temporary and did not persist at 18 months of age. Their fi ndings are in 
line with observations from a study among 737 children participating in the EU Childhood 
Obesity Project.8 In this study, the authors observed that infants aged 6 months who received 
high protein infant formula had signifi cantly larger kidney volume compared with infants 
who received low protein formula or breastfeeding. Kidney volume in breastfed infants did 
not diff er from those receiving low protein formula.8 In our study, we observed that breastfed 
children had larger kidney volumes, which is not consistent with previous studies. The main 
diff erences between our and previous studies, are that our analysis were performed on a 
larger population-based study group and that kidney outcomes were measures at a later age. 
The long-term eff ects of breastfeeding on kidney outcomes might be diff erent from the short-
term eff ects as indicated by Schmidt et al.9 Escribano et al,8 observed that breastfed infants 
had lower renal overload, defi ned as urine urea levels and urine osmolarity, but higher levels 
of eGFR compared to formula fed infants. They suggest that this may be due to the action of 
other physiologic mechanisms promoted by diff erent compounds of human milk or a higher 
bioavailability of human milk proteins. In accordance with this hypothesis, we observed that 
ever and exclusively breastfed children had a higher eGFR. A limitation of our study is that we 
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could not use the extended formula by Schwartz,16 because we had no urea measurements 
available in our study population. Kidney size is correlated positively with eGFR.28, 29 We ob-
served that associations of infant feeding with kidney function were explained by increased 
kidney volume. In the same population as the present study, we previously observed that 
children with smaller kidneys had higher creatinine blood levels, leading to lower eGFR.13 It is 
suggested that kidney size is related to the amount of lean body mass.30 In our population ef-
fect estimates of breastfeeding on kidney size did not change when we additionally adjusted 
the model for lean body mass. Interestingly, shorter breastfeeding duration was also related 
to lower risk of microalbuminuria. We cannot explain this fi nding.
Potential mechanisms by which breastfeeding may aff ect kidney structure and func-
tion include the diff erence in proteins found in breast milk and infant formula. Breast milk 
has lower protein content than formula. On average, 100 ml breast milk contains 1.0 g of 
proteins, whereas the average protein content of formula milk is 2.0 g.31 Also, protein types 
found in breast milk diff er from those found in formula milk; they may be easier to digest 
and absorb.32 It is suggested that higher protein intake leads to a rise in eGFR, as a result 
of increased glomerular plasma fl ow and trans glomerular pressure.8, 28, 33 In our study we 
observed a higher eGFR in breastfed children. In a subgroup of the present study group 
(N=2,876), we had dietary data at the age of 1year.When we adjusted our models additionally 
for child protein intake at the age of 1 year, the regression coeffi  cients remained similar in this 
subgroup, suggesting that protein intake at the age of 1 year does not aff ect the association 
between breastfeeding and kidney outcomes at age of 6 years. Next to protein intake, other 
nutrients and bioactive substances in breast milk also might infl uence kidney outcomes in 
childhood. Although diff erences between the early feeding categories are small, they may be 
relevant on population level. Further studies of animals and humans are needed to identify 
the mechanisms by which infant feeding infl uences kidney function.
In conclusion, in this population-based prospective cohort study, we observed that 
compared with children exclusively breastfed for 4 months, those who were non-exclusively 
breastfed or breastfed for a shorter period had smaller kidneys and lower eGFR. Although 
the observed diff erences are not clinically relevant, small diff erences in kidney function at 
a young age might relate to clinically relevant kidney outcomes at older ages. Other health 
consequences of breastfeeding need to be considered when developing advice on infant 
feeding. Further studies are needed to evaluate the long-term consequences of breastfeed-
ing on kidney health.
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Supplementary Table 3.2.1. Maternal and child characteristics for observed and imputed data (N=5,043)
Observed Imputed
Maternal characteristics
Pre-pregnancy body mass index, kg/m2 23.5 (18.2, 34.2) 22.7 (18.2, 34.1)
Missing, % 24.2 
Ethnicity, %
- European 65.4 66
- Non - European 32.9 34
Missing, % 1.7
Educational level, %
- No higher education 44.4 49
- Higher education 49.2 51
Missing, % 6.4
Net household total income, %
- <1,400 euro 18.6 23.9
- ≥1,400 euro 62.2 76.1
Missing, % 19.2
Smoking during pregnancy, %
- Never smoked 67.8 80.2
- Smoke until pregnancy was known 8.1 7.6
- Continued smoking 12.7 12.2
Missing, % 11.4
Alcohol during pregnancy, %
- Never alcohol in pregnancy 33.8 53.1
- Alcohol until pregnancy was known 11.2 11.2
- Continued alcohol 35.7 35.7
Missing, % 19.3
Folic acid supplement use, %
- No 14.8 23.2
- During early pregnancy 55.7 76.8
Missing, % 29.5
Energy adjusted protein intake, g 74.9 (10.2) 74.9 (11.9)
Missing, % 31.6
Birth characteristics
Girls, % 50.2 NI
Gestational age, weeks 40.1 (36.0, 42.3) 40.1 (36.0, 42.3)
Missing, % 0.1
Birth weight, g 3,452 (540) 3,452 (540)
Missing, % 0.06
Breastfeeding, %
- No 7.6 NI
- Yes 92.4 NI
Breastfeeding duration, %
- >0-1.9 months 19.7 NI
- 2-3.9 months 16.6 NI
- 4-5.9 months 9.5 NI
- ≥6 months 24.8 NI
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Supplementary Table 3.2.1. Maternal and child characteristics for observed and imputed data (N=5,043) 
(continued)
Observed Imputed
Missing, % 29.4
Breastfeeding exclusivity, %
- Non-exclusively in the fi rst 4 months 52.6 NI
- Exclusively in the fi rst 4 months 20.6 NI
Missing, % 26.8
Introduction of solid foods, %
- <4 months 5.5 NI
- 4-4.9 months 40.3 NI
- ≥5 months 20.3 NI
Missing, % 33.9
Child characteristics
Age, years 6.0 (5.6, 7.4) NI
Height, cm 118.8 (5.7) 118.9 (5.7)
Missing, % 0.02
Weight, kg 22.2 (17.4, 32.6) 22.2 (17.4, 32.6)
Missing, % 0.02
Body mass index, kg/m2 15.8 (13.6, 20.6) 15.8 (13.6, 20.6)
Missing, % 0.02
Body surface area, m2 0.86 (0.7, 1.1) 0.86 (0.7, 1.1)
Missing, % 0.02
Kidney volume combined, cm3 120 (23) NI
Missing, % 8.4
eGFR, ml/min/1.73m2 119 (16) NI
Missing, % 32.6
Microalbuminuria, % 7.6 NI
Missing % 4.1
Creatinine, μmol/l 37.2 (5.5) NI
Missing, % 32.6
Cystatin C, μg/l 738 (81.4) NI
Missing, % 32.6
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. eGFR-estimated 
glomerular fi ltration.
NI-not imputed
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Supplementary Table 3.2.2. Subject characteristics according to category of breastfeeding in the subjects 
with eGFR measurements (N=3,404)
Total group
N=3,404
Never breastfed
N=254
Ever breastfed
N=3,150 P-value
Maternal characteristics
Pre-pregnancy body mass index (kg/m2) 22.7 (18.3, 34.0) 23.6 (18.1, 38.4) 22.6 (18.2, 33.6) <0.01
Ethnicity (%) <0.01
- European 66.4 76.9 65.6
- Non - European 33.6 23.1 34.4
Education (%) <0.01
- No higher education 48.1 69.7 46.4
- Higher education 51.9 30.3 53.6
Net household total income (%) 0.71
- <1,400 euro 23.3 24.6 23.2
- ≥1,400 euro 76.9 75.4 76.8
Smoking during pregnancy (%) <0.01
- Never smoked 80.6 66.1 81.8
- Smoke until pregnancy was known 7.7 8.3 7.6
- Continued smoking 11.7 25.6 10.6
Alcohol during pregnancy (%) <0.01
- Never alcohol in pregnancy                      51.9 60.6 51.2
- Alcohol until pregnancy was known        11.3 8.3 11.5
- Continued alcohol during pregnancy        36.8 31.1 37.3
Folic acid supplement use, (%) 0.54
- No 23.2 22.3 23.3
- During early pregnancy 76.8 77.7 76.7
Energy adjusted protein intake (g) 75 (10.1) 73.1 (9.7) 75.2 (10.1) <0.01
Birth characteristics
Girls (%) 49.1 48.0 49.1 0.80
Gestational age (weeks) 40.1 (36.0, 42.3) 39.9 (35.9, 42.1) 40.1 (36.0, 42.3) <0.01
Weight (grams) 3,480 (540) 3,430 (542) 3,467 (539) 0.08
Child protein intake at 1 year (g) 26 (29,6) 27.8 (29.4) 25.8 (29.6) 0.37
Breastfeeding duration (%)
- >0-1.9 months (N=651) 19.1 0 20.7
- 2-3.9 months (N=565) 16.6 0 17.9
- 4-5.9 months (N=338) 9.9 0 10.7
- ≥6 months (N=857) 25.2 0 27.2
Missing (N=993) 29.2
Breastfeeding exclusivity (%) 
- Non-exclusively in the fi rst 4 months (N=1,791) 52.6 0 56.9
- Exclusively in the fi rst 4 months (N=712) 20.9 0 22.6
Missing (N=901) 26.5
Introduction of solid foods (%) <0.01
- <4 months (N=201) 5.9 10.6 5.5
- 4-4.9 months (N=1,372) 40.3 42.5 40.1
- ≥5 months (N=693) 20.4 7.9 21.4
Missing (N=1,138) 33.4
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Supplementary Table 3.2.2. Subject characteristics according to category of breastfeeding in the subjects 
with eGFR measurements (N=3,404) (continued)
Total group
N=3,404
Never breastfed
N=254
Ever breastfed
N=3,150 P-value
Child characteristics
Age (years) 6.0 (5.6, 7.4) 6.0 (5.7, 7.2) 6.0 (5.6, 7.5) 0.94
Height (cm) 119.2 (5.6) 119 (5.7) 119.2 (5.6) 0.13
Weight (kg) 22.4 (17.5, 32.6) 22.4 (17.4, 34.8) 22.4 (17.6, 32.4) 0.40
Body mass index, (kg/m2) 15.8 (13.7, 20.5) 15.9 (13.6, 22.0) 15.8 (13.7, 20.5) 0.40
Body surface area, (m2) 0.86 (0.7, 1.1) 0.86 (0.7, 1.1) 0.86 (0.7, 1.1) 0.17
Kidney volume combined, (cm3) 120 (22.6) 116.8 (21.6) 120.4 (22.7) <0.01
eGFR, (ml/min/1.73m2) 119 (16.5) 116 (14.1) 119 (16.7) <0.01
Microalbuminuria (%)* 7.7 5.5 7.7 0.14
Creatinine (μmol/l) 37.2 (5.5) 37.9 (4.9) 37.1 (5.5) 0.04
Cystatin C (μg/l) 783 (81.3) 792 (84.6) 782 (80.9) 0.04
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Diff erences in 
maternal, infant and childhood characteristics (compared with the never breastfed group) were evaluated using T-test for 
continuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests 
for categorical variables. 
eGFR - estimated glomerular fi ltration rate
*Defi ned as levels between 2.5 and 25.0 mg/mmol (boys) and 3.5 and 25.0 mg/mmol (girls)
Supplementary Table 3.2.3. Subject characteristics according to category of breastfeeding in the subjects 
with microalbuminuria measurements (N=4,855)
Total group
N=4,855
Never breastfed
N=371
Ever breastfed
N=4,484 P-value
Maternal characteristics
Pre-pregnancy body mass index (kg/m2) 22.6 (18.2, 34.1) 23.5 (18.2, 38.0) 22.6 (18.2, 33.6) <0.01
Ethnicity (%) <0.01
- European 65.7 76.3 64.8
- Non - European 34.3 23.7 35.2
Education (%) <0.01
- No higher education 49.2 69.7 47.6
- Higher education 50.8 30.3 52.4
Net household total income (%) 0.71
- <1,400 euro 24 25.4 23.9
- ≥1,400 euro 76 74.6 76.1
Smoking during pregnancy (%) <0.01
- Never smoked 80.1 67.7 80.0
- Smoke until pregnancy was known 7.7 7.8 8.3
- Continued smoking 12.2 24.5 11.7
Alcohol during pregnancy (%) <0.01
- Never alcohol in pregnancy                      53.0 62.3 52.3
- Alcohol until pregnancy was known        11.2 8.1 11.4
- Continued alcohol during pregnancy        35.8 29.6 36.3
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Supplementary Table 3.2.3. Subject characteristics according to category of breastfeeding in the subjects 
with microalbuminuria measurements (N=4,855) (continued)
Total group
N=4,855
Never breastfed
N=371
Ever breastfed
N=4,484 P-value
Folic acid supplement use, (%) 0.54
- No 23.2 22.3 23.3
- During early pregnancy 76.8 77.7 76.7
Energy adjusted protein intake (g) 74.8 (10.2) 73.0 (10.2) 75 (10.2) <0.01
Birth characteristics
Girls (%) 49.6 50.4 49.5 0.80
Gestational age (weeks) 40.1 (36.1, 42.3) 39.9 (35.9, 42.4) 40.1 (36.1, 42.3) <0.01
Weight (grams) 3,453 (538) 3,409 (556) 3,457 (536) 0.08
Child protein intake at 1 year (g)
Breastfeeding duration (%) 
25.4 (29.3) 28 (29) 25.2 (29.3) 0.37
- >0-1.9 months (N=958) 19.7 0 21.3
- 2-3.9 months (N=815) 16.8 0 18.2
- 4-5.9 months (N=456) 9.4 0 10.2
- ≥6 months (N=1,203) 24.8 0 26.8
Missing (N=1,423) 29.3
Breastfeeding exclusivity (%) 
- Non-exclusively in the fi rst 4 months (N=2,559) 52.7 0 57.1
- Exclusively in the fi rst 4 months (N=999) 20.6 0 22.3
Missing (N=1,297) 26.7
Introduction of solid foods (%) <0.01
- <4 months (N=266) 5.5 11.3 5.1
- 4-4.9 months (N=1,965) 40.5 43.5 40.1
- ≥5 months (N=987) 20.3 9.3 21.3
Missing (N=1,637) 33.7
Child characteristics
Age (years) 6.0 (5.6, 7.4) 6.0 (5.6, 7.2) 6.0 (5.6, 7.4) 0.94
Height (cm) 119 (5.6) 118.5 (5.9) 118.6 (5.6) 0.15
Weight (kg) 22.2 (17.4, 32.6) 22.2 (17.1, 35.6) 22.2 (17.4, 32.4) 0.40
Body mass index, (kg/m2) 15.8 (13.6, 20.6) 15.8 (13.6, 22.0) 15.8 (13.6, 20.5) 0.40
Body surface area, (m2) 0.86 (0.7, 1.1) 0.85 (0.7, 1.1) 0.86 (0.7, 1.1) 0.17
Kidney volume combined, (cm3) 120 (22.5) 116 (23.3) 120 (22.4) <0.01
eGFR, (ml/min/1.73m2) 119 (16.5) 116.5 (14.1) 119 (16.7) <0.01
Microalbuminuria (%)* 7.6 5.7 7.8 0.14
Creatinine (μmol/l) 37.2 (5.5) 37.8 (4.9) 37.1 (5.2) 0.04
Cystatin C (μg/l) 783 (81.2) 793 (86.5) 782 (80.7) 0.04
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Diff erences in 
maternal, infant and childhood characteristics (compared with the never breastfed group) were evaluated using T-test for 
continuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests 
for categorical variables. 
eGFR-estimated glomerular fi ltration rate
*Defi ned as levels between 2.5 and 25.0 mg/mmol (boys) and 3.5 and 25.0 mg/mmol (girls)
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Supplementary Table 3.2.4. Maternal and child characteristics for population for analysis (N=5,043) and 
the group with information on dietary data but no follow-up at 6 years (N=1,573)
Population for 
analysis
(N=5,043)
No follow-up at 6 
years
(N=1,573) P value
Maternal characteristics
Pre-pregnancy body mass index, kg/m2 22.7 (18.2, 34.1) 22.3 (17.8, 35.5) 0.02
Ethnicity, % <0.01
- European 66 57.3
- Non - European 34 42.7
Educational level, % <0.01
- No higher education 49 56.7
- Higher education 51 43.3
Net household total income, % <0.01
- <1,400 euro 23.9 5.9
- ≥1,400 euro 76.1 94.1
Smoking during pregnancy, % 0.02
- Never smoked 80.2 55
- Smoke until pregnancy was known 7.6 5
- Continued smoking 12.2 40
Alcohol during pregnancy, % 0.57
- Never alcohol in pregnancy 53.1 57.9
- Alcohol until pregnancy was known 11.2 10.5
- Continued alcohol 35.7 31.6
Folic acid supplement use, % 0.37
- No 23.2 22.2
- During early pregnancy 76.8 77.8
Energy adjusted protein intake, g 74.9 73.4 0.62
Birth characteristics
Girls, % 50.2 43.8 0.20
Gestational age, weeks 40.1 (36.0, 42.3) 40.0 (35.9, 42.3) 0.13
Birth weight, g 3,452 (540) 3,417 (564) 0.03
Child protein intake 1y, g 25.4 (29.4) 25.8 (31) 0.76
Breastfeeding, % 0.76
- No 7.6 9.6
- Yes 92.4 90.4
Breastfeeding duration, % <0.01
- >0-1.9 months 19.7 39.4
- 2-3.9 months 16.6 23.6
- 4-5.9 months 9.5 10.5
- ≥6 months 24.9 26.5
Breastfeeding exclusivity, % <0.01
- Non-exclusively in the fi rst 4 months 52.8 73.8
- Exclusively in the fi rst 4 months 20.6 21.7
Introduction of solid foods, %
- <4 months 5.5 -
- 4-4.9 months 40.3 45.5
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Supplementary Table 3.2.4. Maternal and child characteristics for population for analysis (N=5,043) and 
the group with information on dietary data but no follow-up at 6 years (N=1,573) (continued)
Population for 
analysis
(N=5,043)
No follow-up at 6 
years
(N=1,573) P value
- ≥5 months 20.3 54.5
Child characteristics
Age, years 6.0 (5.6, 7.4) -
Height, cm 118.8 (5.7) -
Weight, kg 22.2 (17.4, 32.6) -
Body mass index, kg/m2 15.8 (13.6, 20.6) -
Body surface area, m2 0.86 (0.7, 1.1) -
Kidney volume combined, cm3 120 (23) -
eGFR, ml/min/1.73m2 119 (16) -
Microalbuminuria, % 7.6 -
Creatinine, μmol/l 37.2 (5.5) -
Cystatin C, μg/l 738(81.4) -
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Diff erences in 
maternal, infant and childhood characteristics (compared with the non-followed up group) were evaluated using T-test 
for continuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests 
for categorical variables. eGFR-estimated glomerular fi ltration rate. Non response group, children with no kidney measure-
ments but with available information on breastfeeding. 
Supplementary Table 3.2.5. Subject characteristics for children with and without blood sample available 
at the age of 6 years (among population for analysis)
With blood sample
(N=3,413)
Without blood 
sample
(N=1,630) P value
Maternal characteristics
Pre-pregnancy body mass index, kg/m2 22.7 (18.2, 34.0) 22.6 (18.2, 34.2) 0.69
Ethnicity, % 0.37
- European 66.4 65
- Non - European 33.6 35
Educational level, % 0.04
- No higher education 48 50.9
- Higher education 52 49.1
Net household total income, % 0.09
- <1,400 euro 23.3 25.2
- ≥1,400 euro 76.7 74.8
Smoking during pregnancy, % 0.37
- Never smoked 79.5 78.5
- Smoke until pregnancy was known 8.3 7.8
- Continued smoking 12.2 13.7
Alcohol during pregnancy, % <0.01
- Never alcohol in pregnancy 51.9 55.4
- Alcohol until pregnancy was known 11.3 11.0
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Supplementary Table 3.2.5. Subject characteristics for children with and without blood sample available 
at the age of 6 years (among population for analysis) (continued)
With blood sample
(N=3,413)
Without blood 
sample
(N=1,630) P value
- Continued alcohol 36.8 33.6
Folic acid supplement use, % 0.91
- No 23.2 23.1
- During early pregnancy 76.8 76.9
Energy adjusted protein intake, g 75.0 74.6 0.18
Birth characteristics
Girls, % 49.1 52.5 0.03
Gestational age, weeks 40.1 (36.0, 42.3) 40.1 (36.3, 42.3) 0.92
Birth weight, g 3,464 (539) 3,430 (538) 0.04
Child protein intake 1y, g 25.4 (29.4) 24.3 (29) 0.16
Breastfeeding, % 0.69
- No 7.5 7.8
- Yes 92.5 92.2
Breastfeeding duration, % 0.22
- >0-1.9 months 19.1 20.9
- 2-3.9 months 16.6 16.5
- 4-5.9 months 9.9 8.5
- ≥6 months 25.2 24.2
Breastfeeding exclusivity, % 0.56
- Non-exclusively in the fi rst 4 months 52.7 52.5
- Exclusively in the fi rst 4 months 20.9 19.9
Introduction of solid foods, % 0.25
- <4 months 5.9 4.7
- 4-4.9 months 60.5 40.3
- ≥5 months 30.6 20.1
Child characteristics
Age, years 6.0 (5.6, 7.2) 6.0 (5.6, 7.4) 0.26
Height, cm 118.8 (5.6) 118.3 (5.7) <0.01
Weight, kg 22.4 (17.5, 32.6) 22.0 (17.2, 32.6) <0.01
Body mass index, kg/m2 15.8 (13.7, 20.5) 15.8 (13.5, 20.8) 0.50
Body surface area, m2 0.86 (0.7, 1.1) 0.85 (0.7, 1.1) <0.01
Kidney volume combined, cm3 120 (22.6) 118.6 (22.5)    0.04
eGFR, ml/min/1.73m2 119 (16) -
Microalbuminuria, % 7.7 7.5 0.76
Creatinine, μmol/l 37.2 (5.5) -
Cystatin C, μg/l 738 (81.4) -
Values are means (SD), percentages (%), or medians (95 % range) for variables with skewed distribution. Diff erences in 
maternal, infant and childhood characteristics (compared with the non-blood sample group) were evaluated using T-test 
for continuous normally distributed variables, Mann Whitney for non-normally distributed variables, and Chi-squared tests 
for categorical variables. 
eGFR-estimated glomerular fi ltration rate
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Supplementary Table 3.2.6. Associations of infant feeding with creatinine and cystatin C at the age of 6 
years adjusted for child age, sex, family-based socio-demographic, maternal lifestyle and childhood factors 
Diff erence in outcome measure (95 % Confi dence Interval)
Creatinine
(μmol/l)
N=3,411
Cystatin C
(μg/L)
N=3,410
§Creatinine
(μmol/l)
Adjusted for kidney 
volume
N=3,171
§Cystatin C
(μg/L)
Adjusted for kidney 
volume
N=3,178
Breastfeeding
Never (N=382) 0.44 (- 0.29, 1.16)   1.53 (- 9.75, 12.81)   0.16 (- 0.56, 0.88) -0.50 (-11.73, 10.74)
Ever (N=4,661) Reference Reference Reference Reference
Duration 
>0-1.9 months (N=993) 0.47 (-0.10, 1.04) -1.63 (-10.45, 7.19)   0.31 (-0.26, 0.88) -2.69 (-11.67, 6.30)
2-3.9 months (N=836) 0.57 (-0.01, 1.14)   1.72 (-7.19, 10.64)   0.54 (-0.03, 1.12) 3.12 (-5.97, 12.21)
4-5.9 months (N=477) 0.10 (-0.59, 0.78) -1.35 (-11.94, 9.24)   0.16 (-0.52, 0.85) -1.43 (-12.23, 9.37)
≥6 months (N=1,253) Reference Reference Reference Reference
P for trend 0.05 0.87 0.15 0.78
Exclusive for 4 months
No (N=2,653) 0.63 (0.15, 1.11)* 3.81 (-3.57, 11.19)    0.43 (-0.06, 0.92) 2.26 (-5.31, 9.84)
Yes (N=1,063) Reference Reference Reference Reference
First solid foods 
<4 months (N=263) 0.27 (-0.61, 1.15)  -2.33 (-15.72, 11.05)   0.14 (-0.74, 1.01)  -4.05 (-17.47, 9.37)
4-4.9 months (N=1,864) 0.27 ( 0.23, 0.76)   2.39 (-5.20, 9.97)   0.28 (-0.22, 0.78) 2.33 (-5.33, 9.97)
≥5 months (N=989) Reference Reference Reference Reference
P for trend 0.35 0.94 0.45 0.91
Values are linear regression coeffi  cients (95 % confi dence intervals). Models are adjusted for child’s age at visit, sex, plus 
family-based socio-demographic confounders (maternal education, ethnicity, income), maternal lifestyle related factors 
(pre-pregnancy BMI, smoking and alcohol usage during pregnancy, folic acid supplements and protein-energy intake 
during pregnancy), childhood factors (birthweight, gestational age, body surface area). Non-exclusive breastfeeding until 
4 months includes partial until 4 months, partial thereafter; and partial until 4 months, not thereafter. Exclusive breastfeed-
ing until 4 months includes exclusive until 6 months; exclusive until 4 months, partial thereafter; exclusive until 4 months, 
not thereafter. *P <0.05 § creatinine and § cystatin C are additionally adjusted for kidney volume.
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Supplementary Table 3.2.9. Associations of infant feeding with kidney volume at the age of 6 years ad-
justed for child age, sex, family-based socio-demographic, maternal lifestyle, childhood factors, and lean 
body mass (N=4,637)
Kidney volume (cm3)
N=4,637
Breastfeeding
Never (N=354) -2.56 (-4.69, -0.44)*
Ever (N=4,283) Reference
Duration 
>0-1.9 months (N=925) -2.40 (-4.09, -0.70)*
2-3.9 months (N=775) -1.13 (-2.86, 0.60)
4-5.9 months (N=438) -0.18 (-2.26, 1.90)
≥6 months (N=1,143) Reference
P for trend <0.01
Exclusive for 4 months
No (N=2,542) -2.34 (-3.80, -0.88)*
Yes (N=952) Reference
First solid foods 
<4 months (N=225) 0.01 (-3.89, 3.90)
4-4.9 months (N=1,716) -0.72 (-2.87, 1.43)
≥5 months (N=914) Reference
P for trend 0.93
Values are linear regression coeffi  cients (95 % confi dence intervals). Models are adjusted for child’s sex, plus family-based 
socio-demographic confounders (maternal education, income), maternal lifestyle related factors (pre-pregnancy BMI, 
smoking and alcohol usage during pregnancy, folic acid supplements and protein-energy intake during pregnancy), child-
hood factors (birth weight, BSA and lean body mass). Non-exclusive breastfeeding until 4 months includes partial until 
4 months, partial thereafter; and partial until 4 months, not thereafter. Exclusive breastfeeding until 4 months includes 
exclusive until 6 months; exclusive until 4 months, partial thereafter; exclusive until 4 months, not thereafter. *P <0.05 
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ABSTRACT
Background: Creatinine and cystatin C concentrations are commonly used to estimate 
glomerular fi ltration rate (eGFR) in clinical practice and epidemiological studies. To estimate 
the infl uence of diff erent body composition measures on eGFR from creatinine and cystatin 
C blood concentrations, we compared the associations of diff erent anthropometric and body 
composition measures with eGFR derived from creatinine (eGFRcreat) and cystatin C (eGFRcystC) 
blood concentrations.
Methods: In a population-based cohort study among 4,305 children aged 6.0 years (95 % 
range 5.7–8.0), we measured weight and height and calculated body mass index and body 
surface area, and lean and fat mass by Dual-energy X-ray Absorptiometry. At the same age, 
we measured creatinine and cystatin C blood concentrations and estimated the GFR. 
Results: Correlation between eGFR based on creatinine and cystatin C concentrations was 
r  =  0.40 (p-value <0.01). Higher body mass index was associated with lower eGFRcystC but 
not with eGFRcreat. Higher body surface area was associated with higher eGFRcreat and lower 
eGFRcystC (p-values <0.05). Lean and fat mass percentages were associated with eGFRcreat but 
not with eGFRcystC.
Conclusions: Our fi ndings suggest that both eGFRcreat and eGFRcystC are infl uenced by body 
mass index and body surface area. eGFRcreat is more strongly infl uenced by body composition 
than eGFRcystC. 
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INTRODUCTION
Glomerular fi ltration rate (GFR) plays a key role in the management of kidney disease. Ide-
ally, measuring GFR should be based on renal clearances of exogenous markers such as 
inulin, but this approach is complex, invasive and expensive.1 Therefore, GFR is commonly 
estimated based on creatinine blood concentrations.2 Using creatinine as marker of renal 
function has some limitations. Creatinine, is actively secreted by the proximal tubule, and is 
related to muscle mass, age, sex, ethnicity and dietary factors.1, 3 Creatinine concentrations 
can be higher in individuals with an increased muscle mass, independent of kidney func-
tion, leading to an underestimation of eGFR.4 Studies in adults suggest that eGFR based on 
creatinine concentrations can be improved if lean mass percentage could be incorporated in 
the formula.4 
An alternative marker for the estimation of GFR is cystatin C, the concentrations of which 
are reported to be independent of muscle mass in children.5, 6 Some authors report a superior 
sensitivity of cystatin C for detecting impaired GFR in pediatric patients to that of creatinine, 
especially in children with low muscle mass.7 However, studies in kidney disease patients 
suggest that lean mass aff ects cystatin C concentrations.8, 9 Many studies have explored the 
associations between body mass index (BMI) and eGFR, using BMI as a proxy for body com-
position.10–11 To our knowledge, large population based studies in healthy children comparing 
the correlations and associations of detailed body composition measures, next to BMI, with 
the estimates of GFR are lacking.
To estimate the infl uence of diff erent body composition measures on eGFR from creatinine 
and cystatin C blood concentrations, we compared the associations of diff erent anthropo-
metric and body composition measures with eGFR derived from creatinine (eGFRcreat) and 
cystatin C (eGFRcystC) blood concentrations in a population-based prospective cohort study 
among 4,305 children who were 6 years of age.
METHODS
Design and study population
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from fetal life onwards in Rotterdam, the Netherlands, which has been described in 
detail previously.12 The study has been approved by Medical Ethical Committee of Erasmus 
MC, University Medical Center Rotterdam. All children were born between April 2002 and 
January 2006 and form a largely prenatally enrolled birth cohort that is currently being 
followed until young adulthood. Written consent was obtained for all children. The present 
analyses were performed among 4,305 children with body composition and kidney function 
measures available (Supplementary Figure 3.3.1).  
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Body composition measurements
Children’s anthropometrics and body composition were measured at a median age of 6.0 
years (95 % range 5.7 to 8.0).12 Height (m) was determined in standing position to the near-
est millimeter without shoes using a Harpenden stadiometer (Holtain Limited, Dyfed, U.K.). 
Weight was measured using a mechanical personal scale (SECA, Almere, The Netherlands). 
We calculated BMI (kg/m2) and body surface area (BSA) (m2). For BSA, we used the DuBois 
formula: BSA = weight (kg)0.425 x height (cm)0.725 x 0.007184. Whole body dual-energy X-ray 
absorptiometry (DXA) scans (iDXA, GE-Lunar, 2008, Madison, WI, USA) were performed to 
estimate fat and lean mass. We calculated lean mass percentage as (lean mass (kg) /weight 
(kg)) and fat mass percentage as (fat mass (kg) /weight (kg)). 
Kidney function measurements
Non-fasting blood samples were drawn by antecubital venipuncture and centrifuged for 
10 minutes and stored at -80 °C at one location in the STAR-MDC laboratory. As previously 
described, creatinine concentrations were measured with enzymatic methods and cystatin C 
concentrations with a particle enhanced immunoturbidimetric assay (using Cobas 8000 ana-
lyzers, Roche, Almere, the Netherlands). Quality control samples demonstrated intra-assay 
and inter-assay coeffi  cients of variation of 0.51 % for creatinine and 1.65 % for cystatin C, and 
1.37 % for creatinine and 1.13 % for cystatin C, respectively.13 We calculated the eGFR based on 
creatinine concentrations according to the revised Schwartz 2009 formula: eGFRcreat = 36.5 * 
(height (cm)/ serum creatinine (μmol/l)),14 and eGFR based on cystatin C concentrations using 
Zappitelli’s formula: eGFRcystC = 75.94/[CysC (mg/L)1.17].15
Statistical analysis
We performed a non-response analysis by comparing subject characteristics between chil-
dren with and without kidney function measurements using T-tests, Chi-square tests and 
Mann-Whitney tests. We created standard deviations scores (SDS) for all body composition 
measures to enable comparison between eff ect estimates. Next, we examined the Pearson 
rank correlation coeffi  cients between childhood anthropometrics, body composition and 
eGFR measures. Third, we used multiple linear regression analyses to examine the associa-
tions of anthropometric and body composition measures with creatinine, cystatin C, eGFRcreat 
and eGFRcystC. The linear regression models were adjusted for child sex, age at measurements, 
and ethnicity. Additionally, we explored the associations of childhood BMI clinical cut-off s 
with creatinine, cystatin C and eGFRs. Because of the already reported associations of ethnic-
ity with kidney function markers, we performed a sensitivity analysis in children of European 
ethnicity, the largest ethnic subgroup.16 Based on previous literature we assessed whether 
the explored association diff ered by sex, which was not the case in this study.17, 18 All analyses 
were performed using the Statistical Package for the Social Sciences version 21.0 for Windows 
(SPSS IBM, Chicago, IL, USA).
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RESULTS 
Participant characteristics
Supplementary Figure 3.3.1 describes the selection of the study population. At the median 
age of 6 years (95 % range 5.7, 8.0) a total of 8,305 children participated in the study follow-up 
measurements. Of these children, 6,509 (78 %) visited the research center for body composi-
tion measurements. In this study, we excluded children with congenital kidney abnormalities 
(N=12). A total of 6,497 children were available for kidney function measurements. Of these 
children, N=2,192 did not have kidney measurements. The present analyses were performed 
among 4,305 children with body composition and kidney function measures available.
Table 3.3.1 shows the characteristics of the participants. In the full group the mean (SD) eG-
FRcreat and eGFRcystC were 118.9 ml/min/1.73m2 (15.9) and 101.6 ml/min/1.73m2 (11.2), respectively. 
The histograms of creatinine, cystatin C, eGFRcreat and eGFRcystC are provided in Supplemen-
tary Figure 3.3.2. Results from the non-response analyses are given in the Supplementary 
Table 3.3.1. Children with kidney function measurements had higher lean mass percentage 
and lower fat mass percentage compared to children who did not have kidney function 
measurements.
Table 3.3.1. Subjects characteristics (N=4,305)
Subjects characteristics
Age at measurements (y) 6.0 (5.7, 8.0)
Sex, Girls (%) 48.3
Ethnicity (%)
- Dutch or European 65.1
- Non-European 34.9
Height (cm) 119.7 (6.0)
*SD-score (mean, sd) -0.2 (1.0)
Weight (kg) 23.4 (4.2)
*SD-score (mean, sd) 0.1 (1.0)
Body mass index (kg/m2) 16.2 (1.8)
*SD-score (mean, sd) 0.3 (0.9)
Body surface area (m2) 0.88 (0.09)
Lean mass percentage (%) 71.7 (5.4)
Fat mass percentage (%) 24.7 (5.6)
Creatinine (μmol/l) 37.4 (5.3)
Cystatin C (μg/l) 787.3 (74.4)
eGFRcreat (ml/min/1.73m2) 118.9 (15.9)
eGFRcystC (ml/min/1.73m2) 101.6 (11.2)
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. *The standard deviation scores were obtained using 
Dutch reference growth curves (Growth Analyzer 3.0, Dutch Growth Research Foundation, Rotterdam, the Netherlands).
Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood concentrations; eGFR-
creat = 36.5 * (height (cm)/ serum creatinine (μmol/l)); eGFRcystC estimated glomerular fi ltration rate calculated based on 
cystatin C blood concentrations eGFRcystC = 75.94/[CysC(mg/L)1.17].
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Correlations of childhood anthropometrics and body composition measures 
with eGFR
The Pearson rank correlation coeffi  cient between eGFRcreat and eGFRcystC was r = 0.40 (p-value 
<0.01) (Table 3.3.2). Childhood height, weight, BMI and BSA were positively correlated with 
creatinine and cystatin C concentrations, with stronger coeffi  cients for creatinine concentra-
tions (p-values <0.01). Lean mass percentage was positively correlated with creatinine con-
centrations and negatively correlated with eGFRcreat (r = 0.13, p-value <0.01). Similar results, 
but in opposite directions were observed for fat mass percentage. Lean mass percentage and 
fat mass percentage were not correlated with cystatin C concentrations or eGFRcystC. 
Associations of childhood body composition measures with eGFR
Table 3.3.3 shows the results from the linear regression models. Childhood height was as-
sociated with creatinine concentrations (p-value <0.05), but not with cystatin C concentra-
tions. Higher childhood weight was associated with both higher creatinine and cystatin C 
concentrations (p-value <0.01). Higher childhood height was associated with higher eGFRcreat 
(p-value <0.01), but not with eGFRcystC whereas higher childhood weight was associated with 
higher eGFRcreat and lower eGFRcystC (p-value <0.01). 
Each 1-SD increase in BSA was associated with 1.81 ml/min/1.73m2 (95 % confi dence interval 
(CI) 1.24, 2.37) higher eGFRcreat and 0.57 ml/min/1.73m2 (95 % CI -0.98, -0.17) lower eGFRcystC. BMI 
was negatively associated with eGFRcystC (p-value <0.05) but not with eGFRcreat. We observed 
tendencies for similar eff ect estimates when we restricted the analyses to Europeans only 
(N=2,727) (Supplementary Table 3.3.2). The associations of BMI clinical cut-off s with creati-
nine, cystatin C and the eGFR are given in Supplementary Table 3.3.3. 
Higher lean mass percentage was associated with higher creatinine concentrations and 
with lower cystatin C concentrations (Table  3.3.3) (p-values <0.05). A 1-SD increase in lean 
Table 3.3.2. Correlation coeffi  cients of the investigated variables
Height Weight BMI BSA FMP LMP Creat Cyst C eGFRcreat eGFRcystC
Height 1.00
Weight 0.77** 1.00
BMI 0.31** 0.83** 1.00
BSA 0.90** 0.97** 0.69** 1,00
FMP 0.18** 0.57** 0.69** 0.46** 1,00
LMP -0.19** -0.56** -0.68** -0.45** -0.999** 1,00
Creat 0.30** 0.28** 0.16** 0.30** -0.05** 0.05** 1,00
Cyst C 0.05** 0.06** 0.05** 0.06** -0.001 0.003 0.40** 1,00
eGFRcreat 0.06** 0.01 -0.04** 0.03 0.12** -0.13** -0.92** -0.40** 1,00
eGFRcystC -0.05** -0.06** -0.05** -0.06** 0.01 -0.01 -0.39** -0.99** 0.40** 1,00
** Correlation is signifi cant at the 0.01 level (2-tailed).
Abbreviations: BMI- body mass index, BSA- body surface area, FMP- fat mass percentage, LMP- lean mass percentage, 
Creat- creatinine, Cyst C- cystatin C, eGFRcreat estimated glomerular fi ltration creatinine-based, eGFRcystC estimated glo-
merular fi ltration cystatin C-based.
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mass percentage was associated with 2.74 ml/min/1.73m2 (95 % CI -3.27, -2.20) lower childhood 
eGFRcreat. No association was observed of lean mass percentage with eGFRcystC. 
Similar results but in an opposite direction were observed for fat mass percentage (Ta-
ble 3.3.3). We observed similar eff ect estimates when we restricted our analyses to European 
subjects only, although not all associations were signifi cant (Supplementary Table 3.3.2).
DISCUSSION
Results of this cross-sectional study in healthy 6-year-old children suggest that BMI and BSA 
are associated with creatinine-based eGFR and cystatin C-based eGFR. Lean mass percentage 
and fat mass percentage are associated with creatinine-based eGFR, but not with cystatin 
C-based eGFR.
Interpretation of main fi ndings 
To our knowledge, this is the fi rst large population-based study in healthy school-age chil-
dren comparing the association of detailed measures of body composition using DXA scans 
with estimates of GFR based on creatinine and cystatin C concentrations. Both creatinine 
and cystatin C concentrations can be infl uenced by diff erent factors. Creatinine is produced 
in active muscle and is reported to be determined by muscle mass and dietary intake, which 
may account for the variations in the concentrations of serum creatinine observed among 
diff erent age and ethnic groups.1, 3 However, we have previously reported that childhood 
protein intake does not infl uence the eGFR.19 Cystatin C is another marker to evaluate renal 
function, although is not used as commonly as creatinine.6, 20 Cystatin C is produced by all 
nucleated cells and is reported to be less strongly related to body weight and height in chil-
Table 3.3.3. Associations of anthropometric and body composition measures with creatinine, cystatin C 
and eGFR (N=4,305)
Diff erence (95 % Confi dence Interval)
Creatinine
(μmol/l)
Cystatin C
(μg/l)
eGFRcreat
(ml/min/1.73m2)
eGFRcystC 
(ml/min/1.73m2)
Anthropometrics and 
body composition (SDS)
Height 0.97 (0.79, 1.15)*** 1.99 (-0.70, 4.70) 2.78 (2.22, 3.35)*** -0.29 (-0.70, 0.12)
Weight 0.91 (0.73, 1.08)*** 4.49 (1.91, 7.07)*** 1.16 (0.61, 1.71)*** -0.66 (-1.05, -0.27)**
Body mass index 0.52 (0.36, 0.68)*** 4.15 (1.80, 6.51)*** -0.37 (-0.87, 0.13) -0.61 (-0.96, -0.26)**
Body surface area 1.02 (0.84, 1.20)*** 3.93 (1.27, 6.59)** 1.81 (1.24, 2.37)*** -0.57 (-0.98, -0.17)**
Lean mass percentage 0.30 (0.07, 0.54)* -2.73 (-5.28, -0.18)* -2.74 (-3.27, -2.20)*** 0.36 (-0.03, 0.74)
Fat mass percentage -0.48 (-0.65, -0.31)*** 2.86 (0.32, 5.40)* 2.68 (2.14, 3.21)*** -0.38 (-0.76, 0.01)
Values are beta coeffi  cients and 95 % confi dence intervals, from linear regression models adjusted for child age, sex and 
ethnicity. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood concentra-
tions; eGFRcystC estimated glomerular fi ltration rate calculated based on cystatin C blood concentrations 
 P value for the associations *<0.05 **<0.01 ***<0.001.
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dren compared to creatinine.5, 7 Besides, adult studies suggest that cystatin C concentrations 
are related to age, sex, height and weight and infl uenced by corticosteroid use.17, 21
In children, the Schwartz formula is widely used to estimate GFR from creatinine concen-
trations.14 The Schwartz formula is known to overestimate eGFR compared to inulin clearance 
GFR.6, 22, 23 Schwartz formula estimates GFR using creatinine concentrations and child height.14 
Therefore, the observed eff ect estimates in the current study of height on eGFRcreat might be 
clinically not relevant. Next to Schwartz’s formula we estimated GFR using the Zappitelli’s 
formula.15 This formula is not dependent of any anthropometric measures. It estimates GFR 
by using only the cystatin C concentrations.15 In a study among 42 healthy adults, eGFR using 
creatinine and cystatin C concentrations was compared with measured GFR. This study sug-
gested that eGFR based on cystatin C concentrations was a better marker then eGFR based 
on creatinine concentrations for estimating kidney function.24
It has previously been reported that lean body mass, indicating muscular mass, is an im-
portant determinant of the GFR.25 So far results from studies comparing the eff ects of body 
composition measures on creatinine and cystatin C concentrations and their derived eGFR 
are contradictory.8, 26 A number of studies have explored the associations of BMI with eGFR, 
using BMI as a proxy of body composition.10–11 The associations of BMI with creatinine and cys-
tatin C diff ered between populations studied. We observed that higher BMI was associated 
with higher creatinine and cystatin C concentrations and with lower eGFRcystC, but not with 
eGFRcreat. In the subgroup of Europeans, we observed that BMI was associated with creatinine, 
cystatin C concentrations, and their derived eGFRs. In line with our fi ndings in the European 
subgroup, in the general Japanese population, BMI was associated with lower eGFRcreat.11 Simi-
lar to what we observe, studies among both healthy and kidney diseased adults suggested 
that eGFR based on cystatin C concentrations is not independent of BMI.8, 27 These fi ndings 
appear to be diff erent among children with various kidney diseases, where BMI does not 
have a clinically relevant eff ect on eGFRcystC.10 Next to BMI, we observed that higher BSA was 
associated with higher creatinine, cystatin C concentrations, eGFRcreat and lower eGFRcystC. The 
eff ect estimates for the associations of BMI and BSA with eGFRs are relatively small. Studying 
detailed measures of body composition will therefore likely add to the understanding of the 
associations of body composition and kidney function measures.
Studies among healthy adults have shown lean mass to be associated with serum creati-
nine but not with cystatin C concentrations.4, 26 A study among 67 healthy individuals of ages 
between 18 and 52 years has shown that creatinine concentrations were highly aff ected by 
muscle mass, whereas cystatin C concentrations were aff ected by fat mass.28 The associa-
tions between lean mass and cystatin C are reported to be diff erent among kidney disease 
patients.8 Among 77 chronic kidney disease patients lean mass aff ected cystatin C concentra-
tions and GFR estimation based on cystatin C concentrations improved when lean mass was 
included in the formula, especially in patients with extreme body composition.8 In severely 
obese children lean mass percentage has been reported to correlate with both creatinine and 
cystatin C concentrations.29 In the current study, we observed that lean and fat mass percent-
age correlate with creatinine concentrations and eGFRcreat. Higher lean mass percentage and 
lower fat mass percentage were associated with higher creatinine concentrations and lower 
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eGFRcreat. We did not observe a signifi cant correlation of lean mass percentage or fat mass 
percentage with cystatin C concentrations. Our study shows that eGFR based on cystatin C 
concentrations is independent of lean mass percentage and fat mass percentage.
Our fi ndings suggest that eGFRcreat is more strongly infl uenced by body composition than 
eGFRcystC. However, their impact on clinical care may be limited. As the revised Schwartz for-
mula (eGFRcreat) is the most widely used formula both in epidemiological studies and clinical 
practice, our fi ndings suggest that body composition measures should be considered when 
GFR is estimated based on creatinine concentrations. Ideally, body composition measures 
would have been incorporated in the eGFRcreat equations and compared with GFR based on 
renal clearances of exogenous markers, but unfortunately this is not possible in our study. 
Considering the feasibility and costs of performing DXA scans in school-aged children, 
whether and to what extent detailed body composition measures should be used in the 
clinical practice when eGFR can be argued. Other studies are needed to assess whether using 
eGFRcystC instead of eGFRcreat leads to better care for pediatric kidney patients.  
Strengths and limitations
To the best of our knowledge, this is the fi rst and largest cross-sectional multiethnic study in a 
healthy pediatric population-based cohort examining the associations of body composition 
with estimates of GFR. GFR was estimated based on creatinine and cystatin C concentrations. 
Except height and weight to calculate BMI and BSA, we also measured fat mass and lean mass 
with DXA. Of all children 61 % provided blood samples for measuring creatinine and cystatin 
C concentrations. Children without data on kidney function measures were shorter, had a 
higher fat mass percentage and lower lean mass percentage. The diff erence in fat and lean 
mass percentage may be explained by the higher percentage of girls in the group without 
available kidney measures. There was no diff erence in BMI between children with and with-
out available kidney function measures. We observed tendencies for similar eff ect estimates 
among Europeans only, although not all associations were signifi cant in this subgroup. This 
might be due to the smaller study group, but may also refl ect an eff ect of ethnicity. Ideally, 
we would have been able to compare the explored associations with the measured GFR and 
validate our fi ndings. Unfortunately, we do not have the urinary or plasma clearance of an 
ideal fi ltration marker, such as inulin, iothalamate or iohexol, as the gold standard for the 
measurement of GFR.30 Our fi ndings are based on a healthy pediatric population of a narrow 
age category and may not be generalizable to older, younger, or diseased populations. 
CONCLUSION
Our results suggest that eGFR based on both creatinine and cystatin C concentrations are 
infl uenced by BMI and BSA, whereas only eGFR based on creatinine concentrations is infl u-
enced by lean mass percentage and fat mass percentage. Beside anthropometric measure-
ments, body composition measures should be considered when estimating GFR in children. 
Further studies to compare these results with measured GFR are needed.
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Supplementary Figure 3.3.1. Flowchart of the study participants
Children participating at 6 years’ 
measurements  
N=8,305 
Children with body composition 
measurement  
N=6,509 
N=1,796 Excluded children without body 
composition measures  
N=12 Excluded children with congenital 
kidney abnormalities  
Children available for kidney function 
measurements  
N=6,497 
N=2,192 Excluded children who did not have 
kidney function measures 
Children available for the analysis with 
estimated glomerular filtration rate data 
available:  
N=4,305 
Creatinine  
Cystatin C   
eGFRcreat   
eGFRcystC    
Supplementary Figure 3.3.2. Histograms of kidney function measures
229
Body composition and GFR estimates
3.3
Supplementary Table 3.3.1. Subject characteristics between children with and without kidney function 
measurements (N=6,509)
Subjects characteristics
With eGFR data
(N=4,305)
Without eGFR data
(N=2,204) P-value
Age at measurements (y) 6.0 (5.7, 8.0) 6.0 (5.7, 7.6) 0.20
Sex, Girls (%) 48.3 53.4 0.07
Ethnicity (%) 0.26
- Dutch or European 65.1 63.8
- Non-European 34.9 36.2
Height (m) 119.7 (6.0) 119.0 (6.0) <0.01
*SD-score (mean, sd) -0.2 (1.0) -0.3 (1.1) <0.01
Weight (kg) 23.4 (4.2) 23.1 (4.3) 0.01
*SD-score (mean, sd) 0.1 (1.0) 0 (1.1) 0.07
Body mass index (kg/m2) 16.2 (1.8) 16.2 (1.9) 0.74
*SD-score (mean, sd) 0.3 (0.9) 0.3 (1.0) 0.91
Body surface area (m2) 0.88 (0.09) 0.87 (0.09) <0.01
Fat mass percentage (%) 24.7 (5.6) 25.3 (5.9) <0.01
Lean mass percentage (%) 71.7 (5.4) 71.1 (5.7) <0.01
Values are percentages for categorical variables, means (SD) for continuous variables with a normal distribution, or medi-
ans (95 % range) for continuous variables with a skewed distribution. *The standard deviation scores were obtained using 
Dutch reference growth curves (Growth Analyzer 3.0, Dutch Growth Research Foundation, Rotterdam, the Netherlands).
Supplementary Table 3.3.2. Associations of anthropometric and body composition measures with creati-
nine, cystatin C and eGFR in European children (N=2,727)
Diff erence (95 % Confi dence Interval)
Creatinine 
(μmol/l)
Cystatin C 
(μg/l)
eGFRcreat 
(ml/min/1.73m2)
eGFRcystC 
(ml/min/1.73m2)
Anthropometrics and 
body composition (SDS)
Height 0.83 (0.60, 1.05)*** 2.33 (-1.15, 5.80) 3.13 (2.42, 3.84)*** -0.35 (-0.87, 0.17)
Weight 1.16 (0.92, 1.39)*** 5.84 (2.16, 9.51)** 0.75 (-0.01, 1.52) -0.85 (-1.40, -0.30)**
Body mass index 0.86 (0.64, 1.08)*** 5.33 (1.94, 8.72)** -1.53 (-2.23, -0.83)*** -0.78 (-1.29, -0.27)**
Body surface area 1.13 (0.90, 1.36)*** 4.80 (1.18, 8.43)** 1.72 (0.97, 2.47)*** -0.71 (-1.25, -0.17)*
Lean mass percentage 0.30 (0.07, 0.54)* -2.60 (-6.17, 0.98) -2.11 (-2.85, -1.37)*** 0.29 (-0.25, 0.82)
Fat mass percentage -0.28 (-0.52, -0.05)* 2.83 (-0.74, 6.40) 2.02 (1.28, 2.75)*** -0.32 (-0.85, 0.21)
Values are beta coeffi  cients and 95 % confi dence intervals, from linear regression models adjusted for child age and sex. 
Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood concentrations; eGFRcystC 
estimated glomerular fi ltration rate calculated based on cystatin C blood concentrations 
 P value for the associations *<0.05 **<0.01 ***<0.001. 
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Supplementary Table  3.3.3. Associations of BMI clinical cut-off s with creatinine, cystatin C and eGFR 
(N=4,305)
Diff erence (95 % Confi dence Interval)
Creatinine (μmol/l) Cystatin C (μg/l)
eGFRcreat 
(ml/min/1.73m2)
eGFRcystC 
(ml/min/1.73m2)
Body mass index (kg/m2)
Underweight (n=201) -0.87 (-1.62, -0.12)* 5.14 (-5.45, 15.73) 1.90 (-0.36, 4.17) -0.60 (-2.20, 1.00)
Normal weight (n=3,383) Reference Reference Reference Reference
Overweight (n=547) 0.98 (0.50, 1.46)*** 5.54 (-1.28, 12.36) -0.38 (-1.83, 1.08) -0.77 (-1.80, 0.26)
Obese (n=166) 1.61 (0.77, 2.45)*** 12.36 (0.45, 24.27)* 1.23 (-1.31, 3.78) -1.78 (-3.58, 0.02)
Values are beta coeffi  cients and 95 % confi dence intervals, from linear regression models adjusted for child age, sex and 
ethnicity. Abbreviations: eGFRcreat estimated glomerular fi ltration rate calculated based on creatinine blood levels; eGFRcystC 
estimated glomerular fi ltration rate calculated based on cystatin C blood levels. P value for the associations *<0.05 ** <0.01 
***<0.001. 
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INTRODUCTION
Chronic kidney disease prevalence is increasing.1 Epidemiological evidence suggests that 
the susceptibility for chronic kidney disease is established in early life.2 Studies relate fetal 
growth restriction and low birth weight with increased risks of chronic kidney disease in 
later life.3, 4 In addition, historical studies associate maternal undernutrition with an increased 
risk of cardiovascular and renal disease in the adult off spring.5, 6 All these observations relate 
with the “Developmental Origins of Health and Disease” Hypothesis, which proposes that an 
organism may develop in diff erent ways, depending on the environment it is exposed to.7, 8 
Adverse exposures, such as maternal malnutrition, during fetal life may lead to impaired fetal 
growth, low birth weight and smaller kidneys with a reduced number of nephrons.3, 9 Post 
mortem studies in humans have shown that lower nephron number is associated with low 
birth weight.10–12 The “Glomerular Hyperfi ltration Theory” suggests that a reduced nephron 
number in smaller kidneys in early life may lead to glomerular hyperfi ltration and hypertro-
phy, which in turn lead to glomerulosclerosis and chronic kidney disease and hypertension 
in later life.13–15 An impaired renal function in childhood, possibly as a consequence of smaller 
kidney with a lower number of nephrons, could be an early sign of developing renal disease. 
The aim of this thesis was to identify specifi c nutritional factors during fetal life, and ge-
netic and childhood factors related with early growth and measures of kidney volume and 
function in school-aged children. In this chapter, we provide a brief summary of the main 
fi ndings of the studies in this thesis, a general discussion of methodological issues, and pos-
sible clinical implications of these studies. Furthermore, this chapter provides suggestions 
for future research.
MAIN FINDINGS
Fetal factors
Various adverse maternal nutritional and lifestyle-related characteristics have been associ-
ated with the risk of adverse birth outcomes, and child cardiovascular and renal health.5, 6, 16–20 
Evidence from the Dutch Hunger studies suggest that the fetal nutrition supply line may 
be directly aff ected by the dietary intake of the mother during pregnancy.6, 21 Thus far, not 
much is known about common, contemporary nutritional exposures during pregnancy that 
aff ect fetal growth and off spring kidney health. As fetal life is a critical period for growth and 
nephron formation, identifi cation of specifi c nutrients and life style determinants may be 
important for early prevention of adverse birth outcomes and of renal and cardiovascular 
disease in adulthood. 
First, we analysed whether protein intake in early pregnancy was associated with child-
hood kidney function. The results of our study suggested that higher maternal total protein 
intake in early pregnancy was associated with higher estimated glomerular fi ltration rate 
(eGFR) in children. These association were indipendent of many maternal lifestyle and so-
ciodemografi c factors and child characteristics. Further analyses showed that the observed 
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associations were mainly driven by maternal vegetable protein intake, rather than animal 
protein intake. Additionally the associations of maternal protein intake with childhood eGFR 
were not explained by later diet of the child. In the literature, contraversary fi ndings are 
reported on the eff ect of protein intake in renal health.22, 23 However, our fi ndings are in line 
with animals studies which suggest that specifi cally maternal dietary protein intake during 
pregnancy infl uences off spring’s kidney function.20, 24 Our results shade light on the potential 
porgraming role of maternal protein consumption during pregnancy on childhood kidney 
development. Maternal diet may program the embryonic kidney by altering cell turnover and 
gene expression at a time when nephrons and glomeruli have yet to form.25 Other underlying 
pathways that may drive these associations can be marked changes in the renal expression 
of the glucocorticoid receptor and components of the renin-angiotensin system due to a low 
protein diet. Also, protein restriction during pregnancy could aff ect the growth hormone-
insulin-like growth factor and the prostaglandins axis in the off spring.26
Strong relations have been reported between various micronutrients and risk factors for 
cardiovascular and renal disease in the off spring.16, 27 During periods of rapid cell growth 
and division maternal folate need increases. A defi cient folate supply may result in impaired 
deoxyribonucleic acid (DNA) synthesis and inability to methylate cellular proteins, lipids, and 
DNA. In this scenario complications such as neural tube defects may occur.28 In healthy infants, 
a relationship between maternal folate concentrations during pregnancy and vascular endo-
thelial function has been demonstrated.29 Whereas, adults studies have shown associations 
of elevated homocysteine concentrations with an accelerated decline in kidney function.30 
However, no previous study has explored the associations of fi rst trimester maternal and cord 
blood folate, vitamin B12 and homocysteine concentrations with kidney outcomes in children. 
The results of our study suggest that higher maternal folate concentrations were associated 
with larger childhood combined kidney volume, whereas higher maternal vitamin B12 concen-
trations were associated with higher childhood (estimated glomerular fi ltration rate based on 
cystatin C concentrations) eGFRcystC. These associations were independent of homocysteine 
concentrations. Higher maternal homocysteine concentrations were associated with smaller 
combined kidney volume and lower childhood eGFRcystC. Further analysis showed that the 
association of maternal homocysteine concentrations with childhood eGFRcystC was largely 
explained by combined kidney volume. Higher cord blood homocysteine concentrations 
were associated with larger combined kidney volume and lower eGFRcystC. Low folate and 
high homocysteine concentrations are previously shown to be associated with endothelial 
dysfunction and altered vascular development.29, 30 The potential underlying pathway can be 
that high homocysteine concentrations may impair endothelial vasodilatation by inhibiting 
the generation of endothelial mediators and promoting adhesion between neutrophil and 
endothelial cells.31 Suboptimal vascular development and endothelial dysfunction could lead 
to hypertension in childhood which could be a predictor to chronic kidney diseases in later 
life.13, 32 
Vitamin D is widely recognised for its benefi cial eff ects, especially on bone health.33 Next to 
the skeletal health, associatons of vitamin D and extraskeletal outcomes are reported.17, 34–36 
Vitamin D defi ciency, defi ned as 25-hydroxyvitamin D concentrations (25(OH)D) <50nmol/L, 
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is becoming a public health concern, especially among pregnant women.37, 38 Many authors 
debate if vitamin D defi ciency is really pandemic.39 It is important to acknowledge the 
controversy behind the assesment of adequate vitamin D status and recommended dietary 
allowance of vitamin D intake.39 We measured 25(OH)D concentrations in women during mid-
pregnancy and at birth in cord blood. Based on the Institute of Medicine (IOM), the Endocrine 
Society recommendations and based on previous cohort studies, we created four vitamin D 
groups, including severely defi cient (<25.0 nmol/L), defi cient (25.0 to 49.9 nmol/L), suffi  cient 
(50.0 to 74.9 nmol/L) and optimal (≥75.0 nmol/L).18, 40–42 IOM defi nes vitamin D as defi cient 
(<50nmol/L), and suffi  cient (≥50nmol/L), which would lead to categorizing our severely de-
fi cient and defi cient groups as defi cient, and categorizing the suffi  cient and optimal groups 
as suffi  cient or adequate. We consider an advantage of our categories as compared to IOM 
categories that we have more groups and can compare our results with previous pregnancy 
studies. In our cohort (N=7,176), 53 % of the pregnant mothers were 25(OH)D defi cient (<50 
nmol/L). We analyzed vitamin D continuously, using quartiles and using cut-off s based on 
current recommendation.
We fi rst explored the associations of mid-pregnancy maternal vitamin D and fetal growth 
patterns and birth outcomes. So far, most published studies focused on the associations of 
maternal vitamin D status during pregnancy with fetal development were mainly based on 
birth weight and showed inconsistent results.43–46 Nonetheless, birth weight is just a proxy 
for fetal growth and development. Diff erent fetal growth patterns and body proportions may 
lead to the same birth weight. We observed that mothers with mid-pregnancy 25(OH)D con-
centrations in the lower quartiles had off spring with third trimester fetal growth restriction 
leading to a smaller birth head circumference, shorter birth length and lower weight at birth 
as compared to mothers with 25(OH)D concentrations in the highest quartile. Mothers who 
had 25(OH)D concentrations in the lowest quartile had increased risks of preterm delivery and 
small-size for gestational age children. Most importantly we observed that the associations 
were not based on extreme 25(OH)D defi ciency, but present within the common ranges. A 
recent Mendelian Randomization study provided some evidence to support a possible causal 
association with birthweight, still further exploration in larger numbers of pregnancies are 
required.47
Second, we explored the associations of mid-pregnancy maternal and cord blood 
25(OH)D concentrations with childhood body composition and cardiovascular outcomes. We 
observed that as compared to children from mothers with optimal 25(OH)D concentrations, 
those of severely defi cient vitamin D mothers had higher fat mass percentage and lower lean 
mass percentage. Additional analyses suggested that these associations were independent 
of child current vitamin D status. Potential pathways of vitamin D on body composition have 
been shown.48 Vitamin D may increase adipose tissue lipolysis and decrease adipogenesis, 
suggesting a programing eff ect on childhood body composition.48 In our study, maternal 
and cord blood 25(OH)D concentrations were not associated with cardiovascular risk factors 
in children.
Third, we explored the associations of mid-pregnancy and cord blood 25(OH)D concen-
trations with kidney structure and function in children. We observed that higher maternal 
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25(OH)D concentrations were associated with lower childhood eGFR. These associations 
were partly explained by childhood vitamin D status. Maternal 25(OH)D concentrations were 
not consistently associated with childhood combined kidney volume whereas, cord blood 
25(OH)D concentrations were not associated with childhood kidney outcomes. More research 
is needed in replicating these fi ndings, establishing the causality of the associations, the 
underlying mechanisms, and the long term-clinical consequences. 
One of the most important determinants of the fetal supply line is placental function, re-
fl ected by placental weight and hemodynamic function. Gestational hypertensive disorders 
are considered as the most extreme form of hemodynamic placental dysfunction. According 
to previous studies, gestatonal hypertensive disorders have been associated with elevated 
blood pressure in off spring during childhood and adolescence.49, 50 However, gestational 
hypertensive disorders do not represent the full spectrum of blood pressure development 
during pregnancy. We examined the associations of maternal blood pressure throughout 
pregnancy and hypertensive disorders in pregnancy with childhood blood pressure. Specifi c 
focus was on the comparison with paternal blood pressure eff ects, the identifi cation of criti-
cal periods and the role of birth outcomes and childhood body mass index in the observed 
associations. Both maternal and paternal blood pressure were positively associated with 
childhood blood pressure. Since both maternal and paternal blood pressure were associated 
with childhood blood pressure, we must be careful to conclude direct intra-uterine eff ects. 
Early, mid- and late pregnancy maternal blood pressure were all independent and positively 
associated with childhood blood pressure, with the strongest eff ect estimates for early preg-
nancy. As compared to children from mothers without hypertensive disorders in pregnancy, 
those from mothers with hypertensive disorders in pregnancy had higher diastolic blood 
pressure. Further analyses suggested that the observed associations were not materially af-
fected by birth outcomes and childhood body mass index.
Some of these factors are potentially modifi able and might provide targets for intervention 
to improve fetal growth, renal and cardiovascular health on a population level. Altogether, 
the fi ndings of these studies indicate the importance of a balanced diet during fetal life, rich 
in protein and vitamins may support healthy growth and childhood kidney development. 
Genetic and childhood factors 
Large genome wide association studies (GWAS) in adults have identifi ed common genetic 
variants associated with impaired kidney function.51–53 An impaired renal function in child-
hood, possibly as a consequence of smaller kidney with a lower number of nephrons, could 
be an early sign of developing renal disease. The associations of kidney measures in early life 
with kidney disease in later life can be partly explained by common genetic variants that lead 
to both smaller kidneys with lower kidney function in early childhood and kidney disease 
in adulthood. We examined the associations of a genetic risk score combining previously 
identifi ed common genetic variants related to adult (estimated glomerular fi ltration rate 
based on creatinine concentrations) eGFRcreat with kidney outcomes in children aged 6.0 
years. The genetic risk score based on variants related to impaired kidney function in adults 
was associated with lower kidney volume and lower eGFR in children. These fi ndings suggest 
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that subjects who develop kidney disease in later life do already have smaller kidneys with 
lower eGFR in early life. 
Infant diet is a key component of in infant growth. Infant diet habits are related with the 
risk of overweight and cardiovascular health in early childhood.54, 55, 56 However these results 
are not consistent.56 Nevertheless, the results of a meta analyses acknowledge the long-
term protective eff ects of breastfeeding on blood pressure, obesity and diabetes.57 Whether 
breastfeeding also infl uences childhood kidney development is unknown. Only one small 
study has examined the associations of breastfeeding versus formula feeding and kidney 
outcomes and observed that infants who were exclusively formula fed had increased kidney 
growth during the fi rst 3 months, but this diff erence was no longer apparent at the age of 18 
months.58 We examined the associations of breastfeeding duration and exclusivity, and age 
at introduction of solid foods with kidney outcomes at school-aged children. The results of 
our study showed that never breastfed children had a smaller kidney volume compared to 
ever breastfed children. Among breastfed children, shorter duration of breastfeeding was as-
sociated with a smaller kidney volume and with a lower risk of microalbuminuria. Compared 
to exclusive breastfeeding for 4 months, non-exclusive breastfeeding in the fi rst 4 months 
was associated with a smaller kidney volume and a lower eGFR. Further analysis showed that 
the associations with eGFR were largely explained by kidney volume. Age at introduction of 
solid foods was not associated with any of the kidney outcomes. It is imperative to explore 
whether early life nutrition also aff ects the risk of kidney disease in adulthood and what are 
the potential mechanisms that drive these associations.
Throughout this thesis we have used eGFR when we express kidney function. It is widely 
recognised that the best measure to asses kidney function is GFR.59 Due to the diffi  culties and 
cost in measuring GFR, kidney function is estimated using creatinine blood concentrations.60 
Next to creatinine, cystatin C blood concentrations can be used to estimate GFR.61, 62 In children 
estimation of GFR is challenging. Creatinine, is actively secreted by the proximal tubule, and 
is related to muscle mass, age, sex, ethnicity and dietary factors.59, 63 Some authors report a 
superior sensitivity of cystatin C for detecting impaired GFR in pediatric patients compared to 
that of creatinine, especially in children with low muscle mass.64 An advantage of cystatin C in 
children is that it is considered less related to body weight and height.64, 65 Still, it is reported 
that lean mass aff ects cystatin C concentrations in kidney disease patients.66, 67 We explored 
the infl uence of diff erent body composition measures on eGFR from creatinine and cystatin C 
blood concentrations. Additionally we compared the associations of diff erent anthropometric 
and body composition measures with eGFR derived from creatinine (eGFRcreat) and cystatin C 
(eGFRcystC) blood concentrations. We observed that higher body mass index was associated 
with lower eGFRcystC but not with eGFRcreat. Our results suggest that eGFR based on both creati-
nine and cystatin C concentrations are infl uenced by BMI and BSA, whereas only eGFR based 
on creatinine concentrations is infl uenced by lean mass percentage and fat mass percentage. 
eGFRcreat is more strongly infl uenced by body composition than eGFRcystC. Although our study 
lacked the actual measurements of GFR, it suggests that beside anthropometric measurements, 
body composition measures should be considered when estimating GFR in children. Further 
studies to compare these results with measured GFR are needed.
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Main fi ndings
• Higher total and vegetable, but not animal, maternal protein intake during early pregnancy is associated with 
a higher eGFR in childhood.
• Folate, vitamin B12 and homocysteine concentrations during fetal life are associated with off spring kidney 
development.
• Low maternal 25(OH)D concentrations are associated with proportional fetal growth restriction and with 
increased risks of preterm birth and small-size for gestational age at birth.
• Severe maternal 25(OH)D defi ciency during pregnancy is associated with an adverse childhood body fat 
profi le, but not with childhood cardiovascular risk factors.
• Maternal 25(OH)D levels during pregnancy may infl uence childhood kidney outcomes. These results should 
be considered hypothesis-generating.
• Both maternal and paternal blood pressure aff ect childhood blood pressure, independent of fetal and 
childhood growth measures, with the strongest eff ect for maternal blood pressure in early pregnancy.
• Common genetic variants related to impaired kidney function in adults already lead to subclinical changes in 
childhood kidney outcomes.
• Breastfeeding is associated with subclinical changes in kidney outcomes in childhood.
• Both eGFRcreat and eGFRcystC are infl uenced by body mass index and body surface area. eGFRcreat is more 
strongly infl uenced by body composition than eGFRcystC.
METHODOLOGICAL CONSIDERATIONS 
Specifi c strengths and limitations for the studies presented in this thesis are described in 
Chapter 2 and Chapter 3 of this thesis. In the following paragraphs, we discuss general meth-
odological considerations regarding selection bias, information bias and confounding bias.
Selection bias
Selection bias may occur if the association between the determinant and outcome of interest 
is diff erent in subjects who participate in the study and those who did not participate in the 
study, but were eligible for the study. Of all children eligible at birth, the overall response 
to participate in the Generation R Study was 61 %. The participants in the study were more 
of a Dutch ethnicity and belonged to a higher socio-economic class as compared to non-
participants. Furthermore, the percentages of participating women with gestational hyper-
tensive disorders or preterm born children were lower than expected from the population 
fi gures in Rotterdam. Altogether, these suggest a selection towards a relatively more affl  uent 
and healthy population.68 This selection towards a more affl  uent and healthy population 
at baseline may have led to reduced statistical power, due to lower prevalence rates, and 
subsequently aff ecting the generalizability of our fi ndings to other populations. However, 
we consider it less likely because in large cohort studies biased estimates mainly arise from 
loss to follow-up rather than from non-response at baseline.69 Selective loss to follow-up may 
result in selection bias when the association between the determinant and the outcome of 
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interest is diff erent between those who continued participation in the study and those who 
were lost to follow-up. At the age of 6 years children were invited to participate in body 
composition, cardiovascular and kidney follow-up measurements. The response rate for the 
studies presented in this thesis was around 70 %. Overall, mothers of children who were lost 
to follow-up had more often a lower socio-economic status and unhealthy life style habits. 
This selection might have biased the eff ect estimates presented in this thesis.
Information bias
Information bias is a bias that arises in a study because of misclassifi cation of determinant 
or outcome measurements.70 Misclassifi cation of either determinant or outcome can be clas-
sifi ed as non-diff erential or diff erential. Non-diff erential misclassifi cation involves misclas-
sifi cation where the determinant status is not related to the outcome status, and vice versa. 
Non-diff erential misclassifi cation generally leads to an underestimation or dilution of the 
eff ect estimates. Diff erential misclassifi cation involves misclassifi cation of determinant status 
related to the outcome status, and vice versa. Diff erential misclassifi cation may lead to biased 
eff ect estimates. Most of the determinant data used in this thesis were assesed before the 
outcome, therefore the diff erential missclasifi cation of the determinant is unlikely. Whereas, 
non-diff erential misclassifi cation might have occured.
In some of the stuides presented in this thesis we have used questionnaires to asses infor-
mation on the determinant. Dietary assessment in epidemiological studies is challenging. 
Questions on the frequency and amount of consumption of regularly eaten foods by a food 
frequency questionnaire (FFQ) is a commonly used method. However, a disadvantage of 
this method is its dependence on recall. Validation studies have shown that reported values 
from FFQs are subject to substantial error, in cohort studies in principle non-diff erential.71 It 
may be that especially overweight women tend to underestimate their intake. To deal with 
this issue, the dietary analyses were corrected for pre-pregnancy BMI. Furthermore, energy 
adjustment may also help to resolve the issue of under- or over-reporting.72 Also, information 
on infant feeding was obtained by questionnaires, which has been proven to be diffi  cult to 
acquire reliable measurement of adverse lifestyle‐related factors by self‐reported question-
naires. Studying biomarkers that describe nutritional status may help to reduce the issue of 
misclassifi cation. In the studies presented in this thesis we had biomarkers of folate,vitamin 
B12, homocysteine and vitamin D. In our studies, the outcome was assessed using medical 
records, or standardized hands-on assessments of body composition, cardiovascular and 
kidney development. Furthermore, the observers were blinded to the determinant status, 
which makes diff erential misclassifi cation of the outcomes less likely.
Confounding
A confounder is an extraneous variable that is associated with both the determinant and 
the outcome of interest and is not an intermediate step in the causal pathway between the 
determinant and outcome.70 We adjusted our analyses for many potential confounders. The 
confounders were selected based on previous literature or a change of more than 10 % in the 
eff ect estimates. In some of the studies, adjustment for potential confounders attenuated 
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signifi cant associations into non-signifi cant, indicating that the unadjusted association is 
confounded. In other studies, the association did not attenuate or only slightly, indicating 
the association is possibly a true association between the determinant and the outcome. 
Although in the Generation R Study, there are many potential confounders available, it still 
may be that we did not measure all potential confounders. Also, measurement error of the 
confounding variables can occur. Therefore, residual confounding might still be an issue. 
Where possible, we assessed the associations of both maternal and paternal determinants 
during pregnancy. This in order to understand, if the explored associations were through 
direct intra-uterine mechanisms.73
CAUSALITY
Due to the observational design of our study, we were unable to establish causality in the 
observed associations. Bradford Hill’s Criteria on Causation attempt to establish scientifi -
cally valid causal connections between potential exposures and outcomes.74 They outline the 
minimal conditions needed to establish a causal relationship between the two items.74 In our 
observational study, Hill’s criteria on causation were applicable as detailed below. 
Hill’s criteria on causation
1. Strength 
  In the studies presented in this thesis we observe associations of early life determinants with fetal growth 
and kidney function in children. The eff ect estimates on eGFR are relatively small.
2. Consistency
  The results of studies presented in this thesis are consistent with previous studies showing that early life 
exposures are associated with kidney function in later life.
3. Specifi city
  We observed that diff erent specifi c early life factors were associated with kidney structure and function 
measures in children. Furthermore, maternal vitamin D concentrations were associated with fetal growth 
patterns, body composition, and kidney function in children. 
4. Temporality
  In our studies, the exposures were collected before the outcomes.
5. Biological gradient
  Dose response eff ects were observed in most of the studies. Changes in the outcomes rates followed the 
corresponding changes in exposure. 
6. Plausibility
  For the associations observed plausible underlying mechanisms are suggested.
7. Coherence
  The observed associations are compatible with existing knowledge. There is coherence from animal 
studies showing that adverse factors during early life can aff ect nephrogenesis and subsequently 
predispose the individual to chronic kidney disease in later life. 
8. Experiment 
  The experimental criteria could not be fulfi lled.
9. Analogy
  The analogous criteria could not be fulfi lled.
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To establish causation and possibly identifying mechanisms that underlie the associations, 
randomized controlled trials are preferred. Still, this design is not possible when exploring 
exposures such as gestational hypertensive disorders. Studies on causality are not easy to 
perform when the exposure of interest is diffi  cult to modify. For other exposures, like maternal 
nutrition or breastfeeding, this might be feasible and randomized controlled trials could over-
come the residual confounding issue. Observational studies that can provide sophisticated 
tools to obtain further insight into causality are important. Mendelian randomization studies 
use genetic variants, which are associated with the exposure of interest and not aff ected 
by confounding, as an instrumental variable for a specifi c exposure, to examine whether an 
exposure is causally related to the outcome.75, 76 For this type of study large sample sizes are 
necessary in order to obtain suffi  cient statistical power. Another method to compare intra-
uterine mechanisms from associations explained by shared family-based lifestyle-related 
characteristics is by comparing eff ect size of maternal-off spring and paternal-off spring as-
sociations.77 Therefore it is important that fathers are included in future studies, and have 
information of the same exposures as mothers to allow these types of comparisons.
CLINICAL IMPLICATIONS
In the studies presented in this thesis, fetal life, genetic and childhood determinants were 
associated with fetal growth and kidney function in children. Although the results presented 
in this thesis alone do not provide a basis to make strong statements and further research is 
certainly warranted, they provide suggestions for future prevention strategies. Implications 
for prevention are:
• Supporting population-strategies to improve vitamin D concentrations and to increase 
folate and vitamin B12 concentrations in pregnant women.
• Improving maternal diet during pregnancy. A diet rich in vegetable protein may support 
off spring kidney development.
• Considering parental factors in screening guidelines for childhood hypertension. 
• Supporting the World Health Organization recommendations on infant breastfeeding.
Developing preventive strategies focused on consuming a healthy diet, sun exposure, and 
vitamin supplements for pregnant women may help to improve fetal growth, off spring kid-
ney function, and prevent future kidney disease. This thesis highlights that both fetal life and 
early childhood provide a possible window of opportunity to improve renal health.
FUTURE RESEARCH
The results of our studies together with previous published evidence suggest that both fetal 
life and early childhood are important periods for growth and kidney health.78 Future studies 
should be focused on the causality, underlying mechanisms, and potential population eff ects 
for the observed associations. 
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Detailed and better markers on kidney development and kidney function are required 
to provide further insights in the studied associations. So far, the best surrogate marker 
for assessing nephron number in epidemiological studies is kidney weight or kidney size 
measured by ultrasound.79 In our studies we used ultrasound to estimate kidney volume, as 
a measure of nephron number, which seems to be a reliable surrogate for nephron endow-
ment.14 More reliable ways should be used to determine nephron number in the general 
population. Animal studies have suggested that magnetic resonance imaging techniques 
can provide individual counts of glomerular number, which is equivalent to the nephron 
number.80 If these techniques can be implemented in humans we can assess how early life 
determinants aff ect nephron number and thereafter the development of chronic kidney 
disease and hypertension. 
GFR is the most widely used marker to asses kidney function.61 The estimation of GFR in 
children remains challenging in daily practice: even though the Lund strategy appears to 
give reliable results in adults, to date in children there is no real consensus.81 With the design 
of our study it was not possible to compare and validate the explored associations of body 
composition with the estimates of GRF based on creatinine and cystatin C concentrations 
with the measured GFR. Thus, eff ort should be made on evaluating creatinine- and cystatin-
derived formulas, to help physicians in daily practice and also epidemiological studies to 
assess renal function in the general pediatric population. 
A potential mechanism on renal development is alterations in nephron endowment due 
to adverse fetal exposures.82 The number of nephrons, which is determined during fetal de-
velopment, is an important determinant of chronic kidney disease and hypertension during 
adult life. Autopsy studies in humans have shown that a lower nephron number is associated 
with hypertension.10, 12 Therefore, biopsy studies can help to assess nephron number, which 
can help in distinguishing the mechanisms of the observed associations. However, this ap-
proach can only be used in clinical settings and may be diffi  cult and risky to perform due to 
its invasive procedure, potential complications and costs.83 
In addition, epigenetic changes that persist throughout life may lead to the development 
of risk factors for chronic kidney disease and hypertension in adult off spring. Epigenetic 
modifi cations such as DNA methylation may occur in response to fetal nutrition, regulat-
ing gene activity.84 These epigenetic modifi cations may have phenotypic consequences 
throughout the life course, subsequently aff ecting the risk of kidney disease in later life.84 The 
largest variation of methylation is expected periconceptionally, therefore it is important that 
future population-based cohort studies start early in preconceptional or fetal life.85 Future 
studies are needed to obtain insight in the role of epigenetics in the associations between 
adverse fetal nutritional exposures and chronic kidney disease in adult life.86
The observed eff ect estimates for the associations of fetal, genetic and childhood determi-
nants with fetal growth and childhood kidney outcomes were small. However, they provide 
insights from a developmental perspective and may be important in a population level. It 
is previously shown that childhood cardiovascular and kidney measures track from child-
hood into adulthood.87, 88 Therefore, the observed subclinical diff erences in kidney function 
in childhood may be related to the development of chronic disease in later life. Health care 
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approaches should start early in life and take a cross-generational perspective.89 We should 
be aware of the importance of nutrition during pregnancy and its long-lasting eff ects in off -
spring health. Research and clinical practice should focus on identifying high risk individuals 
and developing preventive strategies or interventions from early pregnancy onwards.
CONCLUSION 
The fi ndings from this thesis suggest that early life nutrition is associated with fetal growth 
patterns and childhood kidney function. Future studies should focus on elucidating the 
underlying mechanisms and confi rming the long-term consequences of these fi ndings.
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SUMMARY 
In this thesis, we examined the fetal, genetic and childhood determinants of growth and 
childhood kidney function. Adverse environmental exposures during early life may lead to 
fetal growth adaptations and infl uence on the development of chronic kidney disease in 
later life, as indicated by many lines of evidence. From both an etiological and a prevention 
perspective, it is important to identify specifi c factors, especially modifi able factors that lead 
to an impaired kidney development. The studies presented in this thesis were mainly focused 
on the identifi cation of specifi c nutritional factors during fetal life and early childhood factors. 
Chapter 1 gives the background of the studies presented in this thesis. It describes the 
aim of the performed studies and describes the outline of the thesis. The studies included in 
this thesis were conducted within the Generation R Study, a population-based prospective 
cohort study from fetal life onwards. 
Chapter 2 describes the associations of fetal life factors with early growth, cardiovascular 
and kidney outcomes in childhood. In Chapter 2.1 we explored the associations of early 
pregnancy maternal protein intake with childhood kidney volume and measures of kidney 
function. We observed that higher total and vegetable, but not animal, maternal protein in-
take during early pregnancy was associated with a higher estimated glomerular fi ltration rate 
(eGFR) in childhood. These associations were not explained by protein intake in early child-
hood. In Chapter 2.2 we explored the associations of folate, vitamin B12 and homocysteine 
concentrations measured in early pregnancy and at birth with childhood kidney outcomes. 
We concluded that folate, vitamin B12 and homocysteine concentrations during fetal life were 
associated with off spring kidney development. These associations were independent of ma-
ternal, birth and childhood potential confounders. In Chapter 2.3 we investigated whether 
maternal vitamin D concentrations in mid-pregnancy were associated with fetal growth 
patterns and subsequently adverse birth outcomes. We showed that low maternal vitamin D 
concentrations were associated with proportional fetal growth restriction and with increased 
risks of preterm birth and small-size for gestational age at birth. These associations were not 
restricted to the extremes, but tended to be present across the full spectrum of maternal 
vitamin D concentrations. In Chapter 2.4 we examined the associations of mid- pregnancy 
maternal and cord blood vitamin D concentrations with childhood body composition, blood 
pressure, lipids and insulin concentrations. We observed that severe maternal vitamin D 
defi ciency during pregnancy was associated with an adverse childhood body fat profi le, but 
not with childhood cardiovascular risk factors. Cord blood vitamin D concentrations were 
not associated with childhood body composition or cardiovascular risk factors. In addition, 
in Chapter 2.5 we explored whether maternal vitamin D concentrations were associated 
with childhood kidney health. Our fi ndings suggest an association of maternal vitamin D 
concentrations during mid- pregnancy with childhood eGFR. The associations of maternal 
vitamin D concentrations with childhood eGFR were partly explained by childhood vitamin D 
status. In Chapter 2.6 we examined the associations of maternal blood pressure throughout 
pregnancy and hypertensive disorders in pregnancy with childhood blood pressure. Our 
specifi c focus was on the comparison with paternal blood pressure eff ects, the identifi cation 
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of critical periods and the role of birth outcomes and childhood body mass index in these 
associations. We observed that both maternal and paternal blood pressure were associated 
with childhood blood pressure with similar eff ect estimates. Early, mid- and late pregnancy 
maternal blood pressure were all independent and positively associated with childhood 
blood pressure, with the strongest eff ect estimates for early pregnancy. All the observed 
associations were independent of fetal and childhood growth measures. 
Chapter 3 describes the associations of genetic and childhood exposures with kidney 
outcomes. In Chapter 3.1 we observed that common genetic variants related to impaired 
kidney function in adults were associated with kidney volume and eGFR in school-aged chil-
dren. This chapter suggests that the well-known associations of kidney measures in early life 
with kidney disease in later life may at least be partly explained by common genetic variants. 
Chapter 3.2 explores the associations of breastfeeding duration, exclusivity, and age at in-
troduction of solid foods with kidney outcomes at school-aged children. This chapter shows 
that breastfeeding was associated with subclinical changes in kidney outcomes in childhood. 
Children who were shorter or non-exclusively breastfed had smaller kidney and a lower eGFR. 
In Chapter 3.3 we compared the associations of diff erent anthropometric and body composi-
tion measures with eGFR derived from creatinine and cystatin C blood concentrations. This 
chapter suggests that eGFR based on both creatinine and cystatin C concentrations were in-
fl uenced by body mass index and body surface area, whereas only eGFR based on creatinine 
concentrations was infl uenced by lean mass percentage and fat mass percentage. However, 
this chapter concludes that further studies are needed to assess whether using eGFRcystC 
instead of eGFRcreat leads to better care for pediatric kidney patients. Finally, in Chapter 4 
the main fi ndings of this thesis are evaluated. It discusses the methodological issues of the 
included studies and concludes with suggestions for future research and clinical application.
In conclusion, the fi ndings of this thesis suggest that early life nutrition is associated with 
fetal growth patterns and childhood kidney function. Further studies are needed to unravel 
these mechanisms and to identify whether these subclinical changes in kidney development 
have consequences for the development of chronic kidney disease in later life.
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SAMENVATTING  
In dit proefschrift hebben we verschillende determinanten van vroege groei en nierfunctie 
op de leeftijd van 6 jaar onderzocht. We hebben gekeken naar genetische determinanten 
en naar determinanten tijdens de foetale tijd en de kindertijd. Zoals eerder aangetoond kan 
blootstelling aan nadelige omgevingsfactoren tijdens het vroege leven leiden tot aanpas-
singen in de foetale groei en mogelijk invloed hebben op de ontwikkeling van chronische 
nierziekten op latere leeftijd. Vanuit etiologisch perspectief en voor de ontwikkeling van 
preventiestrategieën is het belangrijk om factoren te identifi ceren die kunnen leiden tot een 
verminderde ontwikkeling van de nierfunctie, in het bijzonder beïnvloedbare factoren. De 
studies die beschreven worden in dit proefschrift zijn met name gericht op de identifi catie 
van voedingsgerelateerde factoren tijdens de foetale tijd en de vroege kindertijd. 
In Hoofdstuk 1 beschrijven we de achtergrond van de studies die zijn opgenomen in 
dit proefschrift. Tevens wordt het doel van elke studie en de opbouw van het proefschrift 
beschreven. De studies die in dit proefschrift zijn opgenomen, zijn uitgevoerd binnen het 
Generation R onderzoek,  een populatie-gebaseerd prospectief cohort onderzoek vanaf het 
foetale leven tot in de jongvolwassenheid.  
In Hoofdstuk 2 beschrijven we de associaties tussen foetale factoren met vroege groei, 
cardiovasculaire uitkomsten en de ontwikkeling van de nieren in de kindertijd. In Hoofdstuk 
2.1 hebben we de associaties onderzocht tussen eiwitinname door de moeder tijdens de 
vroege zwangerschap en niervolume en nierfunctie van het kind op 6-jarige leeftijd. We 
zagen dat een hogere totale eiwitinname en een hogere inname van plantaardige eiwitten, 
maar niet van dierlijke eiwitten, tijdens de vroege zwangerschap was geassocieerd met een 
hogere geschatte glomerulaire fi ltratiesnelheid (estimated glomerular fi ltration rate: eGFR) 
van het kind op de leeftijd van 6 jaar. Deze associaties werden niet verklaard door eiwitin-
name van het kind. In Hoofdstuk 2.2 hebben we de relatie onderzocht tussen foliumzuur-, 
vitamine B12- en homocysteïne-concentraties, gemeten in de vroege zwangerschap en bij 
de geboorte, en nierfunctie van het kind op 6-jarige leeftijd. We hebben geconcludeerd 
dat foliumzuur, vitamine B12 en homocysteïne concentraties tijdens het foetale leven zijn 
geassocieerd met de ontwikkeling van de nierfunctie van het kind. Deze associaties waren 
onafhankelijk van mogelijke confounders met betrekking tot moeder, geboorte en kind. In 
Hoofdstuk 2.3 hebben we onderzocht of vitamine D concentraties bij de moeder tijdens 
de zwangerschap geassocieerd waren met foetale groeipatronen en complicaties bij de ge-
boorte. We hebben aangetoond dat lage maternale vitamine D concentraties mogelijk leiden 
tot proportionele foetale groeirestrictie en tot een verhoogd risico op vroeggeboorte en een 
laag geboortegewicht in verhouding tot de zwangerschapsduur. Deze associaties werden 
gezien in het gehele spectrum van maternale vitamine D concentraties en waren dus niet 
alleen zichtbaar bij extreme vitamine D waarden. In Hoofdstuk 2.4 hebben we de associaties 
onderzocht tussen vitamine D concentraties tijdens het tweede trimester van de zwanger-
schap, gemeten in maternaal bloed en navelstrengbloed, met lichaamssamenstelling, bloed-
druk, lipiden en insulineconcentraties bij het kind. We zagen dat ernstige maternale vitamine 
D-defi ciëntie tijdens de zwangerschap kan leiden tot een schadelijk lichaamsvetprofi el bij het 
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kind, maar geen invloed heeft op cardiovasculaire risicofactoren. Vitamine D concentraties in 
navelstrengbloed waren niet geassocieerd met lichaamssamenstelling of cardiovasculaire 
risicofactoren bij het kind. Daarnaast hebben we in Hoofdstuk 2.5 onderzocht of mater-
nale vitamine D concentraties geassocieerd waren met de nierfunctie van het kind. Onze 
bevindingen suggereren een verband tussen maternale vitamine D concentraties tijdens het 
tweede trimester en eGFR in de kindertijd. Deze associaties werden gedeeltelijk verklaard 
door vitamine D status in de kindertijd. In Hoofdstuk 2.6 hebben we het verband onderzocht 
tussen maternale bloeddruk door de zwangerschap heen en hypertensieve aandoeningen 
tijdens de zwangerschap met de bloeddruk van het kind. In deze associaties lag onze focus 
op de vergelijking met het eff ect van paternale bloeddruk, op de identifi catie van kritieke 
perioden en op de rol van geboorte uitkomsten en body mass index van het kind. We zagen 
dat zowel maternale als paternale bloeddruk geassocieerd waren met de bloeddruk van het 
kind. Beiden hadden een vergelijkbaar eff ect. Gedurende de gehele zwangerschap was de 
maternale bloeddruk onafhankelijk en positief geassocieerd met de bloeddruk van het kind. 
Het sterkste verband werd gevonden tijdens de vroege zwangerschap. Alle associaties waren 
onafhankelijk van foetale groei en groei tijdens de kindertijd.
In Hoofdstuk 3 beschrijven we de relatie tussen genetische determinanten en determi-
nanten in de kindertijd met nierfuncties op de leeftijd van 6 jaar. In Hoofdstuk 3.1 zagen 
we dat veel voorkomende genetische varianten, geassocieerd met verminderde nierfunctie 
in volwassenen, waren geassocieerd met niervolume en eGFR in basisschoolkinderen. Dit 
hoofdstuk suggereert dat eerder onderzochte verbanden tussen nierfunctie in het vroege 
leven en nierziekten in het latere leven mogelijk deels worden verklaard door veel voorko-
mende genetische varianten. In Hoofdstuk 3.2 onderzochten we de associaties tussen de 
duur van borstvoeding, het geven van uitsluitend borstvoeding en de leeftijd waarop vaste 
voeding wordt geïntroduceerd met nierfunctie in de kindertijd. Dit hoofdstuk toont aan dat 
borstvoeding is geassocieerd met subklinische veranderingen in de nierfunctie op 6-jarige 
leeftijd. Kinderen die korter of niet uitsluitend borstvoeding kregen hadden kleinere nieren 
en een lagere eGFR. In Hoofdstuk 3.3 hebben we de associaties vergeleken van verschillende 
maten van antropometrie en lichaamssamenstelling met eGFR, afgeleid van creatinine en 
cystatine C concentraties. Dit hoofdstuk suggereert dat eGFR gebaseerd op zowel creatinine 
en cystatine C concentraties werd beïnvloed door body mass index en lichaamsoppervlakte, 
terwijl eGFR gebaseerd op enkel creatinine concentraties werd beïnvloed door vetvrije massa 
en vetpercentage. In dit hoofdstuk werd geconcludeerd dat verder onderzoek nodig is om te 
beoordelen of het gebruik van eGFRcyst in plaats van eGFRcreat leidt tot betere zorg voor jonge 
nierpatiënten. Tot slot zijn in Hoofdstuk 4 de belangrijkste bevindingen van dit proefschrift 
weergegeven. Ook worden hier de methodologische aspecten van de geïncludeerde studies 
besproken en worden de conclusies weergegeven, waarbij tevens ingegaan wordt op sug-
gesties voor vervolgonderzoek en toepassing in de klinische setting.
Concluderend suggereren de bevindingen van dit proefschrift dat voeding tijdens het 
vroege leven is geassocieerd met foetale groeipatronen en nierfunctie in de kindertijd. Ver-
der onderzoek is nodig om de onderliggende mechanismen te achterhalen en om te identi-
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fi ceren of deze subklinische veranderingen in de ontwikkeling van de nieren consequenties 
hebben voor de ontwikkeling van chronische nierziekten op latere leeftijd. 
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Faleminderit për kohën, kafet, bisedat, të dalat, festat…! Ju e lehtësuat këtë rrugëtim për 
mua. Goca dhe çuna, jeni të mrekullueshem! Ȅshtë fat që ju kam njohur! E kam shijuar çdo 
moment me ju.
Nelës dhe Genës, mikeshat më të mira që mund të ekzistojnë! Zoti më ka bekuar me ju të 
dyja. Xhaxhi Kiçi faleminderit për mbështetjen tënde! Do më mungojë prania jote ditën e 
diplomimit! 
Thank you to my precious paranymphs: Suzanne and Enisa, you girls are amazing! I am 
lucky to be defending my thesis having you by my side. Thank you for your friendship, your 
advices, positive attitude, and kindness! Thank you for your support in many happy and dif-
fi cult times! Suzanne, the example of perfection. I still must learn from you. It was “gezellig” 
working together. Enisa, the sweetest person I have ever known. I thought I was the one 
“locking” Erasmus MC but you broke my record! Your hard work will be paid off . 
Special thanks to my families, relatives and friends. Së pari po e fi lloj me Itan, Mirin, Arba-
nën, mami Nexhin dhe babi Çimin. Miri dhe Arbana faleminderit që kujdeseni për mamin 
271
A
Word of Gratitude
dhe babin, Itani i ka lumturuar. Mami dhe babi, keni rritur 2 djem të mrekullueshëm. Unë dhe 
Arbana jemi me fat që i kemi pjesë të jetës. Babi, faleminderit për gjithë ndihmën tënde në 
realizim e kësaj teze. 
Të shtrënjtit e mi, Dorisa, Guçi, mami, babi, për çfarë tu falenderoj më parë! Dorisa, topce, 
faleminderit për mirësinë që rrezaton. Jam shumë e lumtur që tani kam një motër. Suksese 
me provimet, do dalësh shumë mirë! Guçi, jetë e motrës, shoku im më i mirë, edhe pse më i 
vogël gjithmonë ke ditur të kujdesesh për mua. Çdo gjë në jetën time lidhet me ty. Falemin-
derit që më ke zbukuruar jetën! Jam motra më krenare në botë. 
Nocka dhe babka im, nuk e di si do tua shpërblej ndonjë ditë gjithcka që keni bërë për mua. 
Sakrifi konit çdo gjë tuajën që mua mos më mungonte asgjë. Gjithmonë më keni motivuar të 
ec përpara me kokën lart dhe asnjëherë të mos dorezohem kollaj. Nuk mund të kisha shem-
buj më të mirë se ju. Faleminderit! Pa mbështetjen tuaj nuk do të isha këtu sot. 
Enri, bashkëshorti im, miku im, mbështetja ime! Kjo arritje është falë teje! Asgjë nuk do 
ishte e mundur pa mbështetjen, pozitivitetin dhe dashurinë tend. Nuk më le të hiqja dorë 
nga bursa e doktoraturës, por erdhe në Hollandë për të ndërtuar jetën të dy. Zoti do e bekoje 
martesën tonë këtë verë! Mezi po pres 16 Korrikun! Uroj që kur të jemi në Kanada të mos të 
zërë gjumi në zyren time duke pritur që unë të mbaroj edhe pse do jetë gdhirë një ditë e re ☺. 
Mbeshtetja jote më ka realizuar! 
Faleminderit Zot!
COVER
Format: 353x240 mm
Spine:  12 mm BOOKMARKFormat: 60x230 mm
Optima Grafische Communicatie
https://ogc.nl
Order: Kozeta - Cover en boekenlegger 3
Date: 18/04/2017 
